{"0825a7b4df2562051386a726f10e5ce14560a69e": [["IntroductionBelonging to the Mononegavirales order, Paramyxoviridae family and Avulavirus genus, Newcastle disease virus (NDV) is an enveloped virus containing linear, non-segmented single-stranded RNA (Lamb et al., 2005) .", [["Newcastle disease", "DISEASE", 97, 114], ["Avulavirus genus", "ORGANISM", 79, 95], ["Newcastle disease virus", "ORGANISM", 97, 120], ["NDV", "ORGANISM", 122, 125], ["Newcastle disease virus", "SPECIES", 97, 120], ["NDV", "SPECIES", 122, 125], ["Newcastle disease virus", "SPECIES", 97, 120], ["NDV", "SPECIES", 122, 125], ["Newcastle disease virus (NDV", "PROBLEM", 97, 125], ["an enveloped virus", "PROBLEM", 130, 148], ["enveloped", "OBSERVATION_MODIFIER", 133, 142], ["virus", "OBSERVATION", 143, 148], ["linear", "OBSERVATION_MODIFIER", 160, 166], ["stranded RNA", "OBSERVATION_MODIFIER", 189, 201]]], ["NDV strains are classified into one of three major pathotypes: velogenic, mesogenic and lentogenic (Beard and Hanson, 1984) .", [["NDV", "ORGANISM", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV strains", "PROBLEM", 0, 11], ["velogenic", "PROBLEM", 63, 72], ["velogenic", "OBSERVATION", 63, 72], ["mesogenic", "OBSERVATION_MODIFIER", 74, 83], ["lentogenic", "OBSERVATION_MODIFIER", 88, 98]]], ["Highly virulent velogenic strains cause acute infections with high mortality, mesogenic (intermediately virulent) strains cause respiratory disease in young chickens and decreased egg production, whereas lentogenic (avirulent) strains cause mild respiratory infection or give no symptoms in poultry (Seal et al., 1995) .", [["respiratory", "ANATOMY", 128, 139], ["egg", "ANATOMY", 180, 183], ["respiratory", "ANATOMY", 246, 257], ["infections", "DISEASE", 46, 56], ["respiratory disease", "DISEASE", 128, 147], ["respiratory infection", "DISEASE", 246, 267], ["velogenic strains", "ORGANISM", 16, 33], ["chickens", "ORGANISM", 157, 165], ["egg", "ORGANISM_SUBSTANCE", 180, 183], ["chickens", "SPECIES", 157, 165], ["chickens", "SPECIES", 157, 165], ["Highly virulent velogenic strains", "PROBLEM", 0, 33], ["acute infections", "PROBLEM", 40, 56], ["high mortality", "PROBLEM", 62, 76], ["mesogenic (intermediately virulent) strains", "PROBLEM", 78, 121], ["respiratory disease", "PROBLEM", 128, 147], ["young chickens", "PROBLEM", 151, 165], ["decreased egg production", "PROBLEM", 170, 194], ["lentogenic (avirulent) strains", "PROBLEM", 204, 234], ["mild respiratory infection", "PROBLEM", 241, 267], ["symptoms", "PROBLEM", 279, 287], ["virulent", "OBSERVATION_MODIFIER", 7, 15], ["velogenic strains", "OBSERVATION", 16, 33], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["infections", "OBSERVATION", 46, 56], ["high mortality", "OBSERVATION_MODIFIER", 62, 76], ["mesogenic", "OBSERVATION_MODIFIER", 78, 87], ["respiratory disease", "OBSERVATION", 128, 147], ["young chickens", "OBSERVATION", 151, 165], ["decreased", "OBSERVATION_MODIFIER", 170, 179], ["egg production", "OBSERVATION", 180, 194], ["mild", "OBSERVATION_MODIFIER", 241, 245], ["respiratory", "ANATOMY", 246, 257], ["infection", "OBSERVATION", 258, 267]]], ["Studies conducted by Rott and Klenk (1988) revealed the key role of a small amino acid motif at the cleavage site of the F0 protein of NDV in the molecular determination of the pathotype.", [["amino acid", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 76, 86], ["amino acid", "AMINO_ACID", 76, 86], ["NDV", "ORGANISM", 135, 138], ["small amino acid motif", "PROTEIN", 70, 92], ["cleavage site", "PROTEIN", 100, 113], ["F0 protein", "PROTEIN", 121, 131], ["NDV", "SPECIES", 135, 138], ["Studies", "TEST", 0, 7], ["a small amino acid motif", "TREATMENT", 68, 92], ["NDV", "PROBLEM", 135, 138], ["NDV", "OBSERVATION", 135, 138], ["pathotype", "OBSERVATION", 177, 186]]], ["The presence of two pairs of basic amino acids at positions 112, 113, 115 and 116 and phenyloalanine at position 117, at fusion protein cleavage site, makes this site susceptible to cleavage by common subtilisin-like protease and easier spread throughout the host.", [["amino acids", "CHEMICAL", 35, 46], ["112, 113, 115 and 116", "CHEMICAL", 60, 81], ["phenyloalanine", "CHEMICAL", 86, 100], ["amino acids", "CHEMICAL", 35, 46], ["phenyloalanine", "CHEMICAL", 86, 100], ["amino acids", "AMINO_ACID", 35, 46], ["phenyloalanine", "AMINO_ACID", 86, 100], ["subtilisin-like protease", "GENE_OR_GENE_PRODUCT", 201, 225], ["position 117", "PROTEIN", 104, 116], ["fusion protein cleavage site", "PROTEIN", 121, 149], ["common subtilisin-like protease", "PROTEIN", 194, 225], ["basic amino acids", "TEST", 29, 46], ["phenyloalanine", "TEST", 86, 100], ["fusion protein cleavage site", "TREATMENT", 121, 149], ["this site", "PROBLEM", 157, 166], ["common subtilisin-like protease", "PROBLEM", 194, 225], ["amino acids", "OBSERVATION", 35, 46]]], ["The sequence (C-112 R/K-R-Q-K/R-R-F 117 -N) is observed in highly virulent strains.", [["strains", "ANATOMY", 75, 82], ["The sequence", "TEST", 0, 12], ["C", "TEST", 14, 15], ["K", "TEST", 22, 23], ["highly virulent strains", "PROBLEM", 59, 82], ["virulent strains", "OBSERVATION", 66, 82]]], ["In the low virulence strains, there are only two basic Abbreviations: AIV, avian influenza virus; APMV, avian paramyxovirus; CSFV, classical swine fever virus; EID, egg infective dose; ICPI, intercerebral pathogenicity index; NDV, Newcastle disease virus; PCR, polymerase chain reaction.Introduction* Corresponding author.", [["avian influenza virus", "DISEASE", 75, 96], ["avian paramyxovirus", "DISEASE", 104, 123], ["swine fever", "DISEASE", 141, 152], ["Newcastle disease", "DISEASE", 231, 248], ["AIV", "ORGANISM", 70, 73], ["avian influenza virus", "ORGANISM", 75, 96], ["APMV", "ORGANISM", 98, 102], ["avian paramyxovirus", "ORGANISM", 104, 123], ["CSFV", "ORGANISM", 125, 129], ["classical swine fever virus", "ORGANISM", 131, 158], ["NDV", "ORGANISM", 226, 229], ["Newcastle disease virus", "ORGANISM", 231, 254], ["avian influenza virus", "SPECIES", 75, 96], ["avian paramyxovirus", "SPECIES", 104, 123], ["CSFV", "SPECIES", 125, 129], ["swine fever virus", "SPECIES", 141, 158], ["NDV", "SPECIES", 226, 229], ["avian influenza virus", "SPECIES", 75, 96], ["APMV", "SPECIES", 98, 102], ["CSFV", "SPECIES", 125, 129], ["swine fever virus", "SPECIES", 141, 158], ["NDV", "SPECIES", 226, 229], ["Newcastle disease virus", "SPECIES", 231, 254], ["the low virulence strains", "PROBLEM", 3, 28], ["AIV", "PROBLEM", 70, 73], ["avian influenza virus", "PROBLEM", 75, 96], ["APMV", "TREATMENT", 98, 102], ["avian paramyxovirus", "PROBLEM", 104, 123], ["CSFV", "PROBLEM", 125, 129], ["classical swine fever virus", "PROBLEM", 131, 158], ["ICPI", "PROBLEM", 185, 189], ["intercerebral pathogenicity index", "PROBLEM", 191, 224], ["NDV", "PROBLEM", 226, 229], ["Newcastle disease virus", "PROBLEM", 231, 254], ["PCR", "TEST", 256, 259], ["polymerase chain reaction", "PROBLEM", 261, 286], ["low virulence", "OBSERVATION_MODIFIER", 7, 20], ["influenza virus", "OBSERVATION", 81, 96]]], ["Tel.: +48 58 5236336; fax: +48 58 3057312.IntroductionE-mail address: dawid.nidzworski@biotech.ug.gda.pl (D. Nidzworski). amino acids at position 113 and 116, along with leucine at position 117 (C-112 G/E-K/R-Q-G/E-R-L 117 -N).", [["+48 58 5236336", "CHEMICAL", 6, 20], ["amino acids", "CHEMICAL", 122, 133], ["leucine", "CHEMICAL", 170, 177], ["+48 58 5236336", "CHEMICAL", 6, 20], ["amino acids", "CHEMICAL", 122, 133], ["leucine", "CHEMICAL", 170, 177], ["amino acids", "AMINO_ACID", 122, 133], ["leucine", "AMINO_ACID", 170, 177], ["K", "PROTEIN", 205, 206], ["R-Q", "PROTEIN", 207, 210], ["E", "PROTEIN", 213, 214], ["amino acids", "TEST", 122, 133], ["leucine", "TEST", 170, 177], ["C", "TEST", 195, 196], ["G/E", "TEST", 201, 204], ["K", "TEST", 205, 206]]], ["This motif is recognized only by trypsin-like proteases, which are present mainly in the respiratory tract (Collins et al., 1996; Nagai et al., 1976) .", [["respiratory tract", "ANATOMY", 89, 106], ["trypsin", "GENE_OR_GENE_PRODUCT", 33, 40], ["respiratory tract", "ORGANISM_SUBDIVISION", 89, 106], ["trypsin-like proteases", "PROTEIN", 33, 55], ["trypsin-like proteases", "PROBLEM", 33, 55], ["respiratory tract", "ANATOMY", 89, 106]]], ["Because of the role of the cleavage site in pathogenicity, the F gene is the major target for differentiation of Newcastle disease virus.", [["Newcastle disease", "DISEASE", 113, 130], ["F", "GENE_OR_GENE_PRODUCT", 63, 64], ["Newcastle disease virus", "ORGANISM", 113, 136], ["F gene", "DNA", 63, 69], ["Newcastle disease virus", "SPECIES", 113, 136], ["the cleavage site", "PROBLEM", 23, 40], ["Newcastle disease virus", "PROBLEM", 113, 136], ["Newcastle disease", "OBSERVATION", 113, 130]]], ["The variability in the virulence of NDV causes diagnostic difficulties because only viral infections with an ICPI of 0.7 or greater are notifiable (OIE, 2009) .", [["NDV", "DISEASE", 36, 39], ["viral infections", "DISEASE", 84, 100], ["NDV", "ORGANISM", 36, 39], ["NDV", "SPECIES", 36, 39], ["NDV", "PROBLEM", 36, 39], ["diagnostic difficulties", "PROBLEM", 47, 70], ["viral infections", "PROBLEM", 84, 100], ["an ICPI", "TEST", 106, 113], ["variability", "OBSERVATION_MODIFIER", 4, 15], ["viral", "OBSERVATION_MODIFIER", 84, 89], ["infections", "OBSERVATION", 90, 100]]], ["Therefore, detection of the virus only is not a sufficient for notification and should be followed by methods that evaluate the pathogenicity of isolates.IntroductionThe sensitivity and short time analysis of real-time PCR are its two most important advantages (Higuchi et al., 1992) .", [["the virus", "PROBLEM", 24, 33], ["the pathogenicity of isolates", "PROBLEM", 124, 153], ["The sensitivity", "TEST", 166, 181], ["short time analysis", "TEST", 186, 205], ["real-time PCR", "TEST", 209, 222], ["virus", "OBSERVATION", 28, 33]]], ["Several methods for the detection and differentiation of NDV have been previously described.", [["NDV", "ORGANISM", 57, 60], ["NDV", "SPECIES", 57, 60], ["the detection", "TEST", 20, 33], ["NDV", "PROBLEM", 57, 60], ["NDV", "OBSERVATION", 57, 60]]], ["Most assays are based on the detection of the fusion gene (Pham et al., 2005) or the matrix and fusion genes (Wise et al., 2004; Steyer et al., 2010) .", [["matrix", "ANATOMY", 85, 91], ["matrix", "CELLULAR_COMPONENT", 85, 91], ["fusion gene", "DNA", 46, 57], ["matrix and fusion genes", "DNA", 85, 108], ["the matrix and fusion genes", "TREATMENT", 81, 108]]], ["However, other regions are also used for general detection and differentiation (Fuller et al., 2010; Tan et al., 2009 ).", [["general detection", "TEST", 41, 58]]], ["The first SYBR Green I assay for the detection of NDV was described by Tan et al. (2004) , but this assay could not be used for differentiation of pathotypes of the virus.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 10, 22], ["NDV", "ORGANISM", 50, 53], ["NDV", "SPECIES", 50, 53], ["NDV", "PROBLEM", 50, 53], ["this assay", "TEST", 95, 105], ["pathotypes", "PROBLEM", 147, 157], ["the virus", "PROBLEM", 161, 170]]], ["Pham et al. (2005) described a SYBR Green I real-time PCR melting curve analysis assay for differentiation, although the differences in the Tm values between the three genotypes were not very significant and could cause false characterization of the virus.", [["a SYBR", "TEST", 29, 35], ["PCR melting curve analysis assay", "TEST", 54, 86], ["the Tm values", "TEST", 136, 149], ["the virus", "PROBLEM", 246, 255]]], ["Many real-time PCR assays for NDV detection and differentiation using different TaqMan probes were developed but degenerated primers were not used very often.", [["NDV", "ORGANISM", 30, 33], ["TaqMan probes", "DNA", 80, 93], ["NDV", "SPECIES", 30, 33], ["Many real-time PCR assays", "TEST", 0, 25], ["NDV detection", "TEST", 30, 43], ["different TaqMan probes", "TREATMENT", 70, 93], ["degenerated primers", "PROBLEM", 113, 132]]], ["Also, false negative results were reported (Cattoli et al., 2009; Wise et al., 2004) .", [["false negative", "OBSERVATION", 6, 20]]], ["In some cases, to differentiate between pathotypes of NDV, it was necessary to use two or three pairs of primers and several different TaqMan probes in one reaction were necessary (Wise et al., 2004; Farkas et al., 2009) .IntroductionDegenerated primers have been proven to be a good tool for the detection of the highly variable Newcastle disease virus (Farkas et al., 2009; Li et al., 2009; Steyer et al., 2010) .", [["Newcastle disease", "DISEASE", 330, 347], ["NDV", "ORGANISM", 54, 57], ["Newcastle disease virus", "ORGANISM", 330, 353], ["TaqMan probes", "DNA", 135, 148], ["NDV", "SPECIES", 54, 57], ["Newcastle disease virus", "SPECIES", 330, 353], ["NDV", "PROBLEM", 54, 57], ["primers", "TREATMENT", 105, 112], ["several different TaqMan probes", "TREATMENT", 117, 148], ["Degenerated primers", "PROBLEM", 234, 253], ["the detection", "TEST", 293, 306], ["the highly variable Newcastle disease virus", "PROBLEM", 310, 353], ["NDV", "OBSERVATION", 54, 57]]], ["In this study, a one tube diagnostic method is described for the detection and differentiation of Newcastle disease virus using degenerated primers.Virus strains and RNA extractionThe NDV strains that were analyzed in this study are listed in Table 1 .", [["Newcastle disease", "DISEASE", 98, 115], ["tube", "TISSUE", 21, 25], ["Newcastle disease virus", "ORGANISM", 98, 121], ["Virus", "ORGANISM", 148, 153], ["NDV", "ORGANISM", 184, 187], ["Newcastle disease virus", "SPECIES", 98, 121], ["NDV", "SPECIES", 184, 187], ["this study", "TEST", 3, 13], ["a one tube diagnostic method", "TREATMENT", 15, 43], ["the detection", "TEST", 61, 74], ["Newcastle disease virus", "PROBLEM", 98, 121], ["degenerated primers", "PROBLEM", 128, 147], ["Virus strains", "PROBLEM", 148, 161], ["RNA extraction", "TREATMENT", 166, 180], ["The NDV strains", "PROBLEM", 180, 195], ["this study", "TEST", 218, 228], ["RNA extraction", "OBSERVATION", 166, 180]]], ["All of the strains were derived from the collection of the National Veterinary Research Institute (Pulawy, Poland) and were classified into three major pathotypes based on the intracerebral pathogenicity index (ICPI) and comparison with reference strains.", [["intracerebral", "ANATOMY", 176, 189], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 176, 189], ["the strains", "PROBLEM", 7, 18], ["the intracerebral pathogenicity index", "TEST", 172, 209]]], ["Avian influenza virus (AIV) subtype H5N2, Coronavirus (165/08 5-8), rotavirus (G036/10 1-5), Gumboro virus (131/92), and classical swine fever virus (CSVF) Cellpest strain were from the National Veterinary Research Institute (Pulawy, Poland).", [["Avian influenza virus (AIV) subtype H5N2", "DISEASE", 0, 40], ["rotavirus", "DISEASE", 68, 77], ["G036/10 1-5", "CHEMICAL", 79, 90], ["swine fever", "DISEASE", 131, 142], ["Avian influenza virus", "ORGANISM", 0, 21], ["AIV) subtype H5N2", "ORGANISM", 23, 40], ["Coronavirus", "ORGANISM", 42, 53], ["rotavirus", "ORGANISM", 68, 77], ["G036/10 1-5", "ORGANISM", 79, 90], ["Gumboro virus", "ORGANISM", 93, 106], ["classical swine fever virus", "ORGANISM", 121, 148], ["Avian influenza virus", "SPECIES", 0, 21], ["H5N2", "SPECIES", 36, 40], ["rotavirus", "SPECIES", 68, 77], ["Gumboro virus", "SPECIES", 93, 106], ["swine fever virus", "SPECIES", 131, 148], ["Avian influenza virus", "SPECIES", 0, 21], ["AIV", "SPECIES", 23, 26], ["Gumboro virus", "SPECIES", 93, 106], ["classical swine fever virus", "SPECIES", 121, 148], ["CSVF", "SPECIES", 150, 154], ["Avian influenza virus (AIV) subtype H5N2", "PROBLEM", 0, 40], ["Coronavirus", "TEST", 42, 53], ["rotavirus (G036/10", "TEST", 68, 86], ["Gumboro virus", "PROBLEM", 93, 106], ["classical swine fever virus (CSVF) Cellpest strain", "PROBLEM", 121, 171], ["influenza virus", "OBSERVATION", 6, 21]]], ["APMV strains were bought from x-OvO Limited (Dunfermline, United Kingdom).", [["APMV", "SPECIES", 0, 4], ["APMV strains", "PROBLEM", 0, 12]]], ["Reovirus (Reo S1133) and Infectious Bronchitis virus (IB K+ 4/91) were vaccine components of Nobilis REO 1133 and Nobilis IB 4-91 (Intervet/Schering-Plough Animal Health, Holland).Virus strains and RNA extractionRNA was extracted from allantoic fluid of SPF embryonated eggs (Lohman, Germany), and inoculated with NDV strains in accordance with the OIE Diagnostic Manual (OIE, 2009) using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) protocol.", [["allantoic fluid", "ANATOMY", 235, 250], ["eggs", "ANATOMY", 270, 274], ["Infectious Bronchitis virus", "DISEASE", 25, 52], ["K", "CHEMICAL", 57, 58], ["Nobilis REO 1133", "CHEMICAL", 93, 109], ["Nobilis IB 4-91", "CHEMICAL", 114, 129], ["Reo S1133", "ORGANISM", 10, 19], ["Infectious Bronchitis virus", "ORGANISM", 25, 52], ["Nobilis REO 1133", "CELL", 93, 109], ["Virus", "ORGANISM", 180, 185], ["allantoic fluid", "ORGANISM_SUBSTANCE", 235, 250], ["NDV", "ORGANISM", 314, 317], ["Infectious Bronchitis virus", "SPECIES", 25, 52], ["Infectious Bronchitis virus (IB K+ 4/91", "SPECIES", 25, 64], ["Nobilis REO 1133", "SPECIES", 93, 109], ["Nobilis IB 4-91", "SPECIES", 114, 129], ["SPF", "SPECIES", 254, 257], ["NDV", "SPECIES", 314, 317], ["Reovirus", "TEST", 0, 8], ["Infectious Bronchitis virus", "PROBLEM", 25, 52], ["IB K", "TEST", 54, 58], ["Nobilis REO", "TEST", 93, 104], ["Nobilis IB", "TEST", 114, 124], ["Virus strains", "PROBLEM", 180, 193], ["RNA extractionRNA", "PROBLEM", 198, 215], ["allantoic fluid", "TEST", 235, 250], ["SPF embryonated eggs", "TREATMENT", 254, 274], ["NDV strains", "PROBLEM", 314, 325], ["an RNeasy Mini Kit", "TREATMENT", 389, 407], ["CA, USA) protocol", "TREATMENT", 427, 444], ["Infectious", "OBSERVATION_MODIFIER", 25, 35], ["Bronchitis", "OBSERVATION", 36, 46], ["Nobilis", "ANATOMY", 93, 100], ["allantoic", "OBSERVATION_MODIFIER", 235, 244], ["fluid", "OBSERVATION_MODIFIER", 245, 250]]], ["Additionally, RNA from oral and cloacal swabs and homogenized tissues was isolated using the same kit.Primer designA set of degenerated primers based on the F0 gene of NDV was used in this study:Primer designNDV-F (position 4826-4842) 5 -CTT GGT GAY TCY ATC CG-3 NDV R (position 4901-4917) 5 -ACA CYG CCD ATA ATG GC-3Primer designwhere Y = C or T; D = A or G or T. The amplified cDNA fragment was 92 base pairs (bp) long and contained the region encoding the F cleavage site.cDNA synthesis and real-time PCRSynthesis of the first strand of cDNA was carried out according to the procedure described for the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany).", [["oral", "ANATOMY", 23, 27], ["cloacal swabs", "ANATOMY", 32, 45], ["tissues", "ANATOMY", 62, 69], ["oral", "ORGANISM_SUBDIVISION", 23, 27], ["cloacal swabs", "ORGANISM_SUBSTANCE", 32, 45], ["tissues", "TISSUE", 62, 69], ["NDV", "ORGANISM", 168, 171], ["Y = C", "GENE_OR_GENE_PRODUCT", 336, 341], ["D = A", "GENE_OR_GENE_PRODUCT", 348, 353], ["G", "GENE_OR_GENE_PRODUCT", 357, 358], ["F0 gene", "DNA", 157, 164], ["Primer designNDV-F (position 4826-4842) 5 -CTT GGT GAY TCY ATC CG-3 NDV R", "DNA", 195, 268], ["position 4901-4917) 5 -ACA CYG CCD ATA ATG GC-3Primer", "DNA", 270, 323], ["amplified cDNA fragment", "DNA", 369, 392], ["92 base pairs", "DNA", 397, 410], ["F cleavage site", "DNA", 459, 474], ["cDNA", "DNA", 540, 544], ["NDV", "SPECIES", 168, 171], ["RNA", "TEST", 14, 17], ["oral and cloacal swabs", "TEST", 23, 45], ["homogenized tissues", "PROBLEM", 50, 69], ["degenerated primers", "PROBLEM", 124, 143], ["NDV", "PROBLEM", 168, 171], ["this study", "TEST", 184, 194], ["CTT GGT GAY", "TEST", 238, 249], ["TCY", "TEST", 250, 253], ["ATC", "TEST", 254, 257], ["CG", "TEST", 258, 260], ["ACA", "TEST", 293, 296], ["ATG", "TEST", 309, 312], ["GC", "TEST", 313, 315], ["3Primer", "TEST", 316, 323], ["The amplified cDNA fragment", "PROBLEM", 365, 392], ["base pairs", "TEST", 400, 410], ["bp", "TEST", 412, 414], ["the first strand of cDNA", "TREATMENT", 520, 544], ["the procedure", "TREATMENT", 574, 587], ["degenerated", "OBSERVATION", 124, 135]]], ["The reaction mixture contained: viral RNA, random hexamer primers and water that was incubated for 10 min at 65 \u2022 C. Subsequently, the reaction buffer, RNase inhibitor, dNTPs, DTT, and reverse transcriptase were added.", [["dNTPs", "CHEMICAL", 169, 174], ["DTT", "CHEMICAL", 176, 179], ["dNTPs", "CHEMICAL", 169, 174], ["DTT", "CHEMICAL", 176, 179], ["RNase", "GENE_OR_GENE_PRODUCT", 152, 157], ["dNTPs", "SIMPLE_CHEMICAL", 169, 174], ["DTT", "SIMPLE_CHEMICAL", 176, 179], ["viral RNA", "RNA", 32, 41], ["RNase", "PROTEIN", 152, 157], ["reverse transcriptase", "PROTEIN", 185, 206], ["The reaction mixture", "PROBLEM", 0, 20], ["viral RNA", "PROBLEM", 32, 41], ["random hexamer primers", "TREATMENT", 43, 65], ["the reaction buffer", "TREATMENT", 131, 150], ["RNase inhibitor", "TREATMENT", 152, 167], ["dNTPs", "TREATMENT", 169, 174], ["DTT", "TREATMENT", 176, 179], ["reverse transcriptase", "TREATMENT", 185, 206], ["viral RNA", "OBSERVATION", 32, 41]]], ["The final mixture contained: 1\u00d7 reaction buffer [250 mM Tris-HCl, 150 mM KCl, 40 mM MgCl 2 ; pH 8.5], 20 U of RNase inhibitor [in: 20 mM Hepes-KOH, 50 mM KCl, 8 mM DTT, 50% glycerol; pH 7.6], 60 M of random hexamer primers, Table 1 Melting-curve analysis of viral strains.", [["Tris-HCl", "CHEMICAL", 56, 64], ["KCl", "CHEMICAL", 73, 76], ["KCl", "CHEMICAL", 154, 157], ["glycerol", "CHEMICAL", 173, 181], ["Tris-HCl", "CHEMICAL", 56, 64], ["KCl", "CHEMICAL", 73, 76], ["MgCl 2", "CHEMICAL", 84, 90], ["Hepes-KOH", "CHEMICAL", 137, 146], ["KCl", "CHEMICAL", 154, 157], ["DTT", "CHEMICAL", 164, 167], ["glycerol", "CHEMICAL", 173, 181], ["Tris-HCl", "SIMPLE_CHEMICAL", 56, 64], ["RNase", "GENE_OR_GENE_PRODUCT", 110, 115], ["glycerol", "SIMPLE_CHEMICAL", 173, 181], ["Tris", "TEST", 56, 60], ["HCl", "TEST", 61, 64], ["KCl", "TEST", 73, 76], ["MgCl", "TEST", 84, 88], ["pH", "TEST", 93, 95], ["RNase inhibitor", "TREATMENT", 110, 125], ["Hepes", "TEST", 137, 142], ["KOH", "TEST", 143, 146], ["KCl", "TEST", 154, 157], ["DTT", "TEST", 164, 167], ["glycerol", "TEST", 173, 181], ["pH", "TEST", 183, 185], ["random hexamer primers", "TREATMENT", 200, 222], ["Table 1 Melting", "TEST", 224, 239], ["curve analysis", "TEST", 240, 254], ["viral strains", "PROBLEM", 258, 271], ["viral strains", "OBSERVATION", 258, 271]]], ["Lineages by Aldous et al. (2003) .cDNA synthesis and real-time PCRAPMV -9 NA ---28cDNA synthesis and real-time PCRCoronavirus 165 1 mM of each dNTPs, 5 mM of DTT, and 10 U of reverse transcriptase (in: 200 mM potassium phosphate, 2 mM DTT, 0.2% Triton X-100, 50% glycerol, pH 7.2).", [["PCRAPMV -9 NA", "CHEMICAL", 63, 76], ["dNTPs", "CHEMICAL", 143, 148], ["DTT", "CHEMICAL", 158, 161], ["potassium phosphate", "CHEMICAL", 209, 228], ["Triton X-100", "CHEMICAL", 245, 257], ["glycerol", "CHEMICAL", 263, 271], ["dNTPs", "CHEMICAL", 143, 148], ["DTT", "CHEMICAL", 158, 161], ["potassium phosphate", "CHEMICAL", 209, 228], ["DTT", "CHEMICAL", 235, 238], ["Triton X-100", "CHEMICAL", 245, 257], ["glycerol", "CHEMICAL", 263, 271], ["DTT", "SIMPLE_CHEMICAL", 158, 161], ["potassium phosphate", "SIMPLE_CHEMICAL", 209, 228], ["DTT", "SIMPLE_CHEMICAL", 235, 238], ["Triton X-100", "SIMPLE_CHEMICAL", 245, 257], ["glycerol", "SIMPLE_CHEMICAL", 263, 271], ["reverse transcriptase", "PROTEIN", 175, 196], ["synthesis", "TEST", 39, 48], ["PCRAPMV", "TEST", 63, 70], ["NA ---28cDNA synthesis", "TEST", 74, 96], ["PCRCoronavirus", "TEST", 111, 125], ["dNTPs", "TEST", 143, 148], ["DTT", "TEST", 158, 161], ["reverse transcriptase", "TREATMENT", 175, 196], ["mM potassium phosphate", "TREATMENT", 206, 228], ["DTT", "TEST", 235, 238], ["pH", "TEST", 273, 275]]], ["SYBR Green I real-time PCR was performed using a LightCycler 2.0 TM (Roche Diagnostics, Mannheim, Germany).", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 0, 12], ["PCR", "TEST", 23, 26], ["a LightCycler", "TEST", 47, 60]]], ["10 l of the final mixture contained 9 l of reaction mixture: 1\u00d7 LC DNA Master SYBR Green I (Roche Diagnostics, Mannheim, Germany), MgCl 2 (4 mM), 0.2 M of each primer, and 1 l of cDNA.", [["cDNA", "DNA", 179, 183]]], ["A negative control lacking cDNA was also prepared.", [["cDNA", "DNA", 27, 31], ["negative", "OBSERVATION", 2, 10]]], ["The samples were initially denatured at 95 \u2022 C for 10 min, followed by 50 cycles of the following: 95 \u2022 C (denaturation) for 10 s, 48 \u2022 C (annealing) for 10 s, and 72 \u2022 C (extension) for 11 s.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["To confirm the specificity of the amplified product, a melting curve analysis step was included.", [["a melting curve analysis step", "TEST", 53, 82]]], ["The internal temperature of the LightCycler was increased rapidly to 95 \u2022 C, then decreased at 0.1 \u2022 C/s to 70 \u2022 C, and then the sample was incubated for 15 s.", [["sample", "ANATOMY", 129, 135], ["the LightCycler", "TEST", 28, 43], ["the sample", "TEST", 125, 135], ["internal", "OBSERVATION_MODIFIER", 4, 12]]], ["The fluorescence at 530 nm was measured continuously.", [["The fluorescence", "TEST", 0, 16]]], ["The melting peaks were generated using LightCycler software by plotting the first negative derivative of the fluorescence over the temperature versus the temperature (\u2212dF/dT).Detection limit, cloning, sequencing and specificity of the assayThe detection limit was determined using the target copy number and virus titer (50% egg infective dose -EID 50 ) as reference units. (i) A fragment (320 bp) of the F gene of the LaSota strain was cloned into pGEM-T easy vector (Promega, Madison, WI, USA).", [["F", "GENE_OR_GENE_PRODUCT", 405, 406], ["LaSota", "GENE_OR_GENE_PRODUCT", 419, 425], ["pGEM-T", "GENE_OR_GENE_PRODUCT", 449, 455], ["F gene", "DNA", 405, 411], ["The melting peaks", "PROBLEM", 0, 17], ["LightCycler software", "TEST", 39, 59], ["the temperature", "TEST", 127, 142], ["the temperature", "TEST", 150, 165], ["the assay", "TEST", 231, 240], ["virus titer", "TREATMENT", 308, 319], ["A fragment", "PROBLEM", 378, 388], ["bp", "TEST", 394, 396], ["the LaSota strain", "TREATMENT", 415, 432], ["fragment", "OBSERVATION", 380, 388]]], ["Plasmid DNA was extracted from the bacteria by using a Plasmid mini Kit (A&A Biotechnology, Gdansk, Poland).", [["Plasmid", "ANATOMY", 0, 7], ["Plasmid DNA", "CELLULAR_COMPONENT", 0, 11], ["Plasmid DNA", "DNA", 0, 11], ["Plasmid DNA", "PROBLEM", 0, 11], ["the bacteria", "PROBLEM", 31, 43], ["DNA", "OBSERVATION", 8, 11], ["bacteria", "OBSERVATION_MODIFIER", 35, 43]]], ["The concentration of the plasmid DNA was determined spectrophotometrically.", [["plasmid", "ANATOMY", 25, 32], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["plasmid DNA", "DNA", 25, 36], ["the plasmid DNA", "TREATMENT", 21, 36], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["plasmid DNA", "OBSERVATION", 25, 36]]], ["The DNA copy number was calculated using the formula described by Ke et al. (2006) .", [["DNA", "CELLULAR_COMPONENT", 4, 7]]], ["The plasmid was serially 10-fold diluted to serve as a standard for determining the sensitivity of the real-time PCR assay. (ii) Serial 10-fold dilutions of the known EID 50 stock solution of lentogenic (LaSota) and velogenic (Italy/2736/00) strains were prepared using sterile dH 2 0.", [["plasmid", "ANATOMY", 4, 11], ["plasmid", "DNA", 4, 11], ["The plasmid", "TREATMENT", 0, 11], ["Serial 10-fold dilutions", "TREATMENT", 129, 153], ["lentogenic (LaSota)", "TREATMENT", 192, 211], ["velogenic", "PROBLEM", 216, 225], ["strains", "PROBLEM", 242, 249]]], ["RNA was extracted and transcribed as described above. cDNA was added to the reaction mixture as a template.Detection limit, cloning, sequencing and specificity of the assayThe SYBR Green I melting peaks analysis assay was compared with the method described by Mia Kim et al. (2008) .Detection limit, cloning, sequencing and specificity of the assayThe sequencing was carried out by Genomed Ltd.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 176, 188], ["RNA", "RNA", 0, 3], ["cDNA", "DNA", 54, 58], ["the reaction mixture", "TREATMENT", 72, 92], ["the assay", "TEST", 163, 172], ["analysis assay", "TEST", 203, 217], ["the assay", "TEST", 339, 348], ["The sequencing", "TEST", 348, 362]]], ["(Warsaw, Poland) using a Roche GS FLX/Titanium sequencer.", [["FLX", "CHEMICAL", 34, 37], ["a Roche GS FLX/Titanium sequencer", "TREATMENT", 23, 56]]], ["MultAlin software (Corpet, 1988) was used to align the sequences to check for homology with reference NDV sequences.Detection limit, cloning, sequencing and specificity of the assayThe specificity of the SYBR Green I real-time PCR assay was investigated using the RNA extracted from NDV strains and 14 other avian viruses shown in Table 1 .Phylogenetic analysisPhylogenetic analysis of members of 6 lineages of Newcastle disease virus (Aldous et al., 2003) was performed utilizing the neighbor-joining method (Saitou and Nei, 1987) in MEGA 4 software.", [["Newcastle disease", "DISEASE", 411, 428], ["NDV", "ORGANISM", 102, 105], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 204, 216], ["NDV", "ORGANISM", 283, 286], ["Newcastle disease virus", "ORGANISM", 411, 434], ["reference NDV sequences", "DNA", 92, 115], ["NDV", "SPECIES", 102, 105], ["NDV", "SPECIES", 283, 286], ["Newcastle disease virus", "SPECIES", 411, 434], ["reference NDV sequences", "TEST", 92, 115], ["the assay", "TEST", 172, 181], ["the SYBR", "TEST", 200, 208], ["PCR assay", "TEST", 227, 236], ["the RNA", "TREATMENT", 260, 267], ["NDV strains", "TREATMENT", 283, 294], ["Phylogenetic analysis", "TEST", 340, 361], ["Phylogenetic analysis", "TEST", 361, 382], ["Newcastle disease virus", "PROBLEM", 411, 434], ["Newcastle disease", "OBSERVATION", 411, 428]]], ["Strains of NDV were derived from GenBank or from the Polish strains sequenced previously.Detection and differentiation of NDV strains by melting peak analysisThe representatives of 4 lineages of NDV strains were tested.", [["NDV", "ORGANISM", 11, 14], ["NDV", "ORGANISM", 122, 125], ["NDV", "ORGANISM", 195, 198], ["NDV", "SPECIES", 11, 14], ["NDV", "SPECIES", 195, 198], ["NDV", "SPECIES", 11, 14], ["NDV", "SPECIES", 122, 125], ["NDV", "SPECIES", 195, 198], ["Strains of NDV", "PROBLEM", 0, 14], ["Detection", "TEST", 89, 98], ["NDV strains", "PROBLEM", 122, 133], ["melting peak analysis", "TEST", 137, 158], ["NDV strains", "PROBLEM", 195, 206], ["NDV", "OBSERVATION", 11, 14], ["NDV strains", "OBSERVATION", 195, 206]]], ["Using the SYBR Green I real-time PCR melting peak analysis, it was possible to detect and differentiate virulent and avirulent strains of Newcastle disease virus.", [["Newcastle disease virus", "DISEASE", 138, 161], ["Newcastle disease virus", "ORGANISM", 138, 161], ["Newcastle disease virus", "SPECIES", 138, 161], ["PCR melting peak analysis", "TEST", 33, 58], ["virulent", "PROBLEM", 104, 112], ["Newcastle disease virus", "PROBLEM", 138, 161], ["Newcastle disease", "OBSERVATION", 138, 155]]], ["Eighteen NDV strains (including ten lentogenic, two mesogenic and six velogenic isolates) were analyzed.", [["strains", "ANATOMY", 13, 20], ["NDV", "ORGANISM", 9, 12], ["NDV", "SPECIES", 9, 12], ["NDV", "SPECIES", 9, 12], ["Eighteen NDV strains", "PROBLEM", 0, 20], ["six velogenic isolates", "TREATMENT", 66, 88]]], ["Melting curve analysis revealed that all 18 strains were divided into two distinct groups (Fig. 1) .", [["Melting curve analysis", "TEST", 0, 22], ["all 18 strains", "PROBLEM", 37, 51]]], ["T m values for lentogenic (avirulent) strains were estimated to be between 80.00 and 83.80 \u2022 C, and the T m values for mesogenic and velogenic (virulent) strains were higher than 83.80 \u2022 C ( Table 1 ).", [["T m", "GENE_OR_GENE_PRODUCT", 0, 3], ["T m", "GENE_OR_GENE_PRODUCT", 104, 107], ["T m values", "TEST", 0, 10], ["lentogenic (avirulent) strains", "PROBLEM", 15, 45], ["the T m values", "TEST", 100, 114], ["mesogenic and velogenic (virulent) strains", "PROBLEM", 119, 161]]], ["The boundary line was calculated as the medium between the highest T m value for avirulent strains and the lowest for virulent strains.", [["T m", "GENE_OR_GENE_PRODUCT", 67, 70], ["The boundary line", "TREATMENT", 0, 17], ["avirulent strains", "PROBLEM", 81, 98], ["virulent strains", "PROBLEM", 118, 134], ["boundary line", "OBSERVATION", 4, 17]]], ["The phylogenetic relationship of the NDV strains used in this study is depicted in Fig. 2.Specificity of real-time PCR assay and detection limitThe specificity of this real-time PCR assay was investigated by analysing 18 NDV strains and 14 samples of other viruses (Table 1) .", [["samples", "ANATOMY", 240, 247], ["NDV", "ORGANISM", 37, 40], ["NDV", "ORGANISM", 221, 224], ["NDV", "SPECIES", 37, 40], ["NDV", "SPECIES", 37, 40], ["NDV", "SPECIES", 221, 224], ["the NDV strains", "PROBLEM", 33, 48], ["this study", "TEST", 57, 67], ["PCR assay", "TEST", 115, 124], ["this real-time PCR assay", "TEST", 163, 187], ["18 NDV strains", "PROBLEM", 218, 232], ["NDV strains", "OBSERVATION", 37, 48]]], ["No amplification products were detected when templates originating from these fourteen unrelated viruses were used, while all templates from NDV strains gave distinctive products.Specificity of real-time PCR assay and detection limitThe detection limit of this assay was assessed by analysing the serial dilutions of a plasmid carrying s 320 bp fragment of the F gene of NDV and the serial dilutions of the known stock of NDV.", [["plasmid", "ANATOMY", 319, 326], ["NDV", "ORGANISM", 141, 144], ["F", "GENE_OR_GENE_PRODUCT", 361, 362], ["NDV", "ORGANISM", 371, 374], ["NDV", "ORGANISM", 422, 425], ["plasmid", "DNA", 319, 326], ["320 bp fragment", "DNA", 338, 353], ["F gene", "DNA", 361, 367], ["NDV", "SPECIES", 141, 144], ["NDV", "SPECIES", 371, 374], ["NDV", "SPECIES", 422, 425], ["amplification products", "TREATMENT", 3, 25], ["these fourteen unrelated viruses", "PROBLEM", 72, 104], ["NDV strains", "PROBLEM", 141, 152], ["distinctive products", "TREATMENT", 158, 178], ["PCR assay", "TEST", 204, 213], ["this assay", "TEST", 256, 266], ["a plasmid carrying s 320 bp fragment", "TREATMENT", 317, 353], ["NDV", "TREATMENT", 371, 374], ["the serial dilutions", "TREATMENT", 379, 399], ["NDV", "PROBLEM", 422, 425], ["viruses", "OBSERVATION", 97, 104], ["NDV", "OBSERVATION", 371, 374], ["NDV", "OBSERVATION", 422, 425]]], ["In the real-time PCR assay, the detection limits were 2 \u00d7 10 2 copies of DNA plasmid per reaction or 10 2 EID 50 concentration range for the velogenic strain (Italy/2736/00) and 10 3 EID 50 for the lentogenic strain (LaSota).", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["DNA plasmid", "DNA", 73, 84], ["DNA plasmid", "TREATMENT", 73, 84], ["the velogenic strain", "PROBLEM", 137, 157], ["the lentogenic strain", "PROBLEM", 194, 215]]], ["Any results with a Ct value higher than 45 were treated as unconvincing and were rejected.", [["a Ct value", "TEST", 17, 27]]], ["The new assay was compared with the method described previously by Mia Kim et al. (2008) -both gave similar results (Table 2A) in oral and cloacal swabs.", [["oral", "ANATOMY", 130, 134], ["cloacal swabs", "ANATOMY", 139, 152], ["oral", "ORGANISM_SUBDIVISION", 130, 134], ["cloacal swabs", "ORGANISM_SUBSTANCE", 139, 152], ["The new assay", "TEST", 0, 13], ["oral and cloacal swabs", "TREATMENT", 130, 152], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["The difference in Ct values resulted from the use of different methods in the assays (TaqMan and SYBR Green I, respectively).", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 97, 109], ["Ct values", "TEST", 18, 27], ["different methods", "TREATMENT", 53, 70], ["the assays", "TEST", 74, 84], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["The new assay detected NDV in three tissue samples while the one described previously detected NDV only in one sample (Table 2B) .Ulster2CQueensland V4/66 (Aldous et al., 2003) .", [["tissue samples", "ANATOMY", 36, 50], ["NDV", "ORGANISM", 23, 26], ["tissue samples", "CANCER", 36, 50], ["NDV", "ORGANISM", 95, 98], ["NDV", "SPECIES", 23, 26], ["NDV", "SPECIES", 95, 98], ["The new assay", "TEST", 0, 13], ["NDV", "PROBLEM", 23, 26], ["NDV", "PROBLEM", 95, 98], ["new", "OBSERVATION_MODIFIER", 4, 7], ["NDV", "OBSERVATION", 23, 26], ["three tissue", "OBSERVATION_MODIFIER", 30, 42], ["NDV", "OBSERVATION", 95, 98]]], ["The Phylogenetic tree was generated using the neighbor-joining method (Saitou and Nei, 1987) .", [["Phylogenetic tree", "OBSERVATION", 4, 21]]], ["Ulster 2C (Table 1) ; Queensland V4/66 (M24693); Roakin (AY289000); Beaudette C/45 (M24697); B1/47 (M24695); 117/90 (Table 1) ; 18/91 (Table 1) ; 111/90 (Table 1) ; 299/92 (Table 1) ; 548/04 (Table 1) ; 549/04 (Table 1) ; 89/90 (Table 1) ; Radom (Table 1) ; BSDCK72176 (AY135752); POK/70 (Y19014); BBGCK68168 (AY175669); BHKPI89165 (AY175672); Herts/33 (M24702); TEXAS (M33855); Mukteswar (AY175676); Miyadera/51 (M24701); Australia/32 (M21881); AR5 (Table 1) ; AR8 (Table 1) ; AR3 (Table 1) ; AR2 (Table 1) ; AR7 (Table 1) ; AR4 (Table 1) ; Italy (Table 1) ; GB1168/84 (AF109885); CH1/95 (AF001132); Kuwait (AF001109); Lebanon/70 (AF139160); Warwick/66 (U52457); BSACK95121 (AY175694); BBECK97037 (AY135741); QGB506/97 (AF109887); Fi1001/96 (AF091623); QGB445/97 (AF109886); CZ3898/96 (AF109883); TW156/99 (AF234031); HFRDK77188 (AY135758).Table 2A comparison of the sensitivity of SYBR Green I real-time PCR melting peaks analysis assay (SYBR MPA) with the previously published system by Mia Kim et al. (2008) .", [["BBGCK68168", "CHEMICAL", 298, 308], ["BHKPI89165", "CHEMICAL", 321, 331], ["BSACK95121", "CHEMICAL", 664, 674], ["BBECK97037", "CHEMICAL", 687, 697], ["Fi1001/96", "CHEMICAL", 732, 741], ["QGB445/97", "CHEMICAL", 754, 763], ["AF109886", "CHEMICAL", 765, 773], ["CZ3898/96", "CHEMICAL", 776, 785], ["AF109883", "CHEMICAL", 787, 795], ["TW156/99", "CHEMICAL", 798, 806], ["HFRDK77188", "CHEMICAL", 819, 829], ["AY135758", "CHEMICAL", 831, 839], ["BBGCK68168", "CHEMICAL", 298, 308], ["BHKPI89165", "CHEMICAL", 321, 331], ["CZ3898/96", "CHEMICAL", 776, 785], ["AF109883", "CHEMICAL", 787, 795], ["TW156/99", "CHEMICAL", 798, 806], ["AF234031", "CHEMICAL", 808, 816], ["HFRDK77188", "CHEMICAL", 819, 829], ["AY135758", "CHEMICAL", 831, 839], ["HFRDK77188", "SIMPLE_CHEMICAL", 819, 829], ["AY135758", "DNA", 831, 839], ["Ulster", "TEST", 0, 6], ["B1", "TEST", 93, 95], ["BHKPI89165", "TEST", 321, 331], ["Herts", "TEST", 344, 349], ["Mukteswar", "TEST", 379, 388], ["Miyadera/", "TEST", 401, 410], ["Australia/", "TEST", 423, 433], ["CZ3898/96", "TEST", 776, 785], ["the sensitivity", "TEST", 864, 879], ["PCR melting", "TEST", 906, 917], ["analysis assay", "TEST", 924, 938]]], ["(A) Three chickens were infected with a lentogenic strain (LaSota) with a dose of 10 7,5 EID50 of the virus.", [["chickens", "ORGANISM", 10, 18], ["chickens", "SPECIES", 10, 18], ["chickens", "SPECIES", 10, 18], ["a lentogenic strain (LaSota)", "TREATMENT", 38, 66], ["the virus", "PROBLEM", 98, 107]]], ["Oral (O) and cloacal (C) swabs were collected 3 and 5 days post infection (dpi).", [["Oral", "ANATOMY", 0, 4], ["cloacal", "ANATOMY", 13, 20], ["swabs", "ANATOMY", 25, 30], ["infection", "DISEASE", 64, 73], ["Oral (O)", "TREATMENT", 0, 8], ["cloacal (C) swabs", "TREATMENT", 13, 30], ["infection", "PROBLEM", 64, 73], ["infection", "OBSERVATION", 64, 73]]], ["(B) One chicken was killed 5 days post infection, and tissues were prepared.", [["tissues", "ANATOMY", 54, 61], ["infection", "DISEASE", 39, 48], ["chicken", "ORGANISM", 8, 15], ["tissues", "TISSUE", 54, 61], ["chicken", "SPECIES", 8, 15], ["chicken", "SPECIES", 8, 15], ["infection", "PROBLEM", 39, 48], ["infection", "OBSERVATION", 39, 48]]], ["RNA was extracted as described above from a homogenate of tissues.DiscussionIn this study, a method for the rapid detection and differentiation of Newcastle disease virus by SYBR Green I melting-curve analysis was described.", [["homogenate", "ANATOMY", 44, 54], ["tissues", "ANATOMY", 58, 65], ["Newcastle disease", "DISEASE", 147, 164], ["tissues", "TISSUE", 58, 65], ["Newcastle disease virus", "ORGANISM", 147, 170], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 174, 186], ["RNA", "RNA", 0, 3], ["Newcastle disease virus", "SPECIES", 147, 170], ["this study", "TEST", 79, 89], ["the rapid detection", "TEST", 104, 123], ["Newcastle disease virus", "PROBLEM", 147, 170], ["curve analysis", "TEST", 195, 209], ["tissues", "ANATOMY", 58, 65]]], ["F gene-specific, degenerated primers were used in the assay.", [["F", "GENE_OR_GENE_PRODUCT", 0, 1], ["F gene", "DNA", 0, 6], ["degenerated primers", "PROBLEM", 17, 36]]], ["The use of degenerated primers made it possible to avoid the previously reported difficulties in the design of primers (Aldous and Alexander, 2001 ) and, additionally, it allowed for the use of only one set of primers for the differentiation of virulent and avirulent strains of Newcastle disease virus.", [["Newcastle disease virus", "DISEASE", 279, 302], ["Newcastle disease virus", "ORGANISM", 279, 302], ["Newcastle disease virus", "SPECIES", 279, 302], ["degenerated primers", "PROBLEM", 11, 30], ["primers", "TREATMENT", 210, 217], ["virulent", "PROBLEM", 245, 253], ["Newcastle disease virus", "PROBLEM", 279, 302], ["Newcastle disease", "OBSERVATION", 279, 296]]], ["This is the first assay based on SYBR Green I that uses degenerated primers to detect virulent and avirulent strains of NDV in one tube reaction with high resolution.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 33, 45], ["NDV", "ORGANISM", 120, 123], ["tube", "TISSUE", 131, 135], ["SYBR Green I", "PROTEIN", 33, 45], ["NDV", "SPECIES", 120, 123], ["degenerated primers", "PROBLEM", 56, 75], ["virulent and avirulent strains of NDV", "PROBLEM", 86, 123], ["one tube reaction", "PROBLEM", 127, 144], ["high resolution", "OBSERVATION_MODIFIER", 150, 165]]], ["The correlations between virulent (ICPI > 0.7) and non-virulent (ICPI < 0.7) strains and melting temperature values are shown in Table 1 .", [["ICPI", "TEST", 35, 39], ["ICPI", "TEST", 65, 69], ["strains", "PROBLEM", 77, 84], ["melting temperature values", "TEST", 89, 115], ["virulent", "OBSERVATION_MODIFIER", 25, 33]]], ["The distinction between lentogenic and mesogenic (3.26 \u2022 C) or lentogenic and velogenic (5.15 \u2022 C) NDV strains was more simple than previously described by Pham et al. (2005) , which yielded values of 1.22 \u2022 C and 2.15 \u2022 C, respectively.", [["NDV", "ORGANISM", 99, 102], ["NDV", "SPECIES", 99, 102], ["lentogenic", "TEST", 24, 34], ["mesogenic", "TEST", 39, 48], ["lentogenic", "TEST", 63, 73], ["velogenic", "TEST", 78, 87], ["C) NDV strains", "PROBLEM", 96, 110], ["values", "TEST", 191, 197], ["C", "TEST", 208, 209], ["mesogenic", "OBSERVATION_MODIFIER", 39, 48], ["velogenic", "OBSERVATION_MODIFIER", 78, 87]]], ["Additionally, such a high difference in melting temperature values makes it possible to calculate a safe boundary line (83.80 \u2022 C) for differentiation of NDV strains.", [["NDV", "ORGANISM", 154, 157], ["NDV", "SPECIES", 154, 157], ["a high difference in melting temperature values", "PROBLEM", 19, 66], ["a safe boundary line", "TREATMENT", 98, 118], ["NDV strains", "PROBLEM", 154, 165]]], ["This in turn allows for a straightforward method to monitor and classify virulent and avirulent strains of NDV in agreement with European Union directive (CEC, 1992) , which calls for the full control of isolates with an intercerebral pathogenicity index (ICPI) greater than 0.7.DiscussionThe sensitivity of the method described in this report is similar to the method described by Mia Kim et al. (2008) and Wise et al. (2004) and by Pham et al. (2005) .", [["NDV", "DISEASE", 107, 110], ["NDV", "ORGANISM", 107, 110], ["NDV", "SPECIES", 107, 110], ["NDV", "SPECIES", 107, 110], ["a straightforward method", "TREATMENT", 24, 48], ["virulent", "PROBLEM", 73, 81], ["an intercerebral pathogenicity index", "TEST", 218, 254], ["ICPI", "TEST", 256, 260]]], ["Differences in Ct values are cause by differences across methods.", [["Ct values", "TEST", 15, 24]]], ["In real-time PCR using the TaqMan method (Mia Kim et al., 2008) , probes are released and degraded during each cycle and fluorescence increases cumulatively during the reaction.", [["the TaqMan method", "TEST", 23, 40], ["the reaction", "PROBLEM", 164, 176]]], ["When the SYBR Green I method is used fluorescence increases proportionally.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 9, 21]]], ["That explains why higher Ct values were obtained while using this method.", [["higher Ct values", "TEST", 18, 34], ["this method", "TREATMENT", 61, 72]]], ["The advantages of using this SYBR Green I method are that its operation costs are lower in comparison to either methods using TaqMan, and it is possible to perform the reaction in a single tube.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 29, 41], ["tube", "TISSUE", 189, 193], ["this SYBR Green I method", "TREATMENT", 24, 48], ["its operation costs", "TREATMENT", 58, 77], ["TaqMan", "TEST", 126, 132], ["the reaction", "PROBLEM", 164, 176], ["a single tube", "TREATMENT", 180, 193], ["lower", "OBSERVATION_MODIFIER", 82, 87], ["tube", "OBSERVATION", 189, 193]]], ["The previous methods employed two or three pairs of primers (Wise et al., 2004) , and their products for lentogenic and velogenic strains (Farkas et al., 2009) , in some cases, were different in length, which excludes the possibility of using the real-time PCR SYBR Green I assay.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 261, 273], ["lentogenic and velogenic strains", "PROBLEM", 105, 137], ["different", "OBSERVATION_MODIFIER", 182, 191]]]], "503fd489285f808a975524f3900a2452a3773e86": [["labor market, shifting from a manufacturing orientation toward domination by financial and service industries in the city center (Fainstein et al. 1992) .", [["labor market", "PROBLEM", 0, 12]]], ["As global cities have become the sites of production and coordination (Sassen 1991) , their spatial patterns have also been transformed and are now characterized by more division, inequality, polarization, and fragmentation (Sassen 2014; Scott 2019) .", [["fragmentation", "PROBLEM", 210, 223], ["polarization", "OBSERVATION_MODIFIER", 192, 204], ["fragmentation", "OBSERVATION_MODIFIER", 210, 223]]], ["This move has been followed by real estate developers building multi-functional condominiums in city centers, targeting single women, high-income couples, urban elites, and the creative classes (Florida 2002; Kern 2010; Koizumi et al. 2011; Kubo and Yui 2011a; Scott 2019) .", [["women", "ORGANISM", 127, 132], ["women", "SPECIES", 127, 132]]]], "acf0093fa2af8c2b455d0fcb121c1cabb3ecf085": [["IntroductionThe pharmaceutical industry is rapidly approaching a crisis situation.", [["pharmaceutical industry", "OBSERVATION", 16, 39]]], ["Epidemics, such as AIDS, increasing rates of cancer, the threat of biological warfare agents, and an increasing elderly population, mean that the demand for useful therapeutic drugs is greater than ever.", [["cancer", "ANATOMY", 45, 51], ["AIDS", "DISEASE", 19, 23], ["cancer", "DISEASE", 45, 51], ["cancer", "CANCER", 45, 51], ["Epidemics", "PROBLEM", 0, 9], ["AIDS", "PROBLEM", 19, 23], ["increasing rates of cancer", "PROBLEM", 25, 51], ["biological warfare agents", "TREATMENT", 67, 92], ["an increasing elderly population", "PROBLEM", 98, 130], ["useful therapeutic drugs", "TREATMENT", 157, 181], ["cancer", "OBSERVATION", 45, 51]]], ["At the same time, pressure is increasing to reduce costs in the face of the daunting challenge of discovering and developing therapeutic agents.", [["therapeutic agents", "TREATMENT", 125, 143], ["pressure", "OBSERVATION_MODIFIER", 18, 26], ["increasing", "OBSERVATION_MODIFIER", 30, 40]]], ["Approximately 50% of drugs in development fail due to safety issues and 25% fail due to efficacy issues.", [["drugs", "TREATMENT", 21, 26], ["safety issues", "PROBLEM", 54, 67], ["efficacy issues", "PROBLEM", 88, 103]]], ["Most researchers estimate that the process of developing a new drug from early screening to drug store shelves costs $600 to $900 million and takes 8 to 15 years.IntroductionIn this chapter, a screen refers to a biochemical test (or assay) to see if small molecules bind to a target.", [["a screen", "TEST", 191, 199], ["a biochemical test", "TEST", 210, 228], ["small molecules bind", "PROBLEM", 250, 270]]], ["There is a hierarchy of results: human clinical trials are the ultimate answer, which are approximated with animal testing, animal testing is approximated with in vitro testing (cell cultures, enzyme studies), and any of the above can be approximated in silico by the use of predictive models (a virtual screen).IntroductionAlthough the greatest expenses in drug discovery and development are incurred in the clinical trials phases, this chapter focuses on the early screening stage, before the first human dose.", [["cell", "ANATOMY", 178, 182], ["human", "ORGANISM", 33, 38], ["cell cultures", "CELL", 178, 191], ["human", "ORGANISM", 501, 506], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 501, 506], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 501, 506], ["animal testing", "TEST", 108, 122], ["animal testing", "TEST", 124, 138], ["vitro testing", "TEST", 163, 176], ["cell cultures", "TEST", 178, 191], ["enzyme studies", "TEST", 193, 207], ["predictive models", "TEST", 275, 292], ["a virtual screen", "TEST", 294, 310], ["the first human dose", "TREATMENT", 491, 511], ["greatest", "OBSERVATION_MODIFIER", 337, 345]]], ["Well-planned studies at this stage have great potential to reduce expenses at later stages of the process.", [["planned studies", "TEST", 5, 20]]], ["If it were possible to weed out the toxic molecules prior to the clinical trials phase, fully 40% of the expenses incurred in clinical trials would be eliminated!", [["the toxic molecules", "PROBLEM", 32, 51], ["the clinical trials phase", "TEST", 61, 86]]], ["Even a small dent in this expensive process would result in enormous savings.", [["a small dent in this expensive process", "PROBLEM", 5, 43], ["small", "OBSERVATION_MODIFIER", 7, 12], ["enormous", "OBSERVATION_MODIFIER", 60, 68], ["savings", "OBSERVATION", 69, 76]]], ["If this could be done through virtual screens using predictive models, then additional savings would be achieved through less animal toxicity testing and this would also reduce the overall drug development time.IntroductionDrug discovery is a multidisciplinary endeavor with critical work at the interface of biology, chemistry, computer science, and informatics.", [["toxicity", "DISEASE", 133, 141], ["virtual screens", "TEST", 30, 45], ["predictive models", "TEST", 52, 69], ["additional savings", "TREATMENT", 76, 94], ["animal toxicity testing", "TEST", 126, 149]]], ["In biology, a major activity is to make the linkages between what can be assayed and a disease response, but activities also include design and validation of animal models, cell cultures, biochemical screen design, and assay variability studies.", [["cell cultures", "ANATOMY", 173, 186], ["cell cultures", "CELL", 173, 186], ["cell cultures", "CELL_LINE", 173, 186], ["a disease response", "PROBLEM", 85, 103], ["animal models", "TEST", 158, 171], ["cell cultures", "TEST", 173, 186], ["biochemical screen design", "TEST", 188, 213], ["assay variability studies", "TEST", 219, 244]]], ["Another important area in biology, the pace of which has especially intensified in the last decade, is the assessment in vivo of the extent of absorption into the blood stream, distribution and binding to tissues, and the rates of metabolism and excretion.", [["blood", "ANATOMY", 163, 168], ["tissues", "ANATOMY", 205, 212], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["tissues", "TISSUE", 205, 212], ["the assessment", "TEST", 103, 117], ["absorption into the blood stream", "PROBLEM", 143, 175], ["important", "OBSERVATION_MODIFIER", 8, 17], ["area", "OBSERVATION_MODIFIER", 18, 22], ["intensified", "OBSERVATION_MODIFIER", 68, 79], ["absorption", "OBSERVATION", 143, 153], ["blood", "ANATOMY", 163, 168], ["stream", "ANATOMY_MODIFIER", 169, 175]]], ["In chemistry, the major responsibility is to provide the creative spark to navigate effectively the large space of possible compounds (another word for molecules) towards the blockbuster drug.", [["the blockbuster drug", "TREATMENT", 171, 191], ["large", "OBSERVATION_MODIFIER", 100, 105]]], ["Other activities include synthesis of new molecules, analytical characterization of existing molecules (including purity of batches, pKa, logP, melting point, and solubility) and construction of libraries.", [["synthesis of new molecules", "TREATMENT", 25, 51], ["analytical characterization", "TEST", 53, 80], ["purity of batches", "TREATMENT", 114, 131], ["pKa", "TREATMENT", 133, 136], ["construction of libraries", "TREATMENT", 179, 204]]], ["Important issues in computer science include data storage and extraction, implementation and scale-up of algorithms, management of biological and chemical databases, and software support.", [["extraction", "TREATMENT", 62, 72], ["algorithms", "TREATMENT", 105, 115], ["management", "TREATMENT", 117, 127], ["software support", "TREATMENT", 170, 186]]], ["Activities in informatics or chemoinformatics (Leach, 2003) include design of experiments, development of new chemical descriptors, simulation, statistical analysis, mathematical modeling, molecular modeling, and the development of machine learning algorithms.IntroductionThe successful development of a new drug depends on a number of criteria.", [["new chemical descriptors", "PROBLEM", 106, 130], ["statistical analysis", "TEST", 144, 164], ["mathematical modeling, molecular modeling", "PROBLEM", 166, 207], ["new", "OBSERVATION_MODIFIER", 304, 307]]], ["Most importantly, the drug should show a substantial beneficial effect in the treatment of a particular disease (efficacy).", [["a particular disease", "PROBLEM", 91, 111]]], ["This implies that, in addition to intrinsic activity, the drug is able to reach its target (a biological gateway that is linked to a disease state-a large organic molecule that may be a receptor, a protein, or an enzyme) and does not produce overwhelming toxic effects.", [["enzyme", "PROTEIN", 213, 219], ["a disease state", "PROBLEM", 131, 146], ["a large organic molecule", "PROBLEM", 147, 171], ["an enzyme", "TEST", 210, 219], ["overwhelming toxic effects", "PROBLEM", 242, 268]]], ["Many active drugs fail in later phases of the development process because they do not reach their intended target.IntroductionThe main challenges in drug discovery fall into four categories:Introduction1.", [["Many active drugs", "TREATMENT", 0, 17], ["active", "OBSERVATION_MODIFIER", 5, 11], ["drugs", "OBSERVATION", 12, 17], ["main", "OBSERVATION_MODIFIER", 130, 134]]], ["Selectivity: the drug should produce only the desired activity and not cause side effects.", [["side effects", "PROBLEM", 77, 89]]], ["There are so many possible targets in the body that achieving high selectivity is difficult.", [["body", "ANATOMY", 42, 46], ["body", "ORGANISM_SUBDIVISION", 42, 46], ["high selectivity", "OBSERVATION", 62, 78]]], ["Side effects may be caused by metabolites of the drug, by-products produced when the body uses enzymes to break down the drug in the elimination process (Section 11.1).", [["body", "ANATOMY", 85, 89], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["enzymes", "PROTEIN", 95, 102], ["Side effects", "PROBLEM", 0, 12], ["enzymes", "TEST", 95, 102]]], ["ADME and pharmacokinetics (or PK ): the drug must reach the site of action.", [["ADME", "CHEMICAL", 0, 4], ["the drug", "TREATMENT", 36, 44]]], ["If taken orally, it must be water soluble, survive the stomach, be absorbed through the intestine, survive attack by many enzymes, and be transported into the target cells across the cell membrane.", [["stomach", "ANATOMY", 55, 62], ["intestine", "ANATOMY", 88, 97], ["cells", "ANATOMY", 166, 171], ["cell membrane", "ANATOMY", 183, 196], ["stomach", "ORGAN", 55, 62], ["intestine", "ORGAN", 88, 97], ["cells", "CELL", 166, 171], ["cell membrane", "CELLULAR_COMPONENT", 183, 196], ["enzymes", "PROTEIN", 122, 129], ["target cells", "CELL_TYPE", 159, 171], ["many enzymes", "TEST", 117, 129], ["stomach", "ANATOMY", 55, 62], ["intestine", "ANATOMY", 88, 97], ["cell membrane", "OBSERVATION", 183, 196]]], ["It must not be metabolised too quickly, but also must not be so stable or protein bound that it accumulates in the body.", [["body", "ANATOMY", 115, 119], ["body", "ORGANISM_SUBDIVISION", 115, 119], ["protein bound", "PROBLEM", 74, 87], ["body", "ANATOMY", 115, 119]]], ["Another important factor to control is whether a compound crosses the blood-brain barrier (or BBB).", [["blood-brain barrier", "ANATOMY", 70, 89], ["BBB", "ANATOMY", 94, 97], ["blood-", "MULTI-TISSUE_STRUCTURE", 70, 76], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 76, 89], ["BBB", "MULTI-TISSUE_STRUCTURE", 94, 97], ["brain", "ANATOMY", 76, 81]]], ["Toxicity: there are many mechanisms by which a compound can be toxic.IntroductionToxicity issues may arise from PK or ADME or selectivity issues, depending on the mechanism.", [["Toxicity", "DISEASE", 0, 8], ["Toxicity", "DISEASE", 81, 89], ["PK", "GENE_OR_GENE_PRODUCT", 112, 114], ["IntroductionToxicity issues", "PROBLEM", 69, 96], ["toxic", "OBSERVATION_MODIFIER", 63, 68]]], ["Alternatively a compound may simply react harmfully with tissues or organs in a direct manner.IntroductionOne may think of an iterative model for the preclinical discovery screening cycle.", [["tissues", "ANATOMY", 57, 64], ["organs", "ANATOMY", 68, 74], ["tissues", "TISSUE", 57, 64], ["organs", "ORGAN", 68, 74]]], ["A large number of compounds are to be mined for compounds that are active; for example, that bind to a particular target.", [["A large number of compounds", "PROBLEM", 0, 27], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["compounds", "OBSERVATION", 18, 27], ["active", "OBSERVATION_MODIFIER", 67, 73]]], ["In fact, the compounds need only to exist in a virtual sense, because in silico predictions in the form of a model can be made in a virtual screen (Section 8) which can then be used to decide which compounds should be physically made and tested.", [["a virtual screen", "TEST", 130, 146]]], ["A mapping from the structure space of compounds to the descriptor space or property space provides covariates or explanatory variables that can be used to build predictive models.", [["A mapping", "TEST", 0, 9], ["property space", "OBSERVATION", 75, 89]]], ["These models can help in the selection process, where a subset of available molecules is chosen for the biological screen.", [["the biological screen", "TEST", 100, 121]]], ["The experimental results of the biological screen (actives and inactives, or numeric potency values) are then used to learn more about the structure-activity relationship (SAR) which leads to new models and a new selection of compounds as the cycle renews.IntroductionThe relationship between the biological responses and the changes in chemical structural motifs is called SAR or QSAR (quantitative structure-activity relationship).", [["the biological screen", "TEST", 28, 49], ["inactives", "TEST", 63, 72], ["numeric potency values", "TEST", 77, 99], ["the changes in chemical structural motifs", "PROBLEM", 322, 363]]], ["Small changes to the chemical structure can often produce dramatic changes in the biological response; when this happens, chemists and biologists will often describe the SAR as nonlinear, by which they mean that the SAR has a \"sensitive\" or \"rough\" or \"unstable\" response surface.", [["surface", "ANATOMY", 272, 279], ["surface", "CELLULAR_COMPONENT", 272, 279], ["Small changes to the chemical structure", "PROBLEM", 0, 39], ["dramatic changes", "PROBLEM", 58, 74], ["chemical structure", "OBSERVATION", 21, 39], ["dramatic", "OBSERVATION_MODIFIER", 58, 66]]], ["Often the chemical compounds are considered to be the experimental unit even though, in actual experiments, an animal or cell culture is the unit and the compound is a treatment.", [["cell", "ANATOMY", 121, 125], ["cell", "CELL", 121, 125], ["cell culture", "TEST", 121, 133], ["a treatment", "TREATMENT", 166, 177]]], ["The vast size of the set of potential experimental units (potential compounds), coupled with the high dimensionality of the response being optimized (potency, selectivity, toxicity, and ADME) and the \"roughness\" of the response landscape make drug discovery a challenging arena.", [["toxicity", "DISEASE", 172, 180], ["toxicity", "PROBLEM", 172, 180], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["size", "OBSERVATION_MODIFIER", 9, 13], ["experimental units", "OBSERVATION_MODIFIER", 38, 56]]], ["The level of noise in biological data can be extremely high as well.IntroductionThis chapter covers a selection of problems and case study examples.", [["biological data", "TEST", 22, 37], ["case study", "TEST", 128, 138], ["high", "OBSERVATION", 55, 59]]], ["The chapter covers both design and analysis issues, and touches on topics such as simulation, computer experiments, and pooling.", [["analysis issues", "TEST", 35, 50]]], ["In Section 3 the issue of false negatives and false positives in drug screening is addressed.", [["false negatives", "PROBLEM", 26, 41], ["false positives", "PROBLEM", 46, 61], ["drug screening", "TEST", 65, 79], ["false positives", "OBSERVATION", 46, 61]]], ["Molecular diversity is discussed in Section 4, and machine learning is the topic of Section 6.", [["diversity", "OBSERVATION", 10, 19]]], ["Section 7 describes a lower-throughput iterative approach to screening and virtual screening in drug discovery projects in an iterative Active Learning strategy.", [["screening", "TEST", 61, 70], ["virtual screening", "TEST", 75, 92]]], ["A brief mention of pooling strategies is made in Section 9 and Section 10 discusses expectations for rare events.", [["pooling strategies", "TREATMENT", 19, 37], ["rare events", "PROBLEM", 101, 112]]], ["Section 11 describes aspects of a molecule that determine its ability to be safely transported to the area of the body where it can be of therapeutic benefit.", [["body", "ANATOMY", 114, 118], ["body", "ORGANISM_SUBDIVISION", 114, 118], ["a molecule", "PROBLEM", 32, 42], ["body", "ANATOMY", 114, 118]]], ["Finally, in Section 12 the problem of multicriteria decision making in drug discovery is addressed.Introduction2 Overview of Drug DesignProcess OverviewThe entire process of drug discovery and development can be depicted as a rocketship with stages, an image that portrays the \"funneling\" effect as fewer compounds are under consideration at successive stages of the process.", [["an image", "TEST", 250, 258], ["drug discovery", "OBSERVATION", 174, 188]]], ["The chemical entity (compound) may be a small molecule, a peptide, or a large protein.", [["a small molecule, a peptide", "PROBLEM", 38, 65], ["a large protein", "PROBLEM", 70, 85], ["small molecule", "OBSERVATION", 40, 54], ["large", "OBSERVATION_MODIFIER", 72, 77], ["protein", "OBSERVATION", 78, 85]]], ["The number of molecules tested is dependent on reagent costs and other practical factors.", [["molecules tested", "OBSERVATION", 14, 30]]], ["A target is validated to establish a direct link (such as a gene or a process in the body, or a virus or a parasite) to the disease state of interest and the feasibility of controlling the target to obtain the desired therapeutic benefit.", [["body", "ANATOMY", 85, 89], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["a process in the body", "PROBLEM", 68, 89], ["a virus", "PROBLEM", 94, 101]]], ["This stage involves scientific study that can be catalyzed by genomic and proteomic technologies.", [["scientific study", "TEST", 20, 36]]], ["Target validation requires careful scientific experiments designed to explore how a target influences a biological response or disease state.", [["disease state", "PROBLEM", 127, 140]]], ["This may involve whole cells, enzymes, or other in vitro targets.", [["whole cells", "ANATOMY", 17, 28], ["cells", "CELL", 23, 28], ["enzymes", "PROTEIN", 30, 37], ["whole cells", "PROBLEM", 17, 28], ["enzymes", "TEST", 30, 37]]], ["Reducing variability is crucial.", [["variability", "OBSERVATION_MODIFIER", 9, 20], ["crucial", "OBSERVATION_MODIFIER", 24, 31]]], ["Sittampalam et al. (1997) introduced the concept of signal window, a method whereby two controls are used to diagnose the ability of the assay to distinguish between actives and inactives in the presence of background noise.", [["a method", "TREATMENT", 67, 75], ["the assay", "TEST", 133, 142], ["background noise", "PROBLEM", 207, 223]]], ["The most promising compounds, or actives, typically numbering from 1000Process Overviewto 5000, are then tested in a secondary screen which involves testing each compound at 5 to 10 different concentrations.", [["a secondary screen", "TEST", 115, 133]]], ["These results are modeled with a nonlinear dose-response curve and for each molecule a summary measure is computed such as a 50% inhibitory concentration (IC50) or a 50% efficacious concentration (EC50).", [["a nonlinear dose-response curve", "TEST", 31, 62]]], ["The secondary assay reduces the set of actives to those for which potency reaches at least 50% of the maximum potency of a reference compound, at some concentration.", [["The secondary assay", "TEST", 0, 19]]], ["(In subsequent sections the distinction between active and hit is blurred.) 5.", [["sections", "ANATOMY", 15, 23], ["blurred", "PROBLEM", 66, 73], ["active", "OBSERVATION_MODIFIER", 48, 54]]], ["The hits are examined in a series of careful studies in an effort often called hit to lead.", [["careful studies", "TEST", 37, 52]]], ["Out of these SARs, the chemists and biologists choose a few hundred compounds to be tested in cell-based or enzyme in vitro screens.", [["cell", "ANATOMY", 94, 98], ["cell", "CELL", 94, 98], ["enzyme in vitro screens", "TEST", 108, 131]]], ["These screens require careful design and validation.", [["These screens", "TEST", 0, 13], ["validation", "TEST", 41, 51]]], ["From the molecules run through the in vitro testing, 100 or so may go through in vivo single-dose tests using a rodent or some other animal model.", [["the in vitro testing", "TEST", 31, 51]]], ["The lead compounds undergo careful studies in an effort known as lead optimization.", [["careful studies", "TEST", 27, 42], ["lead optimization", "TREATMENT", 65, 82]]], ["At this point any remaining issues with metabolism, absorption, toxicity, and so on, are addressed through molecular modification.Process OverviewSome research groups contend that the HTS step should be eliminated and replaced with a number of rounds of iterative medium-throughput screening (Section 7).", [["toxicity", "DISEASE", 64, 72], ["toxicity", "PROBLEM", 64, 72], ["iterative medium", "TREATMENT", 254, 270]]], ["The lower-throughput screens tend to have lower variability (\"noise\") and less dependence on the single concentration test as an initial triage.", [["The lower-throughput screens", "TEST", 0, 28], ["lower variability (\"noise\"", "PROBLEM", 42, 68], ["the single concentration test", "TEST", 93, 122], ["an initial triage", "TEST", 126, 143], ["lower", "ANATOMY_MODIFIER", 4, 9], ["lower variability", "OBSERVATION_MODIFIER", 42, 59], ["less", "OBSERVATION_MODIFIER", 74, 78], ["dependence", "OBSERVATION_MODIFIER", 79, 89]]], ["The iterative approach is closely akin to a strategy in machine learning (Section 6) known as Active Learning.Process OverviewIn a successful project, the steps outlined above will lead to a First Human Dose (FHD) clinical trial.", [["Human", "ORGANISM", 197, 202], ["Human", "SPECIES", 197, 202], ["a First Human Dose (FHD) clinical trial", "TREATMENT", 189, 228], ["closely akin", "OBSERVATION_MODIFIER", 26, 38], ["Active", "OBSERVATION_MODIFIER", 94, 100]]], ["How well those prior steps are done will, in part, determine the success or failure of the human clinical trials.", [["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96]]], ["The adoption of high-throughput screening and combinatorial chemistry methods in the early 1990s offered promise that a shotgun approach to drug discovery would be possible.", [["throughput screening", "TEST", 21, 41], ["combinatorial chemistry methods", "TEST", 46, 77], ["a shotgun approach", "TREATMENT", 118, 136]]], ["The number of potential chemical entities is staggering, being estimated to be between 10 20 and 10 60 .", [["potential", "OBSERVATION_MODIFIER", 14, 23], ["chemical entities", "OBSERVATION", 24, 41], ["staggering", "OBSERVATION_MODIFIER", 45, 55]]], ["The efficient exploration of a landscape of this magnitude requires prudent use of machinery, human expertise, informatics, and, even then, an element of fortuity.", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["efficient", "OBSERVATION_MODIFIER", 4, 13], ["exploration", "OBSERVATION", 14, 25]]], ["On average, for every 5000 compounds that enter a hit-to-lead phase, only five will continue on to clinical trials in humans, and only one will be approved for marketing.", [["humans", "ORGANISM", 118, 124], ["humans", "SPECIES", 118, 124], ["humans", "SPECIES", 118, 124]]], ["It is analogous to searching for a small needle in a whole field of haystacks.", [["haystacks", "CANCER", 68, 77], ["a small needle", "TREATMENT", 33, 47], ["small", "OBSERVATION_MODIFIER", 35, 40], ["needle", "OBSERVATION", 41, 47]]], ["In these terms, the future of drug design lies in no longer searching for the needle but, instead, constructing the needle using available clues.False Negatives and False PositivesIn primary screening, compounds are tested at a single concentration; those whose response exceeds a prespecified threshold are labeled as \"active\" and the rest as \"inactive\".", [["the needle", "TREATMENT", 74, 84], ["False Negatives", "TEST", 145, 160], ["False Positives", "TEST", 165, 180], ["primary screening", "TEST", 183, 200], ["False Positives", "OBSERVATION", 165, 180]]], ["The actives are studied further at multiple concentrations and the inactives are henceforth ignored.", [["actives", "OBSERVATION", 4, 11]]], ["A false positive error occurs when a compound labeled as active is, in fact, inactive when studied in the more careful multiple concentration assay.", [["A false positive error", "PROBLEM", 0, 22], ["false", "OBSERVATION", 2, 7], ["positive error", "OBSERVATION", 8, 22], ["active", "OBSERVATION_MODIFIER", 57, 63], ["inactive", "OBSERVATION", 77, 85]]], ["The false positive rate can be lowered by raising the decision threshold, or \"hit limit\", but at the cost of increasing the false negative error rate.", [["The false positive rate", "TEST", 0, 23], ["false", "OBSERVATION", 4, 9], ["positive rate", "OBSERVATION", 10, 23], ["negative error", "OBSERVATION", 130, 144]]], ["In most HTS screens, of those compounds flagged as active in a primary screen, roughly 30% to 50% are found to be inactive in the multiple concentration-response follow-up study.False Negatives and False PositivesA false negative error occurs when a compound that is actually active is not labeled as active.", [["most HTS screens", "TEST", 3, 19], ["a primary screen", "TEST", 61, 77], ["follow-up study", "TEST", 162, 177], ["False Negatives", "TEST", 178, 193], ["inactive", "OBSERVATION", 114, 122], ["False Positives", "OBSERVATION", 198, 213], ["negative error", "OBSERVATION", 221, 235]]], ["Biological noise, for example, and the choice of hit threshold can affect the false negative error, as well as mechanical failures such as a leaking well.", [["mechanical failures", "PROBLEM", 111, 130], ["negative error", "OBSERVATION", 84, 98], ["leaking", "OBSERVATION", 141, 148]]], ["Mechanical failure errors are unrelated to the true potency of the molecule.", [["Mechanical failure errors", "PROBLEM", 0, 25], ["failure", "OBSERVATION", 11, 18], ["molecule", "OBSERVATION", 67, 75]]], ["The false negative rate is unknowable because the vast majority of compounds are not studied further, but it can be estimated from small studies.", [["The false negative rate", "TEST", 0, 23], ["small studies", "TEST", 131, 144], ["false", "OBSERVATION", 4, 9], ["negative rate", "OBSERVATION", 10, 23], ["compounds", "OBSERVATION", 67, 76], ["small", "OBSERVATION_MODIFIER", 131, 136]]], ["From past HTS screens at Lilly, we have estimated that a mechanical failure false negative occurs in roughly 7% to 12% of compounds in an HTS screen, with a total false negative error rate ranging from 20% to 30%.", [["past HTS screens", "TEST", 5, 21], ["a mechanical failure false", "PROBLEM", 55, 81], ["an HTS screen", "TEST", 135, 148], ["error rate", "TEST", 178, 188], ["mechanical failure", "OBSERVATION", 57, 75], ["false negative", "OBSERVATION", 76, 90]]], ["Aside from the mechanistic type of false negative, the false negative rate can be viewed as a function of the activity levelthe greater the activity of the molecule, the lower the chance of a false negative error.False Negatives and False PositivesExperimental results from an HTS assay are not the \"truth\" but merely an estimate of the true potency of a molecule.", [["a false negative error", "PROBLEM", 190, 212], ["False Negatives", "TEST", 213, 228], ["an HTS assay", "TEST", 274, 286], ["false negative", "OBSERVATION", 35, 49], ["false negative error", "OBSERVATION", 192, 212], ["False Positives", "OBSERVATION", 233, 248]]], ["Because molecules are only measured one time in the HTS setting, there is a high degree of uncertainty.", [["a high degree of uncertainty", "PROBLEM", 74, 102], ["high degree", "OBSERVATION_MODIFIER", 76, 87]]], ["See Goldberg (1978) for further discussion on estimating the error rate.False Negatives and False PositivesOne effective way of dealing with experimental errors is to build a predictive model and score the screening results through the model, then to look at discrepancies between the experimental screening result and the model prediction.", [["False Negatives", "TEST", 72, 87], ["False Positives", "TEST", 92, 107], ["experimental errors", "PROBLEM", 141, 160], ["the screening", "TEST", 202, 215], ["the experimental screening", "TEST", 281, 307], ["False Positives", "OBSERVATION", 92, 107]]], ["Often the highly potent but mechanical failure type of false negatives or false positives can be identified.", [["mechanical failure type of false negatives", "PROBLEM", 28, 70], ["false positives", "PROBLEM", 74, 89], ["highly potent", "OBSERVATION_MODIFIER", 10, 23], ["false negatives", "OBSERVATION", 55, 70], ["false positives", "OBSERVATION", 74, 89]]], ["In practice, the false positives will be tested in the secondary screen and found to be inactive when that screening result is observed.", [["the false positives", "TEST", 13, 32], ["the secondary screen", "TEST", 51, 71], ["false positives", "OBSERVATION", 17, 32]]], ["Some researchers favor raising the threshold to reduce the number of compounds labeled as active.", [["active", "OBSERVATION_MODIFIER", 90, 96]]], ["The false negatives can then be identified by a statistical or predictive model and rescreened.", [["The false negatives", "TEST", 0, 19], ["false negatives", "OBSERVATION", 4, 19]]], ["In one recent project at Lilly we followed up a 150,000 compounds HTS with a small library (that is, a small collection of molecules) of 2300 compounds.", [["a small library", "PROBLEM", 75, 90], ["small", "OBSERVATION_MODIFIER", 103, 108]]], ["The same model was used to identify 250 molecules that were screened in the 150,000 and found to be inactive, yet scored by the model as highly active.", [["inactive", "OBSERVATION", 100, 108], ["highly", "OBSERVATION_MODIFIER", 137, 143], ["active", "OBSERVATION", 144, 150]]], ["Fully 55% of these false negatives were active upon retesting.", [["these false negatives", "TEST", 13, 34], ["active", "OBSERVATION_MODIFIER", 40, 46]]], ["The breakdown of hit rates is given in Table 1 .", [["The breakdown of hit rates", "PROBLEM", 0, 26], ["breakdown", "OBSERVATION_MODIFIER", 4, 13]]], ["The 3% hit rate in the primary screen was a concern, as such a high number suggests a problem in the assay.", [["The 3% hit rate", "TEST", 0, 15], ["the primary screen", "TEST", 19, 37], ["a problem in the assay", "PROBLEM", 84, 106]]], ["It was found that there was a carryover problem in which sticky compounds were not being completely washed from the robotic tips.", [["a carryover problem", "PROBLEM", 28, 47], ["the robotic tips", "TREATMENT", 112, 128], ["robotic tips", "OBSERVATION", 116, 128]]], ["This problem was resolved before the secondary runs (rows 2 to 3 of the table) were made.False Negatives and False PositivesA computer experiment was done to confirm and further explore the above findings.", [["False Negatives", "TEST", 89, 104], ["False PositivesA computer experiment", "TEST", 109, 145], ["False PositivesA", "OBSERVATION", 109, 125]]], ["An iterative medium-throughput screening operation was simulated with different levels of false negative rates, reflecting historical error rates seen across past screens.", [["An iterative medium", "TREATMENT", 0, 19], ["screening operation", "TREATMENT", 31, 50], ["historical error rates", "TEST", 123, 145], ["false negative rates", "OBSERVATION", 90, 110]]], ["For each level of false negative rate, the appropriate proportion of true actives was randomly chosen (from a nonuniform distribution that is a function of the \"true\" activity level of the molecule, based on historical data) and relabeled (incorrectly) as inactive.", [["true actives", "PROBLEM", 69, 81], ["historical data", "TEST", 208, 223], ["false negative rate", "OBSERVATION", 18, 37]]], ["The model was trained on this \"polluted\" data set and used to select the set of compounds for the next round of testing.", [["testing", "TEST", 112, 119]]], ["For this particular experiment, the model was able to find 25 times more false negatives than a random (hypergeometric) search would produce, up to a false negative rate of 30% at which point the enrichment over random decreases from 25-fold to about 15-fold higher than random.False Negatives and False PositivesIn both screening and predictive modeling, the relative cost of false negatives versus false positives is an important component of decision making.", [["False Negatives", "TEST", 278, 293], ["False Positives", "TEST", 298, 313], ["predictive modeling", "TEST", 335, 354], ["false negatives", "TEST", 377, 392], ["false positives", "PROBLEM", 400, 415], ["enrichment", "OBSERVATION", 196, 206], ["decreases", "OBSERVATION_MODIFIER", 219, 228], ["False Positives", "OBSERVATION", 298, 313], ["false negatives", "OBSERVATION", 377, 392]]], ["From a business standpoint, false negatives represent lost opportunities and false positives represent wasted efforts chasing down \"red herrings.\"", [["false negatives", "TEST", 28, 43], ["false positives", "PROBLEM", 77, 92]]], ["The resources wasted chasing false positives is particularly troubling.", [["false positives", "OBSERVATION", 29, 44]]], ["The current trend is to reduce the false positives and to tolerate the increased number of false negatives that results.Molecular Diversity Analysis in Drug DiscoveryIn the last two decades, three technologies have been co-developed that enable a significant shift in the process of lead generation:Molecular Diversity Analysis in Drug DiscoveryCombinatorial Chemistry \u21d2 Large libraries of molecules High-Throughput Screening \u21d2 Many biological data points Cheminformatics \u21d2 Many molecular descriptorsMolecular Diversity Analysis in Drug DiscoveryThe adoption of high-throughput screening and combinatorial chemistry methods in the early 1990s led to an immense interest in molecular diversity.", [["the false positives", "PROBLEM", 31, 50], ["Combinatorial Chemistry", "TEST", 345, 368], ["Large libraries of molecules", "PROBLEM", 371, 399], ["Throughput Screening", "TEST", 405, 425], ["throughput screening", "TEST", 567, 587], ["combinatorial chemistry methods", "TEST", 592, 623], ["false positives", "OBSERVATION", 35, 50], ["Diversity", "OBSERVATION", 130, 139], ["Large", "OBSERVATION_MODIFIER", 371, 376], ["libraries", "OBSERVATION", 377, 386], ["molecular diversity", "OBSERVATION", 673, 692]]], ["It was widely expected that making diverse libraries would provide an increase in the number of hits in biological assays.", [["diverse libraries", "PROBLEM", 35, 52], ["biological assays", "TEST", 104, 121], ["diverse", "OBSERVATION_MODIFIER", 35, 42], ["libraries", "OBSERVATION", 43, 52], ["increase", "OBSERVATION_MODIFIER", 70, 78]]], ["Molecular diversity designs do offer great benefits, but more in the enhancement of the quality, rather than quantity, of information from a screen.", [["a screen", "TEST", 139, 147], ["diversity", "OBSERVATION", 10, 19]]], ["It became clear that other properties of molecules, beyond mere structural novelty, need to be considered in screening.", [["clear", "OBSERVATION", 10, 15]]], ["This led to extensive work on \"druglikeness\" and an attempt to achieve a balance between diversity and medicinal reasonableness of molecules.Molecular Diversity in ScreeningMolecular diversity analysis is useful in several contexts: r Compound acquisition: this avoids purchasing a compound very similar to one that is already owned. r General screening for lead identification: screening a diverse library is a sensible approach when little or nothing is known about the target or possible lead compounds. r Driving an SAR effort away from prior patent claims.Molecular Diversity in ScreeningThe second context, general screening, involves selecting subsets of molecules for lead generation.", [["medicinal reasonableness of molecules", "PROBLEM", 103, 140], ["ScreeningMolecular diversity analysis", "TEST", 164, 201], ["lead identification", "TEST", 358, 377], ["lead compounds", "PROBLEM", 491, 505], ["general screening", "TEST", 613, 630], ["lead generation", "TREATMENT", 676, 691], ["Diversity", "OBSERVATION", 151, 160], ["patent", "OBSERVATION", 547, 553]]], ["Experimental designs are considered because it is not feasible to screen all molecules available.", [["Experimental designs", "PROBLEM", 0, 20]]], ["Even with the application of high-throughput screening, the demand for screening outpaces the capacity.", [["screening", "TEST", 71, 80]]], ["This is due to the growth of in-house chemical databases, the number of molecules synthesized using combinatorial chemistry, and the increasing number of biological targets fueling discovery projects.", [["combinatorial chemistry", "TEST", 100, 123], ["growth", "OBSERVATION_MODIFIER", 19, 25], ["increasing", "OBSERVATION_MODIFIER", 133, 143], ["number", "OBSERVATION_MODIFIER", 144, 150]]], ["In addition, novel screens that are not amenable to HTS automation may be attractive from a competitive standpoint but the gap between screening capacity and screening opportunities in this case is particularly daunting.", [["novel screens", "TEST", 13, 26], ["HTS automation", "TEST", 52, 66], ["screening capacity", "TEST", 135, 153], ["screening opportunities", "TEST", 158, 181]]], ["Given this imbalance, methods for selecting finite subsets of molecules from potentially large chemical databases must be considered.", [["this imbalance", "PROBLEM", 6, 20], ["methods", "TREATMENT", 22, 29], ["selecting finite subsets of molecules", "PROBLEM", 34, 71], ["potentially large chemical databases", "PROBLEM", 77, 113], ["large", "OBSERVATION_MODIFIER", 89, 94], ["chemical databases", "OBSERVATION", 95, 113]]], ["Possible selection strategies include: random, diverse, and representative selection, each of which may be performed as a biased or directed analysis if information such as a druglikeness score is available to weight the analysis in favor of certain classes of molecules.", [["a druglikeness score", "PROBLEM", 173, 193], ["the analysis", "TEST", 217, 229]]], ["A requirement of every selection method considered here is its computational feasibility for the databases of hundreds of thousands to millions of compounds that are now common with the application of combinatorial synthesis.", [["every selection method", "TREATMENT", 17, 39], ["combinatorial synthesis", "TREATMENT", 201, 224], ["combinatorial synthesis", "OBSERVATION", 201, 224]]], ["This is a formidable task, necessitating creative computational solutions.", [["creative computational solutions", "TREATMENT", 41, 73]]], ["Figure 1 illustrates a modern paradigm of drug hunting processes.", [["drug hunting", "OBSERVATION", 42, 54]]], ["In this fictitious two-dimensional projection of the space of feasible druglike molecules, open circles represent compounds that are not active relative to a specific target, solid circles are active compounds, shown in one contiguous series of related molecules, and the star is the blockbuster drug that is still undiscovered.", [["druglike molecules", "PROTEIN", 71, 89], ["feasible druglike molecules", "PROBLEM", 62, 89], ["open circles", "TREATMENT", 91, 103], ["active", "OBSERVATION_MODIFIER", 193, 199], ["compounds", "OBSERVATION_MODIFIER", 200, 209]]], ["In a primary screen, finding a single solid circle is all that is needed.", [["a primary screen", "TEST", 3, 19]]], ["The medicinal chemistry teams can follow up by making systematic changes to any one of the active compounds to explore the whole series and find (or invent) the blockbuster drug.", [["systematic changes", "PROBLEM", 54, 72]]], ["An important point is that the blockbuster may not exist in the corporate collection.", [["may not exist", "UNCERTAINTY", 43, 56]]], ["A typical lead generation or lead optimization project involves not only testing molecules in current libraries, but also synthesis of new molecules.", [["A typical lead generation", "TREATMENT", 0, 25], ["lead optimization", "TREATMENT", 29, 46], ["new molecules", "PROBLEM", 135, 148], ["lead generation", "OBSERVATION", 10, 25], ["new", "OBSERVATION_MODIFIER", 135, 138], ["molecules", "OBSERVATION", 139, 148]]], ["Molecular modification and subsequent testing is the way the trail gets blazed, through characterizing the SAR.Molecular Diversity in ScreeningIn recent years there has been strong dogma contending that, in filling a fixed screening capacity, it is important to screen \"backups\", that is, molecules that are closely related.", [["Molecular modification", "TREATMENT", 0, 22], ["subsequent testing", "TEST", 27, 45], ["a fixed screening capacity", "PROBLEM", 215, 241], ["modification", "OBSERVATION", 10, 22], ["strong", "OBSERVATION_MODIFIER", 174, 180], ["dogma", "OBSERVATION", 181, 186]]], ["This argument is motivated by the high rate of false negatives in primary screening.", [["primary screening", "TEST", 66, 83]]], ["Thus screening two or more compounds from the same related series effectively gives pseudo replicates.", [["screening", "TEST", 5, 14]]], ["If one compound turns out to be a false negative, it is likely that another from the same series will screen as positive and thus, the active series will not be missed.", [["the active series", "PROBLEM", 131, 148]]], ["This rationale is popular in the industry.", [["popular", "OBSERVATION_MODIFIER", 18, 25]]], ["However, at Lilly we have demonstrated, through both simulations and retrospective analysis, that it is better to tolerate the false negatives in favor of sampling a larger number of different series.", [["retrospective analysis", "TEST", 69, 91], ["the false negatives", "TEST", 123, 142]]], ["The motivating principle for this position is that testing two closely related compounds (or analogues) is often equivalent to testing the same hypothesis twice, which comes at the expense of testing a different hypothesis; see Wikel and Higgs (1997) .Molecular Diversity in ScreeningOptimizing molecular diversity has the potential to maximize the information gained about an SAR in the early stages of screening.", [["a different hypothesis", "PROBLEM", 200, 222], ["an SAR", "PROBLEM", 374, 380], ["screening", "TEST", 404, 413], ["Diversity", "OBSERVATION", 262, 271], ["molecular diversity", "OBSERVATION", 295, 314]]], ["Suppose a random screening gives the same number of hits as a diverse screening.", [["a random screening", "TEST", 8, 26], ["a diverse screening", "TEST", 60, 79]]], ["Then one would favor the diverse set of hits, because this increases the chance of at least one structural lead with a favorable ADME and toxicity profile.", [["toxicity", "DISEASE", 138, 146], ["toxicity profile", "PROBLEM", 138, 154]]], ["In fact, for primary screening, it is often better to have 10 novel hits than 200 hits that are analogues of each other.", [["primary screening", "TEST", 13, 30]]], ["The proper focus, in our view, is quality of information gleaned from the screen.Molecular Diversity in ScreeningMost pharmaceutical companies have clusters of compounds (for example, Lilly has many SSRIs, cephalosporins, and so on).", [["Lilly", "CHEMICAL", 184, 189], ["SSRIs", "CHEMICAL", 199, 204], ["cephalosporins", "CHEMICAL", 206, 220], ["cephalosporins", "CHEMICAL", 206, 220], ["Lilly", "SIMPLE_CHEMICAL", 184, 189], ["cephalosporins", "SIMPLE_CHEMICAL", 206, 220], ["the screen", "TEST", 70, 80], ["many SSRIs", "TREATMENT", 194, 204], ["cephalosporins", "TREATMENT", 206, 220], ["proper", "OBSERVATION_MODIFIER", 4, 10], ["focus", "OBSERVATION_MODIFIER", 11, 16], ["Diversity", "OBSERVATION", 91, 100]]], ["There are many analogues clustered tightly in local subregions of chemical space, reflecting historical SARs investigated around related targets.", [["many analogues", "PROBLEM", 10, 24], ["historical SARs", "PROBLEM", 93, 108], ["many", "OBSERVATION_MODIFIER", 10, 14], ["analogues", "OBSERVATION_MODIFIER", 15, 24], ["clustered", "OBSERVATION_MODIFIER", 25, 34], ["tightly", "OBSERVATION_MODIFIER", 35, 42], ["local", "OBSERVATION_MODIFIER", 46, 51], ["subregions", "OBSERVATION_MODIFIER", 52, 62], ["chemical space", "OBSERVATION", 66, 80]]], ["A random sample will reflect the densities of the compound classes in the collection; thus testing a random sample of molecules for a certain biological activity will be equivalent to testing the same hypothesis many times over.DescriptorsComputationally, a structure space (represented as a set of two-dimensional graphs of molecule structures) is mapped to property (or chemical) space (R p ) (for example, Figure 2 called descriptors, or sometimes properties.", [["A random sample", "TEST", 0, 15], ["the compound classes in the collection", "PROBLEM", 46, 84], ["testing", "TEST", 91, 98], ["a certain biological activity", "PROBLEM", 132, 161], ["a structure space", "PROBLEM", 256, 273], ["densities", "OBSERVATION", 33, 42], ["compound", "OBSERVATION_MODIFIER", 50, 58], ["classes", "OBSERVATION_MODIFIER", 59, 66], ["collection", "OBSERVATION", 74, 84]]], ["The descriptors can be binary, integer counts, or continuous variables.", [["integer counts", "TEST", 31, 45]]], ["A descriptor may be as simple as a count of the number of oxygen atoms in a molecule, or as sophisticated as an estimate of the three-dimensional polar surface area around the molecule.", [["surface area", "ANATOMY", 152, 164], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 58, 64], ["oxygen atoms", "SIMPLE_CHEMICAL", 58, 70], ["a count", "TEST", 33, 40], ["may be", "UNCERTAINTY", 13, 19], ["oxygen atoms", "OBSERVATION", 58, 70], ["three", "OBSERVATION_MODIFIER", 128, 133], ["polar", "OBSERVATION_MODIFIER", 146, 151], ["surface", "OBSERVATION_MODIFIER", 152, 159], ["molecule", "ANATOMY", 176, 184]]], ["Molecules are assigned positions in this high-dimensional descriptor space through their properties.", [["positions", "OBSERVATION_MODIFIER", 23, 32]]], ["The relationships defining their molecular diversity are, therefore, represented through their coordinates or positions in this space.", [["molecular diversity", "OBSERVATION", 33, 52]]], ["The distance metrics most often used are Euclidean and Mahalanobis for properties, and Tanimoto (Jaccard) for binary bit strings; see Section 4.5.", [["Tanimoto (Jaccard)", "TREATMENT", 87, 105], ["binary bit strings", "PROBLEM", 110, 128]]], ["Although it is possible to develop distance metrics that are tolerant to missing values, at Lilly we have focused on imputing (replacing) missing values and using distance metrics that assume all descriptor values are present.DescriptorsA set of molecules is commonly described with anywhere from 4 to 10,000 descriptors.", [["missing values", "PROBLEM", 138, 152]]], ["It is also possible to represent molecules with sparse descriptors numbering up to 2 million.", [["sparse descriptors", "PROBLEM", 48, 66], ["also possible to represent", "UNCERTAINTY", 6, 32], ["molecules", "OBSERVATION", 33, 42]]], ["Variable selection, or descriptor subset selection, or descriptor validation, is important, whether the context is supervised or unsupervised learning (Section 6).Molecule SelectionDiscussions about molecular diversity involve the concepts of \"similarity\" and \"dissimilarity\" and may be confusing as their meanings are content related.", [["molecular diversity", "OBSERVATION", 199, 218], ["may be", "UNCERTAINTY", 280, 286]]], ["Similarity is in the eye of the beholder.", [["eye", "ANATOMY", 21, 24], ["eye", "ORGAN", 21, 24], ["eye", "ANATOMY", 21, 24]]], ["Similarity is not absolute, but relative to the space in which it is defined.", [["not", "UNCERTAINTY", 14, 17], ["absolute", "OBSERVATION_MODIFIER", 18, 26]]], ["In chemistry, this means the definitions must always be held in context to the property space used to define the structures.Molecule SelectionIf characteristics are known about the biological target then this target-specific information may be used to select a subset of molecules for biological testing.", [["biological testing", "TEST", 285, 303]]], ["Various database searching methods, molecular similarity methods, and molecular modeling methods could be used to identify a favored (or biased) subset of molecules for biological testing.", [["molecular similarity methods", "TEST", 36, 64], ["biological testing", "TEST", 169, 187]]], ["If very little is known except that the receptor of interest is in the brain, a biased diversity selection would be more useful than an unbiased one.", [["brain", "ANATOMY", 71, 76], ["brain", "ORGAN", 71, 76], ["a biased diversity selection", "TREATMENT", 78, 106], ["brain", "ANATOMY", 71, 76]]], ["For example, one might construct a weight function based on the number of positively charged nitrogen atoms in a molecule, because this is often observed to be present in desirable neuroscience drugs.", [["nitrogen", "CHEMICAL", 93, 101], ["nitrogen atoms", "SIMPLE_CHEMICAL", 93, 107], ["nitrogen atoms", "OBSERVATION", 93, 107]]], ["If there are no positively charged nitrogen atoms, or if there are more than two, the weight function is very low and otherwise very high.", [["nitrogen", "CHEMICAL", 35, 43], ["nitrogen atoms", "SIMPLE_CHEMICAL", 35, 49], ["positively charged nitrogen atoms", "PROBLEM", 16, 49], ["the weight function", "TEST", 82, 101], ["very low", "PROBLEM", 105, 113]]], ["Other factors related to toxicity, solubility, and other aspects of medicinal viability of molecules could be included in the weight function.", [["toxicity", "DISEASE", 25, 33], ["Other factors", "PROBLEM", 0, 13], ["toxicity", "PROBLEM", 25, 33], ["medicinal viability of molecules", "PROBLEM", 68, 100], ["toxicity", "OBSERVATION", 25, 33]]], ["Then a weighted diversity selection could be performed to construct a reasonable starting set for initial screening.Descriptor Validation and Variable SelectionThe concept of molecular similarity is strongly linked with the \"SAR Hypothesis\" of Alexander Crum-Brown (Crum-Brown and Fraser, 1869) which states that compounds that are similar in their structure will, on average, tend to display similar biological activity.", [["a weighted diversity selection", "TREATMENT", 5, 35], ["initial screening", "TEST", 98, 115], ["Descriptor Validation", "TEST", 116, 137], ["Alexander Crum", "TEST", 244, 258], ["molecular similarity", "OBSERVATION", 175, 195], ["Brown", "ANATOMY", 259, 264], ["biological activity", "OBSERVATION", 401, 420]]], ["A modest extension holds that one can build mathematical models from the numerical descriptors to describe a relationship between the chemical structure and the biological activity.", [["modest", "OBSERVATION_MODIFIER", 2, 8], ["chemical structure", "OBSERVATION", 134, 152], ["biological activity", "OBSERVATION", 161, 180]]], ["There is a concept of bioisostere which says that some chemical fragments function in the same way as other chemical fragments (for example, a sulfur may behave like a methyl group).", [["sulfur", "CHEMICAL", 143, 149], ["methyl", "CHEMICAL", 168, 174], ["sulfur", "CHEMICAL", 143, 149], ["methyl", "CHEMICAL", 168, 174], ["bioisostere", "SIMPLE_CHEMICAL", 22, 33], ["sulfur", "SIMPLE_CHEMICAL", 143, 149], ["methyl", "SIMPLE_CHEMICAL", 168, 174], ["some chemical fragments function", "PROBLEM", 50, 82], ["chemical", "OBSERVATION_MODIFIER", 55, 63], ["fragments", "OBSERVATION", 64, 73], ["chemical", "OBSERVATION_MODIFIER", 108, 116], ["fragments", "OBSERVATION", 117, 126]]], ["An ideal set of molecular descriptors would be one that contains properties characterizing all aspects important to potency, selectivity, ADME, and toxicity.", [["toxicity", "DISEASE", 148, 156], ["toxicity", "PROBLEM", 148, 156]]], ["Descriptors considered generally important include those describing lipophilicity, molecular shape, surface area and size, electronic properties, and pharmacophoric elements such as hydrogen bond donors and acceptors.Descriptor Validation and Variable SelectionJust as with variable subset selection in linear regression, there are risks akin to over-fitting a training set.", [["surface", "ANATOMY", 100, 107], ["hydrogen", "CHEMICAL", 182, 190], ["hydrogen bond donors and acceptors", "TREATMENT", 182, 216], ["molecular shape", "OBSERVATION_MODIFIER", 83, 98], ["surface", "OBSERVATION_MODIFIER", 100, 107], ["area", "OBSERVATION_MODIFIER", 108, 112], ["size", "OBSERVATION_MODIFIER", 117, 121], ["electronic properties", "OBSERVATION", 123, 144], ["pharmacophoric elements", "OBSERVATION", 150, 173]]], ["Descriptors x 3 and x 4 are more useful because they separate the different structural classes.Descriptor Validation and Variable SelectionThere are dimensionality issues.", [["Descriptor Validation", "TEST", 95, 116], ["dimensionality issues", "PROBLEM", 149, 170], ["dimensionality", "OBSERVATION_MODIFIER", 149, 163]]], ["Later we propose Mahalanobis distance (Section 4.5) as a good metric for diversity analysis.", [["diversity analysis", "TEST", 73, 91]]], ["In order to obtain accurate estimates of the elements of the covariance matrix, one rule of thumb is that at least five observations per parameter should be made.", [["matrix", "CELLULAR_COMPONENT", 72, 78], ["thumb", "ORGANISM_SUBDIVISION", 92, 97], ["thumb", "ANATOMY", 92, 97]]], ["Thus, some method for subset selection of descriptors is needed.Descriptor Validation and Variable SelectionIn the case of molecular diversity, there is no response to guide the variable subset selection (unsupervised learning) and hence creative ways to do subset selection are needed.", [["some method", "TREATMENT", 6, 17], ["subset selection", "TREATMENT", 258, 274], ["no", "UNCERTAINTY", 153, 155]]], ["Thus, at Lilly, our molecular diversity tools are generic and depend on a generic notion of similarity that is relatively independent of biology (rows 2 and 3 of Table 2 ).Distance MetricsDistance-based methods require a definition of molecular similarity (or distance) in order to be able to select subsets of molecules that are maximally diverse with respect to each other or to select a subset that is representative of a larger chemical database.", [["Distance MetricsDistance", "TREATMENT", 172, 196], ["larger", "OBSERVATION_MODIFIER", 425, 431]]], ["Ideally, to select a diverse subset of size k, all possible subsets of size k would be examined and a diversity measure of a subset (for example, average near neighbor similarity) could be used to select the most diverse subset.", [["size k", "PROBLEM", 71, 77], ["size", "OBSERVATION_MODIFIER", 39, 43], ["size", "OBSERVATION_MODIFIER", 71, 75], ["diverse", "OBSERVATION_MODIFIER", 213, 220], ["subset", "OBSERVATION", 221, 227]]], ["Unfortunately, this approach suffers from a combinatoric explosion in the number of subsets that must be examined and more computationally feasible approximations must be considered, a few of which are presented below.Distance MetricsGiven two molecules a and b, let x and y denote their vectors of descriptors.", [["a combinatoric explosion", "PROBLEM", 42, 66]]], ["The Mahalanobis distance between a and b is defined as:Distance Metricswhere V \u22121 denotes the inverse of the covariance matrix, V, of the vectors of the descriptor values of all the molecules.", [["Mahalanobis distance", "OBSERVATION", 4, 24], ["molecules", "OBSERVATION", 182, 191]]], ["If V = I the result is Euclidean distance:Distance Metricswhere x i and y i are the ith elements of x and y, respectively.Distance MetricsThe effect of the V \u22121 is to divide each descriptor by its standard deviation, so that some descriptors do not dominate others due to mere differences of scale.", [["V \u22121", "DNA", 156, 160], ["the V \u22121", "TREATMENT", 152, 160]]], ["The off-diagonal elements of the inverse covariance matrix adjust for overweighting (due to high correlations between descriptors) of latent aspects of a molecule, such as size.Distance MetricsA common practice is to scale each descriptor to have standard deviation of 1.", [["off-diagonal elements", "DNA", 4, 25], ["the inverse covariance matrix", "TREATMENT", 29, 58], ["standard deviation of 1", "PROBLEM", 247, 270], ["latent", "OBSERVATION_MODIFIER", 134, 140], ["size", "OBSERVATION_MODIFIER", 172, 176]]], ["Another is to compute principal components and confine the analysis to the first h components, where h may range from 1 to 20.", [["the analysis", "TEST", 55, 67]]], ["This is an ad hoc form of dimension reduction that does not remove irrelevant information from the analysis.", [["dimension reduction", "TREATMENT", 26, 45], ["the analysis", "TEST", 95, 107]]], ["At Lilly, we prefer a careful descriptor validation to avoid including many irrelevant descriptors into the analysis, combined with a dimension reduction criterion using the \u221a 2n/5 rule of thumb, followed by a Mahalanobis distance computation using all the descriptors that remain.Distance MetricsFor presence or absence of features in the molecules, represented by binary bit strings x and y as descriptors, the Tanimoto coefficient is a popular metric for similarity:Distance Metrics(bits on in both x and y) (bits on in x) + (bits on in y) \u2212 (bits on in both x and y)Distance Metrics.Distance MetricsNow consider d(a, b) to be a generic distance metric of which Tanimoto, Euclidean, and Mahalanobis are three cases.", [["thumb", "ORGANISM_SUBDIVISION", 189, 194], ["the analysis", "TEST", 104, 116], ["a dimension reduction criterion", "TREATMENT", 132, 163], ["the \u221a 2n/5 rule of thumb", "TREATMENT", 170, 194], ["a Mahalanobis distance computation", "TREATMENT", 208, 242], ["features in the molecules", "PROBLEM", 324, 349], ["binary bit strings", "PROBLEM", 366, 384], ["thumb", "ANATOMY", 189, 194]]], ["Then, the distance between molecule a and the set of molecules B is defined as follows,Distance Metricsand the overall dissimilarity of a set of molecules M is defined asDistance Metricswhere Mdenotes the set M with the molecule a removed.", [["molecules B", "PROTEIN", 53, 64]]], ["These metrics are used by design algorithms for selecting dissimilar molecules for chemical analysis (see Section 5.2).Subset Selection StrategiesA requirement for any subset selection method is the ability to accommodate a set of previously selected molecules, where augmentation of the pre-existing set is desired.", [["chemical analysis", "TEST", 83, 100], ["any subset selection method", "TREATMENT", 164, 191]]], ["For example, when purchasing compounds, the goal is to augment what is already owned so that the current corporate collection would be used in the analysis as the pre-existing set of molecules.", [["the current corporate collection", "PROBLEM", 93, 125], ["the analysis", "TEST", 143, 155]]], ["The goal then is to select a subset of the candidate molecules that optimizes a specified criterion with reference to the molecules in both the candidate set and the previously selected set.Subset Selection StrategiesIn the case of iterative medium-throughput screening, at any given point in the process, the set of molecules that have been screened thus far is the previously selected set for the next round of screening.", [["iterative medium-throughput screening", "TEST", 232, 269], ["screening", "TEST", 413, 422]]], ["In choosing molecules for the next iteration, one may have a selection criterion such as predictive model scores but a diversity criterion may also be applied: it is not desirable to screen something identical, or nearly identical, to that which was screened in previous rounds.Subset Selection StrategiesThere are two main strategies developed to select diverse and representative subsets of molecules, namely, cell-based methods and distance-based methods.Cell-Based MethodsCell-based methods divide the space defined by a set of molecular descriptors into a finite set of \"bins\" or \"buckets\".", [["cell", "ANATOMY", 412, 416], ["Cell", "ANATOMY", 458, 462], ["cell", "CELL", 412, 416], ["Cell", "CELL", 458, 462], ["predictive model scores", "PROBLEM", 89, 112], ["a diversity criterion", "PROBLEM", 117, 138], ["Cell", "TEST", 458, 462], ["MethodsCell-based methods", "TREATMENT", 469, 494], ["main", "OBSERVATION_MODIFIER", 319, 323]]], ["Structurally similar molecules will occupy the same or adjacent bins and dissimilar molecules will occupy bins that are spatially well separated.", [["similar", "OBSERVATION_MODIFIER", 13, 20], ["molecules", "OBSERVATION", 21, 30]]], ["A diverse subset of molecules can be identified by selecting a single molecule from each of the occupied bins.", [["A diverse subset of molecules", "PROBLEM", 0, 29], ["diverse", "OBSERVATION_MODIFIER", 2, 9], ["subset", "OBSERVATION_MODIFIER", 10, 16], ["molecules", "OBSERVATION", 20, 29]]], ["For example, commercial databases such as Comprehensive Medicinal Chemistry (2003), World Drug Index (2002), and Maccs Drug Data Report (2003) contain molecules that can be used to define the historically medicinally active volume (bins) of chemical space.", [["Comprehensive Medicinal Chemistry", "TEST", 42, 75], ["chemical space", "OBSERVATION", 241, 255]]], ["Compounds in another database, or collection, that fall within the bins defined by these databases can then be selected for biological testing.Cell-Based MethodsCell-based methods have the advantage that they are intuitive and computationally more efficient than many distance-based methods.", [["Cell", "ANATOMY", 143, 147], ["Cell", "CELL", 143, 147], ["collection", "PROBLEM", 34, 44], ["biological testing", "TEST", 124, 142], ["Cell", "TEST", 143, 147], ["MethodsCell-based methods", "TREATMENT", 154, 179]]], ["However, cell-based methods suffer from a problem known as the \"curse of dimensionality.\"", [["cell", "ANATOMY", 9, 13], ["cell", "CELL", 9, 13]]], ["Even with large chemical databases, most of the bins will be empty and many bins will contain a single molecule.", [["large chemical databases", "PROBLEM", 10, 34], ["large", "OBSERVATION_MODIFIER", 10, 15], ["chemical databases", "OBSERVATION", 16, 34], ["empty", "OBSERVATION", 61, 66]]], ["Just one molecule whose molecular descriptors take on extreme values will cause the majority of molecules to be allocated to a small number of bins.", [["small", "OBSERVATION_MODIFIER", 127, 132]]], ["In either case, a cell-based method will present problems in selecting a diverse subset of molecules.", [["cell", "ANATOMY", 18, 22], ["cell", "CELL", 18, 22], ["a cell-based method", "TREATMENT", 16, 35]]], ["Thus, cell-based methods require a significant reduction in dimensionality from the many possible molecular descriptors, attention to outliers, and careful consideration of how to subdivide each dimension.", [["cell", "ANATOMY", 6, 10], ["cell", "CELL", 6, 10], ["cell-based methods", "TREATMENT", 6, 24], ["a significant reduction in dimensionality", "PROBLEM", 33, 74], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["reduction", "OBSERVATION_MODIFIER", 47, 56]]], ["An application to drug discovery screening, which addressed the issues of outliers and dimensionality, was applied to large databases by Cummins et al. (1996) .Distance-Based MethodsStatistics has a long-standing role in design of experiments.", [["drug discovery screening", "TEST", 18, 42]]], ["Space filling designs are used in numerous contexts including geographical modeling (literal space filling), modeling response surfaces, multivariate interpolation, and chemical library design.Distance-Based MethodsA more in-depth discussion of three selection methods that are computationally feasible with very large chemical databases is now given to highlight the issues that must be considered when applying many of these molecular diversity selection methods.", [["Space filling designs", "TREATMENT", 0, 21], ["geographical modeling (literal space filling", "PROBLEM", 62, 106], ["modeling response surfaces", "PROBLEM", 109, 135], ["multivariate interpolation", "TEST", 137, 163], ["three selection methods", "TREATMENT", 245, 268], ["filling designs", "OBSERVATION", 6, 21], ["geographical", "OBSERVATION_MODIFIER", 62, 74], ["response", "OBSERVATION_MODIFIER", 118, 126], ["surfaces", "OBSERVATION_MODIFIER", 127, 135], ["chemical library design", "OBSERVATION", 169, 192]]], ["Each design method optimizes a specific objective.Distance-Based Methodsr Edge design objective: obtain minimum variance estimates of parameters in a linear model. r Coverage design objective: select a subset of molecules that is most representative of the entire library.", [["a linear model", "TREATMENT", 148, 162]]], ["Heuristically, the distance from the chosen subset to the remaining candidate points should be small.", [["small", "OBSERVATION_MODIFIER", 95, 100]]], ["One might imagine a set of umbrellas positioned to cover as many candidate points as possible. r Spread design objective: select the maximally dissimilar subset of molecules.Distance-Based MethodsThis requires maximizing the distance of points within the subset from each other.", [["umbrellas", "TREATMENT", 27, 36], ["Distance-Based Methods", "TREATMENT", 174, 196], ["molecules", "OBSERVATION", 164, 173]]], ["One analogy for this is electron repulsion.Distance-Based MethodsEdge designs are often constructed using D-optimal design algorithms.", [["electron", "SIMPLE_CHEMICAL", 24, 32], ["D-optimal design algorithms", "TEST", 106, 133]]], ["Molecules selected using D-optimal designs populate the edge of descriptor space by first filling in the corners and then moving around the boundary.", [["Molecules", "TREATMENT", 0, 9], ["D-optimal designs", "TREATMENT", 25, 42], ["edge", "OBSERVATION_MODIFIER", 56, 60], ["corners", "ANATOMY_MODIFIER", 105, 112]]], ["This is usually the situation in lead optimization, rather than lead generation.Distance-Based MethodsSpread and coverage designs are space-filling designs.", [["lead optimization", "TREATMENT", 33, 50], ["MethodsSpread and coverage designs", "TREATMENT", 95, 129], ["space-filling designs", "TREATMENT", 134, 155], ["filling designs", "OBSERVATION", 140, 155]]], ["Let C be the candidate set, that is, the set of possible design points.", [["Let C", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Once the criterion (space filling) is well defined, selecting the points M \u2282 C to be space filling is simply an optimization problem.Distance-Based MethodsThe objective of a spread design is to identify a subset of molecules in which the molecules are as dissimilar as possible under a given similarity metric.", [["space filling", "PROBLEM", 85, 98], ["optimization problem", "OBSERVATION", 112, 132]]], ["For a given metric to measure the similarity of a subset, all subsets of size k (plus any molecules previously selected) could be evaluated and the subset that produces the lowest similarity measure chosen.", [["size", "OBSERVATION_MODIFIER", 73, 77]]], ["In practice, simple non-optimal sequential algorithms are often used to approximate the maximally dissimilar subset: two such algorithms are described below.Maximum Spread AlgorithmThe goal: out of all n k subsets of k molecules from a candidate set C, find the subset M * where dis(M * ), defined in (1), is largest.", [["k molecules", "PROTEIN", 217, 228], ["simple non-optimal sequential algorithms", "TEST", 13, 53], ["k molecules", "TREATMENT", 217, 228], ["largest", "OBSERVATION_MODIFIER", 309, 316]]], ["The solution is to use a sequential approximation (greedy algorithm).Maximum Spread Algorithma.", [["The solution", "TREATMENT", 0, 12], ["a sequential approximation (greedy algorithm", "TREATMENT", 23, 67], ["Maximum Spread Algorithma", "PROBLEM", 69, 94], ["Spread", "OBSERVATION_MODIFIER", 77, 83], ["Algorithma", "OBSERVATION", 84, 94]]], ["Select the first compound from the edge of the design space. b.", [["edge", "OBSERVATION_MODIFIER", 35, 39], ["design space", "OBSERVATION", 47, 59]]], ["Select subsequent compounds in order to maximize the minimum distance to all previously selected compounds.Maximum Spread AlgorithmThis is the algorithm proposed by Kennard and Stone (1969) .", [["Spread", "OBSERVATION_MODIFIER", 115, 121], ["Stone", "OBSERVATION", 177, 182]]], ["At Lilly we have focused on an efficient implementation of this approach applied to large chemical databases and have not implemented design optimization due to the marginal Figure 3 using a modified Fedorov optimization algorithm (Cook and Nachtsheim (1982) ).", [["this approach", "TREATMENT", 59, 72], ["a modified Fedorov optimization algorithm", "TREATMENT", 189, 230]]], ["The OPTEX procedure seeks to maximize the harmonic mean distance from each design point to all other design points.", [["The OPTEX procedure", "TREATMENT", 0, 19]]], ["Eighty different designs were generated using the sequential method of Kennard and Stone and compared with those obtained by the modified Fedorov optimization method.", [["the sequential method of Kennard and Stone", "TREATMENT", 46, 88], ["Stone", "OBSERVATION", 83, 88]]], ["In larger data sets of 200,000 or more compounds this can mean a choice of eight hours versus three days to find a design.Maximum Coverage AlgorithmDefine the coverage of a set M, where M \u2282 C as:Maximum Coverage Algorithmwhere Cis the set C with the set M removed.", [["Maximum Coverage AlgorithmDefine", "TREATMENT", 122, 154], ["the set M", "TREATMENT", 246, 255], ["larger", "OBSERVATION_MODIFIER", 3, 9]]], ["The goal: out of all n k subsets of k molecules with descriptor vectors in C, find the subset M * where cov(M * ) is smallest.", [["all n k subsets of k molecules", "TREATMENT", 17, 47], ["smallest", "OBSERVATION_MODIFIER", 117, 125]]], ["This is often approximated using cluster analysis (see Zemroch, 1986) .Maximum Coverage AlgorithmIn Section 5.3 the different design types are compared.Graphical Comparison of Design TypesFigures 3-5 show a fictitious two-dimensional data set reproduced from Higgs et al. (1997) with permission.", [["cluster analysis", "TEST", 33, 49], ["Maximum Coverage AlgorithmIn Section", "TREATMENT", 71, 107], ["Design TypesFigures", "TEST", 176, 195]]], ["The data set was constructed to have five tightly packed clusters (bivariate normal), two loosely packed clusters (bivariate normal), and molecules uniformly distributed over the two-dimensional design space.", [["loosely", "OBSERVATION_MODIFIER", 90, 97], ["packed clusters", "OBSERVATION_MODIFIER", 98, 113], ["molecules", "OBSERVATION_MODIFIER", 138, 147], ["uniformly", "OBSERVATION_MODIFIER", 148, 157], ["distributed", "OBSERVATION_MODIFIER", 158, 169]]], ["Future selections should complement these eight molecules.", [["Future selections", "TREATMENT", 0, 17]]], ["The data were simulated in two dimensions to depict how a pharmaceutical compound collection might appear in some two-dimensional projection.", [["The data", "TEST", 0, 8], ["a pharmaceutical compound collection", "PROBLEM", 56, 92], ["pharmaceutical", "OBSERVATION_MODIFIER", 58, 72], ["compound collection", "OBSERVATION", 73, 92]]], ["Certain regions are sparse with low density whereas other regions are highly clustered, reflecting the synthetic legacy of the company.", [["low density", "PROBLEM", 32, 43], ["sparse", "OBSERVATION_MODIFIER", 20, 26], ["low density", "OBSERVATION_MODIFIER", 32, 43]]], ["Figure 4 shows 20 molecules selected using an edge (D-optimal) design to augment the previously selected molecules.", [["an edge (D-optimal) design", "TREATMENT", 43, 69]]], ["Two quadratic terms and one linear interaction term were included in the model used to select this design in order to force some interior points into the selection.", [["quadratic", "OBSERVATION_MODIFIER", 4, 13], ["one", "OBSERVATION_MODIFIER", 24, 27], ["linear", "OBSERVATION_MODIFIER", 28, 34]]], ["Figure 5 shows 20 molecules selected using a k-means clustering approximation to a coverage design to augment the previously selected molecules.", [["a k-means clustering approximation", "TREATMENT", 43, 77], ["a coverage design", "TREATMENT", 81, 98]]], ["Figure 3 shows 20 molecules selected using the Kennard and Stone approximation to a spread design (see, for example, Johnson et al., 1990) to augment the previously selected molecules.Graphical Comparison of Design TypesAlthough not shown in the figures, a random selection is often considered the baseline method of subset selection.", [["the Kennard and Stone approximation", "TREATMENT", 43, 78], ["Design TypesAlthough", "TEST", 208, 228], ["subset selection", "TREATMENT", 317, 333], ["Stone", "OBSERVATION", 59, 64]]], ["Random sampling typically selects many molecules from the dense clusters, and several molecules near the previously selected molecules.", [["Random sampling", "TEST", 0, 15], ["the dense clusters", "PROBLEM", 54, 72], ["dense", "OBSERVATION_MODIFIER", 58, 63], ["clusters", "OBSERVATION_MODIFIER", 64, 72], ["several", "OBSERVATION_MODIFIER", 78, 85], ["molecules", "OBSERVATION_MODIFIER", 86, 95]]], ["Spread designs select the most diverse subset of molecules (relative to the other methods presented here), including molecules near the edges as well as throughout the design space.", [["most diverse", "OBSERVATION_MODIFIER", 26, 38], ["subset", "OBSERVATION_MODIFIER", 39, 45], ["molecules", "OBSERVATION", 49, 58], ["edges", "ANATOMY_MODIFIER", 136, 141]]], ["Spread designs ignore the density of the candidate points and focus rather on efficient exploration of the space populated.", [["density", "OBSERVATION", 26, 33]]], ["Coverage designs select molecules near the center of clusters.", [["center", "OBSERVATION_MODIFIER", 43, 49], ["clusters", "OBSERVATION_MODIFIER", 53, 61]]], ["Molecules near the edges of the design space are naturally avoided because they are unlikely to be near the center of a cluster.Combinatorial Chemistry ExampleThis example illustrates the usefulness of a tool that assigns a rank ordering to molecules in a set.", [["Combinatorial Chemistry", "TEST", 128, 151], ["edges", "OBSERVATION_MODIFIER", 19, 24], ["design space", "OBSERVATION", 32, 44], ["unlikely to be", "UNCERTAINTY", 84, 98], ["cluster", "OBSERVATION_MODIFIER", 120, 127]]], ["A combinatorial chemistry collection at Lilly consisted of a number of separate libraries.", [["A combinatorial chemistry collection", "PROBLEM", 0, 36], ["combinatorial", "OBSERVATION_MODIFIER", 2, 15], ["chemistry collection", "OBSERVATION", 16, 36], ["libraries", "OBSERVATION", 80, 89]]], ["To answer this question, a spread design was used to rank the combinatorial molecules.", [["combinatorial molecules", "PROTEIN", 62, 85]]], ["We pooled 22 combinatorial libraries (105,640 molecules) with a set of 32,262 corporate library molecules.", [["32,262 corporate library molecules", "PROTEIN", 71, 105], ["a set", "TEST", 62, 67], ["library molecules", "OBSERVATION", 88, 105]]], ["We rank ordered the combinatorial molecules relative to the corporate library molecules; that is, the corporate library molecules were marked as pre-selected and the task was for the combinatorial candidates to augment them as well as possible.", [["combinatorial molecules", "PROTEIN", 20, 43], ["corporate library molecules", "PROTEIN", 60, 87], ["the combinatorial molecules", "TREATMENT", 16, 43], ["marked", "OBSERVATION_MODIFIER", 135, 141]]], ["The next molecule was that which was most dissimilar to both the corporate collection and the first molecule, and received a rank of 2, and so on.", [["corporate", "OBSERVATION", 65, 74]]], ["Libraries that were drawn from most frequently by the algorithm in the early stages (early ranks) were taken to be the most diverse libraries.", [["Libraries", "TREATMENT", 0, 9]]], ["In the case of Figure 6 , library A was far better than library B at augmenting the current collection.", [["collection", "OBSERVATION", 92, 102]]], ["This example shows how spread designs can be used to solve practical problems.", [["practical problems", "PROBLEM", 59, 77]]], ["Simulation can be used as a guide.Combinatorial Chemistry ExampleAll of this effort is invested in the first of a number of iterations in the drug discovery cycle and the later stages are much more rewarding.", [["Combinatorial Chemistry", "TEST", 34, 57]]], ["The last decade of machine learning advances has seen tremendous increases in prediction accuracy, largely due to model averaging techniques.", [["machine learning advances", "TREATMENT", 19, 44], ["tremendous", "OBSERVATION_MODIFIER", 54, 64], ["increases", "OBSERVATION_MODIFIER", 65, 74]]], ["A good starting point for reading about such ensemble methods is the paper of Breiman (1996) and a valuable discussion about algorithmic versus parametric modeling approaches is provided by Breiman (2001b) .", [["algorithmic versus parametric modeling approaches", "TREATMENT", 125, 174]]], ["The first step, which is by far the most time consuming, starts from a representation of the structures of the molecules and ends with a \"training set\" of descriptors to be used in the model selection step.", [["a \"training", "TREATMENT", 135, 146]]], ["Medchem filtering, in step 1, is an application of expert judgment to chemical structural data.", [["Medchem filtering", "TREATMENT", 0, 17]]], ["Certain fragments of molecules are known to be highly reactive, or carcinogenic, or unstable, or otherwise undesirable, and these molecules can be eliminated at this first step with a simple rule-based algorithm.", [["Certain fragments of molecules", "PROBLEM", 0, 30], ["a simple rule-based algorithm", "TEST", 182, 211], ["fragments", "OBSERVATION_MODIFIER", 8, 17], ["molecules", "OBSERVATION", 21, 30], ["highly", "OBSERVATION_MODIFIER", 47, 53], ["reactive", "OBSERVATION_MODIFIER", 54, 62], ["carcinogenic", "OBSERVATION_MODIFIER", 67, 79], ["unstable", "OBSERVATION_MODIFIER", 84, 92], ["undesirable", "OBSERVATION_MODIFIER", 107, 118]]], ["Data cleaning is, by far, where most of the time is spent.Overview of Data Handling and Model Building StepsThe data cleaning steps may involve the removal from the data frame of columns (of descriptor values) that are constant or nearly constant, imputing missing values and eliminating columns that are redundant due to a strong relationship with other columns.", [["The data cleaning steps", "TREATMENT", 108, 131], ["the removal", "TREATMENT", 144, 155], ["missing values and eliminating columns", "PROBLEM", 257, 295], ["constant", "OBSERVATION_MODIFIER", 219, 227], ["constant", "OBSERVATION_MODIFIER", 238, 246], ["columns", "OBSERVATION_MODIFIER", 288, 295]]], ["Often the same chemical structure exists more than once in the results file, where the different identifiers refer to different batches of the same material.", [["chemical", "OBSERVATION_MODIFIER", 15, 23], ["structure", "OBSERVATION", 24, 33]]], ["Thus, a Predictive Modeling Tool Architecture large discrepancy in the biological response for two such identifiers suggests that a follow-up meeting with the appropriate biologist is needed in order to resolve the experimental discrepancies.Overview of Data Handling and Model Building StepsAnother aspect of data cleaning arises when data come from different laboratories.", [["a Predictive Modeling", "TEST", 6, 27], ["large", "OBSERVATION_MODIFIER", 46, 51], ["discrepancy", "OBSERVATION", 52, 63]]], ["Another data cleaning task involves the imputation (estimation) of missing values.", [["missing values", "PROBLEM", 67, 81]]], ["However, sometimes a failure is not a reflection of the desirability of the molecule and imputation of the missing values is then a reasonable strategy.Overview of Data Handling and Model Building StepsThe final portion (the sampling step) of the first step of Figure 7 is to create a training set which is the set of data to be used for fitting the model in the model selection stage.", [["a failure", "PROBLEM", 19, 28], ["a training set", "TREATMENT", 283, 297], ["failure", "OBSERVATION", 21, 28]]], ["The simplest is merely to take random subsamples of the data and to split the data into training and test data.", [["the data", "TEST", 52, 60], ["test data", "TEST", 101, 110]]], ["A more rigorous approach involves splitting the data into a training, validation, and test set (Hastie et al., 2001, pages 195-196) , where the test set is used only once for assessing the error of the final model (after the model selection studies have finished) and the training and validation sets are used for model selection to compare competing modeling methods.Overview of Data Handling and Model Building StepsThe \"design\" question of what proportion of the data to use for training, relative to the test set, is an important one.", [["a training", "TREATMENT", 58, 68], ["validation", "TEST", 70, 80], ["the test set", "TEST", 140, 152], ["the model selection studies", "TEST", 221, 248], ["validation sets", "TEST", 285, 300], ["model selection", "TREATMENT", 314, 329]]], ["If the test set is too small, the estimates of error will be unreliable, highly variable, and likely to have a high downward bias.", [["the test set", "TEST", 3, 15], ["a high downward bias", "PROBLEM", 109, 129], ["too small", "OBSERVATION_MODIFIER", 19, 28]]], ["On the other hand, if the training set is too small the estimates of error will have high upward bias.Overview of Data Handling and Model Building StepsThe second step shown in Figure 7 lists the actual model training steps.", [["high upward bias", "PROBLEM", 85, 101]]], ["A key point is that an assay is itself an estimator.", [["an assay", "TEST", 20, 28]]], ["With this in mind, definitions and a discussion of error rates are given in the context of predictive models.", [["error rates", "TEST", 51, 62]]], ["Borrowing from the terminology of signal detection, the \"sensitivity\" of a model refers to the fraction of observed hits that are classified as (or predicted to be) hits by the model, and \"specificity\" refers to the fraction of observed inactives classified as inactives by the model.", [["signal detection", "TEST", 34, 50]]], ["An observed hit is not necessarily an active molecule, but simply a molecule for which the primary screening result exceeded a decision threshold.", [["an active molecule", "PROBLEM", 35, 53], ["the primary screening", "TEST", 87, 108], ["hit", "OBSERVATION", 12, 15], ["not necessarily", "UNCERTAINTY", 19, 34], ["active", "OBSERVATION_MODIFIER", 38, 44], ["molecule", "OBSERVATION", 45, 53]]], ["Whether such a molecule turns out to be an active is a problem that involves the sensitivity of the assay, but the task at hand is for a model to predict accurately the primary screening outcome and to assess the accuracy of the model for that purpose.Error RatesLet\u00ce denote \"predicted by the model to be inactive\" and I denote \"observed to be inactive in the assay by exceeding the decision threshold\", with analogous definitions for\u00c2, \"predicted to be a hit\", and A, \"observed to be a hit\".", [["a molecule turns", "PROBLEM", 13, 29], ["the assay", "TEST", 96, 105], ["active", "OBSERVATION", 43, 49]]], ["With the null hypothesis that a compound is inactive, we have:Error RatesSimilarly, 1 minus the sensitivity gives the probability of Type II error or the false negative rate:Error RatesThe complementary rates are obtained from the opposite conditioning: the fraction of model-predicted hits that are observed hits (A |\u00c2) and the fraction of model-predicted inactives (I |\u00ce ) that are observed inactives.", [["the null hypothesis", "PROBLEM", 5, 24], ["Type II error", "PROBLEM", 133, 146], ["Error Rates", "TEST", 174, 185], ["The complementary rates", "TEST", 185, 208], ["the fraction", "TEST", 325, 337], ["inactive", "OBSERVATION_MODIFIER", 44, 52]]], ["It is important to look at these conditional probabilities; a very clear example is in the analysis of gene chip microarray data where the false discovery rate is 1 minus the positive discovery rate as defined above and in Chapter 6; an excellent discussion is given by Benjamini and Hochberg (1995) .Error RatesAn example in the context of blood-brain barrier (BBB) predictions (see Section 6.5) is shown in Figures 8 and 9 .", [["blood-brain barrier", "ANATOMY", 341, 360], ["blood", "ORGANISM_SUBSTANCE", 341, 346], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 347, 360], ["BBB", "MULTI-TISSUE_STRUCTURE", 362, 365], ["the false discovery rate", "TEST", 135, 159], ["brain", "ANATOMY", 347, 352]]], ["Data from different laboratories at Lilly and from various literature sources were pooled together and molecules were assigned binary class labels, BBB+ and BBB\u2212, depending on whether they crossed the blood-brain barrier.", [["blood", "ANATOMY", 201, 206], ["brain", "ANATOMY", 207, 212], ["BBB+", "SIMPLE_CHEMICAL", 148, 152], ["BBB\u2212", "SIMPLE_CHEMICAL", 157, 161], ["blood-", "MULTI-TISSUE_STRUCTURE", 201, 207], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 207, 220], ["brain", "ANATOMY", 207, 212]]], ["A random forest model, defined in Section 6.3, was trained on this data set and molecules that were not part of the training set (called \"out-ofbag\" in the bagging or random forest terminology) were predicted to be hits BBB+ or inactive BBB\u2212 according to a particular score/decision threshold.", [["BBB+", "SIMPLE_CHEMICAL", 220, 224], ["BBB", "MULTI-TISSUE_STRUCTURE", 237, 240]]], ["These predictions were evaluated and three rates were examined: sensitivity, specificity, and positive discovery rates-shown as a function of decision threshold in Figure 8 , where the scores are multiplied by 10.", [["specificity", "TEST", 77, 88]]], ["Thus we include the positive discovery rate in our analysis.Error RatesBalancing these three rates equally yields an optimal threshold of 0.846.", [["our analysis", "TEST", 47, 59]]], ["Both thresholds are indicated by vertical lines in Figure 8 .", [["vertical lines", "CELL_LINE", 33, 47], ["vertical lines", "OBSERVATION", 33, 47]]], ["Figure 9 shows the actual predicted scores for the molecules that do cross the blood-brain barrier (BBB+) as well as those that do not (BBB\u2212).", [["blood-brain barrier", "ANATOMY", 79, 98], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 85, 98], ["Figure", "TEST", 0, 6], ["brain", "ANATOMY", 85, 90]]], ["The false positive and false negative rates are, of course, direct consequences of which threshold is chosen.", [["false positive", "OBSERVATION", 4, 18], ["false negative", "OBSERVATION", 23, 37], ["rates", "OBSERVATION_MODIFIER", 38, 43]]], ["For example, if the project is a neuroscience project where BBB+ is the goal, it may be that the team wants to find and reject Figure 8 .", [["BBB", "MULTI-TISSUE_STRUCTURE", 60, 63]]], ["Sensitivity, specificity, and positive discovery rate as a function of decision threshold; the two reference lines correspond to two decision thresholds.", [["Sensitivity", "TEST", 0, 11], ["specificity", "TEST", 13, 24]]], ["The rates are estimated from predictions made for molecules not in the training set of the model. compounds that are BBB\u2212 at an early point.", [["BBB\u2212", "GENE_OR_GENE_PRODUCT", 117, 121], ["The rates", "TEST", 0, 9]]], ["Then, the goal would be to maximize sensitivity or to maximize the negative discovery rate (while realizing that going too far with this means losing a number of \"good\" compounds as well), and an appropriately large weight could be given, say, to specificity in computing the weighted average of the three rates to obtain an optimal threshold for that purpose.Machine Learning MethodsSome of the more popular predictive modeling methods used in drug discovery include linear methods, tree-based methods, k-nearest neighbors, and kernel methods.", [["linear methods", "TREATMENT", 468, 482]]], ["In this section, a brief outline of these methods is given, together with references for reading and further details.Machine Learning MethodsLinear methods include simple linear regression, multiple linear regression, partial least squares, logistic regression, and Fisher's linear discriminant analysis; see Hansch et al. (1962) , Frank and Friedman(1993) , and Hastie and Tibshirani (1996b) .", [["Learning MethodsLinear methods", "TREATMENT", 125, 155], ["simple linear regression", "PROBLEM", 164, 188], ["multiple linear regression", "PROBLEM", 190, 216], ["logistic regression", "PROBLEM", 241, 260], ["multiple", "OBSERVATION_MODIFIER", 190, 198], ["linear", "OBSERVATION_MODIFIER", 199, 205], ["regression", "OBSERVATION_MODIFIER", 206, 216], ["partial", "OBSERVATION_MODIFIER", 218, 225]]], ["Random forest BBB predicted scores for molecules assigned as BBB+ and BBB\u2212; horizontal reference lines correspond to two decision thresholds.", [["BBB", "MULTI-TISSUE_STRUCTURE", 14, 17], ["BBB+", "SIMPLE_CHEMICAL", 61, 65], ["horizontal reference lines", "CELL_LINE", 76, 102], ["horizontal reference lines", "TREATMENT", 76, 102]]], ["Random forests is an improvement to the strategy of tree-based models combined with bagging.", [["bagging", "TREATMENT", 84, 91], ["improvement", "OBSERVATION_MODIFIER", 21, 32]]], ["A notable recent advance in this method is given by Hastie and Tibshirani (1996a,b) .", [["this method", "TREATMENT", 28, 39], ["notable", "OBSERVATION_MODIFIER", 2, 9]]], ["In the case of a single descriptor, kernel regression and smoothing splines are useful methods of model fitting.", [["a single descriptor, kernel regression", "TREATMENT", 15, 53], ["smoothing splines", "TREATMENT", 58, 75], ["model fitting", "TREATMENT", 98, 111]]], ["However, far more general is the recent development known as support vector machines.", [["support vector machines", "TREATMENT", 61, 84]]], ["This method is based on a particular hyperplane in the descriptor or property space that separates the active from the inactive compounds.", [["active", "OBSERVATION_MODIFIER", 103, 109], ["inactive compounds", "OBSERVATION", 119, 137]]], ["This plane has the largest possible distance from any of the labeled compounds and is known as the maximum margin separating hyperplane.", [["largest", "OBSERVATION_MODIFIER", 19, 26], ["compounds", "OBSERVATION", 69, 78], ["maximum", "OBSERVATION_MODIFIER", 99, 106], ["margin", "OBSERVATION_MODIFIER", 107, 113]]], ["Support vector machines avoid overfitting by choosing the maximum margin separating the hyperplane from among the many that can separate the positive from negative examples in the feature space.", [["Support vector machines", "TREATMENT", 0, 23]]], ["Standard practice in machine learning is to use inductive learning, that is, taking known molecules and, through training or fitting a model, generating a general understanding of the underlying relationships and then applying that general knowledge to make a prediction about a new molecule, for example, whether it will cross the blood-brain barrier.", [["blood-brain barrier", "ANATOMY", 332, 351], ["blood-", "MULTI-TISSUE_STRUCTURE", 332, 338], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 338, 351], ["inductive learning", "TREATMENT", 48, 66], ["brain", "ANATOMY", 338, 343]]], ["The general model that is best when applied to a universe of observations may not be the model that is best for the specific subset of observations under current scrutiny.Model Selection and AssessmentUsually a variety of different models can be applied to the same data set, each model capturing part of the structural information relating explanatory variables to responses and also part of the noise.", [["Model Selection", "TREATMENT", 171, 186], ["different models", "TREATMENT", 222, 238]]], ["The objective of model selection may be considered, in a general sense, to be that of optimizing the quality of inference.", [["model selection", "TREATMENT", 17, 32]]], ["At Lilly we perform studies to select the best algorithm for a data set as well as the best model for a given algorithm, and finally to assess the error for a given model.", [["studies", "TEST", 20, 27], ["a data", "TEST", 61, 67]]], ["A crucially important issue in model selection is the issue of model complexity, because training set error tends to decrease and test set error tends to increase with increasing model complexity; see, for example, Hastie et al. (2001), pages 194-199.", [["increasing model complexity", "PROBLEM", 168, 195]]], ["For the example of variable subset selection in multiple linear regression, the R 2 statistic increases monotonically as the number of variables added to the regression model increases, leading to the situation dubbed as overfitting.", [["multiple linear regression", "PROBLEM", 48, 74], ["variable", "OBSERVATION_MODIFIER", 19, 27], ["subset selection", "OBSERVATION", 28, 44], ["multiple", "OBSERVATION_MODIFIER", 48, 56], ["linear", "OBSERVATION_MODIFIER", 57, 63], ["regression", "OBSERVATION_MODIFIER", 64, 74], ["increases", "OBSERVATION_MODIFIER", 94, 103], ["monotonically", "OBSERVATION_MODIFIER", 104, 117], ["increases", "OBSERVATION_MODIFIER", 175, 184]]], ["Various methods have been devised for avoiding an overfitted model.", [["Various methods", "TREATMENT", 0, 15], ["an overfitted model", "TREATMENT", 47, 66]]], ["Some methods are simple adjustments to the familar R 2 statistic, such as the adjusted R 2 (R 2 adj ) which adds a simple penalty for the number of covariates included in the model.", [["Some methods", "TREATMENT", 0, 12], ["the adjusted R 2 (R 2 adj )", "TREATMENT", 74, 101], ["a simple penalty", "TREATMENT", 113, 129]]], ["In the context of high-or medium-throughput screening, when little is known about a target or an SAR, and designed experiments are not possible, there are no a priori models that can be assumed and, in any case, the key interest in early stage screening is in predictive accuracy of models rather than inference about model parameters.", [["early stage screening", "TEST", 232, 253], ["not possible", "UNCERTAINTY", 131, 143]]], ["When the model space is large, the problem becomes extreme.", [["model", "OBSERVATION_MODIFIER", 9, 14], ["space", "OBSERVATION", 15, 20], ["large", "OBSERVATION_MODIFIER", 24, 29]]], ["One solution is model averaging, in line with Breiman (1996) .", [["model", "OBSERVATION_MODIFIER", 16, 21], ["averaging", "OBSERVATION_MODIFIER", 22, 31]]], ["One good use for this approach is in recursive partitioning or tree-based models.", [["this approach", "TREATMENT", 17, 30]]], ["The model space for recursive partitioning is huge.", [["space", "OBSERVATION_MODIFIER", 10, 15], ["recursive partitioning", "OBSERVATION", 20, 42], ["huge", "OBSERVATION_MODIFIER", 46, 50]]], ["Thus the model space is much smaller than when the descriptors have more than two values.", [["model", "OBSERVATION_MODIFIER", 9, 14], ["space", "OBSERVATION", 15, 20], ["much", "OBSERVATION_MODIFIER", 24, 28], ["smaller", "OBSERVATION_MODIFIER", 29, 36]]], ["For multiple linear regression and a simple additive model, there are 2 h possible models for h descriptors.", [["multiple linear regression", "PROBLEM", 4, 30], ["multiple", "OBSERVATION_MODIFIER", 4, 12], ["linear", "OBSERVATION_MODIFIER", 13, 19], ["regression", "OBSERVATION", 20, 30], ["simple additive model", "OBSERVATION_MODIFIER", 37, 58]]], ["There is a rough analogy between the choice of parameters in the regression model and the choice of cutpoint along each descriptor in recursive partitioning.", [["recursive partitioning", "OBSERVATION", 134, 156]]], ["Table 3 shows the size of the model space for multiple linear regression and for binary descriptor, two-way split tree models, for up to five descriptors.Model Selection and AssessmentWith great flexibility in model choice comes great power but also great danger of misuse.", [["multiple linear regression", "PROBLEM", 46, 72], ["Model Selection", "TREATMENT", 154, 169], ["size", "OBSERVATION_MODIFIER", 18, 22], ["multiple", "OBSERVATION_MODIFIER", 46, 54], ["linear", "OBSERVATION_MODIFIER", 55, 61], ["regression", "OBSERVATION", 62, 72], ["tree models", "OBSERVATION", 114, 125], ["great", "OBSERVATION_MODIFIER", 189, 194], ["flexibility", "OBSERVATION_MODIFIER", 195, 206]]], ["As the model space spanned by tree models is huge for h \u2265 4, there is need for both a computationally feasible way to search the space and for some way to guard against finding spurious relationships in the data.", [["huge", "OBSERVATION_MODIFIER", 45, 49]]], ["The bagging method of Breiman (1996) was a key advance in this area.Model Selection and AssessmentFor regression models, one metric that we use for sorting the molecules by their predicted activity, which is considered proprietary at Lilly, is similar to a weighted variant of Spearman's \u03c1.", [["Model Selection", "TREATMENT", 68, 83], ["Assessment", "TEST", 88, 98]]], ["The weights are higher earlier in the sorted list to emphasize that, in practice, it is the top of the sorted list that will identify the molecules selected for testing, and that accuracy farther down the list is not nearly as important.", [["testing", "TEST", 161, 168], ["higher", "OBSERVATION_MODIFIER", 16, 22]]], ["We have very little interest in accurately distinguishing the relative activity levels of molecules that are all considered inactive, but a great deal of interest in the degree to which actives will rise to the top of a sorted list of molecules.", [["great", "OBSERVATION_MODIFIER", 140, 145]]], ["Quality assessments have been assigned to various values of S, but these levels in isolation are not meaningful; a very high value of S (or R 2 , or any other metric) can easily be obtained for observations that are in the training set of a model, but does not predict how the model will perform on untested molecules.", [["Quality assessments", "TEST", 0, 19], ["these levels", "TEST", 67, 79]]], ["The thresholds established are based on appropriate test hold-out results, as described below.", [["appropriate test", "TEST", 40, 56]]], ["With this in mind, a value of zero is equivalent to random (the mean value resulting from scrambling the predicted responses and computing S many times).", [["the mean value", "TEST", 60, 74]]], ["A value of 0.40 is considered a minimum standard for a model to be used for decision making at Lilly.", [["A value", "TEST", 0, 7]]], ["Such a model would be considered weak and would not be used at all by some scientists.", [["weak", "PROBLEM", 33, 37]]], ["A model with an S value of 0.60 is considered a solid and useful model and an S value above 0.80 indicates a very good model.", [["an S value", "TEST", 13, 23], ["an S value", "TEST", 75, 85]]], ["A difference in values of less than 0.05 is not considered to be meaningful.", [["A difference in values", "TEST", 0, 22], ["difference", "OBSERVATION_MODIFIER", 2, 12], ["not considered to be", "UNCERTAINTY", 44, 64]]], ["Thus, if one were doing model selection and two competing models were statistically significantly different but the difference in mean S were below 0.05, the two models would be treated as equivalent.", [["mean S", "TEST", 130, 136]]], ["At Lilly, we couple the concept of significant differences with the concept of meaningful differences.Example: Blood-Brain Barrier PenetrationWe examine a data set of 750 molecules with blood-brain barrier penetration measurements.", [["Blood", "ANATOMY", 111, 116], ["blood", "ANATOMY", 186, 191], ["brain", "ANATOMY", 192, 197], ["Blood", "ORGANISM_SUBSTANCE", 111, 116], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 192, 205], ["blood-brain barrier penetration measurements", "TEST", 186, 230], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["Brain", "ANATOMY", 117, 122], ["brain", "ANATOMY", 192, 197], ["barrier penetration", "OBSERVATION", 198, 217]]], ["An important aspect of drug design is the consideration of the potential for penetration of the blood-brain barrier by any new candidate drug molecule.", [["blood", "ANATOMY", 96, 101], ["brain", "ANATOMY", 102, 107], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 102, 115], ["the blood-brain barrier", "TREATMENT", 92, 115], ["brain", "ANATOMY", 102, 107]]], ["Whether the goal is for the potential drug to cross or not to cross the blood-brain barrier, the ability to estimate the blood-brain ratio is an essential part of the drug design process.", [["blood-brain barrier", "ANATOMY", 72, 91], ["blood", "ANATOMY", 121, 126], ["brain", "ANATOMY", 127, 132], ["blood", "MULTI-TISSUE_STRUCTURE", 72, 77], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 78, 91], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["brain", "ORGAN", 127, 132], ["the blood-brain ratio", "TEST", 117, 138], ["brain", "ANATOMY", 78, 83], ["brain", "ANATOMY", 127, 132]]], ["Determination of this aspect of a molecule is a lowthroughput operation and thus having the ability to prioritize molecules in silico through the use of predictive models adds considerable value to the drug discovery process.Example: Blood-Brain Barrier PenetrationThe penetration of a compound across the blood-brain barrier is measured experimentally as the ratio BB of the concentration of the compound in the brain to that in the blood.", [["Blood", "ANATOMY", 234, 239], ["blood", "ANATOMY", 306, 311], ["brain", "ANATOMY", 312, 317], ["brain", "ANATOMY", 413, 418], ["blood", "ANATOMY", 434, 439], ["Blood", "ORGANISM_SUBSTANCE", 234, 239], ["blood-", "MULTI-TISSUE_STRUCTURE", 306, 312], ["brain", "ORGAN", 312, 317], ["brain", "ORGAN", 413, 418], ["blood", "ORGANISM_SUBSTANCE", 434, 439], ["a lowthroughput operation", "TREATMENT", 46, 71], ["predictive models", "TEST", 153, 170], ["Blood", "TEST", 234, 239], ["Brain Barrier Penetration", "TREATMENT", 240, 265], ["a compound across the blood-brain barrier", "PROBLEM", 284, 325], ["molecule", "OBSERVATION", 34, 42], ["Blood", "ANATOMY", 234, 239], ["Brain", "ANATOMY", 240, 245], ["Barrier Penetration", "OBSERVATION", 246, 265], ["penetration", "OBSERVATION_MODIFIER", 269, 280], ["brain", "ANATOMY", 312, 317], ["compound", "OBSERVATION_MODIFIER", 397, 405], ["brain", "ANATOMY", 413, 418], ["blood", "ANATOMY", 434, 439]]], ["This ratio is thought to be related to local hydrophobicity, molecular size, lipophilicity, and molecular flexibility (Crivori et al., 2000) , but no explicit mathematical relationship has been given.", [["This ratio", "TEST", 0, 10], ["local hydrophobicity", "PROBLEM", 39, 59], ["thought to be related to", "UNCERTAINTY", 14, 38], ["local", "OBSERVATION_MODIFIER", 39, 44], ["hydrophobicity", "OBSERVATION", 45, 59], ["size", "OBSERVATION_MODIFIER", 71, 75], ["lipophilicity", "OBSERVATION_MODIFIER", 77, 90], ["flexibility", "OBSERVATION_MODIFIER", 106, 117]]], ["The 750 available results, from an in situ experiment with rats, are responses known as Kin values.", [["rats", "ORGANISM", 59, 63], ["Kin", "GENE_OR_GENE_PRODUCT", 88, 91], ["Kin", "PROTEIN", 88, 91], ["rats", "SPECIES", 59, 63]]], ["These are intended to be related to the BB ratio of these compounds in humans.", [["BB", "SIMPLE_CHEMICAL", 40, 42], ["humans", "ORGANISM", 71, 77], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77], ["compounds", "OBSERVATION", 58, 67]]], ["The current goal of the analysis is to select a subset of descriptors (covariates) from about 1000 possibilities and a modeling method that gives good predictive accuracy of the Kin.", [["Kin", "PROTEIN", 178, 181], ["the analysis", "TEST", 20, 32], ["a modeling method", "TEST", 117, 134]]], ["In this example we compare just two methods: one is based on partial least squares (PLS) with a model-averaging strategy, and the other is the random forest algorithm of Breiman (1999) .Example: Blood-Brain Barrier PenetrationWe split the data set into two equal parts at random.", [["Blood", "ANATOMY", 195, 200], ["Blood", "ORGANISM_SUBSTANCE", 195, 200], ["a model-averaging strategy", "TREATMENT", 94, 120], ["Blood", "TEST", 195, 200], ["Brain", "ANATOMY", 201, 206]]], ["We train our algorithms on one half and score the other half as test data.", [["test data", "TEST", 64, 73]]], ["We started with 200 repetitions, each a random 50/50 split of the 750 data points into equal-sized training and test sets, where after each split the model was retrained and the test hold-out set was scored.", [["test sets", "TEST", 112, 121], ["the test", "TEST", 174, 182]]], ["The conclusion favored the random forest model over partial least squares, and a natural question arises as to whether smaller tests would lead to the same conclusion.Training and Test Set SizesTwo key questions in model selection are what proportion of molecules to use for a training set versus a test set when doing random splits of the data, and how many different training/test splits should be analyzed to obtain reliable inferences about model performance.", [["smaller tests", "TEST", 119, 132], ["a training", "TREATMENT", 275, 285], ["a test", "TEST", 297, 303]]], ["However, it is easy to show that use of the n 3/4 rule does not perform well in settings such as drug discovery where prediction accuracy, rather than selection of the true model, is the objective.", [["the n 3/4 rule", "TREATMENT", 40, 54]]], ["We are sometimes better off with a model that is not the true model but a simpler model for which we can make good estimates of the parameters (leading to more accurate predicted values).Training and Test Set SizesIn order to choose the model that predicts most accurately for the test data, we need a new rule or a new information criterion.", [["the test data", "TEST", 277, 290], ["Sizes", "OBSERVATION_MODIFIER", 209, 214]]], ["This motivated Kerry Bemis to propose a new measure which he called predictive R 2 or pR 2 (described below).Training and Test Set SizesAlthough this is an area of ongoing research, the current opinion at Lilly is that, when comparing candidate modeling methods in a model selection exercise, it is best to look at the entire learning curve (leave 90% out up to leave 10% out) and make a judgment about learning algorithms based on the performance across the whole curve.", [["R 2", "GENE_OR_GENE_PRODUCT", 79, 82], ["learning algorithms", "TREATMENT", 403, 422], ["the whole curve", "TEST", 455, 470], ["area", "OBSERVATION_MODIFIER", 156, 160]]], ["We generated 20 sampling runs for each level of Ptrain, where Ptrain is the proportion of the data assigned randomly to the training set, and used the two methods over a broad profile of training set sizes.", [["a broad profile of training set sizes", "TREATMENT", 168, 205], ["sizes", "OBSERVATION_MODIFIER", 200, 205]]], ["The two lines connect the means of the values of S obtained for the two methods at each Ptrain level.", [["the two methods", "TREATMENT", 64, 79], ["two", "OBSERVATION_MODIFIER", 4, 7], ["lines", "OBSERVATION", 8, 13]]], ["The same train/test splits were used for both the PLS and the random forest methods.", [["the PLS", "TEST", 46, 53], ["the random forest methods", "TREATMENT", 58, 83]]], ["Thus a paired or block analysis was done.", [["a paired or block analysis", "TEST", 5, 31]]], ["Here, we could ask whether the random forest method is superior over all Ptrain levels and use a test such as Tukey's HSD (Honestly Significant Difference; see Tukey, 1997 , Kramer, 1956 .", [["the random forest method", "TREATMENT", 27, 51], ["a test", "TEST", 95, 101]]], ["This is perhaps conservative in that we are not interested in all of the pairwise comparisons but, as we can see from simply looking at the plot, any formal comparison is going to give an unambiguous result for this data set.", [["conservative", "OBSERVATION_MODIFIER", 16, 28]]], ["There is a minimum size of training set necessary for a statistical model to be able to reveal links between vectors of descriptor values and biological activity.", [["descriptor values", "TEST", 120, 137], ["minimum", "OBSERVATION_MODIFIER", 11, 18], ["size", "OBSERVATION_MODIFIER", 19, 23]]], ["Suppose a particular pharmacophoric feature is important for the binding of molecules to a receptor.", [["a particular pharmacophoric feature", "PROBLEM", 8, 43]]], ["Having one molecule that binds and has that feature is not sufficient for that feature to be detected as significant.", [["significant", "OBSERVATION_MODIFIER", 105, 116]]], ["Several examples of molecules that bind and contain that feature are needed before the statistical algorithm can detect it.", [["the statistical algorithm", "TEST", 83, 108]]], ["In the model selection stage, it is possible to place a downward bias on the estimate of the predictive power of an algorithm by selecting for the training set a subset of the data that is too small.", [["a downward bias", "PROBLEM", 54, 69], ["the training", "TREATMENT", 143, 155], ["too small", "OBSERVATION_MODIFIER", 189, 198]]], ["There may be a lack of \"statistical traction\" in the training subset that would not exist when the model is trained on all the available data.", [["\"statistical traction", "PROBLEM", 23, 44]]], ["On the other hand, when the proportion of data selected for the training set is very large, and the test set is correspondingly small, it is more likely that a given test set molecule has a very similar \"neighbor\" in the training set and this gives an upward bias to the estimate of predictive power of the model.Training and Test Set SizesOnce the choice of modeling method has been made, all available data are used to train a final scoring model (to be used in the third step of Figure 7) .", [["the test set", "TEST", 96, 108], ["an upward bias", "PROBLEM", 249, 263], ["very", "OBSERVATION_MODIFIER", 80, 84], ["large", "OBSERVATION", 85, 90], ["small", "OBSERVATION_MODIFIER", 128, 133], ["more likely", "UNCERTAINTY", 141, 152], ["Sizes", "OBSERVATION_MODIFIER", 335, 340]]], ["Sometimes sampling issues arise here; for example, the data sets can be very large, and for classification data there is usually a huge imbalance in the number of examples of one class compared with another.", [["Sometimes sampling issues", "PROBLEM", 0, 25], ["classification data", "TEST", 92, 111], ["a huge imbalance", "PROBLEM", 129, 145], ["huge", "OBSERVATION_MODIFIER", 131, 135], ["imbalance", "OBSERVATION", 136, 145]]], ["In drug hunting, there may be 400,000 examples of inactive compounds and as few as 400 active compounds.", [["inactive compounds", "PROBLEM", 50, 68], ["drug hunting", "OBSERVATION", 3, 15]]], ["If the available modeling methods do not deal well with this situation, there may be motivation either to create a training set that alleviates such a mismatch, or to create a smaller training set to reduce the computational burden.", [["a training", "TREATMENT", 113, 123], ["a smaller training", "TREATMENT", 174, 192], ["the computational burden", "PROBLEM", 207, 231]]], ["Either of these issues may or may not be related to the problem of model selection.", [["model selection", "PROBLEM", 67, 82], ["may not be related to", "UNCERTAINTY", 30, 51]]], ["One strategy for selecting a subset of available data for training a model is as follows.Training and Test Set Sizes1.", [["Test Set Sizes1", "TEST", 102, 117]]], ["Select all the active compounds.", [["active", "OBSERVATION_MODIFIER", 15, 21], ["compounds", "OBSERVATION", 22, 31]]], ["Select a small subset of the inactive compounds whose nearest neighbor among the active compounds is a relatively short distance (by some distance measure such as those of Section 4.5).", [["small", "OBSERVATION_MODIFIER", 9, 14], ["subset", "OBSERVATION_MODIFIER", 15, 21], ["inactive", "OBSERVATION_MODIFIER", 29, 37], ["compounds", "OBSERVATION_MODIFIER", 38, 47], ["active", "OBSERVATION_MODIFIER", 81, 87], ["compounds", "OBSERVATION", 88, 97]]], ["From the remaining inactive compounds, select a maximally diverse subset (as described in Section 5).", [["inactive", "OBSERVATION_MODIFIER", 19, 27], ["compounds", "OBSERVATION", 28, 37], ["diverse", "OBSERVATION_MODIFIER", 58, 65], ["subset", "OBSERVATION", 66, 72]]], ["This augments the space beyond the boundary with an optimal exploration of the chemical space represented by inactives.Training and Test Set SizesAt Lilly we have focused on predictive accuracy in most of our project work.", [["an optimal exploration", "TEST", 49, 71], ["space", "OBSERVATION_MODIFIER", 18, 23], ["optimal", "OBSERVATION_MODIFIER", 52, 59], ["exploration", "OBSERVATION", 60, 71], ["chemical space", "OBSERVATION", 79, 93]]], ["Predictive accuracy and interpretability tend to be inversely proportional.", [["Predictive accuracy", "TEST", 0, 19]]], ["An active area of research at Lilly is an investigation of the question of ways in which the model can help us design a better molecule.", [["active", "OBSERVATION_MODIFIER", 3, 9], ["area", "OBSERVATION_MODIFIER", 10, 14]]], ["This may involve interpretation, and there are excellent tools that can be used for this, such as partial dependence plots.", [["partial dependence plots", "PROBLEM", 98, 122]]], ["It can also be approached through virtual screening-a scientist proposes a scaffold or series and the model provides an evaluation of the prospects of that idea.The Predictive R 2 of BemisIn the area of linear models, Bemis has proposed a \"predictive R 2 \" or pR 2 .", [["R 2", "GENE_OR_GENE_PRODUCT", 251, 254], ["virtual screening", "TEST", 34, 51], ["an evaluation", "TEST", 117, 130]]], ["The pR 2 does not involve training/test split cross-validation, but rather uses an information-theoretic criterion motivated by ideas of Shi and Tsai (2002) .", [["pR 2", "PROTEIN", 4, 8]]], ["To give more clarity, we give an alternative notation of the pR 2 , building up from the familiar R 2 to the adjusted R 2 and finally to the pR 2 .", [["R 2", "GENE_OR_GENE_PRODUCT", 118, 121], ["pR 2", "DNA", 61, 65], ["R 2", "DNA", 98, 101], ["R 2", "DNA", 118, 121], ["pR 2", "DNA", 141, 145]]], ["Figures 11 and 12 illustrate the performance of the pR 2 compared with several of the currently popular criteria on a specific data set resulting from one of the drug hunting projects at Eli Lilly.", [["Figures", "TEST", 0, 7]]], ["This data set has IC50 values for 1289 molecules.", [["This data", "TEST", 0, 9], ["IC50 values", "TEST", 18, 29]]], ["There were 2317 descriptors (or covariates) and a multiple linear regression model was used with forward variable selection; the linear model was trained on half the data (selected at random) and evaluated on the other (hold-out) half.", [["a multiple linear regression model", "TREATMENT", 48, 82], ["forward variable selection", "TREATMENT", 97, 123]]], ["The root mean squared error of prediction (RMSE) for the test hold-out set is minimized when the model has 21 parameters.", [["root", "ANATOMY", 4, 8], ["the test", "TEST", 53, 61], ["root", "OBSERVATION_MODIFIER", 4, 8]]], ["Figure 11 shows the model size chosen by several criteria applied to the training set in a forward selection; for example, the pR 2 chose 22 descriptors, the Bayesian Information Criterion chose 49, Leave One Out crossvalidation chose 308, the adjusted R 2 chose 435, and the Akaike Information Criterion chose 512 descriptors in the model.", [["Figure", "TEST", 0, 6], ["size", "OBSERVATION_MODIFIER", 26, 30]]], ["Although the pR 2 criterion selected considerably fewer descriptors than the other methods, it had the best prediction performance.", [["pR 2 criterion", "DNA", 13, 27]]], ["Also, only pR 2 and BIC had better prediction on the test data set than the null model.Common ErrorsPredictive modeling, statistical modeling, and machine learning are very open areas in the sense that the barrier to admission is very low.", [["pR 2", "GENE_OR_GENE_PRODUCT", 11, 15], ["pR 2", "DNA", 11, 15], ["the test data", "TEST", 49, 62], ["very", "OBSERVATION_MODIFIER", 168, 172], ["open", "OBSERVATION_MODIFIER", 173, 177], ["areas", "OBSERVATION_MODIFIER", 178, 183]]], ["The Bemis pR 2 for an example data set.", [["Bemis pR 2", "DNA", 4, 14], ["an example data", "TEST", 19, 34]]], ["The \"true\" observed R 2 based on the test set, and the pR 2 estimated only from the training set.", [["R 2", "DNA", 20, 23], ["the test set", "TEST", 33, 45], ["the pR", "TEST", 51, 57]]], ["(Reproduced with permission from the author.) start experimenting in this area is a PC and a data analysis package.", [["a data analysis package", "TEST", 91, 114]]], ["Below is a list of the most frequent errors as they occur in this field.Number of Descriptors in the Model1.", [["Model1", "DNA", 101, 107]]], ["Belief that a very small p-value for a predictor (for example, a biomarker) is more likely to occur with high predictive accuracy.", [["a biomarker", "TEST", 63, 74]]], ["The multiple testing problem must not be ignored, and the false discovery rate (FDR) controlled; see also Chapter 6.", [["The multiple testing problem", "PROBLEM", 0, 28]]], ["Failure to pre-process and clean the data.", [["Failure to pre-process", "PROBLEM", 0, 22], ["clean the data", "TEST", 27, 41]]], ["Sometimes even data with missing values are jammed through a learning algorithm with little thought.", [["missing values", "PROBLEM", 25, 39], ["a learning algorithm", "TREATMENT", 59, 79]]], ["For example, a cluster analysis or self-organizing map is used in combination with a post hoc analysis to do prediction.", [["a cluster analysis", "TEST", 13, 31], ["self-organizing map", "PROBLEM", 35, 54], ["a post hoc analysis", "TEST", 83, 102]]], ["Failure to evaluate a method on test data.", [["Failure", "PROBLEM", 0, 7], ["a method on test data", "TEST", 20, 41]]], ["Test data set too small, with these consequences: a.", [["Test data", "TEST", 0, 9], ["too small", "OBSERVATION_MODIFIER", 14, 23]]], ["The test sample and the training sample are likely to be similar in their descriptor values.", [["The test sample", "TEST", 0, 15], ["the training sample", "TEST", 20, 39]]], ["\"Cheating\" in model assessment: using the whole training set to select descriptors, and then splitting the data into train and test sets, and training the model on the descriptor set selected from the whole training set.Number of Descriptors in the Model7.", [["Model7", "DNA", 249, 255], ["the whole training", "TREATMENT", 38, 56], ["test sets", "TEST", 127, 136]]], ["Confusion of model selection with model assessment.", [["Confusion", "DISEASE", 0, 9], ["model assessment", "TEST", 34, 50]]], ["If one chooses the model with the lowest cross-validated error among competing models, that error is not a valid estimate of the prediction error of that model (selection bias).Iterative Medium-Throughput ScreeningResearchers who use high-throughput screening (HTS) methods are troubled with many obstacles such as poor data quality, misleading false-positive and falsenegative information, and the need to confirm and expand the SAR of the identified lead candidates.", [["HTS) methods", "TREATMENT", 261, 273]]], ["Additionally, HTS strategies lead to the large-scale consumption of valuable resources such as proteins and chemicals from the inventory, and may not be applicable to all targets (Major, 1999) .", [["HTS strategies", "TREATMENT", 14, 28]]], ["The problem is fueled, in particular, by the prospects of expanding universes of targets-an increase by a factor of 10 is expected (Drews.", [["expanding universes of targets", "TREATMENT", 58, 88], ["increase", "OBSERVATION_MODIFIER", 92, 100]]], ["As a consequence, there is a need not only to increase the scope of screening, but also the efficiency of each screening experiment.", [["screening", "TEST", 68, 77], ["each screening experiment", "TEST", 106, 131]]], ["Hybrid screening strategies have been suggested that unite in silico and in vitro screening in one integrated process.", [["Hybrid screening strategies", "TEST", 0, 27], ["vitro screening", "TEST", 76, 91]]], ["Iterative medium-throughput screening (MTS) starts with a small (200 to 20,000) and \"diverse\" subset of compounds.", [["Iterative medium-throughput screening", "TEST", 0, 37], ["small", "OBSERVATION_MODIFIER", 58, 63]]], ["This initial sample is subjected to a primary screening where the main objective is to gather SAR data for predictive model building.", [["a primary screening", "TEST", 36, 55], ["predictive model building", "TREATMENT", 107, 132]]], ["This is a key distinction from the older paradigm where the primary objective is to obtain an initial set of screening hits, and any subsequent model building is an added bonus.", [["screening hits", "TEST", 109, 123]]], ["Based on this first SAR, the corporate inventory is screened in silico in order to identify a further, more focused set of compounds, the focused library, for a second round of MTS.", [["MTS", "DISEASE", 177, 180]]], ["Several cycles of testing-analyzing-testing can be applied aimed at either refining the SAR model(s) or the identification of more active compounds.", [["testing", "TEST", 18, 25], ["analyzing-testing", "TEST", 26, 43], ["active", "OBSERVATION_MODIFIER", 131, 137], ["compounds", "OBSERVATION", 138, 147]]], ["Abt et al. (2001) studied the influence of the size of the focused sample and the number of cycles on the effectiveness of the computational approaches.Iterative Medium-Throughput ScreeningOne factor that plays a role in the decision on how compounds are chosen in a given cycle is the stage of a project.", [["Throughput Screening", "TEST", 169, 189], ["size", "OBSERVATION_MODIFIER", 47, 51]]], ["An early stage project may require more diversity to be built into the selection process, whereas a later stage lead optimization effort would draw much more heavily on predictive modeling and expert judgement.Iterative Medium-Throughput ScreeningActive learning is a strategy that is iterative and where the selection of compounds to test in the next iteration is based on all the currently available data (see, for example, Warmuth et al., 2003 and Campbell et al., 2000) .", [["a later stage lead optimization effort", "PROBLEM", 98, 136], ["predictive modeling", "TEST", 169, 188], ["expert judgement", "TEST", 193, 209], ["early", "OBSERVATION_MODIFIER", 3, 8], ["stage", "OBSERVATION_MODIFIER", 9, 14], ["may require", "UNCERTAINTY", 23, 34], ["more diversity", "OBSERVATION_MODIFIER", 35, 49]]], ["A key distinction between active learning and other modeling strategies is that, in active learning, the primary objective for selecting the next batch of compounds for testing is to improve the model optimally, whereas in drug screening programs the primary goal is to find as many potent (and usually novel) compounds as possible.", [["testing", "TEST", 169, 176], ["active", "OBSERVATION_MODIFIER", 26, 32]]], ["This distinction and the consequent effects are dramatic.", [["consequent", "OBSERVATION_MODIFIER", 25, 35], ["effects", "OBSERVATION_MODIFIER", 36, 43], ["dramatic", "OBSERVATION_MODIFIER", 48, 56]]], ["In active learning, the most interesting compounds are the ones for which the model has had difficulty in the assignment of a clear classification whereas, in a typical drug hunting program, the most interesting compounds are the ones that are scored the most unambiguously as active.", [["active", "OBSERVATION_MODIFIER", 3, 9], ["active", "OBSERVATION_MODIFIER", 277, 283]]], ["This has downstream implications on what will come out of future iterations of screening.", [["screening", "TEST", 79, 88]]], ["The traditional business-driven approach will find good compounds faster, but the active learning approach will generate better models faster, and eventually lead to better exploration of chemical space, resulting in finding the best compounds.Iterative Medium-Throughput ScreeningThere is also an analogy with ancillary efforts such as toxicity testing.", [["toxicity", "DISEASE", 337, 345], ["toxicity testing", "TEST", 337, 353]]], ["A drug hunting project tends to focus on finding compounds with potency and selectivity for the target of interest.", [["A drug hunting", "PROBLEM", 0, 14]]], ["When interesting compounds are found, they are submitted for toxicity testing so that a small set of structurally related compounds is tested for the toxic endpoint of interest.", [["toxicity", "DISEASE", 61, 69], ["toxicity testing", "TEST", 61, 77], ["a small set of structurally related compounds", "PROBLEM", 86, 131]]], ["This places a handicap on any toxicity modeling effort.", [["toxicity", "DISEASE", 30, 38], ["a handicap", "PROBLEM", 12, 22], ["any toxicity modeling effort", "PROBLEM", 26, 54]]], ["If the goal is to develop a good toxicity model (which would reduce the need for animal testing and reduce cycle time in the project), then compounds that are not interesting from a potency standpoint would need to be tested for toxicity.", [["toxicity", "DISEASE", 33, 41], ["toxicity", "DISEASE", 229, 237], ["animal testing", "TEST", 81, 95], ["toxicity", "PROBLEM", 229, 237]]], ["This would mean that the interesting potent compounds must wait their turn due to limited capacity in toxicity testing.", [["toxicity", "DISEASE", 102, 110], ["limited capacity", "PROBLEM", 82, 98], ["toxicity testing", "TEST", 102, 118]]], ["The long view, both in terms of active learning for potency and for toxicity, might be to strike some balance between immediate and future gains.Virtual Screening and SynthesisVirtual screening is a simple concept, arising from the need to break out from the confines of the currently available set of in-house chemical libraries.", [["toxicity", "DISEASE", 68, 76], ["toxicity", "PROBLEM", 68, 76], ["Virtual Screening", "TEST", 145, 162], ["SynthesisVirtual screening", "TEST", 167, 193]]], ["It is a simple matter to construct representations of molecules using computers, and this can be done in a combinatorial manner.", [["simple matter", "OBSERVATION_MODIFIER", 8, 21]]], ["Then a number of \"substituents\" are chosen; these can be thought of as the \"appendages\" that gets attached to the backbone at various (preselected) locations.", [["\"substituents\"", "TREATMENT", 17, 31]]], ["All (reasonable) combinations of scaffolds and substituents can be made in silico and these structures form a virtual library.", [["scaffolds and substituents", "TREATMENT", 33, 59]]], ["The library may contain millions of molecules but it is more typical to see something of the order of 500,000 structures.", [["millions of molecules", "PROBLEM", 24, 45], ["millions", "OBSERVATION_MODIFIER", 24, 32]]], ["This is because most virtual screening efforts are knowledge driven; something is known about the SAR before the virtual screen is attempted.", [["the virtual screen", "TEST", 109, 127]]], ["The biological screening is done virtually through the use of the predictive models applied to the virtual library.Virtual Screening and SynthesisSome of the high-ranking structures may be very similar to structures that have already been tested.", [["The biological screening", "TEST", 0, 24], ["the predictive models", "TREATMENT", 62, 83], ["Virtual Screening", "TEST", 115, 132], ["SynthesisSome", "TEST", 137, 150]]], ["These are removed from the list using molecular diversity methods such as a Leader algorithm (Hartigan, 1975) .", [["molecular diversity methods", "TREATMENT", 38, 65]]], ["In this context, the Leader algorithm is not providing a cluster analysis, but simply a post-processing of a rank ordered list.", [["a cluster analysis", "TEST", 55, 73]]], ["From what is left, a relatively small number of molecules are then synthesized and tested for biological activity.", [["a relatively small number of molecules", "PROBLEM", 19, 57], ["left", "ANATOMY_MODIFIER", 13, 17], ["relatively", "OBSERVATION_MODIFIER", 21, 31], ["small", "OBSERVATION_MODIFIER", 32, 37], ["number", "OBSERVATION_MODIFIER", 38, 44], ["molecules", "OBSERVATION", 48, 57]]], ["Because this is a relatively expensive part of the process, it is usually important that some knowledge about the SAR has been gained before the virtual screening is done.", [["the virtual screening", "TEST", 141, 162]]], ["In the drug hunting screening context, chemical compounds can be pooled.", [["chemical compounds", "TREATMENT", 39, 57]]], ["If the mixture is potent, the individual components can then be tested.", [["potent", "OBSERVATION_MODIFIER", 18, 24]]], ["For the use of orthogonal arrays in the design of a pooling study see Phatarfod and Sudbury (1994; and also Dorfman, 1943) .PoolingThe design and deconvolution of pools in drug discovery screening has been approached in different ways by a number of companies.", [["orthogonal arrays", "TREATMENT", 15, 32], ["a pooling study", "TEST", 50, 65], ["Pooling", "PROBLEM", 124, 131], ["drug discovery screening", "TEST", 172, 196]]], ["The deconvolution of these results was done using chemical technology rather than the informatics approach one might use following Phatarfod and Sudbury (1994) .PoolingAn interesting informatics strategy involves pooling covariates in a variable subset selection context.", [["chemical technology", "TREATMENT", 50, 69], ["PoolingAn", "TREATMENT", 161, 170], ["pooling covariates", "PROBLEM", 213, 231]]], ["If the covariates are sparse binary, meaning that each column is mostly zeros with a few ones (a typical scenario), one strategy for data reduction is to pool columns together.", [["sparse binary", "PROBLEM", 22, 35], ["data reduction", "TREATMENT", 133, 147]]], ["This data set is now 100-fold smaller, and a forward selection method might be run to fit a model on the reduced data set.", [["This data", "TEST", 0, 9], ["a forward selection method", "TREATMENT", 43, 69], ["smaller", "OBSERVATION_MODIFIER", 30, 37]]], ["Variables selected by such a procedure can then be collected and the individual covariates unpacked and a second stage of variable selection performed on this reduced data set.Expectations for Discovery of Rare EventsThe hit rate within a set of molecules selected by a virtual screen is primarily determined by two parameters: the unknown proportion of p hits that exist in the set of molecules scored and the false positive error rate (\u03b1) of the classifier used for virtual screening.", [["a procedure", "TREATMENT", 27, 38], ["variable selection", "TEST", 122, 140], ["Rare Events", "PROBLEM", 206, 217], ["The hit rate", "TEST", 217, 229], ["a virtual screen", "TEST", 268, 284], ["virtual screening", "TEST", 468, 485]]], ["To a large extent, the statistics of rare events (true hits within a large compound collection) leads to some initially counterintuitive results in the magnitude of a hit rate within a set of molecules selected by a model.Expectations for Discovery of Rare EventsMost pharmaceutical companies expect to see hit rates in the 0.1% to 1% range for a high-throughput screen.", [["rare events", "PROBLEM", 37, 48], ["true hits", "PROBLEM", 50, 59], ["a large compound collection", "PROBLEM", 67, 94], ["a hit rate", "TEST", 165, 175], ["large", "OBSERVATION_MODIFIER", 5, 10], ["extent", "OBSERVATION_MODIFIER", 11, 17], ["large", "OBSERVATION_MODIFIER", 69, 74]]], ["In the virtual screening context, when the hits are a rare event (of the order of 0.1%) even very good predictive models cannot be expected to lead to arbitrarily high hit rates for the molecules selected.", [["arbitrarily high hit rates", "PROBLEM", 151, 177]]], ["It is quite likely that marginal to good virtual screen models will result in no hits identified in a subset of molecules selected by virtual screening.Expectations for Discovery of Rare EventsThe virtual screen can be considered as a classifier that makes a prediction about whether a molecule is likely to be active or inactive in a biochemical assay.", [["hits", "PROBLEM", 81, 85], ["virtual screening", "TEST", 134, 151], ["Rare Events", "PROBLEM", 182, 193], ["The virtual screen", "TEST", 193, 211], ["a biochemical assay", "TEST", 333, 352], ["quite likely", "UNCERTAINTY", 6, 18]]], ["It can be constructed from training data (for example, a QSAR model) or constructed from a model of a binding site.", [["training data", "TEST", 27, 40], ["a QSAR model", "TEST", 55, 67], ["a binding site", "PROBLEM", 100, 114]]], ["For a given molecule in a virtual library, let the null hypothesis be that the molecule is not a hit.", [["let", "GENE_OR_GENE_PRODUCT", 43, 46], ["hit", "OBSERVATION", 97, 100]]], ["The parameter p is unknown but believed to be very small (<0.01) for large virtual libraries.", [["large virtual libraries", "PROBLEM", 69, 92], ["very", "OBSERVATION_MODIFIER", 46, 50], ["small", "OBSERVATION_MODIFIER", 51, 56]]], ["1 \u2212 \u03b2 is the power (or 1 -type II error, where \u03b2 is the false negative error rate) and \u03b1 is the type I error, also called the \"size\" of a test in the hypothesis testing context, or the false positive error rate.", [["1 \u2212 \u03b2", "SIMPLE_CHEMICAL", 0, 5], ["\u03b2", "PROTEIN", 47, 48], ["\u03b1", "PROTEIN", 87, 88], ["a test", "TEST", 136, 142], ["positive error", "OBSERVATION", 191, 205]]], ["The last equation defines the probability that a molecule is determined to be a hit in a biochemical assay given that the virtual screen predicts the molecule to be a hit.", [["a biochemical assay", "TEST", 87, 106], ["the virtual screen", "TEST", 118, 136], ["hit", "OBSERVATION", 167, 170]]], ["This probability is of great interest because it is valuable to have an estimate of the hit rate one can expect for a subset of molecules that are selected by a virtual screen.", [["a virtual screen", "TEST", 159, 175]]], ["The values of parameters p, \u03b1, and \u03b2 can be varied to observe the effect on equation (3).", [["\u03b1", "GENE_OR_GENE_PRODUCT", 28, 29], ["\u03b2", "GENE_OR_GENE_PRODUCT", 35, 36], ["\u03b1", "PROTEIN", 28, 29], ["\u03b2", "PROTEIN", 35, 36], ["The values", "TEST", 0, 10]]], ["It is straightforward to verify that the \"power\" of the classifier (1 \u2212 \u03b2) has relatively little effect on the hit rate observed in the subset of molecules selected by a virtual screen.", [["the hit rate", "TEST", 107, 119], ["a virtual screen", "TEST", 168, 184], ["little", "OBSERVATION_MODIFIER", 90, 96], ["effect", "OBSERVATION_MODIFIER", 97, 103]]], ["The influence of power is greatly reduced as the probability of a hit existing in the set of compounds being scored decreases (the low prevalence effect) and, for rare events, the relative importance of \u03b1 is greatly intensified.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 203, 204], ["\u03b1", "PROTEIN", 203, 204]]], ["Even for less rare events, say a hit rate of 10% (disturbingly high in drug discovery, suggesting nonspecificity in the assay), the effect of \u03b1 dominates.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 142, 143], ["\u03b1", "PROTEIN", 142, 143], ["less rare events", "PROBLEM", 9, 25], ["a hit rate", "TEST", 31, 41]]], ["11 Drugability of Molecules: ADME, Solubility, ToxicityExpectations for Discovery of Rare EventsThe word drugability is often used to cover all aspects of a molecule beyond initial potency.", [["Toxicity", "DISEASE", 47, 55], ["Rare Events", "PROBLEM", 85, 96]]], ["A potential drug compound must overcome many challenges in order to be a successful therapeutic.", [["A potential drug compound", "PROBLEM", 0, 25]]], ["Critical components of drug design include absorption, permeation, distribution, metabolism, stability, specificity (does it do more than intended?), and toxicity (related but not identical to specificity).", [["toxicity", "DISEASE", 154, 162], ["toxicity", "PROBLEM", 154, 162], ["drug design", "OBSERVATION", 23, 34], ["stability", "OBSERVATION_MODIFIER", 93, 102]]], ["In this section, some of these issues are discussed in more detail.ADMEMany of the compounds entering clinical trials are discontinued, often due to issues directly related to ADME: absorption, distribution, metabolism, and elimination/ excretion of a drug.", [["ADME", "CHEMICAL", 176, 180]]], ["Absorption is of paramount importance, being the extent to which an intact drug is absorbed from the gut lumen into the portal circulation.", [["gut lumen", "ANATOMY", 101, 110], ["portal", "ANATOMY", 120, 126], ["gut lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 110], ["portal circulation", "MULTI-TISSUE_STRUCTURE", 120, 138], ["an intact drug", "TREATMENT", 65, 79], ["intact", "OBSERVATION", 68, 74], ["gut", "ANATOMY", 101, 104], ["lumen", "ANATOMY_MODIFIER", 105, 110], ["portal circulation", "ANATOMY", 120, 138]]], ["A compound may have potent effects in vitro screens involving cells or enzymes, but in a living organism the compound may have no effect because of a distribution problem.", [["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["enzymes", "PROTEIN", 71, 78], ["vitro screens", "TEST", 38, 51], ["enzymes", "TEST", 71, 78], ["a living organism", "PROBLEM", 87, 104], ["a distribution problem", "PROBLEM", 148, 170]]], ["This can be due to a number of things; for example, the compound may bind so tightly to proteins in the bloodstream that it does not leave the bloodstream until it is eliminated by the liver.", [["bloodstream", "ANATOMY", 104, 115], ["bloodstream", "ANATOMY", 143, 154], ["liver", "ANATOMY", 185, 190], ["liver", "ORGAN", 185, 190], ["liver", "ANATOMY", 185, 190]]], ["The opposite extreme can be a problem as well, because proteins in the blood can be important as transport mechanisms.", [["blood", "ANATOMY", 71, 76], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["proteins in the blood", "PROBLEM", 55, 76]]], ["In addition, the unbound drug may penetrate the wall of the blood vessel so that a certain amount of protein binding is desirable.", [["wall", "ANATOMY", 48, 52], ["blood vessel", "ANATOMY", 60, 72], ["wall", "TISSUE", 48, 52], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 60, 72], ["the unbound drug", "TREATMENT", 13, 29], ["protein binding", "PROBLEM", 101, 116], ["wall", "ANATOMY_MODIFIER", 48, 52], ["blood vessel", "ANATOMY", 60, 72], ["protein binding", "OBSERVATION", 101, 116]]], ["Most pharmaceutical companies have models that predict the protein binding affinity of compounds.", [["the protein binding affinity of compounds", "PROBLEM", 55, 96]]], ["Distribution is only one problem that can confound an SAR effort when transitioning from in vitro to in vivo screens.ADMETwo endpoints important to distribution are oral bioavailability and first pass clearance; see Birkett (1990 Birkett ( , 1991 .", [["oral", "ANATOMY", 165, 169], ["oral", "ORGANISM_SUBDIVISION", 165, 169], ["an SAR effort", "PROBLEM", 51, 64]]], ["Oral bioavailability is particularly important because a drug that has, say, only 10% oral bioavailability would require a 10-fold higher dose when given orally as compared with being given intravenously.", [["Oral", "ANATOMY", 0, 4], ["oral", "ANATOMY", 86, 90], ["intravenously", "ANATOMY", 190, 203], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["oral", "ORGANISM_SUBDIVISION", 86, 90], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 203]]], ["Orally administered drugs, after absorption through the gut lumen into the portal circulation, must then pass through the liver before reaching the systemic circulation.", [["gut lumen", "ANATOMY", 56, 65], ["portal circulation", "ANATOMY", 75, 93], ["liver", "ANATOMY", 122, 127], ["gut lumen", "MULTI-TISSUE_STRUCTURE", 56, 65], ["portal circulation", "MULTI-TISSUE_STRUCTURE", 75, 93], ["liver", "ORGAN", 122, 127], ["Orally administered drugs", "TREATMENT", 0, 25], ["portal circulation", "ANATOMY", 75, 93], ["liver", "ANATOMY", 122, 127], ["systemic circulation", "ANATOMY", 148, 168]]], ["Pre-systemic or first pass extraction refers to the removal of drugs during this first pass through the liver.", [["liver", "ANATOMY", 104, 109], ["liver", "ORGAN", 104, 109], ["Pre-systemic or first pass extraction", "TREATMENT", 0, 37], ["the removal of drugs", "TREATMENT", 48, 68], ["liver", "ANATOMY", 104, 109]]], ["First pass clearance is the extent to which a drug is removed by the liver during its first passage from the portal blood on its way to the systemic circulation.", [["liver", "ANATOMY", 69, 74], ["portal blood", "ANATOMY", 109, 121], ["liver", "ORGAN", 69, 74], ["portal", "MULTI-TISSUE_STRUCTURE", 109, 115], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["a drug", "TREATMENT", 44, 50], ["liver", "ANATOMY", 69, 74], ["portal blood", "ANATOMY", 109, 121], ["systemic circulation", "ANATOMY", 140, 160]]], ["Oral bioavailability is the fraction of the dose that reaches the systemic circulation as intact drug.", [["Oral", "ANATOMY", 0, 4], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["systemic circulation", "ANATOMY", 66, 86], ["intact drug", "OBSERVATION", 90, 101]]], ["It is apparent that this will depend both on how well the drug is absorbed and how much escapes being removed by the liver.", [["liver", "ANATOMY", 117, 122], ["liver", "ORGAN", 117, 122], ["liver", "ANATOMY", 117, 122]]], ["In fact, the simple equation for bioavailability isADMEwhere the extraction ratio is the proportion removed by the liver.", [["liver", "ANATOMY", 115, 120], ["liver", "ORGAN", 115, 120], ["bioavailability isADMEwhere the extraction ratio", "TREATMENT", 33, 81], ["liver", "ANATOMY", 115, 120]]], ["The 20% alone does not tell us anything about the metabolism or the absorption of the drug.ADMEBecause there are many ways to achieve a given level of bioavailability, it makes sense to consider using a compartmental model to predict bioavailability rather than simply training a model on a set of bioavailability results.", [["a compartmental model", "TREATMENT", 201, 222]]], ["The role of metabolism tends to dominate most often and variability in drug response is greatly influenced by this.", [["drug response", "OBSERVATION", 71, 84]]], ["Drugs that are efficiently eliminated by the liver often have high variability in the plasma levels both within and between individuals because, in that case, slight changes to the extraction ratio can cause large changes to the resulting bioavailability.ADMETreated as a special case of distribution is the ability of a molecule to cross the blood-brain barrier (BBB).", [["liver", "ANATOMY", 45, 50], ["plasma", "ANATOMY", 86, 92], ["blood-brain barrier", "ANATOMY", 343, 362], ["BBB", "ANATOMY", 364, 367], ["liver", "ORGAN", 45, 50], ["plasma", "ORGANISM_SUBSTANCE", 86, 92], ["blood-", "MULTI-TISSUE_STRUCTURE", 343, 349], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 349, 362], ["BBB", "MULTI-TISSUE_STRUCTURE", 364, 367], ["Drugs", "TREATMENT", 0, 5], ["high variability", "PROBLEM", 62, 78], ["the plasma levels", "TEST", 82, 99], ["slight changes", "PROBLEM", 159, 173], ["large changes", "PROBLEM", 208, 221], ["liver", "ANATOMY", 45, 50], ["high variability", "OBSERVATION", 62, 78], ["slight", "OBSERVATION_MODIFIER", 159, 165], ["brain", "ANATOMY", 349, 354]]], ["This fact is important to know, both for central nervous system (CNS) drugs and for drugs that do not target the central nervous system.", [["central nervous system", "ANATOMY", 41, 63], ["CNS", "ANATOMY", 65, 68], ["central nervous system", "ANATOMY", 113, 135], ["nervous system", "ANATOMICAL_SYSTEM", 49, 63], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["central nervous system", "ANATOMICAL_SYSTEM", 113, 135], ["central nervous system (CNS) drugs", "TREATMENT", 41, 75], ["drugs", "TREATMENT", 84, 89], ["central", "ANATOMY_MODIFIER", 113, 120], ["nervous system", "ANATOMY", 121, 135]]], ["There has been a flurry of research attempts to model and/or predict the BBB propensity of molecules.", [["BBB", "MULTI-TISSUE_STRUCTURE", 73, 76], ["research attempts", "TREATMENT", 27, 44]]], ["Many of these efforts are statistically destitute; for example, a research group may examine only a set of molecules that do cross the BBB.", [["BBB", "ANATOMY", 135, 138], ["BBB", "MULTI-TISSUE_STRUCTURE", 135, 138]]], ["Proper inference must involve examples of compounds that do not cross the BBB as well as compounds that do and this falls in the domain of predictive modeling and machine learning (see Section 6).", [["BBB", "MULTI-TISSUE_STRUCTURE", 74, 77], ["this falls", "PROBLEM", 111, 121]]], ["The BBB is formed by the highly selective capillaries of the central nervous system.", [["BBB", "ANATOMY", 4, 7], ["capillaries", "ANATOMY", 42, 53], ["central nervous system", "ANATOMY", 61, 83], ["BBB", "MULTI-TISSUE_STRUCTURE", 4, 7], ["capillaries", "TISSUE", 42, 53], ["central nervous system", "ANATOMICAL_SYSTEM", 61, 83], ["formed", "OBSERVATION", 11, 17], ["highly", "OBSERVATION_MODIFIER", 25, 31], ["selective", "OBSERVATION_MODIFIER", 32, 41], ["capillaries", "OBSERVATION", 42, 53], ["central", "ANATOMY_MODIFIER", 61, 68], ["nervous system", "ANATOMY", 69, 83]]], ["Passage of drugs through the BBB may occur by passive diffusion or from various specific uptake mechanisms, many of which are there to supply nutrients to the brain.", [["BBB", "ANATOMY", 29, 32], ["brain", "ANATOMY", 159, 164], ["BBB", "MULTI-TISSUE_STRUCTURE", 29, 32], ["brain", "ORGAN", 159, 164], ["drugs", "TREATMENT", 11, 16], ["passive diffusion", "PROBLEM", 46, 63], ["various specific uptake mechanisms", "PROBLEM", 72, 106], ["brain", "ANATOMY", 159, 164]]], ["There are also mechanisms for transporting substances out of the brain.", [["brain", "ANATOMY", 65, 70], ["brain", "ORGAN", 65, 70], ["brain", "ANATOMY", 65, 70]]], ["P-glycoprotein (or Pgp) is an efflux pump that removes many drug compounds from the brain.", [["brain", "ANATOMY", 84, 89], ["P-glycoprotein", "GENE_OR_GENE_PRODUCT", 0, 14], ["Pgp", "GENE_OR_GENE_PRODUCT", 19, 22], ["brain", "ORGAN", 84, 89], ["P-glycoprotein", "PROTEIN", 0, 14], ["Pgp", "PROTEIN", 19, 22], ["an efflux pump", "TREATMENT", 27, 41], ["brain", "ANATOMY", 84, 89]]], ["Thus BBB transport is a complex phenomenon and modeling this is a challenging and ongoing research topic in most pharmaceutical companies.ADMEMetabolism is another critically important aspect for determining the fate of a drug.", [["ADMEMetabolism", "DISEASE", 138, 152], ["BBB", "MULTI-TISSUE_STRUCTURE", 5, 8], ["a complex phenomenon", "PROBLEM", 22, 42], ["complex", "OBSERVATION_MODIFIER", 24, 31], ["phenomenon", "OBSERVATION", 32, 42]]], ["If a drug is metabolized quickly, it may be excreted in the urine before it has a chance to reach the intended site, but the full story is much more complicated than this.", [["urine", "ANATOMY", 60, 65], ["urine", "ORGANISM_SUBSTANCE", 60, 65]]], ["Most successful drugs are lipid-soluble and are reabsorbed from the kidney back into the bloodstream.", [["kidney", "ANATOMY", 68, 74], ["bloodstream", "ANATOMY", 89, 100], ["lipid", "SIMPLE_CHEMICAL", 26, 31], ["kidney", "ORGAN", 68, 74], ["Most successful drugs", "TREATMENT", 0, 21], ["lipid-soluble", "TREATMENT", 26, 39], ["kidney", "ANATOMY", 68, 74], ["bloodstream", "ANATOMY", 89, 100]]], ["These compounds undergo metabolism, which is a way for the body to break down and ultimately eliminate a substance.", [["body", "ANATOMY", 59, 63], ["body", "ORGANISM_SUBDIVISION", 59, 63], ["metabolism", "OBSERVATION_MODIFIER", 24, 34]]], ["The liver uses a number of different enzymes to break a compound down into smaller parts, called metabolites.", [["liver", "ANATOMY", 4, 9], ["liver", "ORGAN", 4, 9], ["enzymes", "PROTEIN", 37, 44], ["different enzymes", "TEST", 27, 44], ["liver", "ANATOMY", 4, 9]]], ["A metabolite may either be pharmacologically similar to the parent compound or harmless, but not pharmacologically active, or may possess life-threatening toxicity.", [["toxicity", "DISEASE", 155, 163], ["life-threatening toxicity", "PROBLEM", 138, 163]]], ["Thus it is essential to know into which of these categories a drug falls and it is desirable to control this aspect in a favorable way.", [["a drug falls", "PROBLEM", 60, 72]]], ["Because humans are genetically diverse, the same compound will be metabolized differently in different people.", [["humans", "ORGANISM", 8, 14], ["people", "ORGANISM", 103, 109], ["humans", "SPECIES", 8, 14], ["people", "SPECIES", 103, 109], ["humans", "SPECIES", 8, 14]]], ["All of these issues are interdependent and are illustrated in the following examples.ADMEA major group of enzymes, not just in the liver but also in the intestines, lung, kidneys, and brain, is known as the Cytochrome P-450 isoenzymes, often abbreviated as CYP450.", [["liver", "ANATOMY", 131, 136], ["intestines", "ANATOMY", 153, 163], ["lung", "ANATOMY", 165, 169], ["kidneys", "ANATOMY", 171, 178], ["brain", "ANATOMY", 184, 189], ["liver", "ORGAN", 131, 136], ["intestines", "ORGAN", 153, 163], ["lung", "ORGAN", 165, 169], ["kidneys", "ORGAN", 171, 178], ["brain", "ORGAN", 184, 189], ["Cytochrome P-450 isoenzymes", "GENE_OR_GENE_PRODUCT", 207, 234], ["CYP450", "GENE_OR_GENE_PRODUCT", 257, 263], ["enzymes", "PROTEIN", 106, 113], ["Cytochrome P-450 isoenzymes", "PROTEIN", 207, 234], ["CYP450", "PROTEIN", 257, 263], ["enzymes", "TEST", 106, 113], ["lung, kidneys, and brain", "PROBLEM", 165, 189], ["the Cytochrome P", "TEST", 203, 219], ["isoenzymes", "TEST", 224, 234], ["issues", "OBSERVATION", 13, 19], ["interdependent", "OBSERVATION_MODIFIER", 24, 38], ["liver", "ANATOMY", 131, 136], ["intestines", "ANATOMY", 153, 163], ["lung", "ANATOMY", 165, 169], ["kidneys", "ANATOMY", 171, 178], ["brain", "ANATOMY", 184, 189]]], ["Some drugs interact with these enzymes.", [["enzymes", "PROTEIN", 31, 38], ["these enzymes", "TEST", 25, 38], ["drugs", "OBSERVATION", 5, 10]]], ["A drug with a high affinity for an enzyme will slow the metabolism of any low-affinity drug; for example, grapefruit juice inhibits a number of CYP450s which results in higher than expected levels in the body of the drugs that are metabolized by those CYP450s.ADMEThe inhibition of CYP450 isoenzymes by grapefruit juice lasts about 24 hours and occurs in all forms of the juice-fresh fruit and fresh and frozen juice.", [["grapefruit juice", "ANATOMY", 106, 122], ["body", "ANATOMY", 204, 208], ["grapefruit juice", "ANATOMY", 303, 319], ["juice", "ANATOMY", 372, 377], ["fruit", "ANATOMY", 384, 389], ["juice", "ANATOMY", 411, 416], ["grapefruit juice", "CHEMICAL", 106, 122], ["grapefruit juice", "CHEMICAL", 303, 319], ["grapefruit juice", "ORGANISM_SUBSTANCE", 106, 122], ["CYP450s", "GENE_OR_GENE_PRODUCT", 144, 151], ["body", "ORGANISM_SUBDIVISION", 204, 208], ["CYP450s", "GENE_OR_GENE_PRODUCT", 252, 259], ["CYP450 isoenzymes", "GENE_OR_GENE_PRODUCT", 282, 299], ["grapefruit juice", "ORGANISM_SUBSTANCE", 303, 319], ["juice", "ORGANISM_SUBSTANCE", 372, 377], ["juice", "ORGANISM_SUBSTANCE", 411, 416], ["CYP450 isoenzymes", "PROTEIN", 282, 299], ["a high affinity", "PROBLEM", 12, 27], ["an enzyme", "TEST", 32, 41], ["grapefruit juice", "PROBLEM", 106, 122], ["CYP450 isoenzymes", "TREATMENT", 282, 299], ["fresh and frozen juice", "TREATMENT", 394, 416], ["higher", "OBSERVATION_MODIFIER", 169, 175]]], ["There is the potential for dangerous arrhythmias for patients taking cisapride, astemizole, and terfenadine.", [["arrhythmias", "DISEASE", 37, 48], ["cisapride", "CHEMICAL", 69, 78], ["astemizole", "CHEMICAL", 80, 90], ["terfenadine", "CHEMICAL", 96, 107], ["cisapride", "CHEMICAL", 69, 78], ["astemizole", "CHEMICAL", 80, 90], ["terfenadine", "CHEMICAL", 96, 107], ["patients", "ORGANISM", 53, 61], ["cisapride", "SIMPLE_CHEMICAL", 69, 78], ["astemizole", "SIMPLE_CHEMICAL", 80, 90], ["terfenadine", "SIMPLE_CHEMICAL", 96, 107], ["patients", "SPECIES", 53, 61], ["dangerous arrhythmias", "PROBLEM", 27, 48], ["cisapride", "TREATMENT", 69, 78], ["astemizole", "TREATMENT", 80, 90], ["terfenadine", "TREATMENT", 96, 107], ["potential for", "UNCERTAINTY", 13, 26], ["dangerous", "OBSERVATION_MODIFIER", 27, 36], ["arrhythmias", "OBSERVATION", 37, 48]]], ["Other substances may induce the opposite effect, that is, upregulate the levels of the enzymes and result in faster metabolism, for example, smoking and the ingestion of charbroiled meats may induce isoenzymes, resulting in increased clearance of drugs (such as theo-phylline).", [["meats", "ANATOMY", 182, 187], ["smoking", "CHEMICAL", 141, 148], ["theo-phylline", "CHEMICAL", 262, 275], ["theo-phylline", "CHEMICAL", 262, 275], ["theo-phylline", "SIMPLE_CHEMICAL", 262, 275], ["enzymes", "PROTEIN", 87, 94], ["the enzymes", "TEST", 83, 94], ["charbroiled meats", "TREATMENT", 170, 187], ["drugs", "TREATMENT", 247, 252], ["theo-phylline", "TREATMENT", 262, 275]]], ["The herb known as St. John's wort causes an increase in the Cytochrome P450 enzymes, especially CYP 3A4, which are responsible for the metabolism and elimination of many drugs.", [["St. John's wort", "ORGANISM", 18, 33], ["Cytochrome P450", "GENE_OR_GENE_PRODUCT", 60, 75], ["CYP 3A4", "GENE_OR_GENE_PRODUCT", 96, 103], ["Cytochrome P450 enzymes", "PROTEIN", 60, 83], ["CYP 3A4", "PROTEIN", 96, 103], ["the Cytochrome P450 enzymes", "TEST", 56, 83], ["CYP 3A4", "TEST", 96, 103], ["increase", "OBSERVATION_MODIFIER", 44, 52]]], ["This is why the birth control pill is rendered less effective by St. John's Wort.", [["the birth control pill", "TREATMENT", 12, 34]]], ["But in addition to being an inducer of CYP 3A4, St. John's Wort is also an inhibitor of CYP 2D6.", [["CYP 3A4", "GENE_OR_GENE_PRODUCT", 39, 46], ["St. John's Wort", "ORGANISM", 48, 63], ["CYP 2D6", "GENE_OR_GENE_PRODUCT", 88, 95], ["CYP 3A4", "PROTEIN", 39, 46], ["CYP 2D6", "PROTEIN", 88, 95]]], ["Hence patients taking St. John's wort are likely to experience an increase in blood levels of therapeutic drugs that are metabolized by the 2D6 family (this includes beta blockers, antidepressants, antipsychotics, cough suppressants, codeine, and others) as well as a decrease in blood levels of drugs that are metabolized by the 3A4 family of CYP 450s (which includes antibiotics, HIV protease inhibitors, antihistamines, calcium channel blockers, and others).ADMEJust two decades ago, the FDA was uninvolved in issues regarding CYP450 metabolism, but currently there are stringent guidelines that must be met to ensure that the metabolic fate of a drug is under control.", [["blood", "ANATOMY", 78, 83], ["blood", "ANATOMY", 280, 285], ["antidepressants", "CHEMICAL", 181, 196], ["cough suppressants", "CHEMICAL", 214, 232], ["codeine", "CHEMICAL", 234, 241], ["CYP 450s", "CHEMICAL", 344, 352], ["calcium", "CHEMICAL", 423, 430], ["codeine", "CHEMICAL", 234, 241], ["calcium", "CHEMICAL", 423, 430], ["patients", "ORGANISM", 6, 14], ["St. John's wort", "ORGANISM", 22, 37], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["2D6", "GENE_OR_GENE_PRODUCT", 140, 143], ["beta blockers", "GENE_OR_GENE_PRODUCT", 166, 179], ["codeine", "SIMPLE_CHEMICAL", 234, 241], ["blood", "ORGANISM_SUBSTANCE", 280, 285], ["3A4", "GENE_OR_GENE_PRODUCT", 330, 333], ["CYP 450s", "GENE_OR_GENE_PRODUCT", 344, 352], ["antihistamines", "SIMPLE_CHEMICAL", 407, 421], ["calcium channel blockers", "SIMPLE_CHEMICAL", 423, 447], ["CYP450", "GENE_OR_GENE_PRODUCT", 530, 536], ["2D6 family", "PROTEIN", 140, 150], ["3A4 family", "PROTEIN", 330, 340], ["CYP450", "PROTEIN", 530, 536], ["patients", "SPECIES", 6, 14], ["HIV", "SPECIES", 382, 385], ["an increase in blood levels", "PROBLEM", 63, 90], ["therapeutic drugs", "TREATMENT", 94, 111], ["beta blockers", "TREATMENT", 166, 179], ["antidepressants", "TREATMENT", 181, 196], ["antipsychotics", "TREATMENT", 198, 212], ["cough suppressants", "TREATMENT", 214, 232], ["codeine", "TREATMENT", 234, 241], ["a decrease in blood levels of drugs", "PROBLEM", 266, 301], ["antibiotics", "TREATMENT", 369, 380], ["HIV protease inhibitors", "TREATMENT", 382, 405], ["antihistamines", "TREATMENT", 407, 421], ["calcium channel blockers", "TREATMENT", 423, 447], ["CYP450 metabolism", "TEST", 530, 547], ["stringent guidelines", "TREATMENT", 573, 593], ["increase", "OBSERVATION_MODIFIER", 66, 74]]], ["There are genetic polymorphisms in some of the genes expressing CYP450 subfamilies.", [["CYP450", "GENE_OR_GENE_PRODUCT", 64, 70], ["CYP450 subfamilies", "PROTEIN", 64, 82], ["genetic polymorphisms", "PROBLEM", 10, 31], ["genetic polymorphisms", "OBSERVATION", 10, 31]]], ["For example, 5 to 10 percent of Caucasians have polymorphic forms of the 2D6 subfamily; such individuals are called \"slow metabolizers.\"", [["2D6", "GENE_OR_GENE_PRODUCT", 73, 76], ["2D6 subfamily", "PROTEIN", 73, 86], ["slow metabolizers", "PROBLEM", 117, 134]]], ["There is a large list of drugs metabolized by 2D6 that can pose a risk to slow metabolizers and dosing must be done carefully.SolubilitySolubility plays a critical role in the absorption of a drug.", [["2D6", "GENE_OR_GENE_PRODUCT", 46, 49], ["drugs", "TREATMENT", 25, 30], ["slow metabolizers", "PROBLEM", 74, 91], ["SolubilitySolubility", "TREATMENT", 126, 146], ["a drug", "TREATMENT", 190, 196], ["large", "OBSERVATION_MODIFIER", 11, 16]]], ["A compound with poor solubility may not achieve high enough levels in the stomach and intestine to be absorbed well.", [["stomach", "ANATOMY", 74, 81], ["intestine", "ANATOMY", 86, 95], ["stomach", "ORGAN", 74, 81], ["intestine", "ORGAN", 86, 95], ["A compound with poor solubility", "PROBLEM", 0, 31], ["poor solubility", "OBSERVATION_MODIFIER", 16, 31], ["stomach", "ANATOMY", 74, 81], ["intestine", "ANATOMY", 86, 95]]], ["However, it is generally true that highly soluble compounds lack sufficient lipophilicity to cross the blood-brain barrier and so, if the compound is an intended CNS drug, a balance must be maintained; see Amidon et al. (1995) .ToxicityToxicity is often related to ADME; for example, when a compound cannot be broken down and eliminated by the body it builds up toxic levels in the system.", [["blood-brain barrier", "ANATOMY", 103, 122], ["CNS", "ANATOMY", 162, 165], ["body", "ANATOMY", 344, 348], ["Toxicity", "DISEASE", 228, 236], ["Toxicity", "DISEASE", 236, 244], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 109, 122], ["CNS", "ANATOMICAL_SYSTEM", 162, 165], ["body", "ORGANISM_SUBDIVISION", 344, 348], ["ToxicityToxicity", "PROBLEM", 228, 244], ["brain", "ANATOMY", 109, 114], ["system", "ANATOMY", 382, 388]]], ["Some other toxicity issues that have recently received heightened attention are discussed below.", [["toxicity", "DISEASE", 11, 19], ["Some other toxicity issues", "PROBLEM", 0, 26], ["heightened attention", "TREATMENT", 55, 75], ["toxicity", "OBSERVATION", 11, 19]]], ["Phospholipidosis (an adaptive storage response to drug administration) and cardiomyopathy (a pathologic condition of the heart muscle) have been reasons for the recent FDA withdrawal of drugs.", [["heart muscle", "ANATOMY", 121, 133], ["Phospholipidosis", "DISEASE", 0, 16], ["cardiomyopathy", "DISEASE", 75, 89], ["heart muscle", "DISEASE", 121, 133], ["heart muscle", "ORGAN", 121, 133], ["Phospholipidosis", "PROBLEM", 0, 16], ["an adaptive storage response to drug administration", "TREATMENT", 18, 69], ["cardiomyopathy", "PROBLEM", 75, 89], ["a pathologic condition of the heart muscle", "PROBLEM", 91, 133], ["the recent FDA withdrawal of drugs", "PROBLEM", 157, 191], ["heart muscle", "ANATOMY", 121, 133]]], ["Another issue concerns the need for additional assurance of the absence of any potential for QT prolongation (an effect on electrical impulse conduction in the heart).", [["heart", "ANATOMY", 160, 165], ["QT prolongation", "DISEASE", 93, 108], ["heart", "ORGAN", 160, 165], ["QT prolongation", "PROBLEM", 93, 108], ["electrical impulse conduction", "TREATMENT", 123, 152], ["heart", "ANATOMY", 160, 165]]], ["Many classes of drugs induce QT prolongation, including antihistamines, antibiotics, antipsychotics, and macrolides.", [["QT prolongation", "DISEASE", 29, 44], ["macrolides", "CHEMICAL", 105, 115], ["macrolides", "CHEMICAL", 105, 115], ["antihistamines", "SIMPLE_CHEMICAL", 56, 70], ["macrolides", "SIMPLE_CHEMICAL", 105, 115], ["drugs", "TREATMENT", 16, 21], ["QT prolongation", "PROBLEM", 29, 44], ["antihistamines", "TREATMENT", 56, 70], ["antibiotics", "TREATMENT", 72, 83], ["antipsychotics", "TREATMENT", 85, 99], ["macrolides", "TREATMENT", 105, 115]]], ["QT prolongation can lead to sudden death.", [["QT prolongation", "DISEASE", 0, 15], ["death", "DISEASE", 35, 40], ["QT prolongation", "PROBLEM", 0, 15], ["sudden death", "PROBLEM", 28, 40]]], ["At least four drugs have been taken off the market due to QT prolongation alone: Terfenadine, Sertindole, Astemizole, and Grepafloxacin.", [["QT prolongation", "DISEASE", 58, 73], ["Terfenadine", "CHEMICAL", 81, 92], ["Sertindole", "CHEMICAL", 94, 104], ["Astemizole", "CHEMICAL", 106, 116], ["Grepafloxacin", "CHEMICAL", 122, 135], ["Terfenadine", "CHEMICAL", 81, 92], ["Sertindole", "CHEMICAL", 94, 104], ["Astemizole", "CHEMICAL", 106, 116], ["Grepafloxacin", "CHEMICAL", 122, 135], ["Terfenadine", "SIMPLE_CHEMICAL", 81, 92], ["Sertindole", "SIMPLE_CHEMICAL", 94, 104], ["Astemizole", "SIMPLE_CHEMICAL", 106, 116], ["Grepafloxacin", "SIMPLE_CHEMICAL", 122, 135], ["four drugs", "TREATMENT", 9, 19], ["QT prolongation", "PROBLEM", 58, 73], ["Terfenadine", "TREATMENT", 81, 92], ["Sertindole", "TREATMENT", 94, 104], ["Astemizole", "TREATMENT", 106, 116], ["Grepafloxacin", "TREATMENT", 122, 135], ["drugs", "OBSERVATION", 14, 19]]], ["Acquired long QT syndrome (LQTS) occurs as a side effect of blockade of cardiac HERG K+ channels by commonly used medications.", [["cardiac", "ANATOMY", 72, 79], ["long QT syndrome", "DISEASE", 9, 25], ["LQTS", "DISEASE", 27, 31], ["K", "CHEMICAL", 85, 86], ["K+", "CHEMICAL", 85, 87], ["cardiac HERG K+ channels", "PROTEIN", 72, 96], ["Acquired long QT syndrome", "PROBLEM", 0, 25], ["LQTS", "PROBLEM", 27, 31], ["cardiac HERG K+ channels", "TREATMENT", 72, 96], ["medications", "TREATMENT", 114, 125]]], ["These issues have inspired modeling efforts aimed at predicting these effects and using those predictions to filter compounds in the early screening stages.", [["filter compounds", "TREATMENT", 109, 125]]], ["Because these models are less than perfect, false negative and false positive rates are an issue.ToxicityA common approach to lead optimization is now parallel optimization, which is discussed in the following section.", [["false positive rates", "PROBLEM", 63, 83], ["lead optimization", "TREATMENT", 126, 143], ["positive rates", "OBSERVATION", 69, 83]]], ["This is an extremely challenging undertaking because it requires the simultaneous control of several medicinal chemistry components.", [["several", "OBSERVATION_MODIFIER", 93, 100], ["medicinal chemistry", "OBSERVATION_MODIFIER", 101, 120]]], ["Furthermore, many of these components are not independent and, in fact, may even be negatively correlated.", [["not", "UNCERTAINTY", 42, 45], ["independent", "OBSERVATION_MODIFIER", 46, 57]]], ["To do parallel optimization, it is also necessary to generate drugability related information in the early stages of lead optimization.Multi-Objective Optimization MethodsDecisions in drug discovery are almost always multidimensional.", [["parallel optimization", "TREATMENT", 6, 27], ["lead optimization", "TREATMENT", 117, 134]]], ["Numerous criteria must be managed in order to develop a successful drug: potency, selectivity, toxicity, and ADME characteristics, and these tend to have conflicting trends so that difficult decisions are forced on scientists.", [["toxicity", "DISEASE", 95, 103], ["toxicity", "PROBLEM", 95, 103]]], ["For example, Zyprexa is an excellent antipsychotic drug but it causes weight gain in most people, a side effect of almost all antipsychotic drugs.", [["Zyprexa", "CHEMICAL", 13, 20], ["weight gain", "DISEASE", 70, 81], ["Zyprexa", "SIMPLE_CHEMICAL", 13, 20], ["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["Zyprexa", "TREATMENT", 13, 20], ["an excellent antipsychotic drug", "TREATMENT", 24, 55], ["weight gain", "PROBLEM", 70, 81], ["all antipsychotic drugs", "TREATMENT", 122, 145]]], ["It is possible to modify an antipsychotic drug so that it does not produce weight gain, but such modifications may reduce the potency of the drug or introduce other side effects which may be even worse.", [["weight gain", "DISEASE", 75, 86], ["an antipsychotic drug", "TREATMENT", 25, 46], ["weight gain", "PROBLEM", 75, 86]]], ["A common side effect, for example, of many antipsychotic drugs is \"extrapyramidal side effects\" (EPS) which produce symptoms such as tremors, rigidity, and slowness of movement.", [["EPS", "DISEASE", 97, 100], ["tremors", "DISEASE", 133, 140], ["rigidity", "DISEASE", 142, 150], ["A common side effect", "PROBLEM", 0, 20], ["many antipsychotic drugs", "TREATMENT", 38, 62], ["extrapyramidal side effects", "PROBLEM", 67, 94], ["symptoms", "PROBLEM", 116, 124], ["tremors", "PROBLEM", 133, 140], ["rigidity", "PROBLEM", 142, 150], ["slowness of movement", "PROBLEM", 156, 176], ["common side", "OBSERVATION_MODIFIER", 2, 13], ["effect", "OBSERVATION", 14, 20]]], ["These are deemed by most to be worse than weight gain.", [["weight gain", "DISEASE", 42, 53], ["weight gain", "PROBLEM", 42, 53]]], ["Less clear-cut trade-offs might involve the propensity for a molecule to cross the blood-brain barrier versus the therapeutic effect desired.", [["blood", "ANATOMY", 83, 88], ["brain", "ANATOMY", 89, 94], ["blood", "MULTI-TISSUE_STRUCTURE", 83, 88], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 89, 102], ["a molecule", "PROBLEM", 59, 69], ["the blood-brain barrier", "TREATMENT", 79, 102], ["clear", "OBSERVATION", 5, 10], ["brain", "ANATOMY", 89, 94]]], ["For example, Benadryl is still a popular drug because, in spite of its tendency to induce a feeling of somnolescence, it is an extremely potent histamine (H1) blocker.", [["Benadryl", "CHEMICAL", 13, 21], ["somnolescence", "DISEASE", 103, 116], ["histamine", "CHEMICAL", 144, 153], ["Benadryl", "CHEMICAL", 13, 21], ["histamine", "CHEMICAL", 144, 153], ["Benadryl", "SIMPLE_CHEMICAL", 13, 21], ["histamine", "SIMPLE_CHEMICAL", 144, 153], ["H1) blocker", "SIMPLE_CHEMICAL", 155, 166], ["Benadryl", "TREATMENT", 13, 21], ["a feeling of somnolescence", "PROBLEM", 90, 116], ["an extremely potent histamine (H1) blocker", "TREATMENT", 124, 166]]], ["Finding a lead compound corresponds to searching on one landscape.", [["a lead compound", "PROBLEM", 8, 23], ["lead compound", "OBSERVATION", 10, 23]]], ["With more than two objectives, the likelihood of failure increases exponentially.", [["failure", "PROBLEM", 49, 56], ["failure", "OBSERVATION", 49, 56], ["increases", "OBSERVATION_MODIFIER", 57, 66], ["exponentially", "OBSERVATION_MODIFIER", 67, 80]]], ["A variety of algorithms exists for finding the best possible trade-offs; these are used surprisingly seldom despite their utility.Multi-Objective Optimization MethodsOne strategy involves restricting a search to only those solutions that are Pareto optimal.", [["Multi-Objective Optimization Methods", "TREATMENT", 130, 166]]], ["A solution is Pareto optimal if there is no other solution that is better under one criterion without being worse for the other criteria.", [["A solution", "TREATMENT", 0, 10]]], ["It is often true that not every response has the same importance; for example, avoiding EPS symptoms might be 50-fold more important to a team than avoiding weight gain.", [["EPS", "DISEASE", 88, 91], ["weight gain", "DISEASE", 157, 168], ["EPS symptoms", "PROBLEM", 88, 100], ["weight gain", "PROBLEM", 157, 168]]], ["This transformation may be linear, quadratic, step function, and so on.", [["may be", "UNCERTAINTY", 20, 26], ["linear", "OBSERVATION_MODIFIER", 27, 33]]], ["The individual desirabilities are then combined using a geometric mean, which is an overall assessment of the desirability of the combined response levels.", [["a geometric mean", "TEST", 54, 70], ["an overall assessment", "TEST", 81, 102]]], ["There are a great many interesting and diverse problems that need to be solved.", [["diverse problems", "PROBLEM", 39, 55], ["great", "OBSERVATION_MODIFIER", 12, 17], ["many", "OBSERVATION_MODIFIER", 18, 22], ["diverse", "OBSERVATION_MODIFIER", 39, 46], ["problems", "OBSERVATION", 47, 55]]], ["Areas that are increasing in research intensity include the areas of genomics, gene chip microarrays (see Chapter 5), proteomics, metabolomics, and other technologies that involve spectral analysis.", [["gene chip microarrays", "PROBLEM", 79, 100], ["proteomics", "TEST", 118, 128], ["metabolomics", "TEST", 130, 142], ["spectral analysis", "TEST", 180, 197], ["increasing", "OBSERVATION_MODIFIER", 15, 25], ["areas", "OBSERVATION_MODIFIER", 60, 65]]], ["There are a host of interesting and challenging problems in these areas and, currently, there is great interest in merging these disciplines with the cheminformatics-related disciplines that have been the focus of this chapter.DiscussionThe future will see dramatic changes in drug discovery and development processes.", [["challenging problems in these areas", "PROBLEM", 36, 71], ["challenging", "OBSERVATION_MODIFIER", 36, 47], ["problems", "OBSERVATION", 48, 56], ["great", "OBSERVATION_MODIFIER", 97, 102], ["interest", "OBSERVATION_MODIFIER", 103, 111]]], ["Within the next decade, researchers will almost certainly find most human genes and their locations.", [["human", "ORGANISM", 68, 73], ["human genes", "DNA", 68, 79], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73]]], ["Explorations into the function of each one is a major challenge extending far into the next century and will shed light on how faulty genes play a role in disease causation.", [["Explorations", "TREATMENT", 0, 12]]], ["With this knowledge, commercial efforts will shift towards developing a new generation of therapeutics based on genes.", [["a new generation of therapeutics", "TREATMENT", 70, 102]]], ["Drug design will be revolutionized as researchers create new classes of medicines based on a reasoned approach using gene sequence and protein structure information rather than the traditional trial-and-error method.", [["medicines", "TREATMENT", 72, 81], ["gene sequence", "TREATMENT", 117, 130], ["the traditional trial", "TEST", 177, 198]]], ["The drugs, targeted to specific sites in the body, will not have the side effects prevalent in many of today's medicines.", [["sites", "ANATOMY", 32, 37], ["body", "ANATOMY", 45, 49], ["body", "ORGANISM_SUBDIVISION", 45, 49], ["The drugs", "TREATMENT", 0, 9], ["today's medicines", "TREATMENT", 103, 120], ["body", "ANATOMY", 45, 49]]], ["Over 150 clinical gene therapy trials are now in progress in the United States, most for different kinds of cancers.DiscussionThe road map of human biology generated by the human genome project will supply an enormous store of genes for studying, and ultimately curing, the ills that beset us.", [["cancers", "ANATOMY", 108, 115], ["cancers", "DISEASE", 108, 115], ["cancers", "CANCER", 108, 115], ["human", "ORGANISM", 142, 147], ["human", "ORGANISM", 173, 178], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 173, 178], ["clinical gene therapy trials", "TREATMENT", 9, 37], ["cancers", "PROBLEM", 108, 115], ["cancers", "OBSERVATION", 108, 115]]], ["As the factors underlying the maladies of the human condition slowly come to light, the challenge will be to use the information effectively and responsibly.", [["human", "ORGANISM", 46, 51], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["the human condition", "PROBLEM", 42, 61], ["maladies", "OBSERVATION", 30, 38]]]], "PMC7110800": [["IntroductionInvasive non-native species are among the greatest threats to global biodiversity (Atkinson, 1996).", [["Invasive non-native species", "PROBLEM", 12, 39], ["Invasive", "OBSERVATION_MODIFIER", 12, 20], ["non-native species", "OBSERVATION", 21, 39]]], ["Non-native species often increase their populations rapidly in a novel ranges where they may be free of the factors, such as disease and predators, that limit populations in their native range.", [["Non-native species", "PROBLEM", 0, 18], ["disease", "PROBLEM", 125, 132], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["populations", "OBSERVATION_MODIFIER", 40, 51], ["rapidly", "OBSERVATION_MODIFIER", 52, 59]]], ["Alternatively, they may be exposed to new pathogens that have the potential to prevent or reduce the rate of establishment (Hilker et al., 2005).", [["new pathogens", "PROBLEM", 38, 51]]], ["This may particularly be the case when small founder populations with reduced genetic diversity render newly established populations particularly vulnerable to novel infections (Hawley et al., 2006).IntroductionThe ecological impacts of invasive species are most pronounced on islands which are often home to a diversity of endemic species that are na\u00efve to predation risk (Simberloff, 2000).", [["infections", "DISEASE", 166, 176], ["small founder populations", "PROBLEM", 39, 64], ["novel infections", "PROBLEM", 160, 176], ["invasive species", "PROBLEM", 237, 253], ["endemic species", "PROBLEM", 324, 339], ["infections", "OBSERVATION", 166, 176], ["ecological", "OBSERVATION_MODIFIER", 215, 225], ["impacts", "OBSERVATION_MODIFIER", 226, 233], ["invasive species", "OBSERVATION", 237, 253], ["most pronounced", "OBSERVATION_MODIFIER", 258, 273], ["endemic species", "OBSERVATION", 324, 339]]], ["Predators, such as stoats Mustela erminea, are a particularly serious problem since many of New Zealand\u2019s endemic birds have evolved in the absence of predators (King, 1984) and there has been considerable public expenditure on large-scale culling of stoats with the aim of reducing stoat predation (McDonald and Murphy, 2000).", [["stoats", "ORGANISM", 19, 25], ["Mustela erminea", "ORGANISM", 26, 41], ["birds", "ORGANISM", 114, 119], ["Mustela erminea", "SPECIES", 26, 41], ["Mustela erminea", "SPECIES", 26, 41], ["Predators", "TREATMENT", 0, 9], ["a particularly serious problem", "PROBLEM", 47, 77], ["New Zealand", "TREATMENT", 92, 103], ["New", "OBSERVATION_MODIFIER", 92, 95], ["considerable", "OBSERVATION_MODIFIER", 193, 205], ["public expenditure", "OBSERVATION", 206, 224], ["large", "OBSERVATION_MODIFIER", 228, 233]]], ["Given that conventional methods of stoat control are limited to trapping and poisoning which are expensive, there are moves towards identifying more cost-effective methods of long term and widespread control of stoat predation.", [["poisoning", "DISEASE", 77, 86], ["stoat", "ORGANISM_SUBDIVISION", 211, 216], ["stoat control", "TREATMENT", 35, 48], ["poisoning", "PROBLEM", 77, 86], ["long term", "OBSERVATION_MODIFIER", 175, 184]]], ["These include conventional biological control using lethal or sub-lethal pathogens and immunocontraception, potentially using a disseminating vector that would be genetically modified from a widespread, host-specific infectious agent (Norbury, 2000, McDonald and Larivi\u00e8re, 2001).", [["conventional biological control", "TREATMENT", 14, 45], ["sub-lethal pathogens", "PROBLEM", 62, 82], ["immunocontraception", "TREATMENT", 87, 106], ["a disseminating vector", "TREATMENT", 126, 148]]], ["This clearly requires knowledge and comparison of the diseases stoats encounter in their native and non-native range.Introduction", [["the diseases stoats", "PROBLEM", 50, 69]]]], "PMC7189391": [["IntroductionCoronaviruses (CoVs) are enveloped single-stranded positive sense RNA viruses that belong to the family Coronaviridae.", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["CoVs", "PROTEIN", 27, 31], ["stranded positive sense RNA viruses", "PROBLEM", 54, 89]]], ["On the basis of genomic organization and phylogenetic relationship, coronaviruses have been classified into the subfamily Coronavirinae that consists of four genera Alphacoronavirus (\u03b1CoV), Betacoronavirus (\u03b2CoV), Gammacoronavirus (\u03b3CoV), and Deltacoronavirus (\u03b4CoV) (Cui et al. 2019).", [["coronaviruses", "ORGANISM", 68, 81], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 122, 135], ["Alphacoronavirus (\u03b1CoV", "ORGANISM", 165, 187], ["Betacoronavirus (\u03b2CoV", "ORGANISM", 190, 211], ["Gammacoronavirus (\u03b3CoV", "GENE_OR_GENE_PRODUCT", 214, 236], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 243, 259], ["\u03b4CoV", "ORGANISM", 261, 265], ["\u03b1CoV", "SPECIES", 183, 187], ["\u03b2CoV", "SPECIES", 207, 211], ["\u03b3CoV", "SPECIES", 232, 236], ["Deltacoronavirus (\u03b4CoV", "SPECIES", 243, 265], ["coronaviruses", "PROBLEM", 68, 81], ["four genera Alphacoronavirus", "TEST", 153, 181], ["Betacoronavirus", "TEST", 190, 205], ["Gammacoronavirus (\u03b3CoV)", "TREATMENT", 214, 237], ["Deltacoronavirus", "TREATMENT", 243, 259], ["genomic organization", "OBSERVATION", 16, 36], ["phylogenetic relationship", "OBSERVATION", 41, 66]]], ["Evolutionary trend analysis of coronaviruses has revealed that \u03b1CoV and \u03b2CoV originated from bats and rodents, while \u03b3CoV and \u03b4CoV were found to have originated from avian species (Ge et al. 2017).", [["coronaviruses", "ORGANISM", 31, 44], ["\u03b1CoV", "ORGANISM", 63, 67], ["\u03b2CoV", "ORGANISM", 72, 76], ["\u03b3CoV", "ORGANISM", 117, 121], ["\u03b4CoV", "ORGANISM", 126, 130], ["\u03b1CoV", "PROTEIN", 63, 67], ["\u03b2CoV", "PROTEIN", 72, 76], ["\u03b3CoV", "PROTEIN", 117, 121], ["\u03b4CoV", "PROTEIN", 126, 130], ["\u03b1CoV", "SPECIES", 63, 67], ["\u03b2CoV", "SPECIES", 72, 76], ["\u03b3CoV", "SPECIES", 117, 121], ["\u03b4CoV", "SPECIES", 126, 130], ["Evolutionary trend analysis", "TEST", 0, 27], ["coronaviruses", "PROBLEM", 31, 44], ["CoV", "PROBLEM", 64, 67], ["\u03b2CoV", "PROBLEM", 72, 76], ["\u03b4CoV", "PROBLEM", 126, 130]]], ["The ability of CoVs to cross the species barrier has resulted in some of the pathogenic CoVs.", [["CoVs", "GENE_OR_GENE_PRODUCT", 15, 19], ["CoVs", "GENE_OR_GENE_PRODUCT", 88, 92], ["CoVs", "PROTEIN", 15, 19], ["CoVs", "PROBLEM", 15, 19], ["the species barrier", "TREATMENT", 29, 48], ["the pathogenic CoVs", "PROBLEM", 73, 92], ["pathogenic CoVs", "OBSERVATION", 77, 92]]], ["HKU1, NL63, OC43, and 229E CoVs are associated with mild symptoms in humans, whereas severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) are known to cause severe disease (Fehr and Perlman 2015).", [["acute respiratory syndrome CoV", "DISEASE", 92, 122], ["SARS-CoV)", "DISEASE", 124, 133], ["Middle East respiratory syndrome CoV", "DISEASE", 138, 174], ["HKU1", "GENE_OR_GENE_PRODUCT", 0, 4], ["NL63", "GENE_OR_GENE_PRODUCT", 6, 10], ["OC43", "GENE_OR_GENE_PRODUCT", 12, 16], ["229E CoVs", "GENE_OR_GENE_PRODUCT", 22, 31], ["humans", "ORGANISM", 69, 75], ["SARS-CoV", "ORGANISM", 124, 132], ["Middle East respiratory syndrome CoV", "ORGANISM", 138, 174], ["MERS-CoV", "ORGANISM", 176, 184], ["HKU1, NL63, OC43, and 229E CoVs", "DNA", 0, 31], ["humans", "SPECIES", 69, 75], ["humans", "SPECIES", 69, 75], ["severe acute respiratory syndrome CoV", "SPECIES", 85, 122], ["SARS-CoV", "SPECIES", 124, 132], ["Middle East respiratory syndrome CoV", "SPECIES", 138, 174], ["MERS-CoV", "SPECIES", 176, 184], ["HKU1", "TEST", 0, 4], ["OC43", "TEST", 12, 16], ["229E CoVs", "PROBLEM", 22, 31], ["mild symptoms in humans", "PROBLEM", 52, 75], ["severe acute respiratory syndrome CoV (SARS-CoV)", "PROBLEM", 85, 133], ["Middle East respiratory syndrome CoV", "PROBLEM", 138, 174], ["severe disease", "PROBLEM", 205, 219], ["OC43", "ANATOMY", 12, 16], ["229E CoVs", "OBSERVATION", 22, 31], ["mild", "OBSERVATION_MODIFIER", 52, 56], ["symptoms", "OBSERVATION", 57, 65], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118], ["Middle", "ANATOMY_MODIFIER", 138, 144], ["respiratory syndrome", "OBSERVATION", 150, 170], ["severe", "OBSERVATION_MODIFIER", 205, 211], ["disease", "OBSERVATION", 212, 219]]], ["In 2002\u20132003, SARS-CoV emerged in China with 8000 clinical cases and 800 deaths.", [["SARS-CoV", "DISEASE", 14, 22], ["deaths", "DISEASE", 73, 79], ["SARS-CoV", "ORGANISM", 14, 22], ["SARS-CoV", "SPECIES", 14, 22]]], ["Since 2012, MERS-CoV has caused persistent epidemics in the Arabian Peninsula.", [["MERS-CoV", "ORGANISM", 12, 20], ["MERS-CoV", "SPECIES", 12, 20], ["persistent epidemics in the Arabian Peninsula", "PROBLEM", 32, 77], ["persistent", "OBSERVATION_MODIFIER", 32, 42], ["epidemics", "OBSERVATION", 43, 52], ["Arabian", "ANATOMY_MODIFIER", 60, 67], ["Peninsula", "ANATOMY_MODIFIER", 68, 77]]], ["Both the viruses have been found to originate from bats and then transmitted into intermediate mammalian host civets in the case of SARS-CoV and camels in the case of MERS-CoV and eventually infected humans (Song et al. 2019).IntroductionSARS-CoV-2 has been declared as a pandemic, with 1,844,683 confirmed cases and 117,021 deaths globally by 14th April 2020 (World Health Organization 2020).", [["SARS", "DISEASE", 132, 136], ["MERS-CoV and eventually infected", "DISEASE", 167, 199], ["deaths", "DISEASE", 325, 331], ["SARS-CoV", "ORGANISM", 132, 140], ["camels", "ORGANISM", 145, 151], ["MERS-CoV", "ORGANISM", 167, 175], ["humans", "ORGANISM", 200, 206], ["humans", "SPECIES", 200, 206], ["SARS-CoV", "SPECIES", 132, 140], ["MERS-CoV", "SPECIES", 167, 175], ["humans", "SPECIES", 200, 206], ["SARS", "PROBLEM", 132, 136], ["CoV", "PROBLEM", 172, 175], ["eventually infected humans", "PROBLEM", 180, 206], ["IntroductionSARS", "TEST", 226, 242], ["viruses", "OBSERVATION", 9, 16], ["infected", "OBSERVATION", 191, 199]]], ["To characterize the novel coronavirus, bronchoalveolar lavage fluid and throat swabs were collected from nine patients who had visited the Wuhan seafood market during the initial outbreak.", [["bronchoalveolar lavage fluid", "ANATOMY", 39, 67], ["throat swabs", "ANATOMY", 72, 84], ["coronavirus", "ORGANISM", 26, 37], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 39, 67], ["throat swabs", "ORGANISM_SUBSTANCE", 72, 84], ["patients", "ORGANISM", 110, 118], ["coronavirus", "SPECIES", 26, 37], ["patients", "SPECIES", 110, 118], ["the novel coronavirus", "PROBLEM", 16, 37], ["bronchoalveolar lavage fluid", "TEST", 39, 67], ["throat swabs", "TEST", 72, 84], ["coronavirus", "OBSERVATION_MODIFIER", 26, 37], ["bronchoalveolar lavage", "OBSERVATION", 39, 61]]], ["Special pathogen-free human airway epithelial (HAE) cells were used for virus isolation.", [["airway epithelial (HAE) cells", "ANATOMY", 28, 57], ["human", "ORGANISM", 22, 27], ["airway epithelial (HAE) cells", "CELL", 28, 57], ["human airway epithelial (HAE) cells", "CELL_TYPE", 22, 57], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["Special pathogen", "TEST", 0, 16], ["free human airway epithelial (HAE) cells", "TREATMENT", 17, 57], ["virus isolation", "TREATMENT", 72, 87], ["airway epithelial", "ANATOMY", 28, 45]]], ["The collected samples were inoculated into the HAE cells through the apical surfaces.", [["samples", "ANATOMY", 14, 21], ["HAE cells", "ANATOMY", 47, 56], ["apical surfaces", "ANATOMY", 69, 84], ["HAE", "DISEASE", 47, 50], ["HAE cells", "CELL", 47, 56], ["apical surfaces", "MULTI-TISSUE_STRUCTURE", 69, 84], ["HAE cells", "CELL_TYPE", 47, 56], ["The collected samples", "TEST", 0, 21], ["apical", "ANATOMY_MODIFIER", 69, 75], ["surfaces", "ANATOMY_MODIFIER", 76, 84]]], ["HAE cells were monitored for cytopathic effects and supernatant was collected to perform RT-PCR assays.", [["HAE cells", "ANATOMY", 0, 9], ["supernatant", "ANATOMY", 52, 63], ["HAE", "DISEASE", 0, 3], ["HAE cells", "CELL", 0, 9], ["HAE cells", "CELL_LINE", 0, 9], ["HAE cells", "PROBLEM", 0, 9], ["cytopathic effects", "PROBLEM", 29, 47], ["RT-PCR assays", "TEST", 89, 102]]], ["Apical samples were collected for next generation sequencing after three passages.", [["Apical samples", "ANATOMY", 0, 14], ["Apical samples", "CANCER", 0, 14], ["Apical samples", "TEST", 0, 14], ["next generation sequencing", "TREATMENT", 34, 60]]], ["The whole-genome sequences of SARS-CoV-2 were generated by a combination of Sanger, Illumina, and Oxford nanopore sequencing (Lu et al. 2020).", [["SARS-CoV-2", "ORGANISM", 30, 40], ["whole-genome sequences", "DNA", 4, 26], ["SARS-CoV-2", "DNA", 30, 40], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "PROBLEM", 30, 34], ["Oxford nanopore sequencing", "TREATMENT", 98, 124]]], ["Phylogenetic analysis has revealed that bats might be at the source of SARS-CoV-2 (Andersen et al. 2020).", [["bats", "ORGANISM", 40, 44], ["SARS-CoV", "SPECIES", 71, 79], ["Phylogenetic analysis", "TEST", 0, 21], ["SARS", "PROBLEM", 71, 75]]], ["Additionally, some studies have suggested that the origin of SARS-CoV-2 is associated with pangolins (Li et al. 2020; Shereen et al. 2020).", [["SARS", "DISEASE", 61, 65], ["Li", "CHEMICAL", 102, 104], ["pangolins", "CHEMICAL", 91, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 61, 71], ["pangolins", "SIMPLE_CHEMICAL", 91, 100], ["SARS-CoV", "SPECIES", 61, 69], ["some studies", "TEST", 14, 26], ["SARS", "PROBLEM", 61, 65], ["SARS", "OBSERVATION", 61, 65]]], ["To decipher the mechanism of replication and development of effective preventive and therapeutic strategies, understanding the structure of SARS-CoV-2, genome organization, and replication is crucial.", [["SARS", "DISEASE", 140, 144], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 140, 150], ["replication", "TREATMENT", 29, 40], ["therapeutic strategies", "TREATMENT", 85, 107], ["SARS", "PROBLEM", 140, 144], ["CoV", "TEST", 145, 148], ["effective", "OBSERVATION_MODIFIER", 60, 69]]], ["Therefore this chapter focuses on the morphology and structure, genomic organization, and replication cycle of SARS-CoV-2.Morphology of SARS-CoV-2SARS-CoV-2 isolated from nasopharyngeal and oropharyngeal samples were inoculated on the vero cells.", [["nasopharyngeal", "ANATOMY", 171, 185], ["oropharyngeal samples", "ANATOMY", 190, 211], ["vero cells", "ANATOMY", 235, 245], ["SARS", "DISEASE", 111, 115], ["SARS-CoV-2", "ORGANISM", 111, 121], ["2SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 145, 156], ["nasopharyngeal", "CANCER", 171, 185], ["oropharyngeal samples", "CANCER", 190, 211], ["vero cells", "CELL", 235, 245], ["vero cells", "CELL_TYPE", 235, 245], ["SARS-CoV", "SPECIES", 111, 119], ["SARS", "TEST", 111, 115], ["CoV", "TEST", 116, 119], ["SARS-CoV-2SARS", "TEST", 136, 150], ["CoV", "TEST", 151, 154], ["nasopharyngeal and oropharyngeal samples", "PROBLEM", 171, 211], ["genomic organization", "OBSERVATION", 64, 84], ["nasopharyngeal", "ANATOMY", 171, 185], ["oropharyngeal", "ANATOMY", 190, 203], ["vero cells", "OBSERVATION", 235, 245]]], ["In order to identify SARS-CoV-2, inoculated cells were prefixed using 2% paraformaldehyde and 2.5% glutaraldehyde, and transmission electron microscopy was performed.", [["cells", "ANATOMY", 44, 49], ["glutaraldehyde", "CHEMICAL", 99, 113], ["paraformaldehyde", "CHEMICAL", 73, 89], ["glutaraldehyde", "CHEMICAL", 99, 113], ["cells", "CELL", 44, 49], ["paraformaldehyde", "SIMPLE_CHEMICAL", 73, 89], ["glutaraldehyde", "SIMPLE_CHEMICAL", 99, 113], ["SARS-CoV", "SPECIES", 21, 29], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["inoculated cells", "PROBLEM", 33, 49], ["2% paraformaldehyde", "TREATMENT", 70, 89], ["transmission electron microscopy", "TEST", 119, 151]]], ["The structure of SARS-CoV-2 observed by examining infected cells after 3 days post infection.", [["cells", "ANATOMY", 59, 64], ["SARS", "DISEASE", 17, 21], ["infection", "DISEASE", 83, 92], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 17, 27], ["cells", "CELL", 59, 64], ["infected cells", "CELL_TYPE", 50, 64], ["SARS-CoV", "SPECIES", 17, 25], ["SARS", "PROBLEM", 17, 21], ["infected cells", "PROBLEM", 50, 64], ["infection", "PROBLEM", 83, 92], ["SARS", "OBSERVATION", 17, 21], ["infected cells", "OBSERVATION", 50, 64], ["infection", "OBSERVATION", 83, 92]]], ["Electron microscopy revealed the coronavirus-specific morphology of SARS-CoV-2 with virus particle sizes ranging from 70 to 90 nm observed under a wide variety of intracellular organelles, most specifically in vesicles (Park et al. 2020).", [["intracellular organelles", "ANATOMY", 163, 187], ["vesicles", "ANATOMY", 210, 218], ["SARS-CoV-2", "ORGANISM", 68, 78], ["intracellular organelles", "CELLULAR_COMPONENT", 163, 187], ["vesicles", "CELLULAR_COMPONENT", 210, 218], ["SARS-CoV", "SPECIES", 68, 76], ["Electron microscopy", "TEST", 0, 19], ["the coronavirus", "TEST", 29, 44], ["SARS", "PROBLEM", 68, 72], ["CoV", "TEST", 73, 76], ["virus particle sizes", "PROBLEM", 84, 104], ["coronavirus", "OBSERVATION", 33, 44], ["SARS", "OBSERVATION", 68, 72], ["sizes", "OBSERVATION_MODIFIER", 99, 104], ["intracellular organelles", "OBSERVATION", 163, 187]]], ["Due to high sequence similarity, the structure of SARS-CoV-2 is speculated to be the same as SARS-CoV (Kumar et al. 2020).", [["SARS", "DISEASE", 50, 54], ["SARS-CoV-2", "ORGANISM", 50, 60], ["SARS-CoV", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 93, 101], ["SARS", "PROBLEM", 50, 54], ["SARS", "OBSERVATION", 50, 54]]], ["The surface viral protein spike, membrane, and envelope of coronavirus are embedded in host membrane-derived lipid bilayer encapsulating the helical nucleocapsid comprising viral RNA (Fig. 3.1) (Finlay et al. 2004).", [["surface", "ANATOMY", 4, 11], ["membrane", "ANATOMY", 33, 41], ["membrane", "ANATOMY", 92, 100], ["lipid bilayer", "ANATOMY", 109, 122], ["surface", "CELLULAR_COMPONENT", 4, 11], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["membrane", "CELLULAR_COMPONENT", 92, 100], ["lipid bilayer", "CELLULAR_COMPONENT", 109, 122], ["helical nucleocapsid", "PROTEIN", 141, 161], ["viral RNA", "RNA", 173, 182], ["The surface viral protein spike", "TEST", 0, 31], ["membrane", "PROBLEM", 33, 41], ["coronavirus", "PROBLEM", 59, 70], ["derived lipid bilayer", "TREATMENT", 101, 122], ["the helical nucleocapsid", "PROBLEM", 137, 161], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["viral protein spike", "OBSERVATION", 12, 31], ["coronavirus", "OBSERVATION", 59, 70], ["host membrane", "OBSERVATION", 87, 100], ["viral RNA", "OBSERVATION", 173, 182]]], ["The structure of spike (Yan et al. 2020) and protease of SARS-CoV-2 (Zhang et al. 2020) has been resolved, which provides an opportunity to develop a newer class of drugs for treatment of COVID-19.", [["COVID-19", "CHEMICAL", 188, 196], ["protease", "PROTEIN", 45, 53], ["SARS-CoV", "SPECIES", 57, 65], ["spike", "PROBLEM", 17, 22], ["SARS", "PROBLEM", 57, 61], ["drugs", "TREATMENT", 165, 170], ["COVID", "TEST", 188, 193], ["spike", "OBSERVATION_MODIFIER", 17, 22]]]], "PMC7309506": [["Definition 1 ::: IntroductionA map", [["IntroductionA map", "TREATMENT", 17, 34]]]], "eb7eb7dea1d2285ba087cc095ed374f6fdaa8280": [["IntroductionCoronaviruses (CoVs) are part of a complex and diverse group of viruses grouped into four different genera cold.", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["CoVs", "PROTEIN", 27, 31], ["IntroductionCoronaviruses (CoVs", "PROBLEM", 0, 31], ["a complex and diverse group of viruses", "PROBLEM", 45, 83], ["viruses", "OBSERVATION", 76, 83], ["four different", "OBSERVATION_MODIFIER", 97, 111], ["genera cold", "OBSERVATION", 112, 123]]], ["The zoonotic severe acute respiratory syndrome-CoV (SARS-CoV) and the Middle East respiratory syndrome-CoV (MERS-CoV), however, are broadly recognized as they have caused significant outbreaks in humans during 2002-3 and 2012-13 respectively, with the MERS-CoV outbreak still ongoing (Bennett et al., 2019) .", [["acute respiratory syndrome-CoV (SARS-CoV)", "DISEASE", 20, 61], ["Middle East respiratory syndrome-CoV", "DISEASE", 70, 106], ["SARS-CoV", "ORGANISM", 52, 60], ["Middle East respiratory syndrome-CoV", "ORGANISM", 70, 106], ["MERS-CoV", "ORGANISM", 108, 116], ["humans", "ORGANISM", 196, 202], ["humans", "SPECIES", 196, 202], ["zoonotic severe acute respiratory syndrome-CoV", "SPECIES", 4, 50], ["SARS-CoV", "SPECIES", 52, 60], ["Middle East respiratory syndrome-CoV", "SPECIES", 70, 106], ["MERS-CoV", "SPECIES", 108, 116], ["humans", "SPECIES", 196, 202], ["MERS-CoV", "SPECIES", 252, 260], ["The zoonotic severe acute respiratory syndrome", "PROBLEM", 0, 46], ["CoV (SARS-CoV)", "PROBLEM", 47, 61], ["the Middle East respiratory syndrome", "PROBLEM", 66, 102], ["CoV", "PROBLEM", 103, 106], ["significant outbreaks in humans", "PROBLEM", 171, 202], ["zoonotic", "OBSERVATION_MODIFIER", 4, 12], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory syndrome", "OBSERVATION", 26, 46], ["Middle", "ANATOMY_MODIFIER", 70, 76], ["respiratory syndrome", "OBSERVATION", 82, 102], ["significant", "OBSERVATION_MODIFIER", 171, 182], ["outbreaks", "OBSERVATION", 183, 192]]], ["SARS-CoV and MERS-CoV are both bat-origin viruses with an intermediate host of masked palm civets/raccoon dogs and dromedary camels respectively (Song et al., 2019) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "ORGANISM", 13, 21], ["palm", "ORGANISM_SUBDIVISION", 86, 90], ["dogs", "ORGANISM", 106, 110], ["dogs", "SPECIES", 106, 110], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 18, 21], ["masked palm civets", "TREATMENT", 79, 97], ["raccoon dogs", "TREATMENT", 98, 110]]], ["Recently, a novel CoV named SARS-CoV-2 emerged and has now caused the global COVID-19 pandemic.", [["SARS", "DISEASE", 28, 32], ["CoV", "ORGANISM", 18, 21], ["SARS-CoV", "ORGANISM", 28, 36], ["SARS-CoV", "SPECIES", 28, 36], ["the global COVID", "TEST", 66, 82], ["pandemic", "PROBLEM", 86, 94]]], ["The disease outbreak started in Wuhan, China, with the virus origin attributed to populations of SARS-like viruses that circulate in wild bats .", [["SARS", "DISEASE", 97, 101], ["SARS-like viruses", "ORGANISM", 97, 114], ["The disease outbreak", "PROBLEM", 0, 20], ["the virus origin", "PROBLEM", 51, 67], ["SARS", "PROBLEM", 97, 101], ["viruses", "PROBLEM", 107, 114], ["disease", "OBSERVATION", 4, 11], ["SARS", "OBSERVATION", 97, 101], ["viruses", "OBSERVATION", 107, 114], ["wild bats", "OBSERVATION", 133, 142]]], ["While pangolins and other animal species from live animal markets have been implicated, there is currently no strong evidence regarding the possible intermediate host(s) that could have facilitated the transmission of SARS-CoV-2 between its bat reservoir and humans Y.-Z. Zhang & Holmes, 2020) .IntroductionIn recent weeks, cats, ferrets and dogs have all drawn attention in the public health battle against COVID-19, based on their proposed infection by owners and handlers and possibility to act as an intermediate host.", [["pangolins", "CHEMICAL", 6, 15], ["SARS", "DISEASE", 218, 222], ["infection", "DISEASE", 442, 451], ["pangolins", "GENE_OR_GENE_PRODUCT", 6, 15], ["SARS-CoV-2", "ORGANISM", 218, 228], ["bat", "ORGANISM", 241, 244], ["humans", "ORGANISM", 259, 265], ["cats", "ORGANISM", 324, 328], ["ferrets", "ORGANISM", 330, 337], ["dogs", "ORGANISM", 342, 346], ["humans", "SPECIES", 259, 265], ["cats", "SPECIES", 324, 328], ["ferrets", "SPECIES", 330, 337], ["dogs", "SPECIES", 342, 346], ["SARS-CoV", "SPECIES", 218, 226], ["SARS", "PROBLEM", 218, 222], ["CoV", "TEST", 223, 226], ["cats", "TREATMENT", 324, 328], ["infection", "OBSERVATION", 442, 451]]], ["With a focus on felines, we review here the evidence for SARS-CoV-2 infection in cats, ferrets and dogs, describe the relationship between SARS-CoV-2 and the natural coronaviruses known to infect these species, and provide a rationale for the relative susceptibility of these species to SARS-CoV-2.Feline coronaviruses and SARS-CoV-2 in felinesFeline coronaviruses (FCoVs) are widely known as agents capable of infection in both domestic and wild felids (Pedersen, 2014) .", [["infection", "DISEASE", 68, 77], ["SARS", "DISEASE", 287, 291], ["Feline coronaviruses", "DISEASE", 298, 318], ["Feline coronaviruses", "DISEASE", 344, 364], ["infection", "DISEASE", 411, 420], ["SARS-CoV-2", "ORGANISM", 57, 67], ["cats", "ORGANISM", 81, 85], ["ferrets", "ORGANISM", 87, 94], ["dogs", "ORGANISM", 99, 103], ["SARS-CoV-2", "ORGANISM", 139, 149], ["coronaviruses", "ORGANISM", 166, 179], ["SARS-CoV-2", "ORGANISM", 287, 297], ["Feline coronaviruses", "ORGANISM", 298, 318], ["SARS-CoV-2", "ORGANISM", 323, 333], ["felines", "ORGANISM", 337, 344], ["Feline coronaviruses", "ORGANISM", 344, 364], ["FCoVs", "CANCER", 366, 371], ["cats", "SPECIES", 81, 85], ["ferrets", "SPECIES", 87, 94], ["dogs", "SPECIES", 99, 103], ["Feline", "SPECIES", 298, 304], ["SARS-CoV-2", "SPECIES", 57, 67], ["ferrets", "SPECIES", 87, 94], ["SARS-CoV", "SPECIES", 139, 147], ["SARS-CoV", "SPECIES", 287, 295], ["Feline coronaviruses", "SPECIES", 298, 318], ["SARS-CoV", "SPECIES", 323, 331], ["Feline coronaviruses", "SPECIES", 344, 364], ["SARS", "PROBLEM", 57, 61], ["CoV", "PROBLEM", 62, 65], ["2 infection in cats", "PROBLEM", 66, 85], ["SARS-CoV", "TEST", 139, 147], ["the natural coronaviruses", "PROBLEM", 154, 179], ["CoV", "TEST", 292, 295], ["Feline coronaviruses", "PROBLEM", 298, 318], ["SARS", "PROBLEM", 323, 327], ["CoV", "TEST", 328, 331], ["Feline coronaviruses (FCoVs)", "PROBLEM", 344, 372], ["infection", "PROBLEM", 411, 420], ["infection", "OBSERVATION", 68, 77], ["infection", "OBSERVATION", 411, 420]]], ["Initial infection causes only a mild localized disease; however, the virus can convert also exist in a form that is responsible for the severe and mostly lethal feline infectious peritonitis (FIP).", [["infection", "DISEASE", 8, 17], ["feline infectious peritonitis", "DISEASE", 161, 190], ["FIP", "DISEASE", 192, 195], ["feline", "SPECIES", 161, 167], ["Initial infection", "PROBLEM", 0, 17], ["a mild localized disease", "PROBLEM", 30, 54], ["the virus", "PROBLEM", 65, 74], ["the severe and mostly lethal feline infectious peritonitis", "PROBLEM", 132, 190], ["infection", "OBSERVATION", 8, 17], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["localized", "OBSERVATION_MODIFIER", 37, 46], ["disease", "OBSERVATION", 47, 54], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["mostly", "OBSERVATION_MODIFIER", 147, 153], ["lethal feline", "OBSERVATION_MODIFIER", 154, 167], ["infectious", "OBSERVATION_MODIFIER", 168, 178], ["peritonitis", "OBSERVATION", 179, 190]]], ["This is most likely through a process of \"internal mutation\"; however circulating virus variants with higher propensity to cause FIP may also exist (Brown et al., 2009; Vennema et al., 1998) .", [["FIP", "DISEASE", 129, 132], ["\"internal mutation\"", "PROBLEM", 41, 60], ["circulating virus variants", "PROBLEM", 70, 96], ["FIP", "PROBLEM", 129, 132], ["most likely", "UNCERTAINTY", 8, 19], ["internal mutation", "OBSERVATION", 42, 59]]], ["The virus is suggested to infect all types of felids and infections have been reported in numerous non-domestic felids; J o u r n a l P r e -p r o o f among the big cats, cheetahs are highly susceptible to FIP (Evermann et al., 1989) .", [["infections", "DISEASE", 57, 67], ["FIP", "DISEASE", 206, 209], ["felids", "ORGANISM", 46, 52], ["cats", "ORGANISM", 165, 169], ["cats", "SPECIES", 165, 169], ["The virus", "PROBLEM", 0, 9], ["infections", "PROBLEM", 57, 67], ["the big cats", "TEST", 157, 169], ["virus", "OBSERVATION", 4, 9], ["infections", "OBSERVATION", 57, 67]]], ["Two different types of FCoV have been described with distinct epidemiological distribution and specific biological and molecular features that prove the diversity of these agents .", [["FCoV", "GENE_OR_GENE_PRODUCT", 23, 27], ["FCoV", "PROTEIN", 23, 27], ["FCoV", "TREATMENT", 23, 27], ["these agents", "TREATMENT", 166, 178], ["different types", "OBSERVATION_MODIFIER", 4, 19], ["FCoV", "OBSERVATION", 23, 27]]], ["The type I FCoV is considered to be the ancestor virus of the feline lineage.", [["type I FCoV", "GENE_OR_GENE_PRODUCT", 4, 15], ["feline", "ORGANISM", 62, 68], ["type I FCoV", "PROTEIN", 4, 15], ["feline lineage", "CELL_TYPE", 62, 76], ["feline", "SPECIES", 62, 68], ["The type I FCoV", "PROBLEM", 0, 15], ["FCoV", "OBSERVATION", 11, 15], ["feline lineage", "OBSERVATION", 62, 76]]], ["It is the most common of the two types and is currently circulating in domestic cat reservoirs globally.", [["cat", "ORGANISM", 80, 83], ["most common", "OBSERVATION_MODIFIER", 10, 21], ["two", "OBSERVATION_MODIFIER", 29, 32], ["types", "OBSERVATION_MODIFIER", 33, 38], ["circulating", "OBSERVATION", 56, 67], ["domestic cat", "OBSERVATION", 71, 83], ["reservoirs", "OBSERVATION_MODIFIER", 84, 94], ["globally", "OBSERVATION_MODIFIER", 95, 103]]], ["In contrast, the type II FCoV has been suggested to have emerged from recombination events between feline and canine CoVs, which is less epidemiologically distributed and displays its own biological and molecular mechanisms of infection, diverting from the FCoV type I viruses (Herrewegh et al., 1998; .", [["infection", "DISEASE", 227, 236], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 17, 29], ["feline", "ORGANISM", 99, 105], ["canine", "ORGANISM", 110, 116], ["CoVs", "GENE_OR_GENE_PRODUCT", 117, 121], ["type II FCoV", "PROTEIN", 17, 29], ["feline", "SPECIES", 99, 105], ["canine", "SPECIES", 110, 116], ["canine", "SPECIES", 110, 116], ["FCoV type I viruses", "SPECIES", 257, 276], ["the type II FCoV", "PROBLEM", 13, 29], ["recombination events between feline and canine CoVs", "PROBLEM", 70, 121], ["infection", "PROBLEM", 227, 236], ["diverting", "TREATMENT", 238, 247], ["canine CoVs", "OBSERVATION", 110, 121], ["less", "OBSERVATION_MODIFIER", 132, 136], ["infection", "OBSERVATION", 227, 236]]], ["We recently reported the complex evolutionary pathway of the Alphacoronavirus-1 species, which includes both FCoV types, as well as canine coronaviruses and transmissible gastroenteritis virus of swine (TGEV) (Whittaker et al., 2018) .", [["canine coronaviruses", "DISEASE", 132, 152], ["transmissible gastroenteritis", "DISEASE", 157, 186], ["Alphacoronavirus-1 species", "ORGANISM", 61, 87], ["FCoV", "GENE_OR_GENE_PRODUCT", 109, 113], ["canine coronaviruses", "ORGANISM", 132, 152], ["transmissible gastroenteritis virus", "ORGANISM", 157, 192], ["swine", "ORGANISM", 196, 201], ["TGEV", "ORGANISM", 203, 207], ["Alphacoronavirus-1", "SPECIES", 61, 79], ["canine", "SPECIES", 132, 138], ["transmissible gastroenteritis virus", "SPECIES", 157, 192], ["swine", "SPECIES", 196, 201], ["Alphacoronavirus-1", "SPECIES", 61, 79], ["canine coronaviruses", "SPECIES", 132, 152], ["transmissible gastroenteritis virus", "SPECIES", 157, 192], ["swine", "SPECIES", 196, 201], ["TGEV", "SPECIES", 203, 207], ["the Alphacoronavirus-1 species", "PROBLEM", 57, 87], ["canine coronaviruses", "PROBLEM", 132, 152], ["transmissible gastroenteritis virus of swine", "PROBLEM", 157, 201], ["FCoV types", "OBSERVATION", 109, 119]]], ["A summary of the relationship of the spike proteins of the Alphacoronavirus-1 species in comparison to animal and human coronaviruses, including four human endemic viruses (human CoVs 229E, OC43, NL63 and HKU1) is shown in Figure 1 .", [["Alphacoronavirus-1 species", "ORGANISM", 59, 85], ["human", "ORGANISM", 114, 119], ["coronaviruses", "ORGANISM", 120, 133], ["human", "ORGANISM", 150, 155], ["human", "ORGANISM", 173, 178], ["CoVs 229E", "CELL", 179, 188], ["spike proteins", "PROTEIN", 37, 51], ["Alphacoronavirus-1 species", "PROTEIN", 59, 85], ["Alphacoronavirus-1", "SPECIES", 59, 77], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 173, 178], ["human coronaviruses", "SPECIES", 114, 133], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 173, 178], ["the spike proteins", "TEST", 33, 51], ["the Alphacoronavirus", "TEST", 55, 75], ["animal and human coronaviruses", "PROBLEM", 103, 133], ["human CoVs", "TEST", 173, 183], ["OC43", "TEST", 190, 194]]], ["A distinct feline coronavirus found in a wild Asian leopard cat is also included in Figure 1 (Dong et al., 2007) .Feline coronaviruses and SARS-CoV-2 in felinesWhile typically considered to be an enteric infection, FCoVs may in fact have more systemic distribution in their host (including in the respiratory tract) before the critical mutation(s) in the viral genome that results in the acquisition of macrophage tropism and progression to FIP, with its effusive (\"wet\") and/or non-effusive (\"dry\") clinical outcome often accompanied by extensive granulomatous lesions (Kipar & Meli, 2014; Pedersen et al., 2009; Sykes, 2014) .", [["respiratory tract", "ANATOMY", 297, 314], ["macrophage", "ANATOMY", 403, 413], ["granulomatous lesions", "ANATOMY", 548, 569], ["feline coronavirus", "DISEASE", 11, 29], ["Feline coronaviruses", "DISEASE", 114, 134], ["enteric infection", "DISEASE", 196, 213], ["FIP", "DISEASE", 441, 444], ["feline coronavirus", "ORGANISM", 11, 29], ["cat", "ORGANISM", 60, 63], ["Feline coronaviruses", "ORGANISM", 114, 134], ["SARS-CoV-2", "ORGANISM", 139, 149], ["felines", "ORGANISM", 153, 160], ["FCoVs", "GENE_OR_GENE_PRODUCT", 215, 220], ["respiratory tract", "ORGANISM_SUBDIVISION", 297, 314], ["macrophage", "CELL", 403, 413], ["granulomatous lesions", "PATHOLOGICAL_FORMATION", 548, 569], ["viral genome", "DNA", 355, 367], ["feline coronavirus", "SPECIES", 11, 29], ["cat", "SPECIES", 60, 63], ["Feline", "SPECIES", 114, 120], ["feline coronavirus", "SPECIES", 11, 29], ["Asian leopard cat", "SPECIES", 46, 63], ["Feline coronaviruses", "SPECIES", 114, 134], ["SARS-CoV", "SPECIES", 139, 147], ["A distinct feline coronavirus", "PROBLEM", 0, 29], ["Feline coronaviruses", "PROBLEM", 114, 134], ["SARS", "PROBLEM", 139, 143], ["CoV", "TEST", 144, 147], ["an enteric infection", "PROBLEM", 193, 213], ["macrophage tropism", "PROBLEM", 403, 421], ["FIP", "PROBLEM", 441, 444], ["its effusive (\"wet\"", "PROBLEM", 451, 470], ["non-effusive", "PROBLEM", 479, 491], ["extensive granulomatous lesions", "PROBLEM", 538, 569], ["distinct", "OBSERVATION_MODIFIER", 2, 10], ["feline coronavirus", "OBSERVATION", 11, 29], ["enteric", "OBSERVATION_MODIFIER", 196, 203], ["infection", "OBSERVATION", 204, 213], ["systemic", "OBSERVATION_MODIFIER", 243, 251], ["distribution", "OBSERVATION_MODIFIER", 252, 264], ["respiratory tract", "ANATOMY", 297, 314], ["macrophage tropism", "OBSERVATION", 403, 421], ["FIP", "OBSERVATION", 441, 444], ["extensive", "OBSERVATION_MODIFIER", 538, 547], ["granulomatous", "OBSERVATION_MODIFIER", 548, 561], ["lesions", "OBSERVATION", 562, 569]]], ["FIP is a complex disease syndrome that is further complicated by the process of antibody-dependent enhancement (ADE) of infection, whereby subneutralizing antibodies can recognize the virus spike protein and lead to enhanced macrophage infection, leading to more rapid disease progression (Olsen et al., 1992; Takano et al., 2008) .Feline coronaviruses and SARS-CoV-2 in felinesJ o u r n a l P r e -p r o o f As described in more detail below, both natural and experimental SARS-CoV and SARS-CoV-2 infection of cats have been reported, generally resulting in mild respiratory signs (Brand et al., 2008; Martina et al., 2003; Shi et al., 2020) .", [["macrophage", "ANATOMY", 225, 235], ["respiratory", "ANATOMY", 564, 575], ["FIP", "DISEASE", 0, 3], ["infection", "DISEASE", 120, 129], ["infection", "DISEASE", 236, 245], ["Feline coronaviruses", "DISEASE", 332, 352], ["SARS", "DISEASE", 474, 478], ["infection", "DISEASE", 498, 507], ["FIP", "GENE_OR_GENE_PRODUCT", 0, 3], ["macrophage", "CELL", 225, 235], ["Feline coronaviruses", "ORGANISM", 332, 352], ["SARS-CoV-2", "ORGANISM", 357, 367], ["SARS-CoV", "ORGANISM", 474, 482], ["SARS-CoV-2", "ORGANISM", 487, 497], ["cats", "ORGANISM", 511, 515], ["subneutralizing antibodies", "PROTEIN", 139, 165], ["virus spike protein", "PROTEIN", 184, 203], ["Feline", "SPECIES", 332, 338], ["cats", "SPECIES", 511, 515], ["Feline coronaviruses", "SPECIES", 332, 352], ["SARS-CoV", "SPECIES", 357, 365], ["SARS-CoV", "SPECIES", 474, 482], ["SARS-CoV", "SPECIES", 487, 495], ["FIP", "PROBLEM", 0, 3], ["a complex disease syndrome", "PROBLEM", 7, 33], ["antibody-dependent enhancement", "PROBLEM", 80, 110], ["infection", "PROBLEM", 120, 129], ["subneutralizing antibodies", "PROBLEM", 139, 165], ["the virus spike protein", "PROBLEM", 180, 203], ["enhanced macrophage infection", "PROBLEM", 216, 245], ["more rapid disease progression", "PROBLEM", 258, 288], ["Feline coronaviruses", "PROBLEM", 332, 352], ["SARS", "PROBLEM", 357, 361], ["CoV", "TEST", 362, 365], ["a l P r e -p r o o f As", "TEST", 388, 411], ["experimental SARS", "PROBLEM", 461, 478], ["CoV", "TEST", 479, 482], ["SARS", "PROBLEM", 487, 491], ["CoV", "TEST", 492, 495], ["2 infection of cats", "PROBLEM", 496, 515], ["mild respiratory signs", "PROBLEM", 559, 581], ["complex", "OBSERVATION_MODIFIER", 9, 16], ["disease", "OBSERVATION", 17, 24], ["antibody", "OBSERVATION", 80, 88], ["dependent", "OBSERVATION_MODIFIER", 89, 98], ["enhancement", "OBSERVATION_MODIFIER", 99, 110], ["infection", "OBSERVATION", 120, 129], ["macrophage", "OBSERVATION_MODIFIER", 225, 235], ["infection", "OBSERVATION", 236, 245], ["SARS", "OBSERVATION", 474, 478], ["mild", "OBSERVATION_MODIFIER", 559, 563], ["respiratory signs", "OBSERVATION", 564, 581]]], ["Additionally, an antibody response has been demonstrated in several cats in Wuhan, China .", [["cats", "ORGANISM", 68, 72], ["an antibody response", "TEST", 14, 34], ["antibody response", "OBSERVATION", 17, 34]]], ["It is important to note that that SARS-like viruses (betacoronaviruses in lineage B) and feline coronaviruses (alphacoronaviruses) are quite distinct ( Figure 1 ).", [["SARS", "DISEASE", 34, 38], ["feline coronaviruses", "DISEASE", 89, 109], ["SARS-like viruses", "ORGANISM", 34, 51], ["lineage B", "CELL", 74, 83], ["feline coronaviruses", "ORGANISM", 89, 109], ["alphacoronaviruses", "CANCER", 111, 129], ["feline coronaviruses", "SPECIES", 89, 109], ["feline coronaviruses", "SPECIES", 89, 109], ["SARS", "PROBLEM", 34, 38], ["viruses", "PROBLEM", 44, 51], ["feline coronaviruses", "PROBLEM", 89, 109]]], ["As such, there is currently no definitive evidence that prior exposure to feline coronaviruses (which are widespread) will protect against SARS-like viruses; however serological testing will need to carefully evaluate any potential cross-reaction.", [["feline coronaviruses", "DISEASE", 74, 94], ["SARS-like viruses", "DISEASE", 139, 156], ["feline coronaviruses", "ORGANISM", 74, 94], ["SARS-like viruses", "ORGANISM", 139, 156], ["feline coronaviruses", "SPECIES", 74, 94], ["feline coronaviruses", "PROBLEM", 74, 94], ["SARS", "PROBLEM", 139, 143], ["viruses", "PROBLEM", 149, 156], ["serological testing", "TEST", 166, 185], ["any potential cross-reaction", "PROBLEM", 218, 246], ["no definitive", "UNCERTAINTY", 28, 41]]], ["Whether antibodies to FCoV can induce ADE upon subsequent infection with a SARS-likeFeline coronaviruses and SARS-CoV-2 in felinesvirus remains an open question.", [["FCoV", "CHEMICAL", 22, 26], ["ADE", "DISEASE", 38, 41], ["infection", "DISEASE", 58, 67], ["SARS", "DISEASE", 75, 79], ["FCoV", "GENE_OR_GENE_PRODUCT", 22, 26], ["SARS-likeFeline coronaviruses", "ORGANISM", 75, 104], ["SARS-CoV-2", "ORGANISM", 109, 119], ["felinesvirus", "ORGANISM", 123, 135], ["antibodies", "PROTEIN", 8, 18], ["FCoV", "PROTEIN", 22, 26], ["SARS-likeFeline coronaviruses", "SPECIES", 75, 104], ["SARS-CoV", "SPECIES", 109, 117], ["antibodies to FCoV", "PROBLEM", 8, 26], ["subsequent infection", "PROBLEM", 47, 67], ["a SARS", "PROBLEM", 73, 79], ["likeFeline coronaviruses", "PROBLEM", 80, 104], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117], ["infection", "OBSERVATION", 58, 67]]], ["Preliminary studies, however, indicate the potential for transmission between individual cats (Halfmann et al., 2020) .Ferret coronaviruses and SARS-CoV-2 in ferretsTwo distinct alphacoronaviruses have been described in ferrets: ferret enteric coronavirus (FRECV) and ferret systemic coronavirus (FRSCV) (Garner et al., 2008; Williams et al., 2000) (Figure 1 ).", [["SARS", "DISEASE", 144, 148], ["enteric coronavirus", "DISEASE", 236, 255], ["systemic coronavirus", "DISEASE", 275, 295], ["cats", "ORGANISM", 89, 93], ["Ferret coronaviruses", "ORGANISM", 119, 139], ["SARS-CoV-2", "ORGANISM", 144, 154], ["ferrets", "ORGANISM", 158, 165], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 178, 196], ["ferrets", "ORGANISM", 220, 227], ["ferret enteric coronavirus", "ORGANISM", 229, 255], ["FRECV", "ORGANISM", 257, 262], ["ferret systemic coronavirus", "ORGANISM", 268, 295], ["alphacoronaviruses", "PROTEIN", 178, 196], ["cats", "SPECIES", 89, 93], ["ferrets", "SPECIES", 158, 165], ["ferrets", "SPECIES", 220, 227], ["ferret enteric coronavirus", "SPECIES", 229, 255], ["ferret", "SPECIES", 268, 274], ["Ferret coronaviruses", "SPECIES", 119, 139], ["SARS-CoV", "SPECIES", 144, 152], ["ferret enteric coronavirus", "SPECIES", 229, 255], ["FRECV", "SPECIES", 257, 262], ["ferret systemic coronavirus", "SPECIES", 268, 295], ["FRSCV", "SPECIES", 297, 302], ["Preliminary studies", "TEST", 0, 19], ["Ferret coronaviruses", "PROBLEM", 119, 139], ["SARS", "TEST", 144, 148], ["CoV", "TEST", 149, 152], ["Two distinct alphacoronaviruses", "PROBLEM", 165, 196], ["distinct", "OBSERVATION_MODIFIER", 169, 177], ["alphacoronaviruses", "OBSERVATION", 178, 196], ["enteric coronavirus", "ANATOMY", 236, 255], ["systemic coronavirus", "ANATOMY", 275, 295]]], ["Infection with FRECV was originally termed epizootic catarrhal enteritis and is characterized by profuse, green mucoid diarrhea, in addition to non-specific signs (Williams et al., 2000) .", [["FRECV", "DISEASE", 15, 20], ["catarrhal enteritis", "DISEASE", 53, 72], ["diarrhea", "DISEASE", 119, 127], ["FRECV", "SPECIES", 15, 20], ["Infection", "PROBLEM", 0, 9], ["epizootic catarrhal enteritis", "PROBLEM", 43, 72], ["profuse, green mucoid diarrhea", "PROBLEM", 97, 127], ["non-specific signs", "PROBLEM", 144, 162], ["epizootic", "OBSERVATION_MODIFIER", 43, 52], ["catarrhal enteritis", "OBSERVATION", 53, 72], ["profuse", "OBSERVATION_MODIFIER", 97, 104], ["green", "OBSERVATION_MODIFIER", 106, 111], ["mucoid", "OBSERVATION_MODIFIER", 112, 118], ["diarrhea", "OBSERVATION", 119, 127], ["non-specific", "OBSERVATION_MODIFIER", 144, 156]]], ["In contrast, FRSCV infection is associated with systemic disease with granulomatous lesions, often described as similar to the dry form of feline infectious peritonitis (FIP) and has been described in laboratory, farm-raised, and pet ferrets (Autieri et al., 2015; Williams et al., 2000) .", [["granulomatous lesions", "ANATOMY", 70, 91], ["infection", "DISEASE", 19, 28], ["systemic disease", "DISEASE", 48, 64], ["granulomatous lesions", "DISEASE", 70, 91], ["feline infectious peritonitis", "DISEASE", 139, 168], ["FIP", "DISEASE", 170, 173], ["granulomatous lesions", "PATHOLOGICAL_FORMATION", 70, 91], ["feline", "ORGANISM", 139, 145], ["ferrets", "ORGANISM", 234, 241], ["feline", "SPECIES", 139, 145], ["ferrets", "SPECIES", 234, 241], ["FRSCV", "SPECIES", 13, 18], ["pet ferrets", "SPECIES", 230, 241], ["FRSCV infection", "PROBLEM", 13, 28], ["systemic disease", "PROBLEM", 48, 64], ["granulomatous lesions", "PROBLEM", 70, 91], ["feline infectious peritonitis", "PROBLEM", 139, 168], ["infection", "OBSERVATION", 19, 28], ["associated with", "UNCERTAINTY", 32, 47], ["systemic", "OBSERVATION_MODIFIER", 48, 56], ["disease", "OBSERVATION", 57, 64], ["granulomatous", "OBSERVATION_MODIFIER", 70, 83], ["lesions", "OBSERVATION", 84, 91], ["feline", "OBSERVATION_MODIFIER", 139, 145], ["infectious", "OBSERVATION_MODIFIER", 146, 156], ["peritonitis", "OBSERVATION", 157, 168]]], ["Currently, there is no obvious mechanistic link between FRECV and FRSV that is equivalent to the \"internal mutation\" of FCoV.", [["FRECV", "GENE_OR_GENE_PRODUCT", 56, 61], ["FRSV", "GENE_OR_GENE_PRODUCT", 66, 70], ["FCoV", "GENE_OR_GENE_PRODUCT", 120, 124], ["FRECV", "PROTEIN", 56, 61], ["FRSV", "PROTEIN", 66, 70], ["FCoV", "PROTEIN", 120, 124], ["FRSV", "SPECIES", 66, 70], ["obvious mechanistic link between FRECV and FRSV", "PROBLEM", 23, 70], ["no obvious", "UNCERTAINTY", 20, 30], ["FCoV", "OBSERVATION", 120, 124]]], ["It is unknown whether antibodies against FRECV or FRSCV would be able to neutralize SARS-CoV-2 or contribute to further disease in ferrets via ADE.Ferret coronaviruses and SARS-CoV-2 in ferretsGenerally speaking, infection with ferret coronavirus is not considered to be respiratory.J o u r n a l P r e -p r o o fThe alphacoronavirus canine coronavirus (CCoV) is widely known to cause enteric infection of dogs and as with FCoV these infections are caused by two distinct types CCoV type I and CCoV type II ( Figure 1 ).J o u r n a l P r e -p r o o fInfection is generally mild in the absence of co-infecting pathogens such as parvovirus, although severe gastroenteritis can occur.", [["FRSCV", "CHEMICAL", 50, 55], ["SARS", "DISEASE", 172, 176], ["infection", "DISEASE", 213, 222], ["ferret coronavirus", "DISEASE", 228, 246], ["canine coronavirus", "DISEASE", 334, 352], ["CCoV", "CHEMICAL", 354, 358], ["enteric infection", "DISEASE", 385, 402], ["FCoV", "CHEMICAL", 423, 427], ["infections", "DISEASE", 434, 444], ["parvovirus", "DISEASE", 627, 637], ["gastroenteritis", "DISEASE", 655, 670], ["FRECV", "GENE_OR_GENE_PRODUCT", 41, 46], ["FRSCV", "SIMPLE_CHEMICAL", 50, 55], ["SARS-CoV-2", "ORGANISM", 84, 94], ["ferrets", "ORGANISM", 131, 138], ["Ferret coronaviruses", "ORGANISM", 147, 167], ["SARS-CoV-2", "ORGANISM", 172, 182], ["ferrets", "ORGANISM", 186, 193], ["ferret coronavirus", "ORGANISM", 228, 246], ["alphacoronavirus", "ORGANISM", 317, 333], ["canine coronavirus", "ORGANISM", 334, 352], ["CCoV", "ORGANISM", 354, 358], ["dogs", "ORGANISM", 406, 410], ["FCoV", "GENE_OR_GENE_PRODUCT", 423, 427], ["parvovirus", "ORGANISM", 627, 637], ["antibodies", "PROTEIN", 22, 32], ["FRECV", "PROTEIN", 41, 46], ["ferrets", "SPECIES", 131, 138], ["ferrets", "SPECIES", 186, 193], ["ferret coronavirus", "SPECIES", 228, 246], ["canine coronavirus", "SPECIES", 334, 352], ["dogs", "SPECIES", 406, 410], ["FRECV", "SPECIES", 41, 46], ["FRSCV", "SPECIES", 50, 55], ["SARS-CoV", "SPECIES", 84, 92], ["ferrets", "SPECIES", 131, 138], ["Ferret coronaviruses", "SPECIES", 147, 167], ["SARS-CoV", "SPECIES", 172, 180], ["ferret coronavirus", "SPECIES", 228, 246], ["canine coronavirus", "SPECIES", 334, 352], ["FCoV", "SPECIES", 423, 427], ["CCoV type I", "SPECIES", 478, 489], ["FRECV", "PROBLEM", 41, 46], ["FRSCV", "PROBLEM", 50, 55], ["CoV", "TEST", 89, 92], ["further disease in ferrets", "PROBLEM", 112, 138], ["Ferret coronaviruses", "PROBLEM", 147, 167], ["SARS", "TEST", 172, 176], ["CoV", "TEST", 177, 180], ["infection", "PROBLEM", 213, 222], ["ferret coronavirus", "PROBLEM", 228, 246], ["fThe", "PROBLEM", 312, 316], ["alphacoronavirus canine coronavirus", "PROBLEM", 317, 352], ["enteric infection of dogs", "PROBLEM", 385, 410], ["FCoV these infections", "PROBLEM", 423, 444], ["fInfection", "PROBLEM", 549, 559], ["generally mild", "PROBLEM", 563, 577], ["co-infecting pathogens", "PROBLEM", 596, 618], ["parvovirus", "PROBLEM", 627, 637], ["severe gastroenteritis", "PROBLEM", 648, 670], ["disease", "OBSERVATION", 120, 127], ["infection", "OBSERVATION", 213, 222], ["infection", "OBSERVATION", 393, 402], ["infections", "OBSERVATION", 434, 444], ["mild", "OBSERVATION", 573, 577], ["parvovirus", "OBSERVATION", 627, 637], ["severe", "OBSERVATION_MODIFIER", 648, 654], ["gastroenteritis", "OBSERVATION", 655, 670]]], ["CCoVs with systemic signs have been also reported, although FIP-like disease does not occur in dogs .", [["FIP-like disease", "DISEASE", 60, 76], ["CCoVs", "GENE_OR_GENE_PRODUCT", 0, 5], ["dogs", "ORGANISM", 95, 99], ["dogs", "SPECIES", 95, 99], ["systemic signs", "TEST", 11, 25], ["FIP-like disease", "PROBLEM", 60, 76], ["systemic", "OBSERVATION", 11, 19], ["FIP", "OBSERVATION", 60, 63], ["disease", "OBSERVATION", 69, 76]]], ["Dogs also have a distinct respiratory coronavirus (CRCoV), which often causes mild clinical signs, though severe clinical signs have been reported (Erles et al., 2003) .", [["respiratory coronavirus", "DISEASE", 26, 49], ["CRCoV", "DISEASE", 51, 56], ["Dogs", "ORGANISM", 0, 4], ["respiratory coronavirus", "ORGANISM", 26, 49], ["CRCoV", "ORGANISM", 51, 56], ["Dogs", "SPECIES", 0, 4], ["respiratory coronavirus", "SPECIES", 26, 49], ["CRCoV", "SPECIES", 51, 56], ["a distinct respiratory coronavirus", "PROBLEM", 15, 49], ["mild clinical signs", "PROBLEM", 78, 97], ["severe clinical signs", "PROBLEM", 106, 127], ["distinct", "OBSERVATION_MODIFIER", 17, 25], ["respiratory coronavirus", "OBSERVATION", 26, 49], ["mild", "OBSERVATION_MODIFIER", 78, 82]]], ["CRCoV is closely related to bovine coronavirus but as a betacoronavirus in lineage A, relatively distant from SARS-like viruses, including SARS-CoV, which are in lineage B. It is unlikely that prior exposure to CRCoV or CCoVs (which are widespread) will protect against SARS-like viruses; ADE is not known to occur with canine coronaviruses.Community and experimental SARS-CoV and SARS-CoV-2 infection of cats and other companion animalsBefore addressing recent concerns about SARS-CoV-2 in companion animals, we first briefly review data from the original SARS outbreak in 2002-03.", [["lineage A", "ANATOMY", 75, 84], ["SARS-like viruses", "DISEASE", 110, 127], ["SARS-CoV", "DISEASE", 139, 147], ["CCoVs", "CHEMICAL", 220, 225], ["SARS-like viruses", "DISEASE", 270, 287], ["ADE", "DISEASE", 289, 292], ["canine coronaviruses", "DISEASE", 320, 340], ["SARS", "DISEASE", 368, 372], ["infection", "DISEASE", 392, 401], ["SARS", "DISEASE", 477, 481], ["SARS", "DISEASE", 557, 561], ["CRCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["bovine coronavirus", "ORGANISM", 28, 46], ["lineage A", "CANCER", 75, 84], ["SARS-like viruses", "ORGANISM", 110, 127], ["SARS-CoV", "ORGANISM", 139, 147], ["CRCoV", "GENE_OR_GENE_PRODUCT", 211, 216], ["CCoVs", "GENE_OR_GENE_PRODUCT", 220, 225], ["SARS-like viruses", "ORGANISM", 270, 287], ["canine coronaviruses", "ORGANISM", 320, 340], ["SARS-CoV", "ORGANISM", 368, 376], ["SARS-CoV-2", "ORGANISM", 381, 391], ["cats", "ORGANISM", 405, 409], ["SARS-CoV-2", "ORGANISM", 477, 487], ["bovine", "SPECIES", 28, 34], ["coronavirus", "SPECIES", 35, 46], ["canine", "SPECIES", 320, 326], ["cats", "SPECIES", 405, 409], ["CRCoV", "SPECIES", 0, 5], ["bovine coronavirus", "SPECIES", 28, 46], ["SARS-CoV", "SPECIES", 139, 147], ["CRCoV", "SPECIES", 211, 216], ["canine coronaviruses", "SPECIES", 320, 340], ["SARS-CoV", "SPECIES", 368, 376], ["SARS-CoV", "SPECIES", 381, 389], ["bovine coronavirus", "PROBLEM", 28, 46], ["a betacoronavirus in lineage A", "PROBLEM", 54, 84], ["SARS", "PROBLEM", 110, 114], ["like viruses", "PROBLEM", 115, 127], ["SARS", "PROBLEM", 139, 143], ["CoV", "PROBLEM", 144, 147], ["prior exposure to CRCoV", "PROBLEM", 193, 216], ["CCoVs", "PROBLEM", 220, 225], ["SARS", "PROBLEM", 270, 274], ["viruses", "PROBLEM", 280, 287], ["canine coronaviruses", "PROBLEM", 320, 340], ["experimental SARS", "PROBLEM", 355, 372], ["CoV", "PROBLEM", 373, 376], ["SARS", "PROBLEM", 381, 385], ["CoV", "PROBLEM", 386, 389], ["2 infection of cats", "PROBLEM", 390, 409], ["SARS", "PROBLEM", 477, 481], ["closely related to", "UNCERTAINTY", 9, 27], ["bovine coronavirus", "OBSERVATION", 28, 46], ["viruses", "OBSERVATION", 120, 127], ["unlikely", "UNCERTAINTY", 179, 187], ["viruses", "OBSERVATION", 280, 287]]], ["During the initial SARS outbreak in Hong Kong, it was first recognized that cats in the Amoy Garden apartment complex (often considered an epicenter of the outbreak) could be infected by SARS-CoV (Martina et al., 2003) .", [["SARS", "DISEASE", 19, 23], ["SARS", "DISEASE", 187, 191], ["cats", "ORGANISM", 76, 80], ["SARS-CoV", "ORGANISM", 187, 195], ["cats", "SPECIES", 76, 80], ["SARS-CoV", "SPECIES", 187, 195]]], ["Subsequently inoculation of experimental cats and ferrets was performed, which did not result in clinical signs in cats, but did lead to lethargy in a subset of ferrets (3/6) and death in a single ferret.", [["lethargy", "DISEASE", 137, 145], ["death", "DISEASE", 179, 184], ["cats", "ORGANISM", 41, 45], ["ferrets", "ORGANISM", 50, 57], ["cats", "ORGANISM", 115, 119], ["ferrets", "ORGANISM", 161, 168], ["ferret", "ORGANISM", 197, 203], ["cats", "SPECIES", 41, 45], ["ferrets", "SPECIES", 50, 57], ["cats", "SPECIES", 115, 119], ["ferrets", "SPECIES", 161, 168], ["ferret", "SPECIES", 197, 203], ["ferrets", "SPECIES", 50, 57], ["experimental cats", "TEST", 28, 45], ["clinical signs in cats", "PROBLEM", 97, 119], ["lethargy", "PROBLEM", 137, 145], ["death", "PROBLEM", 179, 184]]], ["Across both species, the virus was observed to be shed from the pharynx.", [["pharynx", "ANATOMY", 64, 71], ["pharynx", "ORGAN", 64, 71], ["Across both species", "PROBLEM", 0, 19], ["the virus", "PROBLEM", 21, 30], ["virus", "OBSERVATION", 25, 30], ["pharynx", "ANATOMY", 64, 71]]], ["While fecal shedding was not observed, RT-PCR of the GI tract was positive.Community and experimental SARS-CoV and SARS-CoV-2 infection of cats and other companion animalsSeroconversion and the presence of a viral titer were observed in na\u00efve animals group housed with experimentally inoculated animals (Martina et al., 2003) .", [["fecal", "ANATOMY", 6, 11], ["GI tract", "ANATOMY", 53, 61], ["SARS", "DISEASE", 102, 106], ["SARS", "DISEASE", 115, 119], ["infection", "DISEASE", 126, 135], ["fecal", "ORGANISM_SUBSTANCE", 6, 11], ["GI tract", "ORGAN", 53, 61], ["SARS-CoV", "ORGANISM", 102, 110], ["SARS-CoV-2", "ORGANISM", 115, 125], ["cats", "ORGANISM", 139, 143], ["cats", "SPECIES", 139, 143], ["SARS-CoV", "SPECIES", 102, 110], ["SARS-CoV", "SPECIES", 115, 123], ["fecal shedding", "PROBLEM", 6, 20], ["RT-PCR", "TEST", 39, 45], ["the GI tract", "TEST", 49, 61], ["experimental SARS", "PROBLEM", 89, 106], ["CoV", "PROBLEM", 107, 110], ["SARS", "PROBLEM", 115, 119], ["CoV", "PROBLEM", 120, 123], ["2 infection of cats", "PROBLEM", 124, 143], ["Seroconversion", "TREATMENT", 171, 185], ["a viral titer", "PROBLEM", 206, 219], ["GI tract", "ANATOMY", 53, 61], ["positive", "OBSERVATION", 66, 74], ["SARS", "OBSERVATION", 102, 106], ["viral titer", "OBSERVATION", 208, 219]]], ["Experimentally, SARS-CoV has been shown to cause respiratory damage in both cats and ferrets, though only ferrets demonstrated clinical disease (Brand et al., 2008) .", [["respiratory", "ANATOMY", 49, 60], ["SARS", "DISEASE", 16, 20], ["respiratory damage", "DISEASE", 49, 67], ["SARS-CoV", "ORGANISM", 16, 24], ["cats", "ORGANISM", 76, 80], ["ferrets", "ORGANISM", 85, 92], ["ferrets", "ORGANISM", 106, 113], ["cats", "SPECIES", 76, 80], ["ferrets", "SPECIES", 85, 92], ["ferrets", "SPECIES", 106, 113], ["SARS-CoV", "SPECIES", 16, 24], ["ferrets", "SPECIES", 85, 92], ["respiratory damage in both cats and ferrets", "PROBLEM", 49, 92], ["clinical disease", "PROBLEM", 127, 143], ["damage", "OBSERVATION", 61, 67]]], ["The identification of virus in ferrets was commonly found in areas of high receptor (ACE2) expression, as would be expected, though outside of the respiratory tract, ACE2 expression has J o u r n a l P r e -p r o o f also been demonstrated by RT-PCR in the lung, heart, kidney and small intestine of the ferret (Brand et al., 2008; Zamoto et al., 2006) .", [["respiratory tract", "ANATOMY", 147, 164], ["lung", "ANATOMY", 257, 261], ["heart", "ANATOMY", 263, 268], ["kidney", "ANATOMY", 270, 276], ["small intestine", "ANATOMY", 281, 296], ["ferrets", "ORGANISM", 31, 38], ["high receptor", "GENE_OR_GENE_PRODUCT", 70, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["respiratory tract", "ORGANISM_SUBDIVISION", 147, 164], ["ACE2", "GENE_OR_GENE_PRODUCT", 166, 170], ["lung", "ORGAN", 257, 261], ["heart", "ORGAN", 263, 268], ["kidney", "ORGAN", 270, 276], ["small intestine", "ORGAN", 281, 296], ["ferret", "ORGANISM", 304, 310], ["high receptor", "PROTEIN", 70, 83], ["ACE2", "PROTEIN", 85, 89], ["ACE2", "PROTEIN", 166, 170], ["ferrets", "SPECIES", 31, 38], ["ferrets", "SPECIES", 31, 38], ["virus in ferrets", "PROBLEM", 22, 38], ["a l P r e -p r o o f", "TEST", 196, 216], ["RT", "TEST", 243, 245], ["PCR", "TEST", 246, 249], ["virus", "OBSERVATION", 22, 27], ["high", "OBSERVATION_MODIFIER", 70, 74], ["respiratory tract", "ANATOMY", 147, 164], ["lung", "ANATOMY", 257, 261], ["heart", "ANATOMY", 263, 268], ["kidney", "ANATOMY", 270, 276], ["small intestine", "ANATOMY", 281, 296]]], ["In vitro, HeLa cells expressing ferret ACE2 are additionally permissive to SARS-CoV (Zamoto et al., 2006) .", [["HeLa cells", "ANATOMY", 10, 20], ["HeLa cells", "CELL", 10, 20], ["ferret", "ORGANISM", 32, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["SARS-CoV", "ORGANISM", 75, 83], ["HeLa cells", "CELL_LINE", 10, 20], ["ferret ACE2", "PROTEIN", 32, 43], ["ferret", "SPECIES", 32, 38], ["ferret", "SPECIES", 32, 38], ["SARS-CoV", "SPECIES", 75, 83]]], ["In comparison, Middle East respiratory syndrome coronavirus (MERS-CoV)-a betacoronavirus in lineage C-has not been shown to cause active infection in ferrets, although the viral receptor DPP4 shares a high level of homology across humans and ferrets (Peck et al., 2017; Raj et al., 2014) .", [["respiratory syndrome coronavirus", "DISEASE", 27, 59], ["infection", "DISEASE", 137, 146], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 15, 59], ["MERS-CoV", "ORGANISM", 61, 69], ["lineage C", "CELL", 92, 101], ["ferrets", "ORGANISM", 150, 157], ["DPP4", "GENE_OR_GENE_PRODUCT", 187, 191], ["humans", "ORGANISM", 231, 237], ["ferrets", "ORGANISM", 242, 249], ["viral receptor", "PROTEIN", 172, 186], ["DPP4", "PROTEIN", 187, 191], ["ferrets", "SPECIES", 150, 157], ["humans", "SPECIES", 231, 237], ["ferrets", "SPECIES", 242, 249], ["Middle East respiratory syndrome coronavirus", "SPECIES", 15, 59], ["MERS-CoV", "SPECIES", 61, 69], ["ferrets", "SPECIES", 150, 157], ["humans", "SPECIES", 231, 237], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 15, 59], ["a betacoronavirus in lineage C", "PROBLEM", 71, 101], ["active infection in ferrets", "PROBLEM", 130, 157], ["the viral receptor DPP4", "TEST", 168, 191], ["Middle", "ANATOMY_MODIFIER", 15, 21], ["respiratory syndrome", "OBSERVATION", 27, 47], ["active", "OBSERVATION_MODIFIER", 130, 136], ["infection", "OBSERVATION", 137, 146]]], ["There are no reports of SARS-or MERS-like viruses transmitting to dogs.Community and experimental SARS-CoV and SARS-CoV-2 infection of cats and other companion animalsRecent reports in regard to COVID-19 and the identification of SARS-CoV-2 viral RNA in two dogs from Hong Kong, a dog in New York, a cat in Belgium, and a tiger at the Bronx Zoo in New York City have raised many new questions in regard to SARS-CoV-2 (Mallapaty, 2020; USDA APHIS, 2020).", [["SARS", "DISEASE", 24, 28], ["SARS", "DISEASE", 98, 102], ["infection", "DISEASE", 122, 131], ["SARS", "DISEASE", 406, 410], ["MERS-like viruses", "ORGANISM", 32, 49], ["dogs", "ORGANISM", 66, 70], ["SARS-CoV", "ORGANISM", 98, 106], ["SARS-CoV-2", "ORGANISM", 111, 121], ["cats", "ORGANISM", 135, 139], ["COVID-19", "GENE_OR_GENE_PRODUCT", 195, 203], ["SARS-CoV-2", "ORGANISM", 230, 240], ["dogs", "ORGANISM", 258, 262], ["dog", "ORGANISM", 281, 284], ["cat", "ORGANISM", 300, 303], ["COVID-19", "DNA", 195, 203], ["SARS-CoV-2 viral RNA", "DNA", 230, 250], ["dogs", "SPECIES", 66, 70], ["cats", "SPECIES", 135, 139], ["dogs", "SPECIES", 258, 262], ["dog", "SPECIES", 281, 284], ["SARS-CoV", "SPECIES", 98, 106], ["SARS-CoV", "SPECIES", 111, 119], ["SARS-CoV", "SPECIES", 230, 238], ["SARS-CoV", "SPECIES", 406, 414], ["SARS", "PROBLEM", 24, 28], ["MERS", "PROBLEM", 32, 36], ["experimental SARS", "PROBLEM", 85, 102], ["CoV", "PROBLEM", 103, 106], ["SARS", "PROBLEM", 111, 115], ["CoV", "PROBLEM", 116, 119], ["2 infection of cats", "PROBLEM", 120, 139], ["COVID", "TEST", 195, 200], ["SARS", "PROBLEM", 230, 234], ["CoV", "PROBLEM", 235, 238], ["no reports of", "UNCERTAINTY", 10, 23], ["SARS", "OBSERVATION", 24, 28]]], ["These reports also been augmented by two PCR-positive cases in cats in different locations in New York State (SARS-CoV-2/COVID-19, United States of America, 2020).", [["cats", "ORGANISM", 63, 67], ["cats", "SPECIES", 63, 67], ["SARS-CoV-2/COVID-19", "SPECIES", 110, 129], ["two PCR", "TEST", 37, 44], ["positive cases in cats", "PROBLEM", 45, 67], ["CoV", "TEST", 115, 118]]], ["In all cases, infection appears to be limited and restricted to the upper respiratory tract, although viral shedding in the feces is also apparent.", [["upper respiratory tract", "ANATOMY", 68, 91], ["feces", "ANATOMY", 124, 129], ["infection", "DISEASE", 14, 23], ["upper respiratory", "ORGANISM_SUBDIVISION", 68, 85], ["tract", "ORGANISM_SUBDIVISION", 86, 91], ["feces", "ORGANISM_SUBDIVISION", 124, 129], ["infection", "PROBLEM", 14, 23], ["viral shedding in the feces", "PROBLEM", 102, 129], ["infection", "OBSERVATION", 14, 23], ["upper", "ANATOMY_MODIFIER", 68, 73], ["respiratory tract", "ANATOMY", 74, 91], ["viral", "OBSERVATION", 102, 107], ["feces", "ANATOMY", 124, 129]]], ["It has been suggested that these species became infected by their owners or handlers.", [["these species", "PROBLEM", 27, 40]]], ["No evidence of transmission to other animals or to humans has been reported so far, although other tigers and lions in the vicinity of the SARS-CoV-2-positve tiger also had respiratory signs.", [["respiratory", "ANATOMY", 173, 184], ["SARS", "DISEASE", 139, 143], ["respiratory signs", "DISEASE", 173, 190], ["humans", "ORGANISM", 51, 57], ["SARS-CoV-2", "ORGANISM", 139, 149], ["tiger", "ORGANISM", 158, 163], ["humans", "SPECIES", 51, 57], ["CoV-", "SPECIES", 144, 148], ["humans", "SPECIES", 51, 57], ["transmission to other animals", "PROBLEM", 15, 44], ["the SARS", "TEST", 135, 143], ["CoV", "TEST", 144, 147], ["respiratory signs", "PROBLEM", 173, 190], ["evidence of", "UNCERTAINTY", 3, 14], ["respiratory signs", "OBSERVATION", 173, 190]]], ["The finding of animals infected with the SARS-CoV-2 is not particularly surprising, given the widespread nature of the disease in humans and the precedent set by SARS-CoV.", [["SARS", "DISEASE", 41, 45], ["SARS", "DISEASE", 162, 166], ["animals", "ORGANISM", 15, 22], ["SARS-CoV-2", "ORGANISM", 41, 51], ["humans", "ORGANISM", 130, 136], ["SARS-CoV", "ORGANISM", 162, 170], ["humans", "SPECIES", 130, 136], ["SARS-CoV", "SPECIES", 41, 49], ["humans", "SPECIES", 130, 136], ["SARS-CoV", "SPECIES", 162, 170], ["the SARS", "TEST", 37, 45], ["the disease in humans", "PROBLEM", 115, 136], ["animals", "OBSERVATION_MODIFIER", 15, 22], ["infected", "OBSERVATION", 23, 31], ["not particularly", "UNCERTAINTY", 55, 71], ["widespread", "OBSERVATION_MODIFIER", 94, 104], ["disease", "OBSERVATION", 119, 126]]], ["While being distinct viruses, SARS-CoV and SARS-CoV-2 share a common receptor (ACE2) (Hoffmann et al., 2020) .", [["SARS", "DISEASE", 30, 34], ["SARS-CoV", "ORGANISM", 30, 38], ["SARS-CoV-2", "ORGANISM", 43, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["ACE2", "PROTEIN", 79, 83], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 30, 38], ["SARS-CoV", "SPECIES", 43, 51], ["distinct viruses", "PROBLEM", 12, 28], ["SARS", "PROBLEM", 30, 34], ["SARS", "PROBLEM", 43, 47], ["distinct", "OBSERVATION_MODIFIER", 12, 20], ["viruses", "OBSERVATION", 21, 28]]], ["The feline ACE2 protein is among the most closely related to human ACE2, in particular within the receptor binding interface region, which may explain why cross-species transmission may occur with this particular species (see below).Recent experimental investigations of SARS-CoV-2 infections of domestic species, isolation of the virus from upper respiratory samples from a small sample of ferrets was consistent with infection, in additionto the development of clinical signs (Kim et al., 2020; Shi et al., 2020) .", [["respiratory samples", "ANATOMY", 348, 367], ["SARS-CoV-2 infections", "DISEASE", 271, 292], ["infection", "DISEASE", 419, 428], ["feline", "ORGANISM", 4, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["human", "ORGANISM", 61, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["SARS-CoV-2", "ORGANISM", 271, 281], ["ferrets", "ORGANISM", 391, 398], ["feline ACE2 protein", "PROTEIN", 4, 23], ["human ACE2", "PROTEIN", 61, 71], ["receptor binding interface region", "PROTEIN", 98, 131], ["feline", "SPECIES", 4, 10], ["human", "SPECIES", 61, 66], ["ferrets", "SPECIES", 391, 398], ["human", "SPECIES", 61, 66], ["SARS-CoV", "SPECIES", 271, 279], ["ferrets", "SPECIES", 391, 398], ["The feline ACE2 protein", "TEST", 0, 23], ["human ACE2", "TEST", 61, 71], ["this particular species", "PROBLEM", 197, 220], ["Recent experimental investigations", "TEST", 233, 267], ["SARS", "PROBLEM", 271, 275], ["CoV", "PROBLEM", 276, 279], ["2 infections", "PROBLEM", 280, 292], ["domestic species", "PROBLEM", 296, 312], ["the virus", "PROBLEM", 327, 336], ["upper respiratory samples", "PROBLEM", 342, 367], ["a small sample of ferrets", "PROBLEM", 373, 398], ["infection", "PROBLEM", 419, 428], ["feline", "OBSERVATION_MODIFIER", 4, 10], ["ACE2 protein", "OBSERVATION", 11, 23], ["may explain", "UNCERTAINTY", 139, 150], ["domestic species", "OBSERVATION", 296, 312], ["upper", "ANATOMY_MODIFIER", 342, 347], ["respiratory", "ANATOMY", 348, 359], ["small", "OBSERVATION_MODIFIER", 375, 380], ["consistent with", "UNCERTAINTY", 403, 418], ["infection", "OBSERVATION", 419, 428]]], ["In cats that were experimentally J o u r n a l P r e -p r o o f challenged with SARS-CoV-2, viral RNA was detectable in both respiratory tissues and the small intestines of cats sacrificed at day 3 and day 6, however, only at day 3 was viral RNA detectable in the lungs .", [["respiratory tissues", "ANATOMY", 125, 144], ["small intestines", "ANATOMY", 153, 169], ["lungs", "ANATOMY", 264, 269], ["cats", "ORGANISM", 3, 7], ["SARS-CoV-2", "ORGANISM", 80, 90], ["viral", "ORGANISM", 92, 97], ["respiratory tissues", "TISSUE", 125, 144], ["small intestines", "ORGAN", 153, 169], ["cats", "ORGANISM", 173, 177], ["lungs", "ORGAN", 264, 269], ["viral RNA", "RNA", 92, 101], ["viral RNA", "RNA", 236, 245], ["cats", "SPECIES", 3, 7], ["cats", "SPECIES", 173, 177], ["SARS-CoV", "SPECIES", 80, 88], ["a l P r e -p r o o f", "TEST", 43, 63], ["SARS", "PROBLEM", 80, 84], ["CoV", "TEST", 85, 88], ["viral RNA", "PROBLEM", 92, 101], ["viral RNA detectable in the lungs", "PROBLEM", 236, 269], ["viral RNA", "OBSERVATION", 92, 101], ["both", "ANATOMY_MODIFIER", 120, 124], ["respiratory tissues", "ANATOMY", 125, 144], ["small", "OBSERVATION_MODIFIER", 153, 158], ["intestines", "ANATOMY", 159, 169], ["viral RNA", "OBSERVATION", 236, 245], ["lungs", "ANATOMY", 264, 269]]], ["Across both cats and ferrets, viral RNA has detected in feces, similar to observations in human disease and additionally, animals in close proximity to infected conspecifics have detectable levels of viral RNA (Kim et al., 2020; Shi et al., 2020) .", [["feces", "ANATOMY", 56, 61], ["cats", "ORGANISM", 12, 16], ["ferrets", "ORGANISM", 21, 28], ["feces", "ORGANISM_SUBSTANCE", 56, 61], ["human", "ORGANISM", 90, 95], ["viral RNA", "RNA", 30, 39], ["viral RNA", "RNA", 200, 209], ["cats", "SPECIES", 12, 16], ["ferrets", "SPECIES", 21, 28], ["human", "SPECIES", 90, 95], ["ferrets", "SPECIES", 21, 28], ["human", "SPECIES", 90, 95], ["viral RNA", "PROBLEM", 30, 39], ["human disease", "PROBLEM", 90, 103], ["viral RNA", "PROBLEM", 200, 209], ["viral RNA", "OBSERVATION", 30, 39], ["human disease", "OBSERVATION", 90, 103], ["infected", "OBSERVATION", 152, 160], ["viral RNA", "OBSERVATION", 200, 209]]], ["Dogs have also been experimentally inoculated with SARS-CoV-2 and while seroconversion was observed, no virus was isolated and other dogs in close proximity did not show infection .Recent experimental investigations of SARS-CoV-2 infections of domestic species, isolation of the virus from upper respiratory samples from a small sample of ferrets was consistent with infection, in additionA seroprevalence study has shown that nearly 15% of cats (15/102) sampled after the start of the COVID-19 outbreak in Wuhan, China were positive for antibody against SARS-CoV-2 .", [["upper respiratory samples", "ANATOMY", 290, 315], ["infection", "DISEASE", 170, 179], ["SARS-CoV-2 infections", "DISEASE", 219, 240], ["infection", "DISEASE", 367, 376], ["SARS", "DISEASE", 555, 559], ["Dogs", "ORGANISM", 0, 4], ["SARS-CoV-2", "ORGANISM", 51, 61], ["dogs", "ORGANISM", 133, 137], ["SARS-CoV-2", "ORGANISM", 219, 229], ["ferrets", "ORGANISM", 339, 346], ["cats", "ORGANISM", 441, 445], ["SARS-CoV-2", "ORGANISM", 555, 565], ["Dogs", "SPECIES", 0, 4], ["dogs", "SPECIES", 133, 137], ["ferrets", "SPECIES", 339, 346], ["cats", "SPECIES", 441, 445], ["SARS-CoV", "SPECIES", 51, 59], ["SARS-CoV", "SPECIES", 219, 227], ["ferrets", "SPECIES", 339, 346], ["SARS-CoV", "SPECIES", 555, 563], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["seroconversion", "PROBLEM", 72, 86], ["virus", "PROBLEM", 104, 109], ["infection", "PROBLEM", 170, 179], ["Recent experimental investigations", "TEST", 181, 215], ["SARS", "PROBLEM", 219, 223], ["CoV", "PROBLEM", 224, 227], ["2 infections", "PROBLEM", 228, 240], ["domestic species", "PROBLEM", 244, 260], ["the virus", "PROBLEM", 275, 284], ["upper respiratory samples", "PROBLEM", 290, 315], ["a small sample of ferrets", "PROBLEM", 321, 346], ["infection", "PROBLEM", 367, 376], ["seroprevalence study", "TEST", 391, 411], ["cats", "TEST", 441, 445], ["the COVID", "TEST", 482, 491], ["antibody", "TEST", 538, 546], ["SARS", "PROBLEM", 555, 559], ["CoV", "TEST", 560, 563], ["inoculated", "OBSERVATION_MODIFIER", 35, 45], ["infection", "OBSERVATION", 170, 179], ["domestic species", "OBSERVATION", 244, 260], ["upper", "ANATOMY_MODIFIER", 290, 295], ["respiratory", "ANATOMY", 296, 307], ["small", "OBSERVATION_MODIFIER", 323, 328], ["consistent with", "UNCERTAINTY", 351, 366], ["infection", "OBSERVATION", 367, 376]]], ["Among these cats, information regarding owner health status was not provided, nor how this sample compares to the population as a whole as far as owned pets versus strays.", [["cats", "ORGANISM", 12, 16], ["cats", "SPECIES", 12, 16]]], ["The spread of SARS-CoV-2 was additionally investigated in France in a small cohort of veterinary students (n=18) and their 21 pets (9 cats, 12 dogs), of which 11 students had symptoms consistent with COVID-19, though only two were confirmed positive (Temmam et al., 2020) .", [["SARS", "DISEASE", 14, 18], ["cats", "ORGANISM", 134, 138], ["dogs", "ORGANISM", 143, 147], ["cats", "SPECIES", 134, 138], ["dogs", "SPECIES", 143, 147], ["SARS-CoV", "SPECIES", 14, 22], ["symptoms", "PROBLEM", 175, 183], ["COVID", "TEST", 200, 205], ["spread", "OBSERVATION_MODIFIER", 4, 10]]], ["While three of these cats showed clinical signs of respiratory or gastrointestinal disease, no single animal was considered positive via RT-PCR of nasal or rectal swabs, or by the presence of SARS-CoV-2 specific antibodies (Temmam et al., 2020) .", [["respiratory", "ANATOMY", 51, 62], ["gastrointestinal", "ANATOMY", 66, 82], ["nasal", "ANATOMY", 147, 152], ["rectal swabs", "ANATOMY", 156, 168], ["respiratory or gastrointestinal disease", "DISEASE", 51, 90], ["cats", "ORGANISM", 21, 25], ["gastrointestinal", "ORGAN", 66, 82], ["nasal", "ORGANISM_SUBDIVISION", 147, 152], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 156, 168], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 192, 202], ["SARS-CoV-2 specific antibodies", "PROTEIN", 192, 222], ["cats", "SPECIES", 21, 25], ["SARS-CoV", "SPECIES", 192, 200], ["these cats", "TEST", 15, 25], ["respiratory or gastrointestinal disease", "PROBLEM", 51, 90], ["RT-PCR", "TEST", 137, 143], ["nasal or rectal swabs", "PROBLEM", 147, 168], ["SARS", "PROBLEM", 192, 196], ["CoV", "TEST", 197, 200], ["respiratory", "ANATOMY", 51, 62], ["gastrointestinal", "ANATOMY", 66, 82], ["disease", "OBSERVATION", 83, 90], ["nasal", "ANATOMY", 147, 152], ["rectal swabs", "ANATOMY", 156, 168]]], ["However, a case of an asymptomatic cat testing positive for viral antigen after cohabitating with a COVID-19 patient has been reported (Ruiz-Arrondo et al., 2020) .Receptor utilization by SARS-CoV-2 in cats and other mammalian speciesAs described above, the receptor for both SARS-CoV and SARS-CoV-2 is ACE2.", [["SARS", "DISEASE", 276, 280], ["SARS", "DISEASE", 289, 293], ["cat", "ORGANISM", 35, 38], ["patient", "ORGANISM", 109, 116], ["SARS-CoV-2", "ORGANISM", 188, 198], ["cats", "ORGANISM", 202, 206], ["SARS-CoV", "ORGANISM", 276, 284], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 289, 299], ["ACE2", "GENE_OR_GENE_PRODUCT", 303, 307], ["viral antigen", "PROTEIN", 60, 73], ["ACE2", "PROTEIN", 303, 307], ["patient", "SPECIES", 109, 116], ["cats", "SPECIES", 202, 206], ["SARS-CoV", "SPECIES", 188, 196], ["SARS-CoV", "SPECIES", 276, 284], ["an asymptomatic cat testing", "TEST", 19, 46], ["viral antigen", "PROBLEM", 60, 73], ["a COVID", "TEST", 98, 105], ["Receptor utilization", "TREATMENT", 164, 184], ["SARS", "TEST", 188, 192], ["CoV", "TEST", 193, 196], ["other mammalian species", "PROBLEM", 211, 234], ["the receptor", "TREATMENT", 254, 266], ["both SARS", "TEST", 271, 280], ["CoV", "TEST", 281, 284], ["SARS", "TEST", 289, 293], ["CoV", "TEST", 294, 297], ["ACE2", "PROBLEM", 303, 307], ["mammalian species", "OBSERVATION", 217, 234]]], ["Protein alignment and phylogenetic analysis of full-length ACE2 protein in representative mammalian species reveal that as expected simian ACE2 from macaque (Macaca mulatta) and chimpanzee (Pan troglodytes) are the closest to human ACE2 with 94.9-99% sequence identity (Table 2) .", [["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["simian", "ORGANISM", 132, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["macaque", "ORGANISM", 149, 156], ["Macaca mulatta", "ORGANISM", 158, 172], ["chimpanzee", "ORGANISM", 178, 188], ["Pan troglodytes", "ORGANISM", 190, 205], ["human", "ORGANISM", 226, 231], ["ACE2", "GENE_OR_GENE_PRODUCT", 232, 236], ["full-length ACE2 protein", "PROTEIN", 47, 71], ["simian ACE2", "PROTEIN", 132, 143], ["human ACE2", "PROTEIN", 226, 236], ["simian", "SPECIES", 132, 138], ["macaque", "SPECIES", 149, 156], ["Macaca mulatta", "SPECIES", 158, 172], ["chimpanzee", "SPECIES", 178, 188], ["Pan troglodytes", "SPECIES", 190, 205], ["human", "SPECIES", 226, 231], ["Macaca mulatta", "SPECIES", 158, 172], ["Pan troglodytes", "SPECIES", 190, 205], ["human", "SPECIES", 226, 231], ["Protein alignment", "TEST", 0, 17], ["phylogenetic analysis", "TEST", 22, 43], ["full-length ACE2 protein", "TEST", 47, 71], ["macaque (Macaca mulatta)", "TREATMENT", 149, 173], ["chimpanzee (Pan troglodytes", "TREATMENT", 178, 205], ["human ACE2", "TEST", 226, 236], ["mammalian species", "OBSERVATION", 90, 107]]], ["Interestingly, amongst the other mammalian J o u r n a l P r e -p r o o f ACE2 sequences analyzed, the next most closely-related sequence is from the domestic cat (Felis catus) with 85.2% overall identity compared to human ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 74, 78], ["cat", "ORGANISM_SUBDIVISION", 159, 162], ["Felis catus", "ORGANISM", 164, 175], ["human", "ORGANISM", 217, 222], ["ACE2", "GENE_OR_GENE_PRODUCT", 223, 227], ["P r e", "DNA", 57, 62], ["ACE2 sequences", "DNA", 74, 88], ["human ACE2", "PROTEIN", 217, 227], ["cat", "SPECIES", 159, 162], ["Felis catus", "SPECIES", 164, 175], ["human", "SPECIES", 217, 222], ["domestic cat", "SPECIES", 150, 162], ["Felis catus", "SPECIES", 164, 175], ["human", "SPECIES", 217, 222], ["a l P r e -p r o o f ACE2 sequences", "TEST", 53, 88]]], ["Other closely related ACE2 sequences found were from Malayan pangolin (Manis javanica, 84.8% identity) and European rabbit (Oryctolagus cuniculus, 84.8%).", [["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["Manis javanica", "ORGANISM", 71, 85], ["rabbit", "ORGANISM", 116, 122], ["Oryctolagus cuniculus", "ORGANISM", 124, 145], ["ACE2 sequences", "DNA", 22, 36], ["Manis javanica", "SPECIES", 71, 85], ["rabbit", "SPECIES", 116, 122], ["Oryctolagus cuniculus", "SPECIES", 124, 145], ["Malayan pangolin", "SPECIES", 53, 69], ["Manis javanica", "SPECIES", 71, 85], ["European rabbit", "SPECIES", 107, 122], ["Oryctolagus cuniculus", "SPECIES", 124, 145], ["ACE2 sequences", "TEST", 22, 36], ["Malayan pangolin", "TEST", 53, 69], ["European rabbit (Oryctolagus cuniculus", "TEST", 107, 145]]], ["The ACE2 proteins of the intermediate hosts of SARS-CoV raccoon dog (Nyctereutes procyonoides) and masked palm civet (Paguma larvata) also featured a high degree of conservation in sequence with 83.9% and 83.5% sequence identity, respectively.", [["SARS", "DISEASE", 47, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["SARS-CoV raccoon dog", "ORGANISM", 47, 67], ["Nyctereutes procyonoides", "ORGANISM", 69, 93], ["palm civet", "ORGANISM", 106, 116], ["Paguma larvata", "ORGANISM", 118, 132], ["ACE2 proteins", "PROTEIN", 4, 17], ["CoV raccoon dog", "SPECIES", 52, 67], ["Nyctereutes procyonoides", "SPECIES", 69, 93], ["palm", "SPECIES", 106, 110], ["Paguma larvata", "SPECIES", 118, 132], ["SARS-CoV raccoon dog", "SPECIES", 47, 67], ["Nyctereutes procyonoides", "SPECIES", 69, 93], ["palm civet", "SPECIES", 106, 116], ["Paguma larvata", "SPECIES", 118, 132], ["The ACE2 proteins", "TEST", 0, 17], ["SARS", "TEST", 47, 51], ["CoV raccoon dog (Nyctereutes procyonoides", "TREATMENT", 52, 93], ["masked palm civet (Paguma larvata)", "TREATMENT", 99, 133], ["high degree", "OBSERVATION_MODIFIER", 150, 161]]], ["Domestic dog (Canis lupus familiaris) and domestic ferret (Mustela putorius furo) sequences displayed ACE2 sequence identities of 83.4% and 82.6% respectively.", [["dog", "ORGANISM", 9, 12], ["Canis lupus familiaris", "ORGANISM", 14, 36], ["domestic ferret", "ORGANISM", 42, 57], ["Mustela putorius furo", "ORGANISM", 59, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 102, 106], ["ACE2", "PROTEIN", 102, 106], ["dog", "SPECIES", 9, 12], ["Canis", "SPECIES", 14, 19], ["lupus familiaris", "SPECIES", 20, 36], ["ferret", "SPECIES", 51, 57], ["Mustela putorius", "SPECIES", 59, 75], ["Domestic dog", "SPECIES", 0, 12], ["Canis lupus familiaris", "SPECIES", 14, 36], ["ferret", "SPECIES", 51, 57], ["Mustela putorius furo", "SPECIES", 59, 80], ["Domestic dog (Canis lupus familiaris", "TEST", 0, 36], ["ACE2 sequence identities", "TEST", 102, 126]]], ["The bat ACE2 from Rhinolophus sinicus and Hipposideros armiger species known to harbor bat-SARS-related coronaviruses, had lower sequence identities at 80.7% and 80.5% respectively.", [["bat", "ORGANISM", 4, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["Rhinolophus sinicus", "ORGANISM", 18, 37], ["Hipposideros armiger species", "ORGANISM", 42, 70], ["bat-SARS-related coronaviruses", "ORGANISM", 87, 117], ["bat ACE2", "PROTEIN", 4, 12], ["Rhinolophus sinicus", "SPECIES", 18, 37], ["Hipposideros armiger", "SPECIES", 42, 62], ["Rhinolophus sinicus", "SPECIES", 18, 37], ["Hipposideros armiger", "SPECIES", 42, 62], ["The bat ACE2", "TEST", 0, 12], ["Rhinolophus sinicus", "PROBLEM", 18, 37], ["Hipposideros armiger species", "PROBLEM", 42, 70], ["SARS", "PROBLEM", 91, 95], ["coronaviruses", "PROBLEM", 104, 117], ["lower sequence identities", "TEST", 123, 148]]], ["A phylogenetic tree of the relationship between these and other species is shown in Figure 2A .Receptor utilization by SARS-CoV-2 in cats and other mammalian speciesThe structure of SARS-CoV-2 spike receptor binding motif (RBM) bound to the human ACE2 receptor has recently been resolved (Lan et al., 2020; Shang et al., 2020) .", [["SARS-CoV-2", "ORGANISM", 119, 129], ["cats", "ORGANISM", 133, 137], ["SARS-CoV-2 spike receptor binding motif", "GENE_OR_GENE_PRODUCT", 182, 221], ["human", "ORGANISM", 241, 246], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 247, 260], ["SARS-CoV-2 spike receptor binding motif", "DNA", 182, 221], ["RBM", "PROTEIN", 223, 226], ["human ACE2 receptor", "PROTEIN", 241, 260], ["cats", "SPECIES", 133, 137], ["human", "SPECIES", 241, 246], ["SARS-CoV", "SPECIES", 119, 127], ["human", "SPECIES", 241, 246], ["Receptor utilization", "TREATMENT", 95, 115], ["SARS", "TEST", 119, 123], ["CoV", "TEST", 124, 127], ["other mammalian species", "PROBLEM", 142, 165], ["SARS", "PROBLEM", 182, 186], ["CoV-2 spike receptor binding motif (RBM)", "TREATMENT", 187, 227], ["the human ACE2 receptor", "TREATMENT", 237, 260], ["phylogenetic tree", "OBSERVATION", 2, 19], ["mammalian species", "OBSERVATION", 148, 165], ["SARS", "OBSERVATION", 182, 186]]], ["Notably, the ACE2 residues that directly contact the SARS-CoV-2 spike receptor binding domain (RBD) have been identified (Lan et al., 2020) .", [["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 63], ["ACE2", "PROTEIN", 13, 17], ["SARS-CoV-2 spike receptor binding domain", "PROTEIN", 53, 93], ["RBD", "PROTEIN", 95, 98], ["the ACE2 residues", "PROBLEM", 9, 26], ["the SARS", "TEST", 49, 57], ["CoV", "TEST", 58, 61]]], ["To gauge potential use by SARS-CoV-2 of the ACE2 receptor from various mammalian species, a comparative analysis of the amino acid composition of the ACE2 contacting residues in different species was performed ( Figure 2B ).", [["amino acid", "CHEMICAL", 120, 130], ["amino acid", "CHEMICAL", 120, 130], ["SARS-CoV-2", "ORGANISM", 26, 36], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 44, 57], ["amino acid", "AMINO_ACID", 120, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 150, 154], ["ACE2 receptor", "PROTEIN", 44, 57], ["ACE2", "PROTEIN", 150, 154], ["SARS-CoV", "SPECIES", 26, 34], ["CoV", "TEST", 31, 34], ["the ACE2 receptor", "TREATMENT", 40, 57], ["various mammalian species", "PROBLEM", 63, 88], ["a comparative analysis", "TEST", 90, 112], ["the amino acid composition", "TREATMENT", 116, 142], ["the ACE2 contacting residues in different species", "PROBLEM", 146, 195], ["mammalian species", "OBSERVATION", 71, 88]]], ["Such analysis allows the estimation of a score of proximity to human ACE2 contacting residues for a given mammalian ACE2 sequence.", [["human", "ORGANISM", 63, 68], ["ACE2", "GENE_OR_GENE_PRODUCT", 69, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["human ACE2", "PROTEIN", 63, 73], ["mammalian ACE2 sequence", "DNA", 106, 129], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["Such analysis", "TEST", 0, 13], ["mammalian ACE2 sequence", "TREATMENT", 106, 129]]], ["Notably feline ACE2 has a score of 4, indicating that only 4 out of a total of 20 contacting residues were different between feline and human ACE2, with two of those differences conservative substitutions (D30E) and (D38E).", [["feline", "ORGANISM", 8, 14], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["feline", "ORGANISM", 125, 131], ["human", "ORGANISM", 136, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["feline ACE2", "PROTEIN", 8, 19], ["human ACE2", "PROTEIN", 136, 146], ["feline", "SPECIES", 125, 131], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["human ACE2", "TREATMENT", 136, 146], ["conservative substitutions (D30E)", "TREATMENT", 178, 211]]], ["This suggests that SARS-CoV-2 spike is highly likely to bind to feline ACE2.", [["SARS", "DISEASE", 19, 23], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 19, 29], ["feline", "ORGANISM", 64, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["feline ACE2", "PROTEIN", 64, 75], ["SARS", "PROBLEM", 19, 23], ["CoV", "TEST", 24, 27], ["spike", "PROBLEM", 30, 35], ["SARS", "OBSERVATION", 19, 23]]], ["The contacting residues found in canine ACE2 and the ACE2 of the bat Rhinolophus sinicus were also shown to have a relatively high degree of conservation with scores in the 5-6 range.", [["canine", "ORGANISM", 33, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["bat Rhinolophus sinicus", "ORGANISM", 65, 88], ["canine ACE2", "PROTEIN", 33, 44], ["ACE2", "PROTEIN", 53, 57], ["canine", "SPECIES", 33, 39], ["bat", "SPECIES", 65, 68], ["Rhinolophus sinicus", "SPECIES", 69, 88], ["canine", "SPECIES", 33, 39], ["Rhinolophus sinicus", "SPECIES", 69, 88], ["The contacting residues", "PROBLEM", 0, 23], ["scores", "TEST", 159, 165], ["high degree", "OBSERVATION_MODIFIER", 126, 137]]], ["In contrast to the relative overall sequence identity, mouse ACE2 contained a relatively high number of different residues at the ACE2 binding interface, with a score of 8.", [["mouse", "ORGANISM", 55, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 130, 134], ["mouse ACE2", "PROTEIN", 55, 65], ["ACE2", "PROTEIN", 130, 134], ["mouse", "SPECIES", 55, 60], ["mouse", "SPECIES", 55, 60], ["relatively", "OBSERVATION_MODIFIER", 78, 88], ["high", "OBSERVATION_MODIFIER", 89, 93], ["number", "OBSERVATION_MODIFIER", 94, 100], ["different residues", "OBSERVATION", 104, 122], ["binding interface", "OBSERVATION", 135, 152]]], ["This is in line with a report showing that mouse ACE2 cannot be functionally used by SARS-CoV-2 .", [["mouse", "ORGANISM", 43, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["SARS-CoV-2", "ORGANISM", 85, 95], ["mouse ACE2", "PROTEIN", 43, 53], ["mouse", "SPECIES", 43, 48], ["mouse", "SPECIES", 43, 48], ["SARS-CoV", "SPECIES", 85, 93], ["mouse ACE2", "PROBLEM", 43, 53]]], ["Based on these J o u r n a l P r e -p r o o f analyses the susceptibility of cats to infection with SARS-CoV-2 can likely be explained by the high similarities in human and feline ACE2.", [["infection", "DISEASE", 85, 94], ["SARS", "DISEASE", 100, 104], ["cats", "ORGANISM", 77, 81], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 100, 110], ["human", "ORGANISM", 163, 168], ["feline", "ORGANISM", 173, 179], ["ACE2", "GENE_OR_GENE_PRODUCT", 180, 184], ["P", "DNA", 29, 30], ["human and feline ACE2", "PROTEIN", 163, 184], ["human", "SPECIES", 163, 168], ["feline", "SPECIES", 173, 179], ["SARS-CoV", "SPECIES", 100, 108], ["human", "SPECIES", 163, 168], ["the susceptibility of cats to infection", "PROBLEM", 55, 94], ["SARS", "PROBLEM", 100, 104], ["CoV", "TEST", 105, 108], ["infection", "OBSERVATION", 85, 94]]], ["The reason for the susceptibility of ferrets to SARS-CoV-2 remains uncertain, but is unlikely due to the similarities in ACE2, with ferret ACE2 being more divergent that canine ACE2, an apparently less susceptible species for SARS-CoV-2.Summary and PerspectivesIt is now becoming clear that cats are susceptible hosts for the human virus SARS-CoV-2.", [["SARS", "DISEASE", 48, 52], ["SARS", "DISEASE", 226, 230], ["SARS", "DISEASE", 338, 342], ["ferrets", "ORGANISM", 37, 44], ["SARS-CoV-2", "ORGANISM", 48, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 121, 125], ["ferret", "ORGANISM", 132, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["canine", "ORGANISM", 170, 176], ["ACE2", "GENE_OR_GENE_PRODUCT", 177, 181], ["SARS-CoV-2", "ORGANISM", 226, 236], ["cats", "ORGANISM", 291, 295], ["human virus SARS-CoV-2", "ORGANISM", 326, 348], ["ACE2", "PROTEIN", 121, 125], ["ACE2", "PROTEIN", 139, 143], ["canine ACE2", "PROTEIN", 170, 181], ["ferrets", "SPECIES", 37, 44], ["ferret", "SPECIES", 132, 138], ["canine", "SPECIES", 170, 176], ["cats", "SPECIES", 291, 295], ["human", "SPECIES", 326, 331], ["SARS-CoV", "SPECIES", 48, 56], ["ferret", "SPECIES", 132, 138], ["canine", "SPECIES", 170, 176], ["SARS-CoV", "SPECIES", 226, 234], ["human virus SARS-CoV", "SPECIES", 326, 346], ["the susceptibility of ferrets", "PROBLEM", 15, 44], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["ACE2", "TEST", 121, 125], ["ferret ACE2", "PROBLEM", 132, 143], ["canine ACE2", "TEST", 170, 181], ["SARS", "TEST", 226, 230], ["CoV", "TEST", 231, 234], ["the human virus SARS", "TEST", 322, 342], ["less susceptible", "OBSERVATION_MODIFIER", 197, 213], ["clear", "OBSERVATION", 280, 285]]], ["However, much remains to be determined about the extent of infection in the cat population and level of infection and clinical signs in individual cats, as well at the potential for transmission between cats or to other animals, including humans.", [["infection", "DISEASE", 59, 68], ["infection", "DISEASE", 104, 113], ["cat", "ORGANISM", 76, 79], ["cats", "ORGANISM", 147, 151], ["cats", "ORGANISM", 203, 207], ["humans", "ORGANISM", 239, 245], ["cat", "SPECIES", 76, 79], ["cats", "SPECIES", 147, 151], ["cats", "SPECIES", 203, 207], ["humans", "SPECIES", 239, 245], ["humans", "SPECIES", 239, 245], ["infection", "PROBLEM", 59, 68], ["the cat population", "PROBLEM", 72, 90], ["infection", "PROBLEM", 104, 113], ["clinical signs in individual cats", "PROBLEM", 118, 151], ["transmission between cats", "PROBLEM", 182, 207], ["infection", "OBSERVATION", 59, 68], ["infection", "OBSERVATION", 104, 113]]], ["A likely explanation for this susceptibility lies in the high degree of similarity between the human and feline forms of the SARS-CoV-2 receptor, ACE2.", [["human", "ORGANISM", 95, 100], ["feline", "ORGANISM", 105, 111], ["SARS-CoV-2 receptor", "GENE_OR_GENE_PRODUCT", 125, 144], ["ACE2", "GENE_OR_GENE_PRODUCT", 146, 150], ["SARS-CoV-2 receptor", "PROTEIN", 125, 144], ["ACE2", "PROTEIN", 146, 150], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["this susceptibility", "PROBLEM", 25, 44], ["the SARS", "TEST", 121, 129], ["likely explanation for", "UNCERTAINTY", 2, 24], ["high degree", "OBSERVATION_MODIFIER", 57, 68], ["SARS", "OBSERVATION", 125, 129]]], ["However, there are still many unanswered questions related to interactions between the naturally occurring feline coronaviruses (types I and II) and SARS-CoV-2, and what the outcome of co-infection with both human and feline coronaviruses might be.Summary and PerspectivesFerrets are also susceptible hosts for SARS-CoV-2, but the reasons behind this are unclear and do not appear to the linked to receptor similarity.", [["feline coronaviruses", "DISEASE", 107, 127], ["co-infection", "DISEASE", 185, 197], ["feline coronaviruses", "DISEASE", 218, 238], ["SARS", "DISEASE", 311, 315], ["feline coronaviruses", "ORGANISM", 107, 127], ["SARS-CoV-2", "ORGANISM", 149, 159], ["human", "ORGANISM", 208, 213], ["feline coronaviruses", "ORGANISM", 218, 238], ["SARS-CoV-2", "ORGANISM", 311, 321], ["feline", "SPECIES", 107, 113], ["human", "SPECIES", 208, 213], ["feline", "SPECIES", 218, 224], ["feline coronaviruses", "SPECIES", 107, 127], ["SARS-CoV", "SPECIES", 149, 157], ["human", "SPECIES", 208, 213], ["feline coronaviruses", "SPECIES", 218, 238], ["SARS-CoV", "SPECIES", 311, 319], ["SARS", "PROBLEM", 149, 153], ["co-infection", "PROBLEM", 185, 197], ["both human and feline coronaviruses", "PROBLEM", 203, 238], ["SARS", "PROBLEM", 311, 315], ["CoV", "TEST", 316, 319]]], ["It may be that ferrets and human share common properties in relation to the architecture of their respective respiratory tracts, which makes them susceptible hosts (Lakdawala et al., 2015) .", [["respiratory tracts", "ANATOMY", 109, 127], ["ferrets", "ORGANISM", 15, 22], ["human", "ORGANISM", 27, 32], ["ferrets", "SPECIES", 15, 22], ["human", "SPECIES", 27, 32], ["ferrets", "SPECIES", 15, 22], ["human", "SPECIES", 27, 32], ["may be", "UNCERTAINTY", 3, 9], ["ferrets", "OBSERVATION", 15, 22], ["respiratory tracts", "ANATOMY", 109, 127]]], ["Dogs are currently not considered to be susceptible hosts for SARS-CoV-2, despite some positive test results in dogs.", [["SARS", "DISEASE", 62, 66], ["Dogs", "ORGANISM", 0, 4], ["SARS-CoV-2", "ORGANISM", 62, 72], ["dogs", "ORGANISM", 112, 116], ["dogs", "SPECIES", 112, 116], ["SARS-CoV", "SPECIES", 62, 70], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["some positive test results in dogs", "PROBLEM", 82, 116]]], ["Recent reports that SARS-CoV-2 may have originated in stray dogs based on similar genetic signatures between systemic forms of CCoV and SARS-CoV-2 are unlikely to be substantiated (Xia, 2020) .Summary and PerspectivesIn the public health battle against coronaviruses, it is important to note that both cats and ferrets are known hosts of human (and avian) influenza viruses yet are not considered to be a significant risk for human infections.", [["SARS", "DISEASE", 136, 140], ["influenza viruses", "DISEASE", 356, 373], ["infections", "DISEASE", 432, 442], ["SARS-CoV-2", "ORGANISM", 20, 30], ["stray dogs", "ORGANISM", 54, 64], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["coronaviruses", "ORGANISM", 253, 266], ["cats", "ORGANISM", 302, 306], ["ferrets", "ORGANISM", 311, 318], ["human", "ORGANISM", 338, 343], ["avian) influenza viruses", "ORGANISM", 349, 373], ["human", "ORGANISM", 426, 431], ["cats", "SPECIES", 302, 306], ["ferrets", "SPECIES", 311, 318], ["human", "SPECIES", 338, 343], ["human", "SPECIES", 426, 431], ["SARS-CoV", "SPECIES", 20, 28], ["CCoV", "SPECIES", 127, 131], ["SARS-CoV", "SPECIES", 136, 144], ["ferrets", "SPECIES", 311, 318], ["human", "SPECIES", 338, 343], ["human", "SPECIES", 426, 431], ["SARS", "PROBLEM", 20, 24], ["CCoV", "PROBLEM", 127, 131], ["SARS", "PROBLEM", 136, 140], ["coronaviruses", "PROBLEM", 253, 266], ["human (and avian) influenza viruses", "PROBLEM", 338, 373], ["human infections", "PROBLEM", 426, 442], ["infections", "OBSERVATION", 432, 442]]], ["In contrast, dogs maintain their own pool of influenza viruses.", [["influenza viruses", "DISEASE", 45, 62], ["dogs", "ORGANISM", 13, 17], ["influenza viruses", "ORGANISM", 45, 62], ["dogs", "SPECIES", 13, 17], ["influenza viruses", "PROBLEM", 45, 62], ["influenza viruses", "OBSERVATION", 45, 62]]], ["Overall, both cats and ferrets may be part of a common pool of human respiratory infections.", [["respiratory", "ANATOMY", 69, 80], ["respiratory infections", "DISEASE", 69, 91], ["cats", "ORGANISM", 14, 18], ["ferrets", "ORGANISM", 23, 30], ["human", "ORGANISM", 63, 68], ["cats", "SPECIES", 14, 18], ["ferrets", "SPECIES", 23, 30], ["human", "SPECIES", 63, 68], ["ferrets", "SPECIES", 23, 30], ["human", "SPECIES", 63, 68], ["human respiratory infections", "PROBLEM", 63, 91], ["respiratory infections", "OBSERVATION", 69, 91]]], ["Whether this is due to molecular J o u r n a l P r e -p r o o f similarities at the pathogen-host interface, social connection between humans and their companion animals (or with zoo animals) or based on more physiological or immunological parameters within the respiratory tract (or elsewhere) remains to be determined.", [["respiratory tract", "ANATOMY", 262, 279], ["humans", "ORGANISM", 135, 141], ["respiratory tract", "ORGANISM_SUBDIVISION", 262, 279], ["humans", "SPECIES", 135, 141], ["humans", "SPECIES", 135, 141], ["host interface", "OBSERVATION", 93, 107], ["respiratory tract", "ANATOMY", 262, 279]]], ["There is also the issue of viral pathogenesis, by which it is known both cats and ferrets (but not other species) can allow the conversion of what is normally to be a benign yet transmissible coronavirus (FCoV and FRECV) into a lethal, systemic (but typically not transmissible) form.", [["coronavirus", "DISEASE", 192, 203], ["cats", "ORGANISM", 73, 77], ["ferrets", "ORGANISM", 82, 89], ["coronavirus", "ORGANISM", 192, 203], ["FCoV", "CANCER", 205, 209], ["FRECV", "CANCER", 214, 219], ["cats", "SPECIES", 73, 77], ["ferrets", "SPECIES", 82, 89], ["ferrets", "SPECIES", 82, 89], ["FCoV", "SPECIES", 205, 209], ["FRECV", "SPECIES", 214, 219], ["viral pathogenesis", "PROBLEM", 27, 45], ["a benign yet transmissible coronavirus", "PROBLEM", 165, 203], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["pathogenesis", "OBSERVATION", 33, 45]]], ["Clearly, many important investigations lie ahead in understanding feline (and ferret) coronaviruses in their natural host and at the human-animal interface, both within the context of the current COVID-19 pandemic and for its likely continued circulation in the future. sequences from different species.", [["feline (and ferret) coronaviruses", "DISEASE", 66, 99], ["feline", "ORGANISM", 66, 72], ["ferret) coronaviruses", "ORGANISM", 78, 99], ["human", "ORGANISM", 133, 138], ["feline", "SPECIES", 66, 72], ["ferret", "SPECIES", 78, 84], ["human", "SPECIES", 133, 138], ["ferret", "SPECIES", 78, 84], ["human", "SPECIES", 133, 138], ["the current COVID", "TEST", 184, 201], ["pandemic", "PROBLEM", 205, 213]]], ["The ACE2 sequences from various animal species were aligned using MUSCLE and a maximum-likelihood (ML) phylogenetic tree was generated using MEGAX.", [["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["ACE2 sequences", "DNA", 4, 18], ["MEGAX", "PROTEIN", 141, 146], ["The ACE2 sequences", "TEST", 0, 18], ["MEGAX", "TREATMENT", 141, 146], ["MUSCLE", "ANATOMY", 66, 72]]], ["Bootstrap values shown at nodes were calculated from 1000 replicates.", [["nodes", "MULTI-TISSUE_STRUCTURE", 26, 31], ["Bootstrap values", "TEST", 0, 16], ["nodes", "OBSERVATION", 26, 31]]], ["The tree is drawn to scale, with branch lengths measured in the number of substitutions per site.", [["branch lengths", "PROBLEM", 33, 47], ["tree", "OBSERVATION_MODIFIER", 4, 8], ["branch", "OBSERVATION_MODIFIER", 33, 39], ["lengths", "OBSERVATION_MODIFIER", 40, 47], ["substitutions", "OBSERVATION", 74, 87], ["site", "OBSERVATION_MODIFIER", 92, 96]]], ["B. Comparative analysis of ACE2 amino acid composition at residue positions involved in the ACE2-virus binding interface.", [["amino acid", "CHEMICAL", 32, 42], ["amino acid", "CHEMICAL", 32, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["amino acid", "AMINO_ACID", 32, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["ACE2", "PROTEIN", 27, 31], ["ACE2", "PROTEIN", 92, 96], ["Comparative analysis", "TEST", 3, 23], ["ACE2 amino acid composition", "TREATMENT", 27, 54]]], ["The ACE2 sequences of ACE2 from selected species were aligned and the amino acid found at each of the residue positions involved in the binding interface are shown.", [["amino acid", "CHEMICAL", 70, 80], ["amino acid", "CHEMICAL", 70, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["amino acid", "AMINO_ACID", 70, 80], ["ACE2", "PROTEIN", 4, 8], ["ACE2", "PROTEIN", 22, 26], ["The ACE2 sequences", "TEST", 0, 18], ["ACE2", "TEST", 22, 26], ["the amino acid", "TEST", 66, 80], ["residue positions", "OBSERVATION", 102, 119], ["binding interface", "OBSERVATION", 136, 153]]], ["Yellow highlight indicates a substituted residue compared to the human ACE2 sequence.", [["human", "ORGANISM", 65, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["human ACE2 sequence", "DNA", 65, 84], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["a substituted residue", "PROBLEM", 27, 48], ["the human ACE2 sequence", "TEST", 61, 84], ["substituted residue", "OBSERVATION", 29, 48]]], ["A grey highlight indicates a conservative change in residue composition compared to human ACE2 sequence.", [["human", "ORGANISM", 84, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["human ACE2 sequence", "DNA", 84, 103], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["a conservative change in residue composition", "PROBLEM", 27, 71], ["human ACE2 sequence", "TEST", 84, 103], ["conservative", "OBSERVATION", 29, 41]]]], "93425e3efc7561514451b9ea0d4cad0789c42017": [["IntroductionHepatitis E virus (HEV) is the causative agent of hepatitis E, a form of acute viral hepatitis that is endemic to many resourcelimited regions of the world .", [["IntroductionHepatitis E", "DISEASE", 0, 23], ["hepatitis E", "DISEASE", 62, 73], ["acute viral hepatitis", "DISEASE", 85, 106], ["IntroductionHepatitis E virus", "ORGANISM", 0, 29], ["HEV", "ORGANISM", 31, 34], ["hepatitis E", "ORGANISM", 62, 73], ["E virus", "SPECIES", 22, 29], ["IntroductionHepatitis E virus", "SPECIES", 0, 29], ["HEV", "SPECIES", 31, 34], ["hepatitis E", "SPECIES", 62, 73], ["IntroductionHepatitis E virus", "PROBLEM", 0, 29], ["hepatitis E", "PROBLEM", 62, 73], ["acute viral hepatitis", "PROBLEM", 85, 106], ["hepatitis", "OBSERVATION", 62, 71], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["viral hepatitis", "OBSERVATION", 91, 106]]], ["It is estimated that about 2 billion people, which is about a third of the world population, live in areas endemic for HEV and are at risk for infection.", [["infection", "DISEASE", 143, 152], ["people", "ORGANISM", 37, 43], ["HEV", "ORGANISM", 119, 122], ["people", "SPECIES", 37, 43], ["HEV", "SPECIES", 119, 122], ["HEV", "PROBLEM", 119, 122], ["infection", "PROBLEM", 143, 152], ["infection", "OBSERVATION", 143, 152]]], ["In these areas, hepatitis E is the major form of acute hepatitis; in India for example about 50% of acute hepatitis is due to HEV.", [["hepatitis E", "DISEASE", 16, 27], ["acute hepatitis", "DISEASE", 49, 64], ["hepatitis", "DISEASE", 106, 115], ["hepatitis E", "ORGANISM", 16, 27], ["HEV", "ORGANISM", 126, 129], ["hepatitis E", "SPECIES", 16, 27], ["HEV", "SPECIES", 126, 129], ["hepatitis E", "PROBLEM", 16, 27], ["acute hepatitis", "PROBLEM", 49, 64], ["acute hepatitis", "PROBLEM", 100, 115], ["HEV", "PROBLEM", 126, 129], ["areas", "OBSERVATION_MODIFIER", 9, 14], ["hepatitis", "OBSERVATION", 16, 25], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["hepatitis", "OBSERVATION", 55, 64], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["hepatitis", "OBSERVATION", 106, 115]]], ["It results in morbidity and increased mortality during pregnancy; these clinical aspects of hepatitis E are covered in detail in another review in this issue (R. Aggarwal).IntroductionThe recognition that hepatitis E was caused by a distinct agent dates back to the 1970s from investigations undertaken by Khuroo and co-workers who studied jaundice outbreaks in Kashmir, India, and Purcell and co-workers who retrospectively studied the 1955-56 outbreak of jaundice in New Delhi, India.", [["hepatitis", "DISEASE", 92, 101], ["hepatitis E", "DISEASE", 205, 216], ["jaundice", "DISEASE", 340, 348], ["jaundice", "DISEASE", 457, 465], ["hepatitis E", "ORGANISM", 205, 216], ["morbidity", "PROBLEM", 14, 23], ["increased mortality during pregnancy", "PROBLEM", 28, 64], ["hepatitis E", "PROBLEM", 92, 103], ["hepatitis E", "PROBLEM", 205, 216], ["jaundice", "PROBLEM", 457, 465], ["morbidity", "OBSERVATION", 14, 23], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["mortality", "OBSERVATION", 38, 47], ["jaundice", "OBSERVATION", 457, 465]]], ["The history of hepatitis E and HEV is also covered in greater detail in another review in this issue (M.S. Khuroo).", [["hepatitis E", "DISEASE", 15, 26], ["hepatitis E", "ORGANISM", 15, 26], ["HEV", "ORGANISM", 31, 34], ["HEV", "SPECIES", 31, 34], ["hepatitis E", "PROBLEM", 15, 26], ["HEV", "PROBLEM", 31, 34], ["hepatitis", "OBSERVATION", 15, 24]]], ["The discovery of viruses similar to HEV in pigs (swine HEV), chickens (avian HEV) and more recently in rabbits and rodents, as well as the successful transmission of swine HEV to macaques, which are a model for human HEV transmission, led to the idea of HEV as a zoonosis.", [["HEV transmission", "DISEASE", 217, 233], ["zoonosis", "DISEASE", 263, 271], ["HEV", "ORGANISM", 36, 39], ["pigs", "ORGANISM", 43, 47], ["swine HEV", "ORGANISM", 49, 58], ["chickens", "ORGANISM", 61, 69], ["avian HEV", "ORGANISM", 71, 80], ["rabbits", "ORGANISM", 103, 110], ["swine HEV", "ORGANISM", 166, 175], ["macaques", "ORGANISM", 179, 187], ["human", "ORGANISM", 211, 216], ["HEV", "ORGANISM", 254, 257], ["pigs", "SPECIES", 43, 47], ["swine", "SPECIES", 49, 54], ["chickens", "SPECIES", 61, 69], ["avian HEV", "SPECIES", 71, 80], ["rabbits", "SPECIES", 103, 110], ["swine HEV", "SPECIES", 166, 175], ["macaques", "SPECIES", 179, 187], ["human", "SPECIES", 211, 216], ["HEV", "SPECIES", 36, 39], ["pigs", "SPECIES", 43, 47], ["HEV", "SPECIES", 55, 58], ["chickens", "SPECIES", 61, 69], ["HEV", "SPECIES", 77, 80], ["rabbits", "SPECIES", 103, 110], ["swine HEV", "SPECIES", 166, 175], ["human", "SPECIES", 211, 216], ["HEV", "SPECIES", 217, 220], ["HEV", "SPECIES", 254, 257], ["viruses", "PROBLEM", 17, 24], ["viruses", "OBSERVATION", 17, 24]]], ["This belief is further strengthened by studies from Japan that have used nucleotide sequence identity to link viruses recovered from uncooked meat (pigs and deer) and humans who became infected after consuming the meat.", [["meat", "ANATOMY", 142, 146], ["meat", "ANATOMY", 214, 218], ["nucleotide", "CHEMICAL", 73, 83], ["nucleotide", "CHEMICAL", 73, 83], ["meat", "ORGANISM_SUBDIVISION", 142, 146], ["pigs", "ORGANISM", 148, 152], ["deer", "ORGANISM", 157, 161], ["humans", "ORGANISM", 167, 173], ["meat", "ORGANISM_SUBDIVISION", 214, 218], ["meat", "SPECIES", 142, 146], ["pigs", "SPECIES", 148, 152], ["deer", "SPECIES", 157, 161], ["humans", "SPECIES", 167, 173], ["deer", "SPECIES", 157, 161], ["humans", "SPECIES", 167, 173], ["nucleotide sequence identity", "PROBLEM", 73, 101], ["link viruses", "PROBLEM", 105, 117], ["infected", "OBSERVATION", 185, 193]]], ["The discovery and analysis of animal HEVs (X.J. Meng) and the unique transmission situations in Japan (T. Miyamura) are also covered separately in this issue.IntroductionHEV is a small non-enveloped virus with a size of 27-34 nm and is classified as a Hepevirus in the family Hepeviridae .", [["IntroductionHEV", "CHEMICAL", 158, 173], ["HEVs", "CELL", 37, 41], ["T. Miyamura", "ORGANISM", 103, 114], ["T. Miyamura", "SPECIES", 103, 114], ["T. Miyamura", "SPECIES", 103, 114], ["animal HEVs", "TEST", 30, 41], ["a small non-enveloped virus", "PROBLEM", 177, 204], ["small", "OBSERVATION_MODIFIER", 179, 184], ["non-enveloped", "OBSERVATION_MODIFIER", 185, 198], ["virus", "OBSERVATION", 199, 204], ["size", "OBSERVATION_MODIFIER", 212, 216], ["27-34 nm", "OBSERVATION_MODIFIER", 220, 228]]], ["So far only one serotype of HEV has been identified, but there are four phylogenetically distinct genotypes, each dominant in a given geographic area.", [["HEV", "ORGANISM", 28, 31], ["HEV", "SPECIES", 28, 31], ["HEV", "PROBLEM", 28, 31], ["four phylogenetically distinct genotypes", "PROBLEM", 67, 107], ["one", "OBSERVATION_MODIFIER", 12, 15], ["serotype", "OBSERVATION", 16, 24], ["HEV", "OBSERVATION", 28, 31], ["four", "OBSERVATION_MODIFIER", 67, 71], ["phylogenetically", "OBSERVATION_MODIFIER", 72, 88], ["distinct", "OBSERVATION_MODIFIER", 89, 97], ["genotypes", "OBSERVATION", 98, 107], ["dominant", "OBSERVATION_MODIFIER", 114, 122]]], ["Genotype 1 includes strains from Asia and Africa, genotype 2 includes the Mexican strain and a few variants from Africa, and genotypes 3 and 4 include human and swine HEV strains from industrialized countries and Asia (particularly China), respectively.", [["human", "ORGANISM", 151, 156], ["swine HEV", "ORGANISM", 161, 170], ["human", "SPECIES", 151, 156], ["swine", "SPECIES", 161, 166], ["human", "SPECIES", 151, 156], ["swine HEV", "SPECIES", 161, 170], ["Genotype", "TEST", 0, 8], ["strains", "PROBLEM", 20, 27], ["Africa, genotype 2", "PROBLEM", 42, 60], ["the Mexican strain", "PROBLEM", 70, 88], ["Africa", "PROBLEM", 113, 119], ["genotypes", "TEST", 125, 134], ["human and swine HEV strains", "PROBLEM", 151, 178]]], ["While genotypes 1 and 2 have only been found in humans, genotypes 3 and 4 have been recovered from humans as well as pigs and other animal species.", [["2", "GENE_OR_GENE_PRODUCT", 22, 23], ["humans", "ORGANISM", 48, 54], ["4", "GENE_OR_GENE_PRODUCT", 72, 73], ["humans", "ORGANISM", 99, 105], ["pigs", "ORGANISM", 117, 121], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 99, 105], ["pigs", "SPECIES", 117, 121], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 99, 105], ["pigs", "SPECIES", 117, 121], ["genotypes", "TEST", 6, 15], ["genotypes", "TEST", 56, 65]]], ["Genotype 3 is evenly distributed across the world while genotype 4 is found more often in China and Japan.IntroductionEarly studies on HEV transmission and pathogenesis as well as preclinical vaccine development studies have mostly been carried out in non-human primates such as cynomolgus, rhesus and owl monkeys, and chimpanzees (Uchida et al., 1991; Purdy et al., 1992; Ticehurst et al., 1992; McCaustland et al., 2000) .", [["HEV transmission", "DISEASE", 135, 151], ["HEV", "ORGANISM", 135, 138], ["non-human", "ORGANISM", 252, 261], ["primates", "ORGANISM", 262, 270], ["cynomolgus", "ORGANISM", 279, 289], ["rhesus", "ORGANISM", 291, 297], ["owl monkeys", "ORGANISM", 302, 313], ["chimpanzees", "ORGANISM", 319, 330], ["owl monkeys", "SPECIES", 302, 313], ["HEV", "SPECIES", 135, 138], ["owl monkeys", "SPECIES", 302, 313], ["Genotype 3", "PROBLEM", 0, 10], ["IntroductionEarly studies", "TEST", 106, 131], ["HEV transmission", "TEST", 135, 151], ["pathogenesis", "PROBLEM", 156, 168], ["preclinical vaccine development studies", "TEST", 180, 219], ["evenly", "OBSERVATION_MODIFIER", 14, 20], ["distributed", "OBSERVATION_MODIFIER", 21, 32]]], ["More recently, pigs have also been used for transmission and molecular studies (Meng et al., 1998) .", [["pigs", "ORGANISM", 15, 19], ["pigs", "SPECIES", 15, 19], ["pigs", "SPECIES", 15, 19], ["molecular studies", "TEST", 61, 78]]], ["However, a small animal model for HEV is still elusive.", [["HEV", "DISEASE", 34, 37], ["HEV", "ORGANISM", 34, 37], ["HEV", "SPECIES", 34, 37], ["a small animal model for HEV", "PROBLEM", 9, 37], ["small", "OBSERVATION_MODIFIER", 11, 16]]], ["That and the lack of a suitable in vitro cell culture system have hampered virological studies on HEV.", [["cell culture", "ANATOMY", 41, 53], ["cell", "CELL", 41, 45], ["HEV", "ORGANISM", 98, 101], ["HEV", "SPECIES", 98, 101], ["a suitable in vitro cell culture system", "TEST", 21, 60], ["virological studies", "TEST", 75, 94]]], ["However, cell culture systems based on replicon RNA transfection and more recently those using the virus, have become available.", [["cell", "ANATOMY", 9, 13], ["cell", "CELL", 9, 13], ["cell culture systems", "TEST", 9, 29], ["replicon RNA transfection", "TREATMENT", 39, 64], ["the virus", "PROBLEM", 95, 104]]], ["These are covered in greater detail in another review in this issue (Okamoto).Cloning and genome organizationThe HEV genome was first cloned from cDNA libraries prepared from the bile of macaques experimentally inoculated with stool suspensions from human patients (Reyes et al., 1990; Tam et al., 1991) .", [["bile", "ANATOMY", 179, 183], ["HEV", "ORGANISM", 113, 116], ["bile", "ORGANISM_SUBDIVISION", 179, 183], ["macaques", "ORGANISM", 187, 195], ["human", "ORGANISM", 250, 255], ["patients", "ORGANISM", 256, 264], ["HEV genome", "DNA", 113, 123], ["cDNA libraries", "DNA", 146, 160], ["macaques", "SPECIES", 187, 195], ["human", "SPECIES", 250, 255], ["patients", "SPECIES", 256, 264], ["HEV", "SPECIES", 113, 116], ["human", "SPECIES", 250, 255], ["cDNA libraries", "TREATMENT", 146, 160], ["greater", "OBSERVATION_MODIFIER", 21, 28], ["HEV genome", "OBSERVATION", 113, 123], ["bile", "ANATOMY", 179, 183]]], ["Similar and polymerase chain reaction based strategies were later used to clone the genomes of multiple geographically distinct isolates of HEV (Huang et al., 1992; Panda et al., 2000; Emerson et al., 2001) .Cloning and genome organizationThe HEV genome is a single-stranded RNA of \u223c7.2 kb that is positive-sense, with a 5 -methylguanine cap and a 3 poly(A) stretch, and contains three partially overlapping open reading frames (ORFs) -called orf1, orf2 and orf3 (Tam et al., 1991) .", [["5 -methylguanine", "CHEMICAL", 321, 337], ["5 -methylguanine", "CHEMICAL", 321, 337], ["HEV", "ORGANISM", 140, 143], ["orf1", "GENE_OR_GENE_PRODUCT", 443, 447], ["orf2", "GENE_OR_GENE_PRODUCT", 449, 453], ["orf3", "GENE_OR_GENE_PRODUCT", 458, 462], ["HEV genome", "DNA", 243, 253], ["single-stranded RNA", "RNA", 259, 278], ["5 -methylguanine cap", "DNA", 321, 341], ["3 poly(A) stretch", "DNA", 348, 365], ["open reading frames", "DNA", 408, 427], ["ORFs", "DNA", 429, 433], ["orf1", "DNA", 443, 447], ["orf2", "DNA", 449, 453], ["orf3", "DNA", 458, 462], ["HEV", "SPECIES", 140, 143], ["HEV", "SPECIES", 243, 246], ["Similar and polymerase chain reaction", "PROBLEM", 0, 37], ["a 5 -methylguanine cap", "TREATMENT", 319, 341], ["chain", "OBSERVATION_MODIFIER", 23, 28], ["multiple", "OBSERVATION_MODIFIER", 95, 103], ["geographically", "OBSERVATION_MODIFIER", 104, 118], ["distinct", "OBSERVATION_MODIFIER", 119, 127], ["isolates", "OBSERVATION_MODIFIER", 128, 136], ["HEV genome", "OBSERVATION", 243, 253], ["positive", "OBSERVATION", 298, 306]]], ["The viral genome also has short 5 -and 3 -untranslated regions (UTRs) and a conserved 58-nucleotide region within orf1; these elements are likely to fold into conserved stem-loop and hairpin structures.", [["orf1", "GENE_OR_GENE_PRODUCT", 114, 118], ["viral genome", "DNA", 4, 16], ["5 -and 3 -untranslated regions", "DNA", 32, 62], ["UTRs", "DNA", 64, 68], ["58-nucleotide region", "DNA", 86, 106], ["orf1", "DNA", 114, 118], ["The viral genome", "TEST", 0, 16], ["a conserved 58-nucleotide region within orf1", "PROBLEM", 74, 118], ["viral genome", "OBSERVATION", 4, 16], ["short", "OBSERVATION_MODIFIER", 26, 31], ["likely to", "UNCERTAINTY", 139, 148], ["stem", "OBSERVATION_MODIFIER", 169, 173], ["loop", "OBSERVATION_MODIFIER", 174, 178], ["hairpin structures", "OBSERVATION", 183, 201]]], ["These structures and a sequence closer to the 3 end of orf1, which has homology to the alphavirus junction region, are proposed to be important for HEV RNA replication .", [["orf1", "GENE_OR_GENE_PRODUCT", 55, 59], ["HEV", "ORGANISM", 148, 151], ["orf1", "DNA", 55, 59], ["alphavirus junction region", "DNA", 87, 113], ["HEV", "SPECIES", 148, 151], ["a sequence", "TEST", 21, 31], ["orf1", "TREATMENT", 55, 59], ["HEV RNA replication", "TREATMENT", 148, 167], ["alphavirus junction", "ANATOMY", 87, 106], ["RNA replication", "OBSERVATION", 152, 167]]], ["The region between the end of orf1 and start of orf3/orf2 appears to be complex and contains regulatory elements.", [["orf1", "GENE_OR_GENE_PRODUCT", 30, 34], ["orf3", "GENE_OR_GENE_PRODUCT", 48, 52], ["orf2", "GENE_OR_GENE_PRODUCT", 53, 57], ["orf1", "DNA", 30, 34], ["orf3", "DNA", 48, 52], ["orf2", "DNA", 53, 57], ["regulatory elements", "DNA", 93, 112], ["orf1", "TREATMENT", 30, 34], ["orf3/orf2", "TREATMENT", 48, 57], ["appears to be", "UNCERTAINTY", 58, 71], ["complex", "OBSERVATION", 72, 79], ["regulatory elements", "OBSERVATION", 93, 112]]], ["These details are shown in Fig. 1 .Viral RNA speciesIn the liver tissue of macaques experimentally infected with HEV, Tam et al. (1991) detected three RNA species of \u223c7.2, 3.7 and 2 kb, which were designated as the genomic and two subgenomic RNAs, respectively.", [["liver tissue", "ANATOMY", 59, 71], ["liver tissue", "TISSUE", 59, 71], ["macaques", "ORGANISM", 75, 83], ["HEV", "ORGANISM", 113, 116], ["Viral RNA species", "RNA", 35, 52], ["RNA species", "RNA", 151, 162], ["subgenomic RNAs", "RNA", 231, 246], ["macaques", "SPECIES", 75, 83], ["HEV", "SPECIES", 113, 116], ["Viral RNA species", "PROBLEM", 35, 52], ["RNA species", "TEST", 151, 162], ["\u223c", "TEST", 166, 167], ["RNA species", "OBSERVATION", 41, 52], ["liver", "ANATOMY", 59, 64], ["tissue", "ANATOMY_MODIFIER", 65, 71], ["macaques", "OBSERVATION", 75, 83], ["infected", "OBSERVATION_MODIFIER", 99, 107], ["subgenomic RNAs", "OBSERVATION", 231, 246]]], ["In this model, the orf1 stop codon at position 5105 (nucleotide position according to the genotype 1 SAR-55 strain) overlaps with the orf3 start codon at position 5104.", [["nucleotide", "CHEMICAL", 53, 63], ["orf1", "GENE_OR_GENE_PRODUCT", 19, 23], ["orf1 stop codon", "DNA", 19, 34], ["position 5105", "DNA", 38, 51], ["genotype 1 SAR-55 strain", "DNA", 90, 114], ["orf3 start codon", "DNA", 134, 150], ["position 5104", "DNA", 154, 167], ["the orf1 stop codon", "TREATMENT", 15, 34], ["the orf3 start codon", "TREATMENT", 130, 150]]], ["Two in-frame AUG codons at positions 5113 and 5131 were considered to code for methionine residues in the ORF3 protein.", [["methionine", "CHEMICAL", 79, 89], ["methionine", "CHEMICAL", 79, 89], ["methionine", "AMINO_ACID", 79, 89], ["ORF3", "GENE_OR_GENE_PRODUCT", 106, 110], ["AUG codons", "DNA", 13, 23], ["ORF3 protein", "PROTEIN", 106, 118], ["methionine residues", "TREATMENT", 79, 98]]], ["These are followed by another AUG codon in the \u22121 frame, which was proposed to be the orf2 start codon.", [["orf2", "GENE_OR_GENE_PRODUCT", 86, 90], ["AUG codon", "DNA", 30, 39], ["\u22121 frame", "DNA", 47, 55], ["orf2 start codon", "DNA", 86, 102]]], ["Thus, in this model, the 3.7 and 2 kb subgenomic RNAs would be used to translate the ORF3 and ORF2 proteins, respectively.", [["ORF3", "GENE_OR_GENE_PRODUCT", 85, 89], ["ORF2", "GENE_OR_GENE_PRODUCT", 94, 98], ["3.7 and 2 kb subgenomic RNAs", "RNA", 25, 53], ["ORF3", "DNA", 85, 89], ["ORF2 proteins", "PROTEIN", 94, 107], ["2 kb subgenomic RNAs", "TREATMENT", 33, 53], ["the ORF3 and ORF2 proteins", "TEST", 81, 107]]], ["In stable Huh-7 cell lines made from functional HEV RNA replicons expressing the neomycin resistance gene from orf2 and orf3, the genomic RNA and only one subgenomic RNA were observed.", [["Huh-7 cell lines", "ANATOMY", 10, 26], ["neomycin", "CHEMICAL", 81, 89], ["neomycin", "CHEMICAL", 81, 89], ["Huh-7 cell lines", "CELL", 10, 26], ["HEV", "ORGANISM", 48, 51], ["neomycin", "GENE_OR_GENE_PRODUCT", 81, 89], ["orf2", "GENE_OR_GENE_PRODUCT", 111, 115], ["orf3", "GENE_OR_GENE_PRODUCT", 120, 124], ["Huh-7 cell lines", "CELL_LINE", 10, 26], ["HEV RNA replicons", "DNA", 48, 65], ["neomycin resistance gene", "DNA", 81, 105], ["orf2", "DNA", 111, 115], ["orf3", "DNA", 120, 124], ["genomic RNA", "RNA", 130, 141], ["subgenomic RNA", "RNA", 155, 169], ["HEV", "SPECIES", 48, 51], ["cell lines", "TREATMENT", 16, 26], ["functional HEV RNA replicons", "TREATMENT", 37, 65], ["the neomycin resistance gene", "TREATMENT", 77, 105], ["orf3", "TREATMENT", 120, 124], ["the genomic RNA", "PROBLEM", 126, 141], ["one subgenomic RNA", "PROBLEM", 151, 169], ["stable", "OBSERVATION_MODIFIER", 3, 9], ["cell lines", "OBSERVATION", 16, 26], ["HEV RNA replicons", "OBSERVATION", 48, 65], ["neomycin resistance", "OBSERVATION", 81, 100], ["genomic RNA", "OBSERVATION", 130, 141], ["one", "OBSERVATION_MODIFIER", 151, 154], ["subgenomic RNA", "OBSERVATION", 155, 169]]], ["The capped 2.2 kb subgenomic RNA initiated at nucleotide position 5122, which was downstream of the first two methionine codons in orf3, and was bicistronic, for the translation of ORF3 and ORF2 (Fig. 1) .", [["nucleotide", "CHEMICAL", 46, 56], ["methionine", "CHEMICAL", 110, 120], ["nucleotide", "CHEMICAL", 46, 56], ["methionine", "CHEMICAL", 110, 120], ["5122", "AMINO_ACID", 66, 70], ["orf3", "GENE_OR_GENE_PRODUCT", 131, 135], ["ORF3", "GENE_OR_GENE_PRODUCT", 181, 185], ["ORF2", "GENE_OR_GENE_PRODUCT", 190, 194], ["2.2 kb subgenomic RNA", "RNA", 11, 32], ["orf3", "DNA", 131, 135], ["ORF3", "DNA", 181, 185], ["ORF2", "DNA", 190, 194], ["The capped 2.2 kb subgenomic RNA", "TREATMENT", 0, 32], ["methionine codons", "TREATMENT", 110, 127], ["ORF3", "TREATMENT", 181, 185], ["2.2 kb", "OBSERVATION_MODIFIER", 11, 17], ["subgenomic RNA", "OBSERVATION", 18, 32]]], ["This model also rationalizes the reading frame differences observed in genotype 4 HEV isolates, which contain a T base insertion between nucleotides 5116/5117 (in SAR-55), thus taking AUG3 in a different translation frame.", [["nucleotides", "CHEMICAL", 137, 148], ["nucleotides 5116/5117", "DNA", 137, 158], ["AUG3", "DNA", 184, 188], ["translation frame", "DNA", 204, 221], ["HEV", "SPECIES", 82, 85], ["a T base insertion between nucleotides", "TREATMENT", 110, 148]]], ["Translation of the ORF3 protein from AUG3 starting at nucleotide 5131 (in the SAR-55 strain) would be the same in all four genotypes of HEV.", [["nucleotide 5131", "CHEMICAL", 54, 69], ["nucleotide", "CHEMICAL", 54, 64], ["ORF3", "GENE_OR_GENE_PRODUCT", 19, 23], ["AUG3", "GENE_OR_GENE_PRODUCT", 37, 41], ["SAR-55", "GENE_OR_GENE_PRODUCT", 78, 84], ["HEV", "ORGANISM", 136, 139], ["ORF3 protein", "PROTEIN", 19, 31], ["AUG3", "PROTEIN", 37, 41], ["HEV", "SPECIES", 136, 139], ["the ORF3 protein", "TEST", 15, 31], ["the SAR", "TEST", 74, 81]]], ["This model was confirmed by intrahepatic inoculation of wild type and mutant genotype 3 swine HEV replicons into pigs (Huang et al., 2007) .", [["intrahepatic", "ANATOMY", 28, 40], ["HEV", "ORGANISM", 94, 97], ["pigs", "ORGANISM", 113, 117], ["swine", "SPECIES", 88, 93], ["pigs", "SPECIES", 113, 117], ["HEV", "SPECIES", 94, 97], ["pigs", "SPECIES", 113, 117], ["intrahepatic", "ANATOMY", 28, 40], ["inoculation", "OBSERVATION", 41, 52]]], ["Mutation of AUG1 or the insertion of a T base as in genotype 4 did not affect virus infectivity or rescue, but the mutation of AUG3 abolished virus infectivity.Viral RNA speciesThe support for a single subgenomic RNA model also comes from PLC/PRF/5 cells that were either transfected with infectious genotype 3 RNA produced in vitro (from a cloned cDNA) or inoculated with fecal suspension containing genotype 4 HEV.", [["PLC/PRF/5 cells", "ANATOMY", 239, 254], ["AUG1", "GENE_OR_GENE_PRODUCT", 12, 16], ["AUG3", "GENE_OR_GENE_PRODUCT", 127, 131], ["PLC", "GENE_OR_GENE_PRODUCT", 239, 242], ["PRF/5 cells", "CELL", 243, 254], ["HEV", "ORGANISM", 412, 415], ["AUG1", "PROTEIN", 12, 16], ["T base", "DNA", 39, 45], ["AUG3", "PROTEIN", 127, 131], ["Viral RNA species", "RNA", 160, 177], ["PLC/PRF/5 cells", "CELL_LINE", 239, 254], ["infectious genotype 3 RNA", "RNA", 289, 314], ["cloned cDNA", "DNA", 341, 352], ["HEV", "SPECIES", 412, 415], ["Mutation of AUG1", "PROBLEM", 0, 16], ["a T base", "TREATMENT", 37, 45], ["virus infectivity", "PROBLEM", 78, 95], ["AUG3 abolished virus infectivity", "PROBLEM", 127, 159], ["Viral RNA species", "PROBLEM", 160, 177], ["The support", "TREATMENT", 177, 188], ["a single subgenomic RNA model", "PROBLEM", 193, 222], ["PLC/PRF/5 cells", "TREATMENT", 239, 254], ["infectious genotype 3 RNA", "PROBLEM", 289, 314], ["a cloned cDNA", "TREATMENT", 339, 352], ["fecal suspension", "TREATMENT", 373, 389], ["base", "ANATOMY_MODIFIER", 41, 45], ["RNA species", "OBSERVATION", 166, 177]]], ["The RNA isolated from these cells only showed the 2.2 kb subgenomic species, whose 5 end mapped to nucleotide 5122 .Viral RNA speciesA conserved double stem-loop RNA structure is predicted in the junction region (Huang et al., 2007) .", [["cells", "ANATOMY", 28, 33], ["nucleotide 5122", "CHEMICAL", 99, 114], ["nucleotide", "CHEMICAL", 99, 109], ["cells", "CELL", 28, 33], ["2.2 kb subgenomic species", "DNA", 50, 75], ["5 end", "DNA", 83, 88], ["nucleotide 5122", "DNA", 99, 114], ["Viral RNA species", "RNA", 116, 133], ["double stem-loop RNA structure", "RNA", 145, 175], ["The RNA", "TEST", 0, 7], ["these cells", "TEST", 22, 33], ["the 2.2 kb subgenomic species", "PROBLEM", 46, 75], ["nucleotide", "TEST", 99, 109], ["Viral RNA species", "PROBLEM", 116, 133], ["A conserved double stem-loop RNA structure", "TREATMENT", 133, 175], ["2.2 kb", "OBSERVATION_MODIFIER", 50, 56], ["subgenomic species", "OBSERVATION", 57, 75], ["RNA species", "OBSERVATION", 122, 133], ["double stem", "OBSERVATION", 145, 156], ["loop RNA structure", "OBSERVATION", 157, 175], ["junction", "ANATOMY_MODIFIER", 196, 204], ["region", "ANATOMY_MODIFIER", 205, 211]]], ["Its role in viral replication was recently determined in Huh-7 cells transfected with wild type or stem-loop mutant replicons containing reporter genes (Cao et al., 2010) .", [["Huh-7 cells", "ANATOMY", 57, 68], ["Huh-7 cells", "CELL", 57, 68], ["Huh-7 cells", "CELL_LINE", 57, 68], ["stem-loop mutant replicons", "DNA", 99, 125], ["reporter genes", "DNA", 137, 151], ["Huh-7", "SPECIES", 57, 62], ["viral replication", "PROBLEM", 12, 29], ["stem-loop mutant replicons", "TREATMENT", 99, 125], ["viral replication", "OBSERVATION", 12, 29]]], ["The viral negative-strand RNA is proposed to be a template for the synthesis of positive-strand genomic and subgenomic RNAs, the latter from within the junction region in a primer-independent manner.", [["viral negative-strand RNA", "RNA", 4, 29], ["positive-strand genomic and subgenomic RNAs", "RNA", 80, 123], ["junction region", "DNA", 152, 167], ["strand RNA", "PROBLEM", 19, 29], ["the synthesis", "TEST", 63, 76], ["positive-strand genomic and subgenomic RNAs", "PROBLEM", 80, 123], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["negative", "OBSERVATION", 10, 18], ["strand RNA", "OBSERVATION", 19, 29], ["positive", "OBSERVATION_MODIFIER", 80, 88], ["strand genomic", "OBSERVATION", 89, 103], ["subgenomic RNAs", "OBSERVATION", 108, 123], ["junction", "ANATOMY_MODIFIER", 152, 160], ["region", "ANATOMY_MODIFIER", 161, 167]]], ["The junction region negative-strand RNA is predicted to fold into a stable stem-loop structure.", [["junction region negative-strand RNA", "RNA", 4, 39], ["stem-loop structure", "PROTEIN", 75, 94], ["strand RNA", "PROBLEM", 29, 39], ["junction", "ANATOMY_MODIFIER", 4, 12], ["strand RNA", "OBSERVATION", 29, 39], ["stable", "OBSERVATION_MODIFIER", 68, 74], ["stem", "OBSERVATION", 75, 79], ["loop structure", "OBSERVATION", 80, 94]]], ["Mutation of the AGA motif on the loop or sequences that are part of the stem or the subgenomic RNA start site significantly reduced or abolished reporter activity.", [["stem", "ANATOMY", 72, 76], ["AGA", "GENE_OR_GENE_PRODUCT", 16, 19], ["AGA motif", "DNA", 16, 25], ["subgenomic RNA start site", "DNA", 84, 109], ["Mutation of the AGA motif", "PROBLEM", 0, 25], ["the loop or sequences", "TEST", 29, 50], ["stem", "ANATOMY_MODIFIER", 72, 76], ["subgenomic RNA", "OBSERVATION", 84, 98]]], ["Thus, the sequence of the junction region as well as the stem-loop structure within it, play important roles in HEV replication.", [["HEV", "ORGANISM", 112, 115], ["HEV", "SPECIES", 112, 115], ["the sequence of the junction region", "TREATMENT", 6, 41], ["HEV replication", "TREATMENT", 112, 127], ["junction", "ANATOMY_MODIFIER", 26, 34], ["stem", "ANATOMY", 57, 61], ["loop structure", "OBSERVATION", 62, 76], ["HEV replication", "OBSERVATION", 112, 127]]], ["The hepatitis E virus genome.", [["hepatitis E", "DISEASE", 4, 15], ["hepatitis E virus", "ORGANISM", 4, 21], ["hepatitis E virus genome", "DNA", 4, 28], ["hepatitis E virus", "SPECIES", 4, 21], ["hepatitis E virus", "SPECIES", 4, 21], ["The hepatitis E virus genome", "PROBLEM", 0, 28], ["hepatitis", "OBSERVATION", 4, 13], ["virus genome", "OBSERVATION", 16, 28]]], ["The \u223c7.2 kb positive sense RNA genome of HEV has a 7-Me-G cap at its 5 end and a poly A tail at its 3 end.", [["HEV", "ORGANISM", 41, 44], ["\u223c7.2 kb positive sense RNA genome", "DNA", 4, 37], ["7-Me-G cap", "DNA", 51, 61], ["5 end", "DNA", 69, 74], ["poly A tail", "DNA", 81, 92], ["HEV", "SPECIES", 41, 44], ["HEV", "TEST", 41, 44], ["Me-G cap", "TREATMENT", 53, 61], ["a poly A tail", "TREATMENT", 79, 92], ["RNA genome", "OBSERVATION", 27, 37], ["7-Me-G cap", "OBSERVATION_MODIFIER", 51, 61], ["tail", "OBSERVATION_MODIFIER", 88, 92]]], ["There are short stretches of untranslated regions at the 5 and 3 ends that fold into stem-loop structures (shown in blue).", [["stem-loop structures", "ANATOMY", 85, 105], ["untranslated regions", "DNA", 29, 49], ["5 and 3 ends", "DNA", 57, 69], ["short stretches of untranslated regions", "PROBLEM", 10, 49], ["short", "OBSERVATION_MODIFIER", 10, 15], ["stretches", "OBSERVATION_MODIFIER", 16, 25], ["untranslated", "OBSERVATION_MODIFIER", 29, 41], ["regions", "OBSERVATION_MODIFIER", 42, 49], ["stem", "ANATOMY_MODIFIER", 85, 89], ["loop", "ANATOMY_MODIFIER", 90, 94]]], ["The three open reading frames are shown.", [["open reading frames", "DNA", 10, 29]]], ["ORF1 encodes a nonstructural polyprotein and contains a 58-nucleotide stretch near its 5 end that folds into a stem-loop structure (shown in green).", [["nucleotide", "CHEMICAL", 59, 69], ["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF1", "DNA", 0, 4], ["nonstructural polyprotein", "PROTEIN", 15, 40], ["stem-loop structure", "PROTEIN", 111, 130], ["a nonstructural polyprotein", "PROBLEM", 13, 40], ["a 58-nucleotide stretch", "TREATMENT", 54, 77], ["nonstructural polyprotein", "OBSERVATION", 15, 40], ["stem", "ANATOMY", 111, 115], ["loop structure", "OBSERVATION", 116, 130]]], ["The ORF2 and ORF3 proteins are translated from a 2.2 kb subgenomic RNA generated during viral replication.", [["ORF2", "GENE_OR_GENE_PRODUCT", 4, 8], ["ORF3", "GENE_OR_GENE_PRODUCT", 13, 17], ["ORF2", "DNA", 4, 8], ["ORF3 proteins", "PROTEIN", 13, 26], ["2.2 kb subgenomic RNA", "RNA", 49, 70], ["The ORF2 and ORF3 proteins", "TEST", 0, 26], ["a 2.2 kb subgenomic RNA", "PROBLEM", 47, 70], ["viral replication", "TREATMENT", 88, 105], ["viral replication", "OBSERVATION", 88, 105]]], ["The boxed region on the upper right shows the sequence alignment of the junction region between orf1 and orf3 in HEV isolates representative of genotypes 1-4.", [["orf1", "GENE_OR_GENE_PRODUCT", 96, 100], ["orf3", "GENE_OR_GENE_PRODUCT", 105, 109], ["HEV", "ORGANISM", 113, 116], ["boxed region", "DNA", 4, 16], ["orf1", "DNA", 96, 100], ["orf3", "DNA", 105, 109], ["HEV", "SPECIES", 113, 116], ["HEV isolates", "TEST", 113, 125], ["genotypes", "TEST", 144, 153], ["boxed", "ANATOMY_MODIFIER", 4, 9], ["region", "ANATOMY_MODIFIER", 10, 16], ["upper", "ANATOMY_MODIFIER", 24, 29], ["right", "ANATOMY_MODIFIER", 30, 35], ["junction", "ANATOMY_MODIFIER", 72, 80], ["HEV isolates", "OBSERVATION", 113, 125]]], ["The nucleotide positions are shown with respect to HEV genotype 1 (Sar55).", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["HEV genotype 1", "GENE_OR_GENE_PRODUCT", 51, 65], ["Sar55", "GENE_OR_GENE_PRODUCT", 67, 72], ["The nucleotide positions", "TREATMENT", 0, 24], ["HEV genotype", "TEST", 51, 63]]], ["The orf1 stop codon is shown in red.", [["orf1", "GENE_OR_GENE_PRODUCT", 4, 8], ["orf1 stop codon", "DNA", 4, 19], ["The orf1 stop codon", "TREATMENT", 0, 19], ["orf1", "OBSERVATION", 4, 8], ["stop codon", "OBSERVATION", 9, 19], ["red", "OBSERVATION", 32, 35]]], ["There is a single nucleotide insertion (T, indicated with filled triangle) between positions 5116 and 5117 in HEV genotype 4.", [["nucleotide", "CHEMICAL", 18, 28], ["nucleotide", "CHEMICAL", 18, 28], ["a single nucleotide insertion", "TREATMENT", 9, 38], ["HEV genotype", "OBSERVATION", 110, 122]]], ["The four initiation codons within this junction region are shown in yellow boxes, and are at positions 5104, 5113, 5131 and 5145.", [["The four initiation codons", "TREATMENT", 0, 26], ["four", "OBSERVATION_MODIFIER", 4, 8], ["initiation codons", "OBSERVATION", 9, 26], ["yellow boxes", "OBSERVATION", 68, 80]]], ["This region has been predicted to fold into a double stem-loop structure shown in the boxed region on the left.", [["left", "ANATOMY", 106, 110], ["boxed region", "DNA", 86, 98], ["a double stem-loop structure", "TREATMENT", 44, 72], ["double stem", "OBSERVATION", 46, 57], ["loop structure", "OBSERVATION", 58, 72], ["boxed", "ANATOMY_MODIFIER", 86, 91], ["region", "ANATOMY_MODIFIER", 92, 98], ["left", "ANATOMY_MODIFIER", 106, 110]]], ["(For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)Genetic variantsComparative analyses of the nucleotide sequences of complete genomes of HEV isolates has revealed extensive genomic diversity leading to the identification of four major genotypes and several subtypes within each genotype (Lu et al., 2006) .", [["nucleotide", "CHEMICAL", 172, 182], ["HEV", "ORGANISM", 216, 219], ["HEV", "SPECIES", 216, 219], ["Genetic variants", "PROBLEM", 128, 144], ["Comparative analyses", "TEST", 144, 164], ["the nucleotide sequences", "TEST", 168, 192], ["HEV isolates", "TEST", 216, 228], ["extensive genomic diversity", "PROBLEM", 242, 269], ["four major genotypes", "PROBLEM", 303, 323], ["extensive", "OBSERVATION_MODIFIER", 242, 251], ["genomic diversity", "OBSERVATION", 252, 269]]], ["Genomic regions that have been used for phylogenetic purposes include a 301 nt sequence at the 5 end of the orf2 region and a 306 nt sequence in the 3 end of orf1, within the RdRp region.Genetic variantsA virus with about 50% nucleotide sequence identity with mammalian HEVs, called avian HEV, was isolated from chickens affected by the hepatitis-splenomegaly syndrome Huang et al., 2004) .", [["HEVs", "ANATOMY", 270, 274], ["nucleotide", "CHEMICAL", 226, 236], ["hepatitis-splenomegaly syndrome", "DISEASE", 337, 368], ["nucleotide", "CHEMICAL", 226, 236], ["orf1", "GENE_OR_GENE_PRODUCT", 158, 162], ["HEVs", "CELL", 270, 274], ["avian HEV", "ORGANISM", 283, 292], ["chickens", "ORGANISM", 312, 320], ["301 nt sequence", "DNA", 72, 87], ["5 end", "DNA", 95, 100], ["orf2 region", "DNA", 108, 119], ["306 nt sequence", "DNA", 126, 141], ["orf1", "DNA", 158, 162], ["RdRp region", "DNA", 175, 186], ["mammalian HEVs", "CELL_TYPE", 260, 274], ["avian HEV", "SPECIES", 283, 292], ["chickens", "SPECIES", 312, 320], ["HEV", "SPECIES", 289, 292], ["chickens", "SPECIES", 312, 320], ["phylogenetic purposes", "TEST", 40, 61], ["a 301 nt sequence", "TEST", 70, 87], ["a 306 nt sequence", "TEST", 124, 141], ["Genetic variantsA virus", "PROBLEM", 187, 210], ["the hepatitis", "PROBLEM", 333, 346], ["splenomegaly syndrome", "PROBLEM", 347, 368], ["RdRp", "ANATOMY_MODIFIER", 175, 179], ["region", "ANATOMY_MODIFIER", 180, 186], ["hepatitis", "ANATOMY", 337, 346], ["splenomegaly", "OBSERVATION", 347, 359]]], ["Though initially considered as HEV genotype 5, avian HEV is now proposed as a new species within the family Hepeviridae (International Committee for Taxonomy of Viruses; Ninth Report).", [["HEV genotype 5", "ORGANISM", 31, 45], ["avian HEV", "ORGANISM", 47, 56], ["avian HEV", "SPECIES", 47, 56], ["HEV", "SPECIES", 31, 34], ["HEV", "SPECIES", 53, 56], ["HEV genotype", "TEST", 31, 43], ["a new species", "PROBLEM", 76, 89]]], ["A unique strain of HEV was identified from farmed rabbits in China, which shared 74-79% nucleotide sequence identity to existing HEV strains, and 46% identity to avian HEV (Zhao et al., 2009) .", [["nucleotide", "CHEMICAL", 88, 98], ["HEV", "ORGANISM", 19, 22], ["rabbits", "ORGANISM", 50, 57], ["HEV", "ORGANISM", 129, 132], ["HEV", "ORGANISM", 168, 171], ["rabbits", "SPECIES", 50, 57], ["avian", "SPECIES", 162, 167], ["HEV", "SPECIES", 19, 22], ["HEV", "SPECIES", 129, 132], ["HEV", "SPECIES", 168, 171], ["A unique strain of HEV", "PROBLEM", 0, 22], ["HEV strains", "PROBLEM", 129, 140], ["HEV", "OBSERVATION", 19, 22], ["HEV strains", "OBSERVATION", 129, 140]]], ["The rabbit HEV appears to be a distant variant of HEV genotype 3.", [["rabbit", "ORGANISM", 4, 10], ["HEV", "ORGANISM", 11, 14], ["rabbit", "SPECIES", 4, 10], ["rabbit", "SPECIES", 4, 10], ["HEV", "SPECIES", 11, 14], ["HEV", "SPECIES", 50, 53], ["The rabbit HEV", "PROBLEM", 0, 14], ["HEV genotype 3", "PROBLEM", 50, 64], ["appears to be", "UNCERTAINTY", 15, 28], ["HEV genotype", "OBSERVATION", 50, 62]]], ["Two additional unique HEV sequences were isolated recently -one from rats (Johne et al., 2010) and the other from a wild boar .Genetic variantsRecombination in HEV genomes was recently reported .", [["HEV", "ORGANISM", 22, 25], ["rats", "ORGANISM", 69, 73], ["boar", "ORGANISM", 121, 125], ["HEV", "ORGANISM", 160, 163], ["HEV sequences", "DNA", 22, 35], ["HEV genomes", "DNA", 160, 171], ["rats", "SPECIES", 69, 73], ["boar", "SPECIES", 121, 125], ["HEV", "SPECIES", 22, 25], ["HEV", "SPECIES", 160, 163], ["unique HEV sequences", "TEST", 15, 35], ["Genetic variants", "PROBLEM", 127, 143], ["HEV genomes", "OBSERVATION", 160, 171]]], ["Phylogenetic and recombination analyses on 134 complete HEV genomes showed three potentially significant intra-and inter-genotype recombination events.", [["HEV", "ORGANISM", 56, 59], ["HEV genomes", "DNA", 56, 67], ["HEV", "SPECIES", 56, 59], ["recombination analyses", "TEST", 17, 39], ["complete HEV genomes", "TEST", 47, 67], ["significant intra-and inter-genotype recombination events", "PROBLEM", 93, 150], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["inter-genotype recombination", "OBSERVATION", 115, 143]]], ["These results suggest that recombination is rare but possible between human and swine HEV strains, and might also contribute to viral diversity.HEV proteinsThree viral proteins -called the ORF1, ORF2 and ORF3 proteins are expressed from the viral genome.", [["human", "ORGANISM", 70, 75], ["swine HEV", "ORGANISM", 80, 89], ["HEV", "ORGANISM", 144, 147], ["ORF1", "GENE_OR_GENE_PRODUCT", 189, 193], ["ORF2", "GENE_OR_GENE_PRODUCT", 195, 199], ["ORF3", "GENE_OR_GENE_PRODUCT", 204, 208], ["HEV proteins", "PROTEIN", 144, 156], ["viral proteins", "PROTEIN", 162, 176], ["ORF1", "DNA", 189, 193], ["ORF2", "DNA", 195, 199], ["ORF3 proteins", "PROTEIN", 204, 217], ["viral genome", "DNA", 241, 253], ["human", "SPECIES", 70, 75], ["swine", "SPECIES", 80, 85], ["human", "SPECIES", 70, 75], ["swine HEV", "SPECIES", 80, 89], ["HEV", "SPECIES", 144, 147], ["human and swine HEV strains", "PROBLEM", 70, 97], ["viral diversity", "PROBLEM", 128, 143], ["HEV proteins", "TEST", 144, 156], ["Three viral proteins", "TEST", 156, 176], ["ORF2", "TEST", 195, 199], ["ORF3 proteins", "TEST", 204, 217], ["the viral genome", "PROBLEM", 237, 253], ["viral diversity", "OBSERVATION", 128, 143], ["proteins", "OBSERVATION", 148, 156], ["viral genome", "OBSERVATION", 241, 253]]], ["While the kinetics of expression of these proteins during the viral life cycle is not fully understood, their expression during HEV infection is confirmed by the presence of antibodies to these proteins in infected humans and experimental animals (Khudyakov et al., 1994; Panda et al., 1995) .The ORF1 proteinThe orf1 of HEV encodes a protein of 1693 amino acids, which was proposed to encode the viral nonstructural functions .", [["HEV infection", "DISEASE", 128, 141], ["amino acids", "CHEMICAL", 351, 362], ["amino acids", "CHEMICAL", 351, 362], ["HEV", "ORGANISM", 128, 131], ["humans", "ORGANISM", 215, 221], ["ORF1", "GENE_OR_GENE_PRODUCT", 297, 301], ["orf1", "GENE_OR_GENE_PRODUCT", 313, 317], ["HEV", "ORGANISM", 321, 324], ["amino acids", "AMINO_ACID", 351, 362], ["antibodies", "PROTEIN", 174, 184], ["ORF1 protein", "PROTEIN", 297, 309], ["orf1", "PROTEIN", 313, 317], ["humans", "SPECIES", 215, 221], ["HEV", "SPECIES", 128, 131], ["humans", "SPECIES", 215, 221], ["HEV", "SPECIES", 321, 324], ["these proteins", "PROBLEM", 36, 50], ["the viral life cycle", "TREATMENT", 58, 78], ["HEV infection", "PROBLEM", 128, 141], ["antibodies", "PROBLEM", 174, 184], ["The ORF1 protein", "TEST", 293, 309], ["a protein", "TEST", 333, 342], ["amino acids", "TEST", 351, 362], ["infection", "OBSERVATION", 132, 141], ["infected", "OBSERVATION", 206, 214], ["viral nonstructural functions", "OBSERVATION", 397, 426]]], ["This proposal was based on the detection of several functional motifs and domains present in the nonstructural proteins of other positive-stranded RNA viruses.", [["nonstructural proteins", "PROTEIN", 97, 119], ["the detection", "TEST", 27, 40], ["several functional motifs", "PROBLEM", 44, 69], ["the nonstructural proteins", "TEST", 93, 119], ["stranded RNA viruses", "PROBLEM", 138, 158], ["stranded RNA viruses", "OBSERVATION", 138, 158]]], ["The functional domains identified in the HEV nonstructural polyprotein include (starting from the N-terminal end) -methyltransferase (MeT), papain-like cysteine protease (PCP), RNA helicase (Hel) and RNA dependent RNA polymerase (RdRp).", [["N", "CHEMICAL", 98, 99], ["cysteine", "CHEMICAL", 152, 160], ["HEV", "ORGANISM", 41, 44], ["N-terminal end) -methyltransferase", "GENE_OR_GENE_PRODUCT", 98, 132], ["MeT", "GENE_OR_GENE_PRODUCT", 134, 137], ["papain-like cysteine protease", "GENE_OR_GENE_PRODUCT", 140, 169], ["PCP", "GENE_OR_GENE_PRODUCT", 171, 174], ["RNA helicase", "GENE_OR_GENE_PRODUCT", 177, 189], ["Hel", "GENE_OR_GENE_PRODUCT", 191, 194], ["RNA dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 200, 228], ["HEV nonstructural polyprotein", "PROTEIN", 41, 70], ["N-terminal end) -methyltransferase", "PROTEIN", 98, 132], ["MeT", "PROTEIN", 134, 137], ["papain", "PROTEIN", 140, 146], ["cysteine protease", "PROTEIN", 152, 169], ["PCP", "PROTEIN", 171, 174], ["RNA helicase", "PROTEIN", 177, 189], ["Hel", "PROTEIN", 191, 194], ["RNA dependent RNA polymerase", "PROTEIN", 200, 228], ["RdRp", "PROTEIN", 230, 234], ["HEV nonstructural polyprotein", "SPECIES", 41, 70], ["HEV", "SPECIES", 41, 44], ["The functional domains", "PROBLEM", 0, 22], ["the HEV nonstructural polyprotein", "PROBLEM", 37, 70], ["the N-terminal end", "TREATMENT", 94, 112], ["methyltransferase (MeT)", "TREATMENT", 115, 138], ["papain", "TREATMENT", 140, 146], ["cysteine protease", "TREATMENT", 152, 169], ["RNA helicase (Hel)", "TREATMENT", 177, 195], ["RNA dependent RNA polymerase", "PROBLEM", 200, 228], ["HEV", "OBSERVATION", 41, 44], ["nonstructural polyprotein", "OBSERVATION", 45, 70]]], ["Besides these, some uncharacterized domains also found that are homologous to other animal and plant positive-strand RNA viruses.", [["strand RNA viruses", "PROBLEM", 110, 128], ["positive", "OBSERVATION_MODIFIER", 101, 109], ["strand RNA viruses", "OBSERVATION", 110, 128]]], ["The 'Y' domain spans \u223c200 amino acids downstream of the MeT domain and includes a subsequence that scored high on alignments with the nonstructural proteins of Rubella virus (RubV) and beet necrotic yellow vein virus (BNYVV).", [["amino acids", "CHEMICAL", 26, 37], ["amino acids", "CHEMICAL", 26, 37], ["amino acids", "AMINO_ACID", 26, 37], ["Rubella virus", "ORGANISM", 160, 173], ["RubV", "GENE_OR_GENE_PRODUCT", 175, 179], ["beet necrotic yellow vein virus", "ORGANISM", 185, 216], ["Y' domain", "DNA", 5, 14], ["MeT domain", "PROTEIN", 56, 66], ["nonstructural proteins", "PROTEIN", 134, 156], ["Rubella virus", "SPECIES", 160, 173], ["yellow vein virus", "SPECIES", 199, 216], ["Rubella virus", "SPECIES", 160, 173], ["beet necrotic yellow vein virus", "SPECIES", 185, 216], ["BNYVV", "SPECIES", 218, 223], ["amino acids", "TEST", 26, 37], ["a subsequence", "TEST", 80, 93], ["Rubella virus", "PROBLEM", 160, 173], ["beet necrotic yellow vein virus", "PROBLEM", 185, 216], ["Rubella virus", "OBSERVATION", 160, 173], ["necrotic", "OBSERVATION_MODIFIER", 190, 198], ["yellow vein virus", "OBSERVATION", 199, 216]]], ["A conserved domain, earlier called the 'X' domain, but now known as the 'macro' domain flanks the PCP domains in the nonstructural polyproteins of many positive-stranded animal viruses.", [["X' domain", "CELLULAR_COMPONENT", 40, 49], ["X' domain", "DNA", 40, 49], ["macro' domain", "PROTEIN", 73, 86], ["PCP domains", "PROTEIN", 98, 109], ["nonstructural polyproteins", "PROTEIN", 117, 143], ["the 'macro' domain flanks", "PROBLEM", 68, 93], ["the nonstructural polyproteins", "PROBLEM", 113, 143], ["stranded animal viruses", "PROBLEM", 161, 184], ["nonstructural polyproteins", "OBSERVATION", 117, 143], ["stranded animal viruses", "OBSERVATION", 161, 184]]], ["This domain in the HEV ORF1 polyprotein shows significant homology with similar domains in RubV, BNYVV, alphaviruses and some coronaviruses.", [["HEV", "ORGANISM", 19, 22], ["ORF1", "GENE_OR_GENE_PRODUCT", 23, 27], ["RubV", "GENE_OR_GENE_PRODUCT", 91, 95], ["BNYVV", "GENE_OR_GENE_PRODUCT", 97, 102], ["HEV ORF1 polyprotein", "DNA", 19, 39], ["RubV", "PROTEIN", 91, 95], ["BNYVV", "PROTEIN", 97, 102], ["HEV", "SPECIES", 19, 22], ["This domain", "PROBLEM", 0, 11], ["the HEV ORF1 polyprotein", "TEST", 15, 39], ["significant homology", "PROBLEM", 46, 66], ["similar domains in RubV", "PROBLEM", 72, 95], ["BNYVV", "PROBLEM", 97, 102], ["alphaviruses", "PROBLEM", 104, 116], ["some coronaviruses", "PROBLEM", 121, 139], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["alphaviruses", "OBSERVATION", 104, 116], ["coronaviruses", "OBSERVATION", 126, 139]]], ["In HEV and RubV a proline-rich region that might be a flexible hinge between the 'X' domain and upstream domains precedes the 'X' domain ( Fig. 2) .", [["proline", "CHEMICAL", 18, 25], ["proline", "CHEMICAL", 18, 25], ["HEV", "ORGANISM", 3, 6], ["RubV", "GENE_OR_GENE_PRODUCT", 11, 15], ["X' domain", "CELLULAR_COMPONENT", 127, 136], ["proline-rich region", "PROTEIN", 18, 37], ["X' domain", "DNA", 82, 91], ["upstream domains", "DNA", 96, 112], ["X' domain", "DNA", 127, 136], ["HEV", "SPECIES", 3, 6], ["a flexible hinge between the 'X' domain", "PROBLEM", 52, 91], ["upstream domains", "PROBLEM", 96, 112]]], ["This early bioinformatic analysis of the HEV nonstructural protein Koonin and Dolja, 1993; Liu et al., 2009 ) proposed many putative biochemical activities, a few of which have now been characterized in greater detail (discussed below).", [["biochemical activities", "OBSERVATION", 133, 155], ["few", "OBSERVATION_MODIFIER", 159, 162]]], ["It also suggested HEV, RubV and The orf1 gene encodes a nonstructural polyprotein with four predicted functional domains, designated as methyltransferase (MeT), papain-like cysteine protease (PCP), helicase (Hel) and RNA-dependent RNA polymerase (RdRp).", [["cysteine", "CHEMICAL", 173, 181], ["HEV", "ORGANISM", 18, 21], ["RubV", "GENE_OR_GENE_PRODUCT", 23, 27], ["orf1", "GENE_OR_GENE_PRODUCT", 36, 40], ["methyltransferase", "GENE_OR_GENE_PRODUCT", 136, 153], ["MeT", "GENE_OR_GENE_PRODUCT", 155, 158], ["papain-like cysteine protease", "GENE_OR_GENE_PRODUCT", 161, 190], ["PCP", "GENE_OR_GENE_PRODUCT", 192, 195], ["Hel", "GENE_OR_GENE_PRODUCT", 208, 211], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 217, 245], ["RubV", "DNA", 23, 27], ["orf1 gene", "DNA", 36, 45], ["nonstructural polyprotein", "PROTEIN", 56, 81], ["methyltransferase", "PROTEIN", 136, 153], ["MeT", "PROTEIN", 155, 158], ["papain", "PROTEIN", 161, 167], ["cysteine protease", "PROTEIN", 173, 190], ["PCP", "PROTEIN", 192, 195], ["helicase", "PROTEIN", 198, 206], ["Hel", "PROTEIN", 208, 211], ["RNA-dependent RNA polymerase", "PROTEIN", 217, 245], ["RdRp", "PROTEIN", 247, 251], ["HEV", "SPECIES", 18, 21], ["HEV", "PROBLEM", 18, 21], ["The orf1 gene", "TREATMENT", 32, 45], ["a nonstructural polyprotein", "TREATMENT", 54, 81], ["methyltransferase (MeT)", "TREATMENT", 136, 159], ["papain", "TREATMENT", 161, 167], ["cysteine protease", "TREATMENT", 173, 190], ["helicase (Hel)", "TREATMENT", 198, 212], ["RNA", "TEST", 217, 220]]], ["Besides these regions, two other regions designated X (macro domain) and Y share significant homology with nonstructural proteins of other positive-strand RNA viruses.", [["X (macro domain", "DNA", 52, 67], ["Y", "DNA", 73, 74], ["nonstructural proteins", "PROTEIN", 107, 129], ["nonstructural proteins", "TEST", 107, 129], ["other positive-strand RNA viruses", "PROBLEM", 133, 166], ["regions", "ANATOMY_MODIFIER", 14, 21], ["nonstructural proteins", "OBSERVATION", 107, 129], ["strand RNA viruses", "OBSERVATION", 148, 166]]], ["A proline-rich region (V) upstream of the macro domain may act as a flexible hinge.", [["proline", "CHEMICAL", 2, 9], ["proline", "CHEMICAL", 2, 9], ["proline-rich region", "PROTEIN", 2, 21], ["macro domain", "PROTEIN", 42, 54], ["flexible hinge", "PROTEIN", 68, 82], ["A proline-rich region", "TREATMENT", 0, 21]]], ["Numbers indicate the predicted boundaries of the different regions; these are based on the genotype 1 Burmese isolate.The ORF1 proteinBNYVV to form a distinct monophyletic group within the alpha-like supergroup of positive-strand RNA viruses, but this proposal has not passed the test of time and subsequent investigations.The ORF1 proteinIt is not entirely clear whether the ORF1 polyprotein is processed into biochemically distinct units, as is the case with other positive-strand RNA viruses.", [["ORF1 proteinBNYVV", "GENE_OR_GENE_PRODUCT", 122, 139], ["ORF1", "GENE_OR_GENE_PRODUCT", 327, 331], ["ORF1", "GENE_OR_GENE_PRODUCT", 376, 380], ["ORF1 proteinBNYVV", "DNA", 122, 139], ["alpha-like supergroup", "DNA", 189, 210], ["ORF1 proteinIt", "DNA", 327, 341], ["ORF1 polyprotein", "DNA", 376, 392], ["The ORF1 proteinBNYVV", "TEST", 118, 139], ["the alpha", "TEST", 185, 194], ["strand RNA viruses", "PROBLEM", 223, 241], ["subsequent investigations", "TEST", 297, 322], ["The ORF1 proteinIt", "TEST", 323, 341], ["the ORF1 polyprotein", "PROBLEM", 372, 392], ["other positive-strand RNA viruses", "PROBLEM", 461, 494], ["distinct", "OBSERVATION_MODIFIER", 150, 158], ["monophyletic group", "OBSERVATION", 159, 177], ["alpha", "ANATOMY", 189, 194], ["positive", "OBSERVATION", 214, 222], ["strand RNA viruses", "OBSERVATION", 223, 241], ["not entirely", "UNCERTAINTY", 345, 357], ["clear", "OBSERVATION", 358, 363], ["ORF1 polyprotein", "OBSERVATION", 376, 392], ["strand RNA viruses", "OBSERVATION", 476, 494]]], ["When expressed in mammalian cells using recombinant vaccinia viruses, ORF1 yielded processed products of 78 and 107 kDa (Ropp et al., 2000) , whereas its expression in Escherichia coli or HepG2 hepatoma cells showed no processing .", [["cells", "ANATOMY", 28, 33], ["HepG2 hepatoma cells", "ANATOMY", 188, 208], ["mammalian cells", "CELL", 18, 33], ["recombinant vaccinia viruses", "ORGANISM", 40, 68], ["ORF1", "GENE_OR_GENE_PRODUCT", 70, 74], ["Escherichia coli", "ORGANISM", 168, 184], ["HepG2 hepatoma cells", "CELL", 188, 208], ["mammalian cells", "CELL_TYPE", 18, 33], ["ORF1", "DNA", 70, 74], ["HepG2 hepatoma cells", "CELL_LINE", 188, 208], ["Escherichia coli", "SPECIES", 168, 184], ["vaccinia viruses", "SPECIES", 52, 68], ["Escherichia coli", "SPECIES", 168, 184], ["recombinant vaccinia viruses", "TREATMENT", 40, 68], ["Escherichia coli", "PROBLEM", 168, 184], ["HepG2 hepatoma cells", "PROBLEM", 188, 208], ["Escherichia coli", "OBSERVATION", 168, 184], ["no", "UNCERTAINTY", 216, 218]]], ["However, in HepG2 cells transfected with HEV genomic RNA produced in vitro from a cDNA, metabolic labeling and immunoprecipitation showed distinct processed products.", [["HepG2 cells", "ANATOMY", 12, 23], ["HepG2 cells", "CELL", 12, 23], ["HEV", "ORGANISM", 41, 44], ["HepG2 cells", "CELL_LINE", 12, 23], ["HEV genomic RNA", "RNA", 41, 56], ["cDNA", "DNA", 82, 86], ["HEV", "SPECIES", 41, 44], ["HepG2 cells", "PROBLEM", 12, 23], ["HEV genomic RNA", "PROBLEM", 41, 56], ["a cDNA", "TEST", 80, 86], ["metabolic labeling", "TEST", 88, 106], ["immunoprecipitation", "TEST", 111, 130], ["genomic RNA", "OBSERVATION", 45, 56]]], ["Anti-MeT, anti-helicase and anti-RdRp antibodies detected specific products of \u223c35 kDa, \u223c38 kDa and \u223c36 kDa, respectively .", [["MeT", "GENE_OR_GENE_PRODUCT", 5, 8], ["anti-helicase", "GENE_OR_GENE_PRODUCT", 10, 23], ["anti-RdRp antibodies", "GENE_OR_GENE_PRODUCT", 28, 48], ["Anti-MeT, anti-helicase and anti-RdRp antibodies", "PROTEIN", 0, 48], ["\u223c35 kDa", "PROTEIN", 79, 86], ["\u223c38 kDa", "PROTEIN", 88, 95], ["Anti-MeT", "TREATMENT", 0, 8], ["anti-helicase", "TREATMENT", 10, 23], ["anti-RdRp antibodies", "TREATMENT", 28, 48]]], ["Similarly, when a His 6 -ORF1-FLAG fusion protein was expressed in insect cells using recombinant baculoviruses, multiple processed fragments could be detected with anti-hexahistidine or anti-FLAG tag antibodies (Sehgal et al., 2006) .", [["cells", "ANATOMY", 74, 79], ["fragments", "ANATOMY", 132, 141], ["anti-hexahistidine", "CHEMICAL", 165, 183], ["anti-hexahistidine", "CHEMICAL", 165, 183], ["ORF1", "GENE_OR_GENE_PRODUCT", 25, 29], ["FLAG", "GENE_OR_GENE_PRODUCT", 30, 34], ["insect cells", "CELL", 67, 79], ["anti-hexahistidine", "SIMPLE_CHEMICAL", 165, 183], ["His 6 -ORF1", "DNA", 18, 29], ["FLAG fusion protein", "PROTEIN", 30, 49], ["insect cells", "CELL_TYPE", 67, 79], ["anti-hexahistidine", "PROTEIN", 165, 183], ["anti-FLAG tag antibodies", "PROTEIN", 187, 211], ["a His 6 -ORF1-FLAG fusion protein", "TREATMENT", 16, 49], ["recombinant baculoviruses", "TREATMENT", 86, 111], ["multiple processed fragments", "PROBLEM", 113, 141], ["anti-hexahistidine", "TREATMENT", 165, 183], ["anti-FLAG tag antibodies", "TREATMENT", 187, 211], ["fragments", "OBSERVATION", 132, 141]]], ["Of these, a 35-kDa N-terminal fragment was characterized by mass spectrometry to be the methyltransferase protein.", [["N", "CHEMICAL", 19, 20], ["35-kDa N-terminal fragment", "DNA", 12, 38], ["methyltransferase protein", "PROTEIN", 88, 113], ["a 35-kDa N-terminal fragment", "PROBLEM", 10, 38], ["mass spectrometry", "PROBLEM", 60, 77], ["the methyltransferase protein", "PROBLEM", 84, 113], ["terminal", "OBSERVATION_MODIFIER", 21, 29], ["fragment", "OBSERVATION", 30, 38], ["mass", "OBSERVATION", 60, 64]]], ["In the same study, E-64d, a cell-permeable cysteine protease inhibitor blocked ORF1 processing, but it could not be established whether the processing protease was of cellular or viral origin.", [["cell", "ANATOMY", 28, 32], ["cellular", "ANATOMY", 167, 175], ["E-64d", "CHEMICAL", 19, 24], ["E-64d", "CHEMICAL", 19, 24], ["cysteine", "CHEMICAL", 43, 51], ["E-64d", "SIMPLE_CHEMICAL", 19, 24], ["cell", "CELL", 28, 32], ["cysteine", "AMINO_ACID", 43, 51], ["ORF1", "GENE_OR_GENE_PRODUCT", 79, 83], ["cellular", "CELL", 167, 175], ["ORF1", "DNA", 79, 83], ["protease", "PROTEIN", 151, 159], ["the same study", "TEST", 3, 17], ["E", "TEST", 19, 20], ["a cell-permeable cysteine protease inhibitor", "TREATMENT", 26, 70], ["ORF1 processing", "TREATMENT", 79, 94], ["the processing protease", "PROBLEM", 136, 159], ["viral origin", "OBSERVATION", 179, 191]]], ["So far no viral infection study has addressed expression and processing of the ORF1-derived nonstructural polyprotein.MethyltransferaseComputer-assisted alignments of the ORF1 polyprotein suggested that the amino terminal residues 60-240 might serve as the viral methyltransferase .", [["viral infection", "DISEASE", 10, 25], ["amino terminal residues 60-240", "CHEMICAL", 207, 237], ["amino", "CHEMICAL", 207, 212], ["ORF1", "GENE_OR_GENE_PRODUCT", 79, 83], ["ORF1", "GENE_OR_GENE_PRODUCT", 171, 175], ["amino terminal residues", "AMINO_ACID", 207, 230], ["60-240", "AMINO_ACID", 231, 237], ["ORF1", "DNA", 79, 83], ["nonstructural polyprotein", "PROTEIN", 92, 117], ["ORF1 polyprotein", "DNA", 171, 187], ["viral methyltransferase", "PROTEIN", 257, 280], ["viral infection study", "PROBLEM", 10, 31], ["the ORF1", "TREATMENT", 75, 83], ["nonstructural polyprotein", "TREATMENT", 92, 117], ["MethyltransferaseComputer-assisted alignments", "TREATMENT", 118, 163], ["the ORF1 polyprotein", "TREATMENT", 167, 187], ["the amino terminal residues", "TREATMENT", 203, 230], ["the viral methyltransferase", "PROBLEM", 253, 280], ["no", "UNCERTAINTY", 7, 9], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["infection", "OBSERVATION", 16, 25], ["nonstructural polyprotein", "OBSERVATION", 92, 117], ["viral methyltransferase", "OBSERVATION", 257, 280]]], ["The ORF1 sequence also suggested that HEV might belong to the large group of alphavirus-like superfamily of positive-strand RNA viruses.", [["ORF1", "GENE_OR_GENE_PRODUCT", 4, 8], ["HEV", "ORGANISM", 38, 41], ["ORF1 sequence", "DNA", 4, 17], ["alphavirus-like superfamily", "PROTEIN", 77, 104], ["HEV", "SPECIES", 38, 41], ["The ORF1 sequence", "TEST", 0, 17], ["HEV", "PROBLEM", 38, 41], ["alphavirus", "PROBLEM", 77, 87], ["positive-strand RNA viruses", "PROBLEM", 108, 135], ["strand RNA viruses", "OBSERVATION", 117, 135]]], ["Members of this virus superfamily code a distinctive methyltransferase enzyme .", [["virus superfamily", "PROTEIN", 16, 33], ["distinctive methyltransferase enzyme", "PROTEIN", 41, 77], ["a distinctive methyltransferase enzyme", "TEST", 39, 77]]], ["Viral methyltransferases catalyze the capping of viral RNA, and since the HEV genomic and subgenomic RNAs are capped, a methyltransferase was expected to be encoded on the HEV genome.", [["HEV", "ORGANISM", 74, 77], ["HEV", "ORGANISM", 172, 175], ["Viral methyltransferases", "PROTEIN", 0, 24], ["viral RNA", "RNA", 49, 58], ["HEV genomic and subgenomic RNAs", "RNA", 74, 105], ["methyltransferase", "PROTEIN", 120, 137], ["HEV genome", "DNA", 172, 182], ["HEV", "SPECIES", 74, 77], ["HEV", "SPECIES", 172, 175], ["Viral methyltransferases catalyze", "TREATMENT", 0, 33], ["viral RNA", "PROBLEM", 49, 58], ["the HEV genomic and subgenomic RNAs", "PROBLEM", 70, 105], ["a methyltransferase", "TREATMENT", 118, 137], ["capping", "OBSERVATION_MODIFIER", 38, 45], ["viral RNA", "OBSERVATION", 49, 58], ["subgenomic RNAs", "OBSERVATION", 90, 105], ["HEV genome", "OBSERVATION", 172, 182]]], ["Accordingly, Magden et al. (2001) expressed a HEV cDNA fragment encoding amino acids 1-979 in insect cells using the baculovirus expression system.", [["cells", "ANATOMY", 101, 106], ["amino acids 1-979", "CHEMICAL", 73, 90], ["amino acids", "CHEMICAL", 73, 84], ["HEV", "ORGANISM", 46, 49], ["amino acids 1-979", "AMINO_ACID", 73, 90], ["insect cells", "CELL", 94, 106], ["baculovirus", "ORGANISM", 117, 128], ["HEV cDNA fragment", "DNA", 46, 63], ["amino acids 1-979", "PROTEIN", 73, 90], ["insect cells", "CELL_TYPE", 94, 106], ["HEV", "SPECIES", 46, 49], ["baculovirus", "SPECIES", 117, 128], ["a HEV cDNA fragment", "PROBLEM", 44, 63], ["amino acids", "TEST", 73, 84], ["the baculovirus expression system", "TREATMENT", 113, 146]]], ["A 110-kDa protein (P110) expressed in this system was shown to contain guanine-7-methyltransferase as well as guanyltransferase activities.MethyltransferaseThe capping of mRNA is well characterized in mammalian, yeast and several viral systems, in which it follows a common mechanism (Ahola and Kaariainen, 1995) .Methyltransferase1. pppN 1 pN 2 pN 3 -----\u2192 ppN 1 pN 2 pN 3 -----+ Pi 2.", [["guanine", "CHEMICAL", 71, 78], ["Pi", "CHEMICAL", 381, 383], ["guanine", "CHEMICAL", 71, 78], ["P110", "GENE_OR_GENE_PRODUCT", 19, 23], ["guanine-7-methyltransferase", "GENE_OR_GENE_PRODUCT", 71, 98], ["guanyltransferase", "GENE_OR_GENE_PRODUCT", 110, 127], ["Methyltransferase1", "GENE_OR_GENE_PRODUCT", 314, 332], ["Pi 2", "GENE_OR_GENE_PRODUCT", 381, 385], ["110-kDa protein", "PROTEIN", 2, 17], ["P110", "PROTEIN", 19, 23], ["guanine-7-methyltransferase", "PROTEIN", 71, 98], ["guanyltransferase", "PROTEIN", 110, 127], ["mRNA", "RNA", 171, 175], ["Methyltransferase1", "PROTEIN", 314, 332], ["yeast", "SPECIES", 212, 217], ["yeast", "SPECIES", 212, 217], ["guanine", "TEST", 71, 78], ["methyltransferase", "TREATMENT", 81, 98], ["guanyltransferase activities", "TREATMENT", 110, 138], ["MethyltransferaseThe capping of mRNA", "TREATMENT", 139, 175], ["several viral systems", "PROBLEM", 222, 243], ["Methyltransferase1", "TREATMENT", 314, 332], ["capping", "OBSERVATION_MODIFIER", 160, 167], ["several", "OBSERVATION_MODIFIER", 222, 229], ["viral systems", "OBSERVATION", 230, 243]]], ["GTP + enzyme \u2192 enzyme-GMP + PPi 3. enzyme-GMP + ppN 1 pN 2 pN 3 -----\u2192 GpppN 1 pN 2 pN 3 -----+ enzyme 4.", [["GTP", "CHEMICAL", 0, 3], ["enzyme-GMP", "CHEMICAL", 15, 25], ["PPi", "CHEMICAL", 28, 31], ["GTP", "CHEMICAL", 0, 3], ["PPi", "CHEMICAL", 28, 31], ["GTP", "SIMPLE_CHEMICAL", 0, 3], ["enzyme-GMP + PPi 3", "GENE_OR_GENE_PRODUCT", 15, 33], ["GTP + enzyme", "PROTEIN", 0, 12], ["enzyme-GMP", "PROTEIN", 35, 45], ["GTP", "TEST", 0, 3], ["enzyme", "TEST", 6, 12], ["enzyme-GMP", "TEST", 15, 25], ["PPi", "TEST", 28, 31], ["enzyme-GMP", "TEST", 35, 45], ["GpppN", "TEST", 71, 76], ["enzyme", "TEST", 96, 102], ["PPi", "OBSERVATION", 28, 31]]], ["GpppN 1 pN 2 pN 3 -----+ AdoMet \u2192 m 7 GpppN 1 pN 2 pN 3 -----+ AdoHcyMethyltransferaseIn step 1 RNA triphosphatase removes the 5 gamma-phosphate from the nascent RNA molecules.", [["Ado", "CHEMICAL", 25, 28], ["AdoHcy", "CHEMICAL", 63, 69], ["5 gamma-phosphate", "CHEMICAL", 127, 144], ["AdoHcy", "CHEMICAL", 63, 69], ["5 gamma-phosphate", "CHEMICAL", 127, 144], ["AdoHcy", "SIMPLE_CHEMICAL", 63, 69], ["MethyltransferaseIn step 1", "GENE_OR_GENE_PRODUCT", 69, 95], ["MethyltransferaseIn step 1 RNA triphosphatase", "PROTEIN", 69, 114], ["nascent RNA molecules", "PROTEIN", 154, 175], ["AdoMet \u2192 m", "TREATMENT", 25, 35], ["AdoHcy", "TEST", 63, 69], ["MethyltransferaseIn step", "TREATMENT", 69, 93], ["the 5 gamma-phosphate", "TREATMENT", 123, 144], ["RNA molecules", "OBSERVATION", 162, 175]]], ["In steps 2 and 3 the mRNA gyanyltransferase donates a GMP moiety to this RNA to form a 5 -5 -triphosphate linkage in the cap structure.", [["GMP", "CHEMICAL", 54, 57], ["5 -5 -triphosphate", "CHEMICAL", 87, 105], ["GMP", "CHEMICAL", 54, 57], ["5 -5 -triphosphate", "CHEMICAL", 87, 105], ["gyanyltransferase", "GENE_OR_GENE_PRODUCT", 26, 43], ["GMP", "SIMPLE_CHEMICAL", 54, 57], ["5 -5 -triphosphate", "SIMPLE_CHEMICAL", 87, 105], ["mRNA gyanyltransferase", "RNA", 21, 43], ["a GMP moiety", "TREATMENT", 52, 64], ["cap structure", "OBSERVATION", 121, 134]]], ["Finally, in step 4 the cap is methylated using the guanine-7-methyltransferase activity and S-adenosylmethionine (AdoMet) as the donor to give the 7-methylguanosine capped RNA and S-adenosylhomocysteine (AdoHcy).MethyltransferaseWhile the HEV methyltransferase showed guanine-7methyltransferase and guanyltransferase activities (Magden et al., 2001) , the source of the RNA triphosphatase (step 1) was not clear.", [["guanine", "CHEMICAL", 51, 58], ["S-adenosylmethionine", "CHEMICAL", 92, 112], ["AdoMet", "CHEMICAL", 114, 120], ["7-methylguanosine", "CHEMICAL", 147, 164], ["S-adenosylhomocysteine", "CHEMICAL", 180, 202], ["AdoHcy", "CHEMICAL", 204, 210], ["guanine", "CHEMICAL", 268, 275], ["guanine", "CHEMICAL", 51, 58], ["S-adenosylmethionine", "CHEMICAL", 92, 112], ["AdoMet", "CHEMICAL", 114, 120], ["7-methylguanosine", "CHEMICAL", 147, 164], ["S-adenosylhomocysteine", "CHEMICAL", 180, 202], ["AdoHcy", "CHEMICAL", 204, 210], ["guanine", "CHEMICAL", 268, 275], ["guanine-7-methyltransferase", "GENE_OR_GENE_PRODUCT", 51, 78], ["S-adenosylmethionine", "SIMPLE_CHEMICAL", 92, 112], ["AdoMet", "SIMPLE_CHEMICAL", 114, 120], ["7-methylguanosine", "SIMPLE_CHEMICAL", 147, 164], ["S-adenosylhomocysteine", "SIMPLE_CHEMICAL", 180, 202], ["AdoHcy", "SIMPLE_CHEMICAL", 204, 210], ["HEV methyltransferase", "GENE_OR_GENE_PRODUCT", 239, 260], ["guanine-7methyltransferase", "SIMPLE_CHEMICAL", 268, 294], ["guanyltransferase", "SIMPLE_CHEMICAL", 299, 316], ["guanine-7-methyltransferase", "PROTEIN", 51, 78], ["7-methylguanosine capped RNA", "RNA", 147, 175], ["HEV methyltransferase", "PROTEIN", 239, 260], ["RNA triphosphatase", "PROTEIN", 370, 388], ["HEV", "SPECIES", 239, 242], ["the guanine", "TREATMENT", 47, 58], ["S-adenosylmethionine (AdoMet)", "TREATMENT", 92, 121], ["the donor", "TREATMENT", 125, 134], ["the 7-methylguanosine capped RNA", "TREATMENT", 143, 175], ["S-adenosylhomocysteine (AdoHcy)", "TREATMENT", 180, 211], ["the HEV methyltransferase", "TEST", 235, 260], ["guanine", "TEST", 268, 275], ["the RNA triphosphatase", "TEST", 366, 388], ["clear", "OBSERVATION", 406, 411]]], ["A recent report (Karpe and Lole, 2010b) suggests that this activity may reside in the HEV helicase.", [["HEV", "ORGANISM", 86, 89], ["HEV helicase", "PROTEIN", 86, 98], ["HEV", "SPECIES", 86, 89], ["HEV helicase", "OBSERVATION", 86, 98]]], ["When a purified recombinant HEV helicase protein was incubated with either alpha-32 P-RNA or gamma-32 P-RNA, it removed 32 P only from the latter, suggesting that it possesses a gamma-phosphatase activity, which might catalyze the first step in RNA cap formation.MethyltransferaseTwo reports have shown the presence of a 5 m 7 G cap on the HEV genomic RNA.", [["cap", "ANATOMY", 249, 252], ["HEV", "ORGANISM", 28, 31], ["gamma-32", "GENE_OR_GENE_PRODUCT", 93, 101], ["purified recombinant HEV helicase protein", "PROTEIN", 7, 48], ["alpha-32 P-RNA", "RNA", 75, 89], ["gamma-32 P-RNA", "RNA", 93, 107], ["32 P", "DNA", 120, 124], ["phosphatase", "PROTEIN", 184, 195], ["5 m 7 G cap", "DNA", 321, 332], ["HEV genomic RNA", "RNA", 340, 355], ["HEV", "SPECIES", 28, 31], ["HEV", "SPECIES", 340, 343], ["HEV helicase protein", "TEST", 28, 48], ["alpha", "TEST", 75, 80], ["gamma", "TEST", 93, 98], ["a gamma-phosphatase activity", "TEST", 176, 204], ["RNA cap", "OBSERVATION", 245, 252], ["HEV genomic RNA", "OBSERVATION", 340, 355]]], ["The HEV genomic RNA transcribed in vitro from viral cDNA is infectious for primates only when it is capped (Emerson et al., 2001) .", [["HEV", "ORGANISM", 4, 7], ["primates", "ORGANISM", 75, 83], ["HEV genomic RNA", "RNA", 4, 19], ["viral cDNA", "DNA", 46, 56], ["HEV", "SPECIES", 4, 7], ["The HEV genomic RNA", "TREATMENT", 0, 19], ["genomic RNA transcribed", "OBSERVATION", 8, 31], ["viral cDNA", "OBSERVATION", 46, 56], ["infectious", "OBSERVATION", 60, 70]]], ["A 5 RNA ligase-mediated rapid amplification of cDNA ends (RACE) method designed to select capped RNAs amplified the 5 ends of the SAR-55 (genotype 1) and MEX-14 (genotype 2), confirming the HEV genomic RNA to be capped (Zhang et al., 2001a,b) .MethyltransferaseWhy is it important for viral RNAs to be capped?", [["MethyltransferaseWhy", "CHEMICAL", 244, 264], ["SAR-55", "GENE_OR_GENE_PRODUCT", 130, 136], ["MEX-14", "GENE_OR_GENE_PRODUCT", 154, 160], ["HEV", "ORGANISM", 190, 193], ["MethyltransferaseWhy", "GENE_OR_GENE_PRODUCT", 244, 264], ["5 RNA ligase", "PROTEIN", 2, 14], ["cDNA ends", "DNA", 47, 56], ["RACE", "DNA", 58, 62], ["SAR-55", "DNA", 130, 136], ["MEX-14", "DNA", 154, 160], ["HEV genomic RNA", "RNA", 190, 205], ["viral RNAs", "RNA", 285, 295], ["HEV", "SPECIES", 190, 193], ["A 5 RNA ligase", "TREATMENT", 0, 14], ["rapid amplification of cDNA ends (RACE) method", "TREATMENT", 24, 70], ["capped RNAs", "TREATMENT", 90, 101], ["the SAR", "TEST", 126, 133], ["MEX", "TEST", 154, 157], ["the HEV genomic RNA", "TREATMENT", 186, 205], ["viral RNAs", "TREATMENT", 285, 295], ["HEV", "OBSERVATION", 190, 193], ["genomic RNA", "OBSERVATION", 194, 205]]], ["Interferons provide the most important innate defense against viruses and viral double-stranded RNA (dsRNA) was found to be a potent trigger of the interferon response (Colby and Morgan, 1971 ).", [["interferon", "GENE_OR_GENE_PRODUCT", 148, 158], ["Interferons", "PROTEIN", 0, 11], ["viral double-stranded RNA", "RNA", 74, 99], ["interferon", "PROTEIN", 148, 158], ["Interferons", "TREATMENT", 0, 11], ["viruses", "PROBLEM", 62, 69], ["viral double-stranded RNA (dsRNA", "PROBLEM", 74, 106], ["stranded RNA", "OBSERVATION_MODIFIER", 87, 99]]], ["More recently, the 5 triphosphate (5 ppp) group on an RNA molecule was also shown to be a potent activator of the interferon response and could be an additional or alternative trigger to dsRNA (Pichlmair et al., 2006) .", [["5 triphosphate", "CHEMICAL", 19, 33], ["5 ppp", "CHEMICAL", 35, 40], ["5 triphosphate", "CHEMICAL", 19, 33], ["5 triphosphate", "SIMPLE_CHEMICAL", 19, 33], ["5 ppp", "SIMPLE_CHEMICAL", 35, 40], ["interferon", "GENE_OR_GENE_PRODUCT", 114, 124], ["interferon", "PROTEIN", 114, 124], ["the 5 triphosphate (5 ppp) group", "TREATMENT", 15, 47], ["an RNA molecule", "PROBLEM", 51, 66]]], ["RNA polymerase-directed RNA synthesis initiates with a 5 ppp nucleotide and thus all RNA molecules initially carry an exposed 5 ppp moiety, which is removed by processing.", [["nucleotide", "CHEMICAL", 61, 71], ["nucleotide", "CHEMICAL", 61, 71], ["RNA polymerase", "PROTEIN", 0, 14], ["5 ppp nucleotide", "DNA", 55, 71], ["5 ppp moiety", "PROTEIN", 126, 138], ["RNA polymerase", "TEST", 0, 14], ["a 5 ppp nucleotide", "TREATMENT", 53, 71], ["all RNA molecules", "PROBLEM", 81, 98], ["an exposed 5 ppp moiety", "TREATMENT", 115, 138]]], ["Thus, capping of the viral RNA, besides aiding its translation through recognition by the ribosome, would also be important in protecting the virus from innate host responses.ProteaseThe computer-assisted assignment of functional domains also predicted the presence of a papain-like cysteine protease (PCP) in ORF1 with moderate similarity to the Rubella virus protease .", [["ribosome", "ANATOMY", 90, 98], ["cysteine", "CHEMICAL", 283, 291], ["ribosome", "CELLULAR_COMPONENT", 90, 98], ["Protease", "GENE_OR_GENE_PRODUCT", 175, 183], ["papain-like cysteine protease", "GENE_OR_GENE_PRODUCT", 271, 300], ["ORF1", "GENE_OR_GENE_PRODUCT", 310, 314], ["Rubella virus", "ORGANISM", 347, 360], ["viral RNA", "RNA", 21, 30], ["papain", "PROTEIN", 271, 277], ["cysteine protease", "PROTEIN", 283, 300], ["PCP", "PROTEIN", 302, 305], ["ORF1", "DNA", 310, 314], ["Rubella virus protease", "PROTEIN", 347, 369], ["Rubella virus", "SPECIES", 347, 360], ["Rubella virus", "SPECIES", 347, 360], ["the viral RNA", "PROBLEM", 17, 30], ["functional domains", "PROBLEM", 219, 237], ["a papain-like cysteine protease", "PROBLEM", 269, 300], ["moderate similarity", "PROBLEM", 320, 339], ["the Rubella virus protease", "PROBLEM", 343, 369], ["viral RNA", "OBSERVATION", 21, 30], ["moderate", "OBSERVATION_MODIFIER", 320, 328], ["Rubella virus", "OBSERVATION", 347, 360]]], ["Though the alignment score was low, the prediction was strengthened by conservation of the 'X' domain in HEV, which in other systems was found exclusively in association with the PCP.", [["PCP", "DISEASE", 179, 182], ["PCP", "CHEMICAL", 179, 182], ["HEV", "ORGANISM", 105, 108], ["X' domain", "DNA", 92, 101], ["HEV", "SPECIES", 105, 108], ["the alignment score", "TEST", 7, 26], ["the 'X' domain in HEV", "PROBLEM", 87, 108]]], ["This alignment placed the putative PCP domain in the region of amino acids 433-592 of the ORF1 polyprotein.", [["amino acids 433-592", "CHEMICAL", 63, 82], ["amino acids", "CHEMICAL", 63, 74], ["amino acids", "AMINO_ACID", 63, 74], ["433-592", "AMINO_ACID", 75, 82], ["ORF1", "GENE_OR_GENE_PRODUCT", 90, 94], ["PCP domain", "PROTEIN", 35, 45], ["amino acids 433-592", "PROTEIN", 63, 82], ["ORF1 polyprotein", "PROTEIN", 90, 106], ["amino acids", "TEST", 63, 74], ["the ORF1 polyprotein", "TREATMENT", 86, 106]]], ["However, no functional activity for the HEV protease has so far been described.", [["HEV", "ORGANISM", 40, 43], ["HEV protease", "PROTEIN", 40, 52], ["HEV", "SPECIES", 40, 43], ["the HEV protease", "TREATMENT", 36, 52], ["no", "UNCERTAINTY", 9, 11], ["functional activity", "OBSERVATION", 12, 31]]], ["As mentioned above, extended incubations of the ORF1 polyprotein expressed using a recombinant vaccinia virus yielded products of 107 kDa and 78 kDa (Ropp et al., 2000) .", [["ORF1", "GENE_OR_GENE_PRODUCT", 48, 52], ["vaccinia virus", "ORGANISM", 95, 109], ["ORF1 polyprotein", "DNA", 48, 64], ["107 kDa", "PROTEIN", 130, 137], ["vaccinia virus", "SPECIES", 95, 109], ["the ORF1 polyprotein", "TREATMENT", 44, 64], ["a recombinant vaccinia virus", "TREATMENT", 81, 109]]], ["But, mutagenesis of Cys483 predicted by sequence alignments to be part of the catalytic dyad, had no effect on the generation of these products.", [["Cys483", "CHEMICAL", 20, 26], ["Cys483", "GENE_OR_GENE_PRODUCT", 20, 26], ["Cys483", "DNA", 20, 26], ["catalytic dyad", "PROTEIN", 78, 92], ["the catalytic dyad", "PROBLEM", 74, 92], ["these products", "TREATMENT", 129, 143]]], ["Further, the other member of the proposed catalytic dyad, His590 is missing from the putative HEV protease.", [["His590", "CHEMICAL", 58, 64], ["His", "CHEMICAL", 58, 61], ["His590", "GENE_OR_GENE_PRODUCT", 58, 64], ["catalytic dyad", "PROTEIN", 42, 56], ["His590", "PROTEIN", 58, 64], ["putative HEV protease", "PROTEIN", 85, 106]]], ["The presence of a functional protease within ORF1 and its role in polyprotein processing thus remains an unanswered question.HelicaseMany positive-stranded RNA viruses encode a RNA helicase, which is essential for replication of the genomes of these viruses (Kadare and Haenni, 1997) .", [["ORF1", "GENE_OR_GENE_PRODUCT", 45, 49], ["protease", "PROTEIN", 29, 37], ["ORF1", "DNA", 45, 49], ["RNA helicase", "PROTEIN", 177, 189], ["a functional protease within ORF1", "PROBLEM", 16, 49], ["polyprotein processing", "TREATMENT", 66, 88], ["HelicaseMany", "TEST", 125, 137], ["stranded RNA viruses", "PROBLEM", 147, 167], ["a RNA helicase", "PROBLEM", 175, 189], ["stranded RNA viruses", "OBSERVATION", 147, 167], ["viruses", "OBSERVATION", 250, 257]]], ["Helicases are divided into six superfamilies (SF-1 to SF-6) and further into subfamilies depending upon whether they unwind in the 3 \u2192 5 (A) or 5 \u2192 3 (B) direction.", [["Helicases", "GENE_OR_GENE_PRODUCT", 0, 9], ["SF-1", "GENE_OR_GENE_PRODUCT", 46, 50], ["SF", "PROTEIN", 46, 48], ["SF", "PROTEIN", 54, 56], ["Helicases", "TREATMENT", 0, 9]]], ["The SF-1 and SF-2 families of helicases are the most common and each has seven signature motifs that are involved in the binding and hydrolysis of nucleotide triphosphates (NTPs), and binding of the nucleic acids (DNA/RNA).", [["nucleotide triphosphates", "CHEMICAL", 147, 171], ["NTPs", "CHEMICAL", 173, 177], ["nucleic acids", "CHEMICAL", 199, 212], ["nucleotide triphosphates", "CHEMICAL", 147, 171], ["NTPs", "CHEMICAL", 173, 177], ["SF-1", "GENE_OR_GENE_PRODUCT", 4, 8], ["SF-2", "GENE_OR_GENE_PRODUCT", 13, 17], ["nucleotide triphosphates", "SIMPLE_CHEMICAL", 147, 171], ["NTPs", "SIMPLE_CHEMICAL", 173, 177], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["SF", "PROTEIN", 4, 6], ["SF", "PROTEIN", 13, 15], ["The SF", "TEST", 0, 6], ["nucleotide triphosphates (NTPs", "TREATMENT", 147, 177], ["the nucleic acids (DNA/RNA", "PROBLEM", 195, 221]]], ["The putative RNA helicase of HEV was shown to contain all the seven conserved motifs found in SF-1 helicases and proposed to have the NTPase as well as RNAbinding domains .", [["HEV", "ORGANISM", 29, 32], ["SF-1", "GENE_OR_GENE_PRODUCT", 94, 98], ["NTPase", "GENE_OR_GENE_PRODUCT", 134, 140], ["putative RNA helicase", "PROTEIN", 4, 25], ["SF-1 helicases", "PROTEIN", 94, 108], ["NTPase", "PROTEIN", 134, 140], ["RNAbinding domains", "PROTEIN", 152, 170], ["HEV", "SPECIES", 29, 32], ["The putative RNA helicase of HEV", "PROBLEM", 0, 32], ["the NTPase", "TREATMENT", 130, 140]]], ["Karpe and Lole (2010b) expressed the region corresponding to ORF1 amino acids 960-1204 in E. coli, and the purified recombinant protein showed both NTPase and RNA unwinding activities.", [["amino acids 960-1204", "CHEMICAL", 66, 86], ["amino acids", "CHEMICAL", 66, 77], ["amino acids", "AMINO_ACID", 66, 77], ["E. coli", "ORGANISM", 90, 97], ["NTPase", "GENE_OR_GENE_PRODUCT", 148, 154], ["ORF1", "DNA", 61, 65], ["purified recombinant protein", "PROTEIN", 107, 135], ["NTPase", "PROTEIN", 148, 154], ["E. coli", "SPECIES", 90, 97], ["E. coli", "SPECIES", 90, 97], ["ORF1 amino acids", "TEST", 61, 77], ["E. coli", "PROBLEM", 90, 97], ["the purified recombinant protein", "TEST", 103, 135], ["RNA unwinding activities", "PROBLEM", 159, 183], ["RNA unwinding", "OBSERVATION", 159, 172]]], ["The enzyme hydrolyzed all rNTPs but also dNTPs with a lower efficiency, and showed unwinding activity only on RNA duplexes with 5 overhangs.", [["dNTPs", "CHEMICAL", 41, 46], ["dNTPs", "CHEMICAL", 41, 46], ["rNTPs", "SIMPLE_CHEMICAL", 26, 31], ["dNTPs", "SIMPLE_CHEMICAL", 41, 46], ["rNTPs", "PROTEIN", 26, 31], ["RNA duplexes", "RNA", 110, 122], ["The enzyme hydrolyzed all rNTPs", "TEST", 0, 31], ["dNTPs", "PROBLEM", 41, 46], ["a lower efficiency", "PROBLEM", 52, 70], ["unwinding activity", "PROBLEM", 83, 101], ["RNA duplexes", "TREATMENT", 110, 122], ["5 overhangs", "PROBLEM", 128, 139], ["lower efficiency", "OBSERVATION_MODIFIER", 54, 70], ["unwinding activity", "OBSERVATION", 83, 101], ["RNA duplexes", "OBSERVATION", 110, 122]]], ["Mutants in the nucleotide-binding motif I (GKS \u2192 GAS) or the Mg2+-binding motif II (DEAP \u2192 AAAP) showed reduced ATPase activity and had no RNA unwinding activity, indicating generation of energy as a critical requirement for helicase activity.", [["nucleotide", "CHEMICAL", 15, 25], ["Mg2", "CHEMICAL", 61, 64], ["nucleotide", "CHEMICAL", 15, 25], ["Mg2+", "CHEMICAL", 61, 65], ["nucleotide-binding motif I", "GENE_OR_GENE_PRODUCT", 15, 41], ["GKS \u2192 GAS", "GENE_OR_GENE_PRODUCT", 43, 52], ["Mg2+-binding motif II", "GENE_OR_GENE_PRODUCT", 61, 82], ["DEAP \u2192 AAAP", "GENE_OR_GENE_PRODUCT", 84, 95], ["ATPase", "GENE_OR_GENE_PRODUCT", 112, 118], ["nucleotide-binding motif I", "DNA", 15, 41], ["GKS", "DNA", 43, 46], ["GAS", "DNA", 49, 52], ["Mg2+-binding motif II", "DNA", 61, 82], ["DEAP", "DNA", 84, 88], ["AAAP", "DNA", 91, 95], ["ATPase", "PROTEIN", 112, 118], ["helicase", "PROTEIN", 225, 233], ["GKS \u2192 GAS", "TEST", 43, 52], ["the Mg2", "TEST", 57, 64], ["reduced ATPase activity", "PROBLEM", 104, 127], ["RNA unwinding activity", "PROBLEM", 139, 161], ["ATPase activity", "OBSERVATION", 112, 127], ["no", "UNCERTAINTY", 136, 138]]], ["The HEV helicase belongs to the 5 \u2192 3 class of SF-1 family of helicases that are also found in other positive-strand RNA viruses such as alphaviruses, arteriviruses, coronaviruses and rubiviruses.HelicaseThe HEV helicase also possesses a RNA 5 -triphosphatase activity, which is proposed to aid the HEV methyltransferase by catalyzing the first step of RNA capping (Karpe and Lole, 2010a).RNA dependent RNA polymeraseThe RdRp is an essential enzyme found in all RNA viruses; it is used to replicate the genomic RNA through an anti-genomic RNA intermediate.", [["rubiviruses", "DISEASE", 184, 195], ["HEV", "ORGANISM", 4, 7], ["SF-1", "GENE_OR_GENE_PRODUCT", 47, 51], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 151, 164], ["coronaviruses", "ORGANISM", 166, 179], ["rubiviruses", "GENE_OR_GENE_PRODUCT", 184, 195], ["Helicase", "GENE_OR_GENE_PRODUCT", 196, 204], ["HEV", "ORGANISM", 208, 211], ["HEV methyltransferase", "GENE_OR_GENE_PRODUCT", 299, 320], ["RdRp", "GENE_OR_GENE_PRODUCT", 421, 425], ["HEV helicase", "PROTEIN", 4, 16], ["SF", "PROTEIN", 47, 49], ["helicases", "PROTEIN", 62, 71], ["Helicase", "PROTEIN", 196, 204], ["HEV helicase", "PROTEIN", 208, 220], ["RNA 5 -triphosphatase", "PROTEIN", 238, 259], ["HEV methyltransferase", "PROTEIN", 299, 320], ["RNA dependent RNA polymerase", "PROTEIN", 389, 417], ["RdRp", "PROTEIN", 421, 425], ["genomic RNA", "RNA", 503, 514], ["anti-genomic RNA intermediate", "RNA", 526, 555], ["HEV", "SPECIES", 4, 7], ["HEV", "SPECIES", 208, 211], ["HEV", "SPECIES", 299, 302], ["helicases", "PROBLEM", 62, 71], ["other positive-strand RNA viruses", "PROBLEM", 95, 128], ["alphaviruses", "PROBLEM", 137, 149], ["coronaviruses", "PROBLEM", 166, 179], ["Helicase", "TREATMENT", 196, 204], ["a RNA", "TREATMENT", 236, 241], ["the HEV methyltransferase", "TREATMENT", 295, 320], ["RNA capping", "TREATMENT", 353, 364], ["RNA dependent RNA polymerase", "PROBLEM", 389, 417], ["The RdRp", "PROBLEM", 417, 425], ["an essential enzyme", "TEST", 429, 448], ["all RNA viruses", "PROBLEM", 458, 473], ["strand RNA viruses", "OBSERVATION", 110, 128], ["HEV methyltransferase", "OBSERVATION", 299, 320], ["RNA capping", "OBSERVATION", 353, 364], ["dependent", "OBSERVATION_MODIFIER", 393, 402], ["RNA polymerase", "OBSERVATION", 403, 417], ["RdRp", "OBSERVATION", 421, 425], ["RNA viruses", "OBSERVATION", 462, 473], ["genomic RNA", "OBSERVATION", 503, 514]]], ["Comparison of the amino acid sequences of HEV and other positive-strand RNA viruses showed a strong homology of the ORF1 region encompassing amino acids 1207-1693 with the RdRp proteins of RubV and BNYVV .", [["amino acid", "CHEMICAL", 18, 28], ["amino acids 1207-1693", "CHEMICAL", 141, 162], ["amino acid", "CHEMICAL", 18, 28], ["amino acids", "CHEMICAL", 141, 152], ["amino acid", "AMINO_ACID", 18, 28], ["amino acids", "AMINO_ACID", 141, 152], ["1207-1693", "AMINO_ACID", 153, 162], ["RubV", "GENE_OR_GENE_PRODUCT", 189, 193], ["amino acid sequences", "PROTEIN", 18, 38], ["ORF1 region", "DNA", 116, 127], ["amino acids 1207-1693", "PROTEIN", 141, 162], ["RdRp proteins", "PROTEIN", 172, 185], ["RubV", "PROTEIN", 189, 193], ["BNYVV", "PROTEIN", 198, 203], ["HEV", "SPECIES", 42, 45], ["the amino acid sequences", "TEST", 14, 38], ["HEV", "TEST", 42, 45], ["other positive-strand RNA viruses", "PROBLEM", 50, 83], ["amino acids", "TEST", 141, 152]]], ["The enzymes of these three viruses form a compact group within the \"alpha-like\" supergroup (III) of positive-strand RNA viruses.", [["alpha", "PROTEIN", 68, 73], ["The enzymes", "TEST", 0, 11], ["the \"alpha", "TEST", 63, 73], ["positive-strand RNA viruses", "PROBLEM", 100, 127], ["viruses", "OBSERVATION", 27, 34], ["strand RNA viruses", "OBSERVATION", 109, 127]]], ["All eight conserved motifs, I-VIII described for positive-strand RNA virus RdRp proteins (Koonin, 1991) are also found in the HEV protein, including the GDD sequence that binds Mg 2+ , which is essential for replicase activity.RNA dependent RNA polymeraseThe RdRp region of HEV comprising nucleotides 3546-5106 was expressed as a 59 kDa His-tagged protein in E. coli (Agrawal et al., 2001) .", [["Mg", "CHEMICAL", 177, 179], ["nucleotides 3546-5106", "CHEMICAL", 289, 310], ["Mg 2+", "CHEMICAL", 177, 182], ["nucleotides", "CHEMICAL", 289, 300], ["His", "CHEMICAL", 337, 340], ["I-VIII", "GENE_OR_GENE_PRODUCT", 28, 34], ["HEV", "ORGANISM", 126, 129], ["GDD", "GENE_OR_GENE_PRODUCT", 153, 156], ["Mg 2+", "SIMPLE_CHEMICAL", 177, 182], ["HEV", "ORGANISM", 274, 277], ["E. coli", "ORGANISM", 359, 366], ["I-VIII", "DNA", 28, 34], ["positive-strand RNA virus RdRp proteins", "PROTEIN", 49, 88], ["1991", "PROTEIN", 98, 102], ["HEV protein", "PROTEIN", 126, 137], ["GDD sequence", "PROTEIN", 153, 165], ["Mg 2", "PROTEIN", 177, 181], ["RNA dependent RNA polymerase", "PROTEIN", 227, 255], ["RdRp region", "DNA", 259, 270], ["nucleotides 3546-5106", "DNA", 289, 310], ["59 kDa His-tagged protein", "PROTEIN", 330, 355], ["E. coli", "SPECIES", 359, 366], ["HEV", "SPECIES", 126, 129], ["E. coli", "SPECIES", 359, 366], ["strand RNA virus RdRp proteins", "TEST", 58, 88], ["the HEV protein", "TEST", 122, 137], ["the GDD sequence", "TEST", 149, 165], ["binds Mg", "TEST", 171, 179], ["RNA dependent RNA polymerase", "PROBLEM", 227, 255], ["HEV comprising nucleotides", "TEST", 274, 300], ["tagged protein in E. coli", "PROBLEM", 341, 366], ["HEV protein", "OBSERVATION", 126, 137], ["essential for", "UNCERTAINTY", 194, 207], ["replicase activity", "OBSERVATION", 208, 226], ["dependent", "OBSERVATION_MODIFIER", 231, 240], ["RNA polymerase", "OBSERVATION", 241, 255], ["RdRp", "OBSERVATION_MODIFIER", 259, 263]]], ["Using gel shift assays, this purified recombinant protein was shown to bind the 3 end of HEV genomic RNA.", [["HEV", "ORGANISM", 89, 92], ["HEV genomic RNA", "RNA", 89, 104], ["HEV", "SPECIES", 89, 92], ["gel shift assays", "TREATMENT", 6, 22], ["this purified recombinant protein", "TREATMENT", 24, 57], ["HEV genomic RNA", "OBSERVATION", 89, 104]]], ["Two stem-loop structures in the 3 end of the HEV RNA as well as the poly(A) stretch were found to be required for this binding.", [["stem-loop structures", "ANATOMY", 4, 24], ["poly", "CHEMICAL", 68, 72], ["poly(A)", "CHEMICAL", 68, 75], ["HEV", "ORGANISM", 45, 48], ["poly(A)", "GENE_OR_GENE_PRODUCT", 68, 75], ["HEV RNA", "RNA", 45, 52], ["poly(A) stretch", "PROTEIN", 68, 83], ["HEV", "SPECIES", 45, 48], ["the HEV RNA", "TREATMENT", 41, 52], ["the poly(A) stretch", "TREATMENT", 64, 83], ["this binding", "PROBLEM", 114, 126], ["stem", "OBSERVATION_MODIFIER", 4, 8], ["loop", "OBSERVATION_MODIFIER", 9, 13], ["3 end", "ANATOMY_MODIFIER", 32, 37], ["HEV RNA", "OBSERVATION", 45, 52]]], ["Further, the recombinant RdRp was also able to use the 3 end of the HEV RNA as a template to synthesize the complementary strand in vitro.", [["RdRp", "GENE_OR_GENE_PRODUCT", 25, 29], ["HEV", "ORGANISM", 68, 71], ["recombinant RdRp", "PROTEIN", 13, 29], ["HEV RNA", "RNA", 68, 75], ["HEV", "SPECIES", 68, 71], ["the recombinant RdRp", "TREATMENT", 9, 29], ["the HEV RNA", "TREATMENT", 64, 75]]], ["Since anti-RdRp antibodies were earlier shown to immunoprecipitate an \u223c37 kDa protein from cells transfected with an infectious replicon, a later study stably expressed an \u223c40 kDa C-terminal region of the ORF1 polyprotein as a fusion with the enhanced green fluorescent protein (EGFP) (Rehman et al., 2008) .", [["cells", "ANATOMY", 91, 96], ["anti-RdRp antibodies", "GENE_OR_GENE_PRODUCT", 6, 26], ["cells", "CELL", 91, 96], ["ORF1", "GENE_OR_GENE_PRODUCT", 205, 209], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 252, 277], ["EGFP", "GENE_OR_GENE_PRODUCT", 279, 283], ["anti-RdRp antibodies", "PROTEIN", 6, 26], ["\u223c37 kDa protein", "PROTEIN", 70, 85], ["\u223c40 kDa C-terminal region", "PROTEIN", 172, 197], ["ORF1 polyprotein", "PROTEIN", 205, 221], ["enhanced green fluorescent protein", "PROTEIN", 243, 277], ["EGFP", "PROTEIN", 279, 283], ["anti-RdRp antibodies", "TEST", 6, 26], ["an infectious replicon", "TREATMENT", 114, 136], ["a later study", "TEST", 138, 151], ["the ORF1 polyprotein", "TREATMENT", 201, 221], ["a fusion", "TREATMENT", 225, 233], ["infectious replicon", "OBSERVATION", 117, 136]]], ["This 68-kDa replicase-EGFP fusion protein localized to the endoplasmic reticulum (ER) and was a functional replicase due to its ability to copy HEV plus-strand RNA transfected into these cells.", [["endoplasmic reticulum", "ANATOMY", 59, 80], ["ER", "ANATOMY", 82, 84], ["cells", "ANATOMY", 187, 192], ["EGFP", "GENE_OR_GENE_PRODUCT", 22, 26], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 59, 80], ["ER", "GENE_OR_GENE_PRODUCT", 82, 84], ["cells", "CELL", 187, 192], ["68-kDa replicase", "PROTEIN", 5, 21], ["EGFP fusion protein", "PROTEIN", 22, 41], ["ER", "PROTEIN", 82, 84], ["HEV plus-strand RNA", "RNA", 144, 163], ["HEV", "SPECIES", 144, 147], ["EGFP fusion protein", "TREATMENT", 22, 41], ["a functional replicase", "PROBLEM", 94, 116], ["strand RNA", "TREATMENT", 153, 163], ["endoplasmic reticulum", "ANATOMY", 59, 80]]], ["These studies also suggest that intracellular (ER) membranes are the likely sites for HEV replicase localization and possibly RNA replication too, as is the case with several other RNA viruses.Macro domainMacro domains are found in a variety of proteins of bacteria, archae and eukaryotes.", [["intracellular", "ANATOMY", 32, 45], ["ER) membranes", "ANATOMY", 47, 60], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["ER", "GENE_OR_GENE_PRODUCT", 47, 49], ["membranes", "CELLULAR_COMPONENT", 51, 60], ["archae", "GENE_OR_GENE_PRODUCT", 267, 273], ["Macro domainMacro domains", "PROTEIN", 193, 218], ["HEV", "SPECIES", 86, 89], ["These studies", "TEST", 0, 13], ["intracellular (ER) membranes", "PROBLEM", 32, 60], ["HEV replicase localization", "TEST", 86, 112], ["RNA replication", "PROBLEM", 126, 141], ["several other RNA viruses", "PROBLEM", 167, 192], ["Macro domainMacro domains", "PROBLEM", 193, 218], ["bacteria", "PROBLEM", 257, 265], ["intracellular", "OBSERVATION_MODIFIER", 32, 45], ["viruses", "OBSERVATION", 185, 192], ["variety", "OBSERVATION_MODIFIER", 234, 241], ["bacteria", "OBSERVATION", 257, 265]]], ["These are domains with homology to the non-histone domain of the histone macroH2A (Pehrson and Fried, 1992) .", [["histone", "GENE_OR_GENE_PRODUCT", 65, 72], ["non-histone domain", "PROTEIN", 39, 57], ["histone macroH2A", "PROTEIN", 65, 81], ["Pehrson", "PROTEIN", 83, 90]]], ["Their association with proteins involved in poly(ADP-ribose) polymerization, ADP-ribosylation and ATP-dependent chromatin remodeling, suggest that macro domains contribute to ADP-ribose metabolism and post-translational modifications (Aguiar et al., 2005) .", [["chromatin", "ANATOMY", 112, 121], ["poly(ADP-ribose", "CHEMICAL", 44, 59], ["ADP", "CHEMICAL", 77, 80], ["ATP", "CHEMICAL", 98, 101], ["ADP", "CHEMICAL", 175, 178], ["ribose", "CHEMICAL", 179, 185], ["poly(ADP-ribose)", "CHEMICAL", 44, 60], ["ADP", "CHEMICAL", 77, 80], ["ATP", "CHEMICAL", 98, 101], ["ADP", "CHEMICAL", 175, 178], ["ribose", "CHEMICAL", 179, 185], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 44, 60], ["ADP", "SIMPLE_CHEMICAL", 77, 80], ["ATP", "SIMPLE_CHEMICAL", 98, 101], ["chromatin", "CELLULAR_COMPONENT", 112, 121], ["ADP", "SIMPLE_CHEMICAL", 175, 178], ["ribose", "SIMPLE_CHEMICAL", 179, 185], ["chromatin", "DNA", 112, 121], ["poly(ADP-ribose) polymerization", "TREATMENT", 44, 75], ["ADP", "TEST", 77, 80], ["ribosylation", "PROBLEM", 81, 93], ["ATP", "PROBLEM", 98, 101], ["dependent chromatin remodeling", "PROBLEM", 102, 132], ["macro domains", "PROBLEM", 147, 160], ["ADP", "PROBLEM", 175, 178], ["ribose metabolism", "PROBLEM", 179, 196], ["post-translational modifications", "PROBLEM", 201, 233], ["chromatin remodeling", "OBSERVATION", 112, 132], ["ribose metabolism", "OBSERVATION", 179, 196]]], ["A few viral families, which include all members of Coronaviridae, rubella virus and alphaviruses (Togaviridae) and HEV, also encode macro domains (Snijder et al., 2003) .", [["rubella virus", "DISEASE", 66, 79], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 51, 64], ["rubella virus", "ORGANISM", 66, 79], ["HEV", "ORGANISM", 115, 118], ["macro domains", "PROTEIN", 132, 145], ["rubella virus", "SPECIES", 66, 79], ["rubella virus", "SPECIES", 66, 79], ["HEV", "SPECIES", 115, 118], ["Coronaviridae", "TREATMENT", 51, 64], ["rubella virus", "PROBLEM", 66, 79], ["alphaviruses (Togaviridae", "TREATMENT", 84, 109], ["few", "OBSERVATION_MODIFIER", 2, 5], ["viral", "OBSERVATION", 6, 11]]], ["All these viruses replicate their RNA in the cytoplasm of animal cells in membraneassociated replication complexes (Salonen et al., 2005) .", [["cytoplasm", "ANATOMY", 45, 54], ["cells", "ANATOMY", 65, 70], ["cytoplasm", "ORGANISM_SUBSTANCE", 45, 54], ["cells", "CELL", 65, 70], ["animal cells", "CELL_TYPE", 58, 70], ["membraneassociated replication complexes", "PROTEIN", 74, 114], ["viruses", "OBSERVATION", 10, 17], ["RNA", "OBSERVATION_MODIFIER", 34, 37], ["cytoplasm", "OBSERVATION_MODIFIER", 45, 54], ["animal cells", "OBSERVATION", 58, 70], ["replication complexes", "OBSERVATION", 93, 114]]], ["In these viruses, macro domains are closely associated with the typical replicase complexes that include RNA helicase and RdRp, and unlike some of their eukaryotic homologs, viral macro domain proteins do not enter the nucleus.Macro domainThe first biochemical activity demonstrated in a macro domain protein was the hydrolysis of ADP-ribose 1 -phosphate (ADPR-1 P), a product of cellular pre-tRNA splicing (Snijder et al., 2003) .", [["nucleus", "ANATOMY", 219, 226], ["cellular", "ANATOMY", 380, 388], ["ADP-ribose 1 -phosphate", "CHEMICAL", 331, 354], ["ADP-ribose 1 -phosphate", "CHEMICAL", 331, 354], ["ADPR-1 P", "CHEMICAL", 356, 364], ["RdRp", "GENE_OR_GENE_PRODUCT", 122, 126], ["nucleus", "CELLULAR_COMPONENT", 219, 226], ["ADP-ribose 1 -phosphate", "SIMPLE_CHEMICAL", 331, 354], ["ADPR-1 P", "GENE_OR_GENE_PRODUCT", 356, 364], ["cellular", "CELL", 380, 388], ["replicase complexes", "PROTEIN", 72, 91], ["RNA helicase", "PROTEIN", 105, 117], ["RdRp", "PROTEIN", 122, 126], ["eukaryotic homologs", "PROTEIN", 153, 172], ["viral macro domain proteins", "PROTEIN", 174, 201], ["macro domain protein", "PROTEIN", 288, 308], ["macro domains", "PROBLEM", 18, 31], ["the typical replicase complexes", "PROBLEM", 60, 91], ["RNA helicase and RdRp", "PROBLEM", 105, 126], ["viral macro domain proteins", "TEST", 174, 201], ["Macro domain", "PROBLEM", 227, 239], ["a macro domain protein", "TEST", 286, 308], ["ADP", "TEST", 331, 334], ["ribose", "TREATMENT", 335, 341], ["phosphate (ADPR", "TREATMENT", 345, 360], ["cellular pre-tRNA splicing", "TREATMENT", 380, 406], ["viruses", "OBSERVATION", 9, 16], ["replicase complexes", "OBSERVATION", 72, 91], ["nucleus", "ANATOMY", 219, 226]]], ["Their ability to bind ADP-ribose and the association with poly(ADPribose) polymerase-1 (PARP-1) has also led to the suggestion that macro domain proteins might regulate apoptosis in eukaryotic cells.", [["cells", "ANATOMY", 193, 198], ["ADP-ribose", "CHEMICAL", 22, 32], ["poly(ADPribose", "CHEMICAL", 58, 72], ["ADP", "CHEMICAL", 22, 25], ["ribose", "CHEMICAL", 26, 32], ["poly(ADPribose)", "CHEMICAL", 58, 73], ["ADP-ribose", "SIMPLE_CHEMICAL", 22, 32], ["poly(ADPribose) polymerase-1", "GENE_OR_GENE_PRODUCT", 58, 86], ["PARP-1", "GENE_OR_GENE_PRODUCT", 88, 94], ["cells", "CELL", 193, 198], ["poly(ADPribose) polymerase-1 (PARP-1", "PROTEIN", 58, 94], ["macro domain proteins", "PROTEIN", 132, 153], ["eukaryotic cells", "CELL_TYPE", 182, 198], ["ribose", "TREATMENT", 26, 32], ["poly(ADPribose) polymerase", "TREATMENT", 58, 84], ["PARP", "TEST", 88, 92], ["macro domain proteins", "PROBLEM", 132, 153], ["apoptosis in eukaryotic cells", "PROBLEM", 169, 198], ["apoptosis", "OBSERVATION_MODIFIER", 169, 178], ["eukaryotic cells", "OBSERVATION", 182, 198]]], ["Though not experimentally demonstrated thus far, this property would be relevant for the viral macro domain proteins since viruses show broad effects on the apoptosis of infected cells.Macro domainTwo reports describe the macro (or X) domain in HEV (Egloff et al., 2006; Neuvonen and Ahola, 2009) .", [["cells", "ANATOMY", 179, 184], ["cells", "CELL", 179, 184], ["HEV", "ORGANISM", 245, 248], ["viral macro domain proteins", "PROTEIN", 89, 116], ["infected cells", "CELL_TYPE", 170, 184], ["macro (or X) domain", "PROTEIN", 222, 241], ["HEV", "SPECIES", 245, 248], ["the viral macro domain proteins", "PROBLEM", 85, 116], ["viruses", "PROBLEM", 123, 130], ["the apoptosis of infected cells", "PROBLEM", 153, 184], ["infected cells", "OBSERVATION", 170, 184]]], ["A region of the HEV ORF1 polyprotein including residues 775-960 (Burmese strain) was expressed with an N-terminal hexahistidine tag and purified from E. coli.", [["residues 775-960", "CHEMICAL", 47, 63], ["N", "CHEMICAL", 103, 104], ["HEV", "ORGANISM", 16, 19], ["ORF1", "GENE_OR_GENE_PRODUCT", 20, 24], ["E. coli", "ORGANISM", 150, 157], ["HEV ORF1 polyprotein", "DNA", 16, 36], ["N-terminal hexahistidine tag", "PROTEIN", 103, 131], ["E. coli", "SPECIES", 150, 157], ["HEV", "SPECIES", 16, 19], ["E. coli", "SPECIES", 150, 157], ["the HEV ORF1 polyprotein", "TEST", 12, 36], ["an N-terminal hexahistidine tag", "TREATMENT", 100, 131], ["E. coli", "PROBLEM", 150, 157], ["HEV ORF1 polyprotein", "OBSERVATION", 16, 36], ["E. coli", "OBSERVATION", 150, 157]]], ["This protein was found to contain ADPR-1 phosphatase activity and bound in vitro to poly(ADP-ribose) and poly(A) (Egloff et al., 2006; Neuvonen and Ahola, 2009) .", [["poly(ADP-ribose", "CHEMICAL", 84, 99], ["poly(A", "CHEMICAL", 105, 111], ["poly(ADP-ribose)", "CHEMICAL", 84, 100], ["poly(A)", "CHEMICAL", 105, 112], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 34, 40], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 84, 99], ["poly(A", "SIMPLE_CHEMICAL", 105, 111], ["ADPR", "PROTEIN", 34, 38], ["phosphatase", "PROTEIN", 41, 52], ["This protein", "TEST", 0, 12], ["ADPR", "TEST", 34, 38], ["vitro to poly(ADP-ribose", "TREATMENT", 75, 99]]], ["While viral macro domain proteins from SARS coronavirus, SFV and HEV bound poly(ADPribose) with high affinity, they showed either poor binding (HEV) or no binding (SFV) to ADP-ribose; the reverse was observed with human macro domain proteins (Neuvonen and Ahola, 2009) .Macro domainWhat might be the function of viral macro domains?", [["SARS coronavirus", "DISEASE", 39, 55], ["ADPribose", "CHEMICAL", 80, 89], ["ADP-ribose", "CHEMICAL", 172, 182], ["poly(ADPribose)", "CHEMICAL", 75, 90], ["ADP", "CHEMICAL", 172, 175], ["ribose", "CHEMICAL", 176, 182], ["SARS coronavirus", "ORGANISM", 39, 55], ["SFV", "ORGANISM", 57, 60], ["HEV", "ORGANISM", 65, 68], ["ADPribose", "SIMPLE_CHEMICAL", 80, 89], ["ADP-ribose", "SIMPLE_CHEMICAL", 172, 182], ["human", "ORGANISM", 214, 219], ["viral macro domain proteins", "PROTEIN", 6, 33], ["human macro domain proteins", "PROTEIN", 214, 241], ["viral macro domains", "PROTEIN", 312, 331], ["coronavirus", "SPECIES", 44, 55], ["human", "SPECIES", 214, 219], ["SARS coronavirus", "SPECIES", 39, 55], ["SFV", "SPECIES", 57, 60], ["HEV", "SPECIES", 65, 68], ["HEV", "SPECIES", 144, 147], ["SFV", "SPECIES", 164, 167], ["human", "SPECIES", 214, 219], ["viral macro domain proteins", "PROBLEM", 6, 33], ["SARS coronavirus", "PROBLEM", 39, 55], ["SFV", "PROBLEM", 57, 60], ["HEV bound poly", "TEST", 65, 79], ["high affinity", "PROBLEM", 96, 109], ["poor binding (HEV", "PROBLEM", 130, 147], ["binding (SFV", "PROBLEM", 155, 167], ["ADP", "TEST", 172, 175], ["ribose", "TREATMENT", 176, 182], ["viral macro domains", "PROBLEM", 312, 331], ["SARS coronavirus", "OBSERVATION", 39, 55], ["SFV", "ANATOMY", 57, 60], ["viral macro", "OBSERVATION", 312, 323]]], ["These are present only in a small subset of RNA viruses that replicate in the cytosol, and form an essential part of the viral genome.", [["cytosol", "ANATOMY", 78, 85], ["cytosol", "CELLULAR_COMPONENT", 78, 85], ["viral genome", "DNA", 121, 133], ["a small subset of RNA viruses", "PROBLEM", 26, 55], ["the viral genome", "PROBLEM", 117, 133], ["small", "OBSERVATION_MODIFIER", 28, 33], ["RNA viruses", "OBSERVATION", 44, 55], ["essential", "OBSERVATION_MODIFIER", 99, 108], ["viral genome", "OBSERVATION", 121, 133]]], ["Egloff et al. (2006) suggested that viral macro domains function as poly(ADP-ribose)-binding modules.", [["poly(ADP-ribose", "CHEMICAL", 68, 83], ["poly(ADP-ribose)", "CHEMICAL", 68, 84], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 68, 84], ["poly(ADP-ribose)-binding modules", "PROTEIN", 68, 100], ["viral macro domains function", "TEST", 36, 64], ["poly(ADP-ribose)", "PROBLEM", 68, 84], ["binding modules", "PROBLEM", 85, 100], ["binding modules", "OBSERVATION", 85, 100]]], ["Based on their in vitro binding and competition experiments, Neuvonen and Ahola (2009) suggest that the viral macro domains could have a role in viral RNA replication and/or transcription.", [["viral macro domains", "PROTEIN", 104, 123], ["the viral macro domains", "PROBLEM", 100, 123], ["viral RNA replication", "TREATMENT", 145, 166]]], ["Since the HEV and SFV macro domains can also bind poly(ADP-ribose) in the presence of poly(A), they could recruit poly(ADP-ribose)-modified cellular factors to the replication complex while bound to viral polyadenylated RNA.", [["cellular", "ANATOMY", 140, 148], ["poly(ADP-ribose", "CHEMICAL", 50, 65], ["poly(A", "CHEMICAL", 86, 92], ["poly(ADP-ribose", "CHEMICAL", 114, 129], ["poly(ADP-ribose)", "CHEMICAL", 50, 66], ["poly(A)", "CHEMICAL", 86, 93], ["poly(ADP-ribose)", "CHEMICAL", 114, 130], ["HEV", "ORGANISM", 10, 13], ["SFV", "ORGANISM", 18, 21], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 50, 65], ["poly(A", "SIMPLE_CHEMICAL", 86, 92], ["poly(ADP-ribose", "GENE_OR_GENE_PRODUCT", 114, 129], ["cellular", "CELL", 140, 148], ["HEV and SFV macro domains", "DNA", 10, 35], ["poly(ADP-ribose)-modified cellular factors", "PROTEIN", 114, 156], ["replication complex", "PROTEIN", 164, 183], ["viral polyadenylated RNA", "RNA", 199, 223], ["HEV", "SPECIES", 10, 13], ["SFV", "SPECIES", 18, 21], ["the HEV and SFV macro domains", "TREATMENT", 6, 35], ["bind poly(ADP-ribose", "TREATMENT", 45, 65], ["poly(ADP-ribose)", "TREATMENT", 114, 130], ["modified cellular factors", "PROBLEM", 131, 156], ["viral polyadenylated RNA", "PROBLEM", 199, 223], ["viral", "OBSERVATION", 199, 204], ["polyadenylated RNA", "OBSERVATION", 205, 223]]], ["These possibilities await experimental confirmation.Expression and glycosylationThe ORF2 of HEV encodes the viral capsid protein of 660 amino acids (nt 5145-7125; SAR-55 isolate; Fig. 1 ), which was proposed to encapsidate the viral RNA genome .", [["amino acids", "CHEMICAL", 136, 147], ["amino acids", "CHEMICAL", 136, 147], ["ORF2", "GENE_OR_GENE_PRODUCT", 84, 88], ["HEV", "ORGANISM", 92, 95], ["amino acids", "AMINO_ACID", 136, 147], ["Fig. 1", "GENE_OR_GENE_PRODUCT", 179, 185], ["ORF2", "DNA", 84, 88], ["viral capsid protein", "PROTEIN", 108, 128], ["viral RNA genome", "DNA", 227, 243], ["HEV", "SPECIES", 92, 95], ["experimental confirmation", "TEST", 26, 51], ["glycosylation", "TREATMENT", 67, 80], ["the viral capsid protein", "TEST", 104, 128], ["amino acids", "TEST", 136, 147], ["nt", "TEST", 149, 151], ["SAR", "TEST", 163, 166], ["the viral RNA genome", "PROBLEM", 223, 243], ["viral RNA genome", "OBSERVATION", 227, 243]]], ["When expressed in animal cells in culture, ORF2 proteins of \u223c74 kDa and \u223c88 kDa were observed, which were proven with tunicamycin and endoglysidase treatment studies to be the nonglycosylated and glycosylated forms, respectively (Jameel et al., 1996) .", [["cells", "ANATOMY", 25, 30], ["tunicamycin", "CHEMICAL", 118, 129], ["endoglysidase", "CHEMICAL", 134, 147], ["tunicamycin", "CHEMICAL", 118, 129], ["cells", "CELL", 25, 30], ["ORF2", "GENE_OR_GENE_PRODUCT", 43, 47], ["tunicamycin", "SIMPLE_CHEMICAL", 118, 129], ["endoglysidase", "SIMPLE_CHEMICAL", 134, 147], ["animal cells", "CELL_TYPE", 18, 30], ["ORF2 proteins", "PROTEIN", 43, 56], ["\u223c74 kDa", "PROTEIN", 60, 67], ["animal cells", "PROBLEM", 18, 30], ["culture", "TEST", 34, 41], ["ORF2 proteins", "TEST", 43, 56], ["kDa", "TEST", 64, 67], ["kDa", "TEST", 76, 79], ["tunicamycin", "TREATMENT", 118, 129], ["endoglysidase treatment", "TREATMENT", 134, 157], ["animal cells", "OBSERVATION", 18, 30]]], ["Pulse-chase studies and the use of microsomal membranes showed the ORF2 protein to contain a N-terminal signal sequence that translocates the protein into the endoplasmic reticulum, where it acquires Nlinked glycosylation (Jameel et al., 1996) .", [["microsomal membranes", "ANATOMY", 35, 55], ["endoplasmic reticulum", "ANATOMY", 159, 180], ["N", "CHEMICAL", 93, 94], ["microsomal membranes", "CELLULAR_COMPONENT", 35, 55], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 159, 180], ["ORF2 protein", "PROTEIN", 67, 79], ["N-terminal signal sequence", "PROTEIN", 93, 119], ["Pulse-chase studies", "TEST", 0, 19], ["microsomal membranes", "TEST", 35, 55], ["the ORF2 protein", "TEST", 63, 79], ["a N-terminal signal sequence", "TEST", 91, 119], ["endoplasmic reticulum", "ANATOMY", 159, 180]]], ["The glycosylation sites on the ORF2 protein were mapped to conserved asparagine (Asn) residues 137, 310 and 562 (Zafrullah et al., 1999) (Fig. 1) .", [["asparagine", "CHEMICAL", 69, 79], ["asparagine", "CHEMICAL", 69, 79], ["Asn", "CHEMICAL", 81, 84], ["ORF2", "GENE_OR_GENE_PRODUCT", 31, 35], ["asparagine", "AMINO_ACID", 69, 79], ["Asn)", "AMINO_ACID", 81, 85], ["glycosylation sites", "PROTEIN", 4, 23], ["ORF2 protein", "PROTEIN", 31, 43], ["The glycosylation sites", "TREATMENT", 0, 23], ["the ORF2 protein", "TEST", 27, 43], ["asparagine (Asn) residues", "TEST", 69, 94]]], ["Though the earlier studies were based on ectopic expression of the orf2 gene in cultured cells, replicon-based expression of the ORF2 protein has subsequently confirmed its N-linked glycosylation (Graff et al., 2008) .", [["cells", "ANATOMY", 89, 94], ["N", "CHEMICAL", 173, 174], ["orf2", "GENE_OR_GENE_PRODUCT", 67, 71], ["cells", "CELL", 89, 94], ["ORF2", "GENE_OR_GENE_PRODUCT", 129, 133], ["orf2 gene", "DNA", 67, 76], ["cultured cells", "CELL_LINE", 80, 94], ["ORF2 protein", "PROTEIN", 129, 141], ["the earlier studies", "TEST", 7, 26], ["ectopic expression", "PROBLEM", 41, 59], ["the orf2 gene in cultured cells", "PROBLEM", 63, 94], ["replicon", "TREATMENT", 96, 104], ["the ORF2 protein", "TEST", 125, 141]]], ["Further, mutations in the glycosylation sites on the ORF2 protein prevented the formation of infectious virus particles from transfected replicons, and these particles had low infectivity in macaques (Graff et al., 2008) .", [["ORF2", "GENE_OR_GENE_PRODUCT", 53, 57], ["macaques", "ORGANISM", 191, 199], ["glycosylation sites", "DNA", 26, 45], ["ORF2 protein", "PROTEIN", 53, 65], ["macaques", "SPECIES", 191, 199], ["mutations in the glycosylation sites", "PROBLEM", 9, 45], ["the ORF2 protein", "TREATMENT", 49, 65], ["infectious virus particles", "PROBLEM", 93, 119], ["transfected replicons", "TREATMENT", 125, 146], ["low infectivity in macaques", "PROBLEM", 172, 199], ["infectious virus", "OBSERVATION", 93, 109], ["transfected replicons", "OBSERVATION", 125, 146], ["low infectivity", "OBSERVATION_MODIFIER", 172, 187]]], ["Recently, Yamada et al. (2009) constructed an infectious clone of HEV that propagates efficiently in cultured PLC/PRF/5 cells.", [["PLC/PRF/5 cells", "ANATOMY", 110, 125], ["clone", "CELL", 57, 62], ["HEV", "ORGANISM", 66, 69], ["PLC", "CELL", 110, 113], ["PRF/5 cells", "CELL", 114, 125], ["cultured PLC/PRF/5 cells", "CELL_LINE", 101, 125], ["HEV", "SPECIES", 66, 69], ["an infectious clone of HEV", "PROBLEM", 43, 69], ["cultured PLC/PRF/5 cells", "TREATMENT", 101, 125], ["infectious", "OBSERVATION", 46, 56]]], ["Using this model they show the intracellular expression and secretion of an 83 kDa ORF2 protein.", [["intracellular", "ANATOMY", 31, 44], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 31, 44], ["ORF2", "GENE_OR_GENE_PRODUCT", 83, 87], ["83 kDa ORF2 protein", "PROTEIN", 76, 95], ["intracellular expression", "OBSERVATION", 31, 55]]], ["Though these authors did not directly test glycosylation of the ORF2 protein, a size significantly larger than the predicted size of \u223c72 kDa, suggests this possibility.", [["ORF2", "GENE_OR_GENE_PRODUCT", 64, 68], ["ORF2 protein", "PROTEIN", 64, 76], ["the ORF2 protein", "TEST", 60, 76], ["size", "OBSERVATION_MODIFIER", 80, 84], ["significantly", "OBSERVATION_MODIFIER", 85, 98], ["larger", "OBSERVATION_MODIFIER", 99, 105], ["size", "OBSERVATION_MODIFIER", 125, 129], ["72 kDa", "OBSERVATION_MODIFIER", 134, 140], ["suggests this possibility", "UNCERTAINTY", 142, 167]]], ["These observations are not in agreement with an earlier suggestion that the glycosylated form of the ORF2 protein is unstable and only the non-glycosylated protein forms the viral capsid (Torresi et al., 1999) .", [["ORF2", "GENE_OR_GENE_PRODUCT", 101, 105], ["ORF2 protein", "PROTEIN", 101, 113], ["non-glycosylated protein", "PROTEIN", 139, 163], ["the ORF2 protein", "TEST", 97, 113], ["the non-glycosylated protein", "TEST", 135, 163]]], ["Various observations suggest a role for cellular membranes in HEV replication and particle maturation.", [["cellular membranes", "ANATOMY", 40, 58], ["cellular membranes", "CELLULAR_COMPONENT", 40, 58], ["HEV", "ORGANISM", 62, 65], ["HEV", "SPECIES", 62, 65], ["cellular membranes", "TREATMENT", 40, 58], ["HEV replication", "TREATMENT", 62, 77], ["HEV replication", "OBSERVATION", 62, 77]]], ["In such a scenario, glycosylation of the ORF2 capsid protein would be of advantage.Self-assembly and virus-like particlesWhen expressed in insect cells using recombinant baculovirus, a N-terminal truncated ORF2 protein (aa 112-660) gave the expected product of 58 kDa, but also a 50 kDa protein that was efficiently secreted in the culture medium as virus-like particles of 23-24 nm diameter (Li et al., 1997) .", [["cells", "ANATOMY", 146, 151], ["N-", "CHEMICAL", 185, 187], ["ORF2", "GENE_OR_GENE_PRODUCT", 41, 45], ["insect cells", "CELL", 139, 151], ["recombinant baculovirus", "ORGANISM", 158, 181], ["ORF2", "GENE_OR_GENE_PRODUCT", 206, 210], ["ORF2 capsid protein", "PROTEIN", 41, 60], ["insect cells", "CELL_TYPE", 139, 151], ["N-terminal truncated ORF2 protein", "PROTEIN", 185, 218], ["aa 112-660", "PROTEIN", 220, 230], ["58 kDa", "PROTEIN", 261, 267], ["50 kDa protein", "PROTEIN", 280, 294], ["baculovirus", "SPECIES", 170, 181], ["glycosylation", "TREATMENT", 20, 33], ["the ORF2 capsid protein", "TREATMENT", 37, 60], ["Self-assembly and virus-like particles", "PROBLEM", 83, 121], ["recombinant baculovirus", "TREATMENT", 158, 181], ["a N-terminal truncated ORF2 protein", "TEST", 183, 218], ["a 50 kDa protein", "TEST", 278, 294], ["the culture medium", "TEST", 328, 346], ["virus", "TEST", 350, 355]]], ["The full-length ORF2 protein when similarly expressed was processed into 63 kDa, 56 kDa and 53 kDa proteins, which correspond to truncated proteins spanning amino acid residues 112-660, 112-607 and 112-578, respectively (Robinson et al., 1998) .", [["amino acid", "CHEMICAL", 157, 167], ["amino acid", "CHEMICAL", 157, 167], ["ORF2", "GENE_OR_GENE_PRODUCT", 16, 20], ["amino acid", "AMINO_ACID", 157, 167], ["full-length ORF2 protein", "PROTEIN", 4, 28], ["63 kDa, 56 kDa", "PROTEIN", 73, 87], ["53 kDa proteins", "PROTEIN", 92, 107], ["truncated proteins", "PROTEIN", 129, 147], ["kDa", "TEST", 84, 87], ["kDa proteins", "TEST", 95, 107], ["truncated proteins", "PROBLEM", 129, 147], ["amino acid residues", "TEST", 157, 176]]], ["Cryoelectron microscopy and image reconstruction methods showed the VLPs to have a T = 1 structure with protruding dimers at the icosahedral twofold symmetry axes such that the 60 monomers were organized as 30 morphological units (Xing et al., 1999) .", [["Cryoelectron microscopy", "TEST", 0, 23], ["image reconstruction methods", "TEST", 28, 56], ["the VLPs", "PROBLEM", 64, 72], ["protruding dimers", "PROBLEM", 104, 121], ["protruding dimers", "OBSERVATION", 104, 121], ["icosahedral", "ANATOMY_MODIFIER", 129, 140], ["twofold symmetry", "OBSERVATION", 141, 157]]], ["Subsequently, amino acids 126-601 in the ORF2 protein were found to be essential for the formation of secreted VLPs in this expression system (Li et al., 2005) .", [["amino acids 126-601", "CHEMICAL", 14, 33], ["amino acids", "CHEMICAL", 14, 25], ["amino acids", "AMINO_ACID", 14, 25], ["126-601", "AMINO_ACID", 26, 33], ["ORF2", "GENE_OR_GENE_PRODUCT", 41, 45], ["VLPs", "GENE_OR_GENE_PRODUCT", 111, 115], ["ORF2 protein", "PROTEIN", 41, 53], ["secreted VLPs", "PROTEIN", 102, 115], ["amino acids", "TEST", 14, 25], ["the ORF2 protein", "TEST", 37, 53], ["secreted VLPs", "OBSERVATION", 102, 115]]], ["The X-ray crystal structures obtained recently show the ORF2 protein monomers to contain three distinct domains -the shell (S), middle (M) and protruding (P) domains (Yamashita et al., 2009; Guu et al., 2009) .", [["ORF2 protein monomers", "PROTEIN", 56, 77], ["protruding (P) domains", "PROTEIN", 143, 165], ["The X-ray crystal structures", "TEST", 0, 28], ["the ORF2 protein monomers", "TEST", 52, 77], ["middle (M) and protruding (P) domains", "PROBLEM", 128, 165], ["distinct", "OBSERVATION_MODIFIER", 95, 103], ["domains", "OBSERVATION_MODIFIER", 104, 111], ["shell", "ANATOMY_MODIFIER", 117, 122], ["middle", "ANATOMY_MODIFIER", 128, 134]]], ["Recently, Xing et al. (2010) have produced a large virion-sized and a small T = 1 particle by expressing the ORF2 protein in insect cells with or without the N-terminal 111 amino acids, respectively.", [["cells", "ANATOMY", 132, 137], ["amino acids", "CHEMICAL", 173, 184], ["N-", "CHEMICAL", 158, 160], ["amino acids", "CHEMICAL", 173, 184], ["ORF2", "GENE_OR_GENE_PRODUCT", 109, 113], ["insect cells", "CELL", 125, 137], ["amino acids", "AMINO_ACID", 173, 184], ["ORF2 protein", "PROTEIN", 109, 121], ["insect cells", "CELL_TYPE", 125, 137], ["N-terminal 111 amino acids", "PROTEIN", 158, 184], ["a small T = 1 particle", "PROBLEM", 68, 90], ["the ORF2 protein in insect cells", "PROBLEM", 105, 137], ["the N-terminal 111 amino acids", "TEST", 154, 184], ["large", "OBSERVATION_MODIFIER", 45, 50], ["virion", "OBSERVATION", 51, 57], ["sized", "OBSERVATION_MODIFIER", 58, 63], ["small", "OBSERVATION_MODIFIER", 70, 75], ["insect cells", "OBSERVATION", 125, 137]]], ["The virion-sized particle showed a T = 3 icosahedral lattice and contained a \u223c2 kb RNA derived from the orf2 gene; the T = 1 particle showed no encapsidated RNA.", [["orf2", "GENE_OR_GENE_PRODUCT", 104, 108], ["T = 1", "GENE_OR_GENE_PRODUCT", 119, 124], ["\u223c2 kb RNA", "RNA", 77, 86], ["orf2 gene", "DNA", 104, 113], ["encapsidated RNA", "RNA", 144, 160], ["The virion-sized particle", "TEST", 0, 25], ["a \u223c2 kb RNA", "TREATMENT", 75, 86], ["encapsidated RNA", "PROBLEM", 144, 160], ["sized", "OBSERVATION_MODIFIER", 11, 16], ["particle", "OBSERVATION_MODIFIER", 17, 25], ["no", "UNCERTAINTY", 141, 143], ["encapsidated RNA", "OBSERVATION", 144, 160]]], ["Though these data suggest that RNA encapsidation drives virion assembly, the presence of subgenomic RNA in the T = 3 particle is surprising, since RNA viruses package only the genomic RNA species.", [["virion", "CELLULAR_COMPONENT", 56, 62], ["T = 3", "GENE_OR_GENE_PRODUCT", 111, 116], ["subgenomic RNA", "RNA", 89, 103], ["genomic RNA species", "RNA", 176, 195], ["these data", "TEST", 7, 17], ["RNA encapsidation drives virion", "PROBLEM", 31, 62], ["subgenomic RNA", "PROBLEM", 89, 103], ["RNA viruses package", "PROBLEM", 147, 166], ["the genomic RNA species", "PROBLEM", 172, 195], ["RNA encapsidation", "OBSERVATION", 31, 48], ["subgenomic RNA", "OBSERVATION", 89, 103], ["genomic RNA species", "OBSERVATION", 176, 195]]], ["Further, a potential packaging signal was identified using a yeast three-hybrid approach towards the 5 end of the genome, within the orf1 gene .", [["orf1", "GENE_OR_GENE_PRODUCT", 133, 137], ["orf1 gene", "DNA", 133, 142], ["yeast", "SPECIES", 61, 66], ["yeast", "SPECIES", 61, 66], ["a potential packaging signal", "TEST", 9, 37], ["a yeast three-hybrid approach", "TREATMENT", 59, 88]]], ["More structural details on the ORF2 capsid can be found in another article in this issue (Mori and Matsuura).Self-assembly and virus-like particlesThe recombinant ORF2 proteins expressed in E. coli have also been shown to assemble into higher order structures.", [["ORF2", "GENE_OR_GENE_PRODUCT", 31, 35], ["ORF2", "GENE_OR_GENE_PRODUCT", 163, 167], ["E. coli", "ORGANISM", 190, 197], ["ORF2", "DNA", 31, 35], ["recombinant ORF2 proteins", "PROTEIN", 151, 176], ["E. coli", "SPECIES", 190, 197], ["E. coli", "SPECIES", 190, 197], ["the ORF2 capsid", "TREATMENT", 27, 42], ["Self-assembly and virus-like particles", "PROBLEM", 109, 147], ["The recombinant ORF2 proteins", "TEST", 147, 176], ["E. coli", "PROBLEM", 190, 197], ["E. coli", "OBSERVATION", 190, 197]]], ["The p239 (aa 368-606), E2 (aa 394-606) and E2a (459-660) proteins (Fig. 3) predominantly occur as homodimers under mildly dissociating conditions, which model the dominant antigenic determinants and neutralizing site of HEV (Zhang et al., 2001a,b; Li et al., 2005a) .", [["p239", "GENE_OR_GENE_PRODUCT", 4, 8], ["E2", "GENE_OR_GENE_PRODUCT", 23, 25], ["E2a (459-660)", "GENE_OR_GENE_PRODUCT", 43, 56], ["Fig. 3", "GENE_OR_GENE_PRODUCT", 67, 73], ["HEV", "ORGANISM", 220, 223], ["p239", "PROTEIN", 4, 8], ["E2", "PROTEIN", 23, 25], ["459-660) proteins", "PROTEIN", 48, 65], ["Fig. 3", "PROTEIN", 67, 73], ["homodimers", "PROTEIN", 98, 108], ["HEV", "SPECIES", 220, 223], ["aa", "TEST", 10, 12], ["E2", "TEST", 23, 25], ["aa", "TEST", 27, 29], ["E2a", "TEST", 43, 46], ["mildly dissociating conditions", "PROBLEM", 115, 145], ["dominant", "OBSERVATION_MODIFIER", 163, 171], ["antigenic", "OBSERVATION_MODIFIER", 172, 181]]], ["Under native conditions, the E2 and E2a proteins form hexamers, and the p239 protein forms a particle of 23 nm (Li et al., 2005a) .", [["E2", "CHEMICAL", 29, 31], ["E2", "GENE_OR_GENE_PRODUCT", 29, 31], ["E2a", "GENE_OR_GENE_PRODUCT", 36, 39], ["p239", "GENE_OR_GENE_PRODUCT", 72, 76], ["E2 and E2a proteins", "PROTEIN", 29, 48], ["p239 protein", "PROTEIN", 72, 84]]], ["Comparison of these three proteins and mutational analysis showed the dimeric interface to include a cluster of six hydrophobic residues (aa 597-602) and the domain involved in particle formation (aa 430-458) to also include a high proportion of hydrophobic residues (Li et al., 2005b) .", [["particle", "CELLULAR_COMPONENT", 177, 185], ["aa 597-602", "PROTEIN", 138, 148], ["these three proteins", "TEST", 14, 34], ["mutational analysis", "TEST", 39, 58], ["the dimeric interface", "PROBLEM", 66, 87], ["six hydrophobic residues", "PROBLEM", 112, 136], ["hydrophobic residues", "PROBLEM", 246, 266], ["hydrophobic residues", "OBSERVATION", 116, 136], ["particle formation", "OBSERVATION", 177, 195], ["hydrophobic residues", "OBSERVATION", 246, 266]]], ["The crystal structure of the E2s protein (aa 455-602) shows it to form a tight homodimer that is essential for HEV interaction with the host cell, and contains the HEV neutralizing antibody recognition site ).Neutralization epitopes and HEV vaccinesVarious studies have looked at the neutralizing domains of the ORF2 capsid protein.", [["cell", "ANATOMY", 141, 145], ["aa 455-602", "CHEMICAL", 42, 52], ["E2s", "GENE_OR_GENE_PRODUCT", 29, 32], ["HEV", "ORGANISM", 111, 114], ["host cell", "CELL", 136, 145], ["HEV", "ORGANISM", 237, 240], ["ORF2", "GENE_OR_GENE_PRODUCT", 312, 316], ["E2s protein", "PROTEIN", 29, 40], ["aa 455-602", "PROTEIN", 42, 52], ["tight homodimer", "PROTEIN", 73, 88], ["host cell", "CELL_TYPE", 136, 145], ["HEV neutralizing antibody recognition site", "PROTEIN", 164, 206], ["neutralizing domains", "PROTEIN", 284, 304], ["ORF2 capsid protein", "PROTEIN", 312, 331], ["HEV", "SPECIES", 111, 114], ["HEV", "SPECIES", 237, 240], ["the E2s protein", "TEST", 25, 40], ["a tight homodimer", "PROBLEM", 71, 88], ["the host cell", "TREATMENT", 132, 145], ["the HEV neutralizing antibody recognition site", "TREATMENT", 160, 206], ["Neutralization epitopes", "TREATMENT", 209, 232], ["HEV vaccines", "TREATMENT", 237, 249], ["Various studies", "TEST", 249, 264], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["host cell", "OBSERVATION", 136, 145]]], ["Using phage display methods, Schofield et al. (2000) identified two neutralizing monoclonal antibodies from chimpanzees that had recovered from experimental HEV infection, and these mapped to overlapping epitopes in the region of amino acids 578-607.", [["HEV infection", "DISEASE", 157, 170], ["amino acids 578-607", "CHEMICAL", 230, 249], ["amino acids", "CHEMICAL", 230, 241], ["chimpanzees", "ORGANISM", 108, 119], ["HEV", "ORGANISM", 157, 160], ["amino acids 578-607", "AMINO_ACID", 230, 249], ["neutralizing monoclonal antibodies", "PROTEIN", 68, 102], ["amino acids 578-607", "PROTEIN", 230, 249], ["HEV", "SPECIES", 157, 160], ["two neutralizing monoclonal antibodies", "PROBLEM", 64, 102], ["experimental HEV infection", "PROBLEM", 144, 170], ["amino acids", "TEST", 230, 241], ["neutralizing", "OBSERVATION_MODIFIER", 68, 80], ["monoclonal antibodies", "OBSERVATION", 81, 102], ["HEV infection", "OBSERVATION", 157, 170]]], ["Meng et al. (2001) generated antibodies to multiple overlapping peptides and truncated ORF2 proteins and tested these in an in vitro cell culture infectivity assay to locate the minimal neutralizing domain to amino acids 452-617.", [["cell", "ANATOMY", 133, 137], ["amino acids 452-617", "CHEMICAL", 209, 228], ["amino acids", "CHEMICAL", 209, 220], ["ORF2", "GENE_OR_GENE_PRODUCT", 87, 91], ["cell", "CELL", 133, 137], ["amino acids", "AMINO_ACID", 209, 220], ["452-617", "AMINO_ACID", 221, 228], ["truncated ORF2 proteins", "PROTEIN", 77, 100], ["minimal neutralizing domain", "PROTEIN", 178, 205], ["amino acids 452-617", "PROTEIN", 209, 228], ["multiple overlapping peptides", "PROBLEM", 43, 72], ["truncated ORF2 proteins", "PROBLEM", 77, 100], ["amino acids", "TEST", 209, 220]]], ["The minimal neutralizing domain has now been mapped to residues 458-607 (Zhou et al., 2004) .", [["minimal neutralizing domain", "PROTEIN", 4, 31], ["The minimal neutralizing domain", "PROBLEM", 0, 31], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["neutralizing", "OBSERVATION", 12, 24]]], ["When combined with structural details, all of these mapping studies place the neutralizing epitope(s) in the protruding (P) domain of the ORF2 protein (Yamashita et al., 2009; Guu et al., 2009; Xing et al., 2011) .Neutralization epitopes and HEV vaccinesThe immunological and structural studies on the ORF2 protein provide a basis for HEV vaccine development.", [["ORF2", "GENE_OR_GENE_PRODUCT", 138, 142], ["HEV", "ORGANISM", 242, 245], ["ORF2", "GENE_OR_GENE_PRODUCT", 302, 306], ["HEV", "ORGANISM", 335, 338], ["neutralizing epitope", "PROTEIN", 78, 98], ["protruding (P) domain", "PROTEIN", 109, 130], ["ORF2 protein", "PROTEIN", 138, 150], ["Neutralization epitopes", "PROTEIN", 214, 237], ["ORF2 protein", "PROTEIN", 302, 314], ["HEV", "SPECIES", 242, 245], ["HEV", "SPECIES", 335, 338], ["these mapping studies", "TEST", 46, 67], ["the ORF2 protein", "TEST", 134, 150], ["Neutralization epitopes", "TREATMENT", 214, 237], ["HEV vaccines", "TREATMENT", 242, 254], ["structural studies", "TEST", 276, 294], ["the ORF2 protein", "TEST", 298, 314], ["HEV vaccine development", "TREATMENT", 335, 358]]], ["Two recombinant vaccines against HEV have undergone successful clinical testing in humans (Shrestha et al., 2007; Zhu et al., 2010) .", [["HEV", "ORGANISM", 33, 36], ["humans", "ORGANISM", 83, 89], ["humans", "SPECIES", 83, 89], ["HEV", "SPECIES", 33, 36], ["humans", "SPECIES", 83, 89], ["Two recombinant vaccines", "TREATMENT", 0, 24], ["successful clinical testing", "TEST", 52, 79]]], ["These are based on recombinant ORF2 proteins either expressed as T = 1 VLPs in insect cells (Shrestha et al., 2007) or as p239 particles in E. coli .", [["cells", "ANATOMY", 86, 91], ["ORF2", "GENE_OR_GENE_PRODUCT", 31, 35], ["T = 1 VLPs", "GENE_OR_GENE_PRODUCT", 65, 75], ["insect cells", "CELL", 79, 91], ["p239", "GENE_OR_GENE_PRODUCT", 122, 126], ["E. coli", "ORGANISM", 140, 147], ["recombinant ORF2 proteins", "PROTEIN", 19, 44], ["insect cells", "CELL_TYPE", 79, 91], ["E. coli", "SPECIES", 140, 147], ["E. coli", "SPECIES", 140, 147], ["recombinant ORF2 proteins", "TEST", 19, 44], ["T", "TEST", 65, 66], ["E. coli", "PROBLEM", 140, 147], ["E. coli", "OBSERVATION", 140, 147]]], ["Further details on these and other recombinant vaccine approaches can be found in another review in this issue (Kamili).", [["other recombinant vaccine approaches", "TREATMENT", 29, 65]]], ["The structural studies also provide a basis for using the ORF2 particles as an epitope presentation system (Xing et al., 2011) , which when combined with the ability of these VLPs to render successful oral immunization (Li et al., 2004) , can provide a powerful vaccine platform.Interactions with target cellsThe biochemical and structural characterization of the ORF2 capsid protein also offers an opportunity to study the interactions of HEV with its target cells.", [["oral", "ANATOMY", 201, 205], ["cells", "ANATOMY", 304, 309], ["cells", "ANATOMY", 460, 465], ["VLPs", "ORGANISM", 175, 179], ["oral", "ORGANISM_SUBDIVISION", 201, 205], ["cells", "CELL", 304, 309], ["ORF2", "GENE_OR_GENE_PRODUCT", 364, 368], ["HEV", "ORGANISM", 440, 443], ["cells", "CELL", 460, 465], ["target cells", "CELL_TYPE", 297, 309], ["ORF2 capsid protein", "PROTEIN", 364, 383], ["target cells", "CELL_TYPE", 453, 465], ["HEV", "SPECIES", 440, 443], ["The structural studies", "TEST", 0, 22], ["the ORF2 particles", "TREATMENT", 54, 72], ["these VLPs", "TREATMENT", 169, 179], ["successful oral immunization", "TREATMENT", 190, 218], ["a powerful vaccine platform", "TREATMENT", 251, 278], ["the ORF2 capsid protein", "TEST", 360, 383]]], ["The purified p239 protein, which structurally and antigenically resembles the HEV capsomere, bound and penetrated different cell lines susceptible in vitro to HEV infection (He et al., 2008) .", [["cell lines", "ANATOMY", 124, 134], ["HEV infection", "DISEASE", 159, 172], ["p239", "GENE_OR_GENE_PRODUCT", 13, 17], ["HEV", "ORGANISM", 78, 81], ["capsomere", "GENE_OR_GENE_PRODUCT", 82, 91], ["cell lines", "CELL", 124, 134], ["HEV", "ORGANISM", 159, 162], ["p239 protein", "PROTEIN", 13, 25], ["HEV capsomere", "PROTEIN", 78, 91], ["cell lines", "CELL_LINE", 124, 134], ["HEV", "SPECIES", 78, 81], ["HEV", "SPECIES", 159, 162], ["The purified p239 protein", "TEST", 0, 25], ["the HEV capsomere", "TREATMENT", 74, 91], ["penetrated different cell lines", "TREATMENT", 103, 134], ["HEV infection", "PROBLEM", 159, 172], ["HEV capsomere", "OBSERVATION", 78, 91], ["penetrated", "OBSERVATION_MODIFIER", 103, 113], ["different cell lines", "OBSERVATION", 114, 134], ["HEV", "OBSERVATION_MODIFIER", 159, 162], ["infection", "OBSERVATION", 163, 172]]], ["In pull-down experiments, p239 showed binding to Grp78/BiP, alpha-tubulin and heat shock protein 90 (HSP90), and inhibitor studies showed HSP90 to be important for the intracellular trafficking of p239 (Zheng et al., 2010) .", [["intracellular", "ANATOMY", 168, 181], ["Grp78", "GENE_OR_GENE_PRODUCT", 49, 54], ["BiP", "GENE_OR_GENE_PRODUCT", 55, 58], ["alpha-tubulin", "GENE_OR_GENE_PRODUCT", 60, 73], ["heat shock protein 90", "GENE_OR_GENE_PRODUCT", 78, 99], ["HSP90", "GENE_OR_GENE_PRODUCT", 101, 106], ["HSP90", "GENE_OR_GENE_PRODUCT", 138, 143], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 181], ["p239", "PROTEIN", 26, 30], ["Grp78", "PROTEIN", 49, 54], ["BiP", "PROTEIN", 55, 58], ["alpha-tubulin", "PROTEIN", 60, 73], ["heat shock protein 90", "PROTEIN", 78, 99], ["HSP90", "PROTEIN", 101, 106], ["HSP90", "PROTEIN", 138, 143], ["Grp78", "TEST", 49, 54], ["BiP", "TEST", 55, 58], ["alpha-tubulin", "TEST", 60, 73], ["heat shock protein", "TEST", 78, 96], ["HSP90", "TEST", 101, 106], ["inhibitor studies", "TEST", 113, 130], ["HSP90", "TEST", 138, 143]]], ["The ORF2 VLPs produced in insect cells were also shown to bind Huh7 liver cells and this binding was dependent upon heparan surface proteoglycans (HSPGs) present on cell surface Syndecans .", [["cells", "ANATOMY", 33, 38], ["Huh7 liver cells", "ANATOMY", 63, 79], ["cell surface", "ANATOMY", 165, 177], ["ORF2", "GENE_OR_GENE_PRODUCT", 4, 8], ["insect cells", "CELL", 26, 38], ["Huh7 liver cells", "CELL", 63, 79], ["heparan surface proteoglycans", "GENE_OR_GENE_PRODUCT", 116, 145], ["HSPGs", "GENE_OR_GENE_PRODUCT", 147, 152], ["cell", "CELL", 165, 169], ["ORF2 VLPs", "DNA", 4, 13], ["insect cells", "CELL_TYPE", 26, 38], ["Huh7 liver cells", "CELL_LINE", 63, 79], ["heparan surface proteoglycans", "PROTEIN", 116, 145], ["HSPGs", "PROTEIN", 147, 152], ["The ORF2 VLPs", "TREATMENT", 0, 13], ["insect cells", "PROBLEM", 26, 38], ["this binding", "PROBLEM", 84, 96], ["heparan surface proteoglycans", "TREATMENT", 116, 145], ["cell surface Syndecans", "TREATMENT", 165, 187], ["insect cells", "OBSERVATION", 26, 38]]], ["Analogous to binding studies with p239 (He et al., 2008) , our studies show that the VLPs also bind to cell lines susceptible to HEV infection; these are further taken up into Huh7 cells through fluid endosomes (M. Kalia, R. Holla, S. Jameel; unpublished results) .", [["cell lines", "ANATOMY", 103, 113], ["Huh7 cells", "ANATOMY", 176, 186], ["fluid endosomes", "ANATOMY", 195, 210], ["HEV infection", "DISEASE", 129, 142], ["VLPs", "ORGANISM", 85, 89], ["cell lines", "CELL", 103, 113], ["HEV", "ORGANISM", 129, 132], ["Huh7 cells", "CELL", 176, 186], ["fluid endosomes", "CELLULAR_COMPONENT", 195, 210], ["cell lines", "CELL_LINE", 103, 113], ["Huh7 cells", "CELL_LINE", 176, 186], ["HEV", "SPECIES", 129, 132], ["binding studies", "TEST", 13, 28], ["our studies", "TEST", 59, 70], ["the VLPs", "PROBLEM", 81, 89], ["cell lines", "TREATMENT", 103, 113], ["HEV infection", "PROBLEM", 129, 142], ["fluid endosomes", "TEST", 195, 210], ["cell lines", "OBSERVATION", 103, 113], ["HEV", "OBSERVATION_MODIFIER", 129, 132], ["infection", "OBSERVATION", 133, 142]]], ["More studies along these lines are likely to identify the cellular receptor for HEV and characterize the virus uptake and uncoating pathway in infected cells.Interactions with target cellsViral capsid proteins are involved in extensive interactions with cellular proteins for the purpose of capsid assembly and virus egress.", [["cellular", "ANATOMY", 58, 66], ["cells", "ANATOMY", 152, 157], ["cells", "ANATOMY", 183, 188], ["cellular", "ANATOMY", 254, 262], ["lines", "CELL", 25, 30], ["cellular", "CELL", 58, 66], ["HEV", "ORGANISM", 80, 83], ["cells", "CELL", 152, 157], ["cells", "CELL", 183, 188], ["cellular", "CELL", 254, 262], ["cellular receptor", "PROTEIN", 58, 75], ["infected cells", "CELL_TYPE", 143, 157], ["target cells", "CELL_TYPE", 176, 188], ["Viral capsid proteins", "PROTEIN", 188, 209], ["cellular proteins", "PROTEIN", 254, 271], ["HEV", "SPECIES", 80, 83], ["HEV", "PROBLEM", 80, 83], ["the virus uptake", "PROBLEM", 101, 117], ["uncoating pathway in infected cells", "PROBLEM", 122, 157], ["Viral capsid proteins", "PROBLEM", 188, 209], ["cellular proteins", "TREATMENT", 254, 271], ["capsid assembly and virus egress", "PROBLEM", 291, 323], ["virus uptake", "OBSERVATION", 105, 117], ["infected cells", "OBSERVATION", 143, 157], ["capsid proteins", "OBSERVATION", 194, 209]]], ["For non-enveloped viruses, the capsid protein interactions are also important for virus entry, intracellular trafficking and signaling (Tsai, 2007; ).", [["intracellular", "ANATOMY", 95, 108], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["capsid protein", "PROTEIN", 31, 45], ["non-enveloped viruses", "PROBLEM", 4, 25], ["the capsid protein interactions", "PROBLEM", 27, 58], ["non-enveloped", "OBSERVATION_MODIFIER", 4, 17], ["viruses", "OBSERVATION", 18, 25]]], ["Very little is known about the interactions of the ORF2 protein with cellular components and pathways, besides that with HSP90 (He et al., 2008) and HSPGs ) summarized above.", [["cellular", "ANATOMY", 69, 77], ["ORF2", "GENE_OR_GENE_PRODUCT", 51, 55], ["cellular", "CELL", 69, 77], ["HSP90", "GENE_OR_GENE_PRODUCT", 121, 126], ["HSPGs", "GENE_OR_GENE_PRODUCT", 149, 154], ["ORF2 protein", "PROTEIN", 51, 63], ["HSP90", "PROTEIN", 121, 126], ["HSPGs", "PROTEIN", 149, 154], ["HSP90", "TEST", 121, 126]]], ["The ORF2 protein expressed in animal cells was observed to localize to the ER, where it causes ER stress and some of the protein is retrotranslocated into the cytoplasm through a canonical ER-associated degradation (ERAD) pathway (Surjit et al., 2007) .", [["cells", "ANATOMY", 37, 42], ["ER", "ANATOMY", 75, 77], ["cytoplasm", "ANATOMY", 159, 168], ["ORF2", "GENE_OR_GENE_PRODUCT", 4, 8], ["cells", "CELL", 37, 42], ["ER", "GENE_OR_GENE_PRODUCT", 75, 77], ["ER", "GENE_OR_GENE_PRODUCT", 95, 97], ["cytoplasm", "ORGANISM_SUBSTANCE", 159, 168], ["ER", "GENE_OR_GENE_PRODUCT", 189, 191], ["ERAD", "GENE_OR_GENE_PRODUCT", 216, 220], ["ORF2 protein", "PROTEIN", 4, 16], ["animal cells", "CELL_TYPE", 30, 42], ["ER", "PROTEIN", 75, 77], ["ER", "PROTEIN", 95, 97], ["ER", "PROTEIN", 189, 191], ["ERAD", "PROTEIN", 216, 220], ["The ORF2 protein", "TEST", 0, 16], ["animal cells", "PROBLEM", 30, 42], ["ER stress", "PROBLEM", 95, 104], ["the protein", "TEST", 117, 128], ["animal cells", "OBSERVATION", 30, 42], ["stress", "OBSERVATION", 98, 104]]], ["Whether these effects of the ORF2 protein have a bearing on HEV assembly and egress or on virus entry and intracellular trafficking remains to be seen.Expression and subcellular localizationThe orf3 of HEV was initially predicted to express a protein of 123 amino acids.", [["intracellular", "ANATOMY", 106, 119], ["subcellular", "ANATOMY", 166, 177], ["amino acids", "CHEMICAL", 258, 269], ["amino acids", "CHEMICAL", 258, 269], ["ORF2", "GENE_OR_GENE_PRODUCT", 29, 33], ["HEV", "ORGANISM", 60, 63], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 119], ["orf3", "GENE_OR_GENE_PRODUCT", 194, 198], ["HEV", "ORGANISM", 202, 205], ["amino acids", "AMINO_ACID", 258, 269], ["ORF2 protein", "PROTEIN", 29, 41], ["orf3", "PROTEIN", 194, 198], ["HEV", "SPECIES", 60, 63], ["HEV", "SPECIES", 202, 205], ["the ORF2 protein", "TREATMENT", 25, 41], ["virus entry", "TREATMENT", 90, 101], ["intracellular trafficking", "PROBLEM", 106, 131], ["subcellular localization", "TEST", 166, 190], ["a protein", "TEST", 241, 250], ["amino acids", "TEST", 258, 269]]], ["It was recently suggested that the ORF3 protein is translated from a bicistronic subgenomic RNA from an AUG codon at position 5131 (in SAR-55 isolate), which would result in a 114 amino acid protein; that would be 9 amino acids shorter at its N-terminus than the earlier proposal (Graff et al., 2006) .", [["amino acid", "CHEMICAL", 180, 190], ["amino acids", "CHEMICAL", 216, 227], ["amino acid", "CHEMICAL", 180, 190], ["amino acids", "CHEMICAL", 216, 227], ["N", "CHEMICAL", 243, 244], ["ORF3", "GENE_OR_GENE_PRODUCT", 35, 39], ["SAR-55", "GENE_OR_GENE_PRODUCT", 135, 141], ["amino acids", "AMINO_ACID", 216, 227], ["ORF3 protein", "PROTEIN", 35, 47], ["bicistronic subgenomic RNA", "RNA", 69, 95], ["AUG codon", "DNA", 104, 113], ["position 5131", "DNA", 117, 130], ["114 amino acid protein", "PROTEIN", 176, 198], ["N-terminus", "PROTEIN", 243, 253], ["the ORF3 protein", "TEST", 31, 47], ["a bicistronic subgenomic RNA", "PROBLEM", 67, 95], ["a 114 amino acid protein", "TEST", 174, 198], ["amino acids", "TEST", 216, 227], ["bicistronic", "OBSERVATION", 69, 80], ["subgenomic RNA", "OBSERVATION", 81, 95]]], ["Using a replicon system based on genomic RNA produced in vitro, orf3 was found to be dispensable for replication in vitro in Huh7 and other cell lines .", [["Huh7", "ANATOMY", 125, 129], ["cell lines", "ANATOMY", 140, 150], ["orf3", "GENE_OR_GENE_PRODUCT", 64, 68], ["Huh7", "CELL", 125, 129], ["cell lines", "CELL", 140, 150], ["genomic RNA", "RNA", 33, 44], ["orf3", "PROTEIN", 64, 68], ["Huh7", "CELL_LINE", 125, 129], ["cell lines", "CELL_LINE", 140, 150], ["a replicon system", "TREATMENT", 6, 23], ["genomic RNA", "TREATMENT", 33, 44], ["vitro in Huh7", "TREATMENT", 116, 129], ["other cell lines", "TREATMENT", 134, 150], ["cell lines", "OBSERVATION", 140, 150]]], ["However, it was required for infection in monkeys that received intrahepatic inoculation of HEV genomic RNA (Graff et al., 2005) .", [["intrahepatic", "ANATOMY", 64, 76], ["infection", "DISEASE", 29, 38], ["monkeys", "ORGANISM", 42, 49], ["HEV", "ORGANISM", 92, 95], ["HEV", "SPECIES", 92, 95], ["infection in monkeys", "PROBLEM", 29, 49], ["intrahepatic inoculation", "TREATMENT", 64, 88], ["HEV genomic RNA", "TREATMENT", 92, 107], ["infection", "OBSERVATION", 29, 38], ["intrahepatic", "ANATOMY", 64, 76], ["HEV genomic RNA", "OBSERVATION", 92, 107]]], ["These observations suggest that the ORF3 protein functions as a viral accessory protein, and is likely to affect the host response to infection.Expression and subcellular localizationThe ORF3 protein has been expressed using various systems that include E. coli (Panda et al., 1995) , the yeast Pichia pastoris (Lal et al., 1997) and mammalian cell lines (Jameel et al., 1996) .", [["subcellular", "ANATOMY", 159, 170], ["cell lines", "ANATOMY", 344, 354], ["infection", "DISEASE", 134, 143], ["ORF3", "GENE_OR_GENE_PRODUCT", 36, 40], ["ORF3", "GENE_OR_GENE_PRODUCT", 187, 191], ["E. coli", "ORGANISM", 254, 261], ["yeast Pichia pastoris", "ORGANISM", 289, 310], ["mammalian cell lines", "CELL", 334, 354], ["ORF3 protein", "PROTEIN", 36, 48], ["viral accessory protein", "PROTEIN", 64, 87], ["ORF3 protein", "PROTEIN", 187, 199], ["mammalian cell lines", "CELL_LINE", 334, 354], ["E. coli", "SPECIES", 254, 261], ["yeast", "SPECIES", 289, 294], ["Pichia pastoris", "SPECIES", 295, 310], ["E. coli", "SPECIES", 254, 261], ["yeast", "SPECIES", 289, 294], ["Pichia pastoris", "SPECIES", 295, 310], ["the ORF3 protein functions", "TEST", 32, 58], ["a viral accessory protein", "PROBLEM", 62, 87], ["infection", "PROBLEM", 134, 143], ["The ORF3 protein", "TEST", 183, 199], ["various systems", "PROBLEM", 225, 240], ["E. coli", "PROBLEM", 254, 261], ["the yeast Pichia pastoris", "PROBLEM", 285, 310], ["mammalian cell lines", "TREATMENT", 334, 354], ["host response", "OBSERVATION", 117, 130], ["infection", "OBSERVATION", 134, 143], ["yeast", "OBSERVATION", 289, 294], ["Pichia pastoris", "OBSERVATION", 295, 310], ["mammalian cell lines", "OBSERVATION", 334, 354]]], ["In mammalian cells orf3 expressed a protein of \u223c13 kDa, which was phosphorylated at a single Serine residue by cellular mitogen-activated protein kinase (MAPK) (Zafrullah et al., 1997) .", [["cells", "ANATOMY", 13, 18], ["cellular", "ANATOMY", 111, 119], ["Serine", "CHEMICAL", 93, 99], ["mammalian cells", "CELL", 3, 18], ["orf3", "CELL", 19, 23], ["cellular mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 111, 152], ["MAPK", "GENE_OR_GENE_PRODUCT", 154, 158], ["orf3", "PROTEIN", 19, 23], ["\u223c13 kDa", "PROTEIN", 47, 54], ["cellular mitogen-activated protein kinase", "PROTEIN", 111, 152], ["MAPK", "PROTEIN", 154, 158], ["a protein", "TEST", 34, 43], ["cellular mitogen", "TEST", 111, 127], ["activated protein kinase", "TEST", 128, 152], ["MAPK", "TEST", 154, 158], ["mammalian cells", "OBSERVATION", 3, 18]]], ["Cells transfected with HEV genomic RNA prepared in vitro were also found to express a protein of the same size, which could be immunoprecipitated with anti-ORF3 antibodies Graff et al., 2005; .", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["HEV", "ORGANISM", 23, 26], ["anti-ORF3", "GENE_OR_GENE_PRODUCT", 151, 160], ["HEV genomic RNA", "RNA", 23, 38], ["anti-ORF3 antibodies", "PROTEIN", 151, 171], ["HEV", "SPECIES", 23, 26], ["HEV genomic RNA", "TREATMENT", 23, 38], ["a protein", "TEST", 84, 93], ["genomic RNA", "OBSERVATION", 27, 38], ["size", "OBSERVATION_MODIFIER", 106, 110]]], ["Subcellular fractionation showed the ORF3 protein to associate with the cytoskeleton (Zafrullah et al., 1997) .", [["Subcellular", "ANATOMY", 0, 11], ["cytoskeleton", "ANATOMY", 72, 84], ["ORF3", "GENE_OR_GENE_PRODUCT", 37, 41], ["cytoskeleton", "CELLULAR_COMPONENT", 72, 84], ["ORF3 protein", "PROTEIN", 37, 49], ["Subcellular fractionation", "TEST", 0, 25], ["the ORF3 protein", "TEST", 33, 49], ["fractionation", "OBSERVATION", 12, 25], ["ORF3 protein", "OBSERVATION", 37, 49]]], ["Confocal microscopy has revealed its punctate and filamentous intracellular distribution; the latter is attributed to its interaction with microtubules (Kannan et al., 2009) .", [["intracellular", "ANATOMY", 62, 75], ["microtubules", "ANATOMY", 139, 151], ["filamentous", "CELLULAR_COMPONENT", 50, 61], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 75], ["microtubules", "CELLULAR_COMPONENT", 139, 151], ["Confocal microscopy", "TEST", 0, 19], ["its punctate and filamentous intracellular distribution", "PROBLEM", 33, 88], ["punctate", "OBSERVATION_MODIFIER", 37, 45], ["filamentous", "OBSERVATION_MODIFIER", 50, 61], ["intracellular distribution", "OBSERVATION", 62, 88]]], ["The punctate distribution of the ORF3 protein localized it to early and recycling endosomes (Chandra et al., 2008a) .Protein domains and effects on cellular functionsPrimary sequence analysis of the ORF3 protein does not show domains homologous to any other protein or any other distinguishing features, except the proline-rich nature of the protein.", [["recycling endosomes", "ANATOMY", 72, 91], ["cellular", "ANATOMY", 148, 156], ["proline", "CHEMICAL", 315, 322], ["proline", "CHEMICAL", 315, 322], ["ORF3", "GENE_OR_GENE_PRODUCT", 33, 37], ["recycling endosomes", "CELLULAR_COMPONENT", 72, 91], ["cellular", "CELL", 148, 156], ["ORF3", "GENE_OR_GENE_PRODUCT", 199, 203], ["ORF3 protein", "PROTEIN", 33, 45], ["Protein domains", "PROTEIN", 117, 132], ["ORF3 protein", "PROTEIN", 199, 211], ["the ORF3 protein", "PROBLEM", 29, 45], ["Protein domains", "PROBLEM", 117, 132], ["cellular functions", "TEST", 148, 166], ["Primary sequence analysis", "TEST", 166, 191], ["the ORF3 protein", "TEST", 195, 211], ["domains homologous", "PROBLEM", 226, 244], ["any other protein", "PROBLEM", 248, 265], ["any other distinguishing features", "PROBLEM", 269, 302], ["punctate", "OBSERVATION_MODIFIER", 4, 12], ["distribution", "OBSERVATION_MODIFIER", 13, 25], ["ORF3 protein", "OBSERVATION", 33, 45], ["endosomes", "OBSERVATION_MODIFIER", 82, 91], ["cellular functions", "OBSERVATION", 148, 166]]], ["It contains two large N-terminal hydrophobic domains -D1 (aa 7-23) and D2 (aa 28-53), and two proline-rich domains -P1 (aa 66-77) and P2 (aa 95-111) (Fig. 4) .Protein domains and effects on cellular functionsOf these, D1 is extremely rich in cysteine residues and is required for the ORF3 protein to associate with the cytoskeleton (Zafrullah et al., 1997) , to bind microtubules (Kannan et al., 2009 ) and a MAPK phosphatase (Kar-Roy et al., 2004) ; however, none of these activities have been linked conclusively to one or more cysteine residues present in this domain.", [["cellular", "ANATOMY", 190, 198], ["cytoskeleton", "ANATOMY", 319, 331], ["microtubules", "ANATOMY", 367, 379], ["proline", "CHEMICAL", 94, 101], ["N", "CHEMICAL", 22, 23], ["proline", "CHEMICAL", 94, 101], ["cysteine", "CHEMICAL", 242, 250], ["cysteine", "CHEMICAL", 530, 538], ["cellular", "CELL", 190, 198], ["D1", "GENE_OR_GENE_PRODUCT", 218, 220], ["cysteine", "AMINO_ACID", 242, 250], ["ORF3", "GENE_OR_GENE_PRODUCT", 284, 288], ["cytoskeleton", "CELLULAR_COMPONENT", 319, 331], ["microtubules", "CELLULAR_COMPONENT", 367, 379], ["MAPK", "GENE_OR_GENE_PRODUCT", 409, 413], ["N-terminal hydrophobic domains", "PROTEIN", 22, 52], ["D1", "PROTEIN", 54, 56], ["aa 7-23", "PROTEIN", 58, 65], ["D2", "PROTEIN", 71, 73], ["aa 28-53", "PROTEIN", 75, 83], ["proline-rich domains", "PROTEIN", 94, 114], ["P1", "PROTEIN", 116, 118], ["P2", "PROTEIN", 134, 136], ["Protein domains", "PROTEIN", 159, 174], ["D1", "PROTEIN", 218, 220], ["ORF3 protein", "PROTEIN", 284, 296], ["MAPK phosphatase", "PROTEIN", 409, 425], ["two large N-terminal hydrophobic domains", "PROBLEM", 12, 52], ["aa", "TEST", 58, 60], ["D2", "TEST", 71, 73], ["aa", "TEST", 75, 77], ["two proline", "TEST", 90, 101], ["aa", "TEST", 120, 122], ["P2", "TEST", 134, 136], ["aa", "TEST", 138, 140], ["Fig", "TEST", 150, 153], ["Protein domains", "PROBLEM", 159, 174], ["cellular functions", "TEST", 190, 208], ["cysteine residues", "PROBLEM", 242, 259], ["the ORF3 protein", "TEST", 280, 296], ["a MAPK phosphatase", "TEST", 407, 425], ["more cysteine residues", "PROBLEM", 525, 547], ["two", "OBSERVATION_MODIFIER", 12, 15], ["large", "OBSERVATION_MODIFIER", 16, 21], ["terminal", "OBSERVATION_MODIFIER", 24, 32], ["hydrophobic domains", "OBSERVATION", 33, 52], ["cellular functions", "OBSERVATION", 190, 208], ["extremely", "OBSERVATION_MODIFIER", 224, 233], ["rich", "OBSERVATION", 234, 238], ["cysteine residues", "OBSERVATION", 242, 259]]], ["Domain P1 contains two overlapping motifs that have homology to kinase substrates -PMSP that is phosphorylated by MAPK and SPLR that has a loose homology to the SPKK motif that is phosphorylated by cdc2 kinase.", [["PMSP", "GENE_OR_GENE_PRODUCT", 83, 87], ["MAPK", "GENE_OR_GENE_PRODUCT", 114, 118], ["SPLR", "GENE_OR_GENE_PRODUCT", 123, 127], ["SPKK", "GENE_OR_GENE_PRODUCT", 161, 165], ["cdc2 kinase", "GENE_OR_GENE_PRODUCT", 198, 209], ["P1", "DNA", 7, 9], ["kinase substrates", "PROTEIN", 64, 81], ["PMSP", "PROTEIN", 83, 87], ["MAPK", "PROTEIN", 114, 118], ["SPLR", "PROTEIN", 123, 127], ["SPKK motif", "PROTEIN", 161, 171], ["cdc2 kinase", "PROTEIN", 198, 209], ["Domain P1", "TREATMENT", 0, 9], ["two overlapping motifs", "TREATMENT", 19, 41], ["kinase substrates", "TEST", 64, 81]]], ["Of these, Ser-80 (now Ser-71 in the 114 aa ORF3 protein) is phosphorylated by MAPK, both in transfected cells as well as in vitro (Zafrullah et al., 1997) ; whether the ORF3 protein expressed during viral infection is also phosphorylated has not been tested.", [["cells", "ANATOMY", 104, 109], ["infection", "DISEASE", 205, 214], ["Ser", "CHEMICAL", 10, 13], ["Ser", "CHEMICAL", 22, 25], ["Ser-80", "AMINO_ACID", 10, 16], ["Ser-71", "AMINO_ACID", 22, 28], ["ORF3", "GENE_OR_GENE_PRODUCT", 43, 47], ["MAPK", "GENE_OR_GENE_PRODUCT", 78, 82], ["cells", "CELL", 104, 109], ["ORF3", "GENE_OR_GENE_PRODUCT", 169, 173], ["114 aa ORF3 protein", "PROTEIN", 36, 55], ["MAPK", "PROTEIN", 78, 82], ["transfected cells", "CELL_LINE", 92, 109], ["ORF3 protein", "PROTEIN", 169, 181], ["Ser", "TEST", 10, 13], ["Ser", "TEST", 22, 25], ["aa ORF3 protein", "TEST", 40, 55], ["MAPK", "TEST", 78, 82], ["the ORF3 protein", "TEST", 165, 181], ["viral infection", "PROBLEM", 199, 214], ["transfected cells", "OBSERVATION", 92, 109], ["viral infection", "OBSERVATION", 199, 214]]], ["The P2 domain has two overlapping PXXP motifs, which have been described in many viral and cellular proteins involved in signal transduction, and bind the Src homology 3 (SH3) domains found in other signal-transducing molecules (Pawson, 1995) .", [["cellular", "ANATOMY", 91, 99], ["PXXP", "GENE_OR_GENE_PRODUCT", 34, 38], ["cellular", "CELL", 91, 99], ["Src homology 3", "GENE_OR_GENE_PRODUCT", 155, 169], ["SH3", "GENE_OR_GENE_PRODUCT", 171, 174], ["P2 domain", "DNA", 4, 13], ["PXXP motifs", "PROTEIN", 34, 45], ["viral and cellular proteins", "PROTEIN", 81, 108], ["Src homology 3 (SH3) domains", "PROTEIN", 155, 183], ["signal-transducing molecules", "PROTEIN", 199, 227], ["two overlapping PXXP motifs", "TREATMENT", 18, 45], ["many viral and cellular proteins", "PROBLEM", 76, 108], ["the Src homology", "TEST", 151, 167], ["overlapping", "OBSERVATION_MODIFIER", 22, 33], ["PXXP motifs", "OBSERVATION", 34, 45], ["viral", "OBSERVATION", 81, 86], ["cellular proteins", "OBSERVATION", 91, 108]]], ["Indeed, this domain was shown to be responsible for the interaction of the ORF3 protein with many cellular SH3 domain-containing proteins (Korkaya et al., 2001) .Protein domains and effects on cellular functionsSuch a domain structure and the ability of the ORF3 protein to interact with multiple cellular proteins suggested a potential role for it in optimizing the cellular environment for viral infection and replication.", [["cellular", "ANATOMY", 98, 106], ["cellular", "ANATOMY", 193, 201], ["cellular", "ANATOMY", 297, 305], ["cellular", "ANATOMY", 367, 375], ["viral infection", "DISEASE", 392, 407], ["ORF3", "GENE_OR_GENE_PRODUCT", 75, 79], ["cellular", "CELL", 98, 106], ["cellular", "CELL", 193, 201], ["ORF3", "GENE_OR_GENE_PRODUCT", 258, 262], ["cellular", "CELL", 297, 305], ["cellular", "CELL", 367, 375], ["ORF3 protein", "PROTEIN", 75, 87], ["cellular SH3 domain-containing proteins", "PROTEIN", 98, 137], ["Protein domains", "PROTEIN", 162, 177], ["ORF3 protein", "PROTEIN", 258, 270], ["cellular proteins", "PROTEIN", 297, 314], ["the ORF3 protein", "TEST", 71, 87], ["many cellular SH3 domain", "PROBLEM", 93, 117], ["Protein domains", "PROBLEM", 162, 177], ["cellular functions", "TEST", 193, 211], ["a domain structure", "PROBLEM", 216, 234], ["the ORF3 protein", "TEST", 254, 270], ["multiple cellular proteins", "PROBLEM", 288, 314], ["viral infection", "PROBLEM", 392, 407], ["cellular SH3", "OBSERVATION", 98, 110], ["cellular functions", "OBSERVATION", 193, 211], ["infection", "OBSERVATION", 398, 407]]], ["Various studies have been carried out in this direction, but most of these are based on ORF3 over-expression in hepatic cell lines and remain to be confirmed in an efficient viral infection system.", [["hepatic cell lines", "ANATOMY", 112, 130], ["viral infection", "DISEASE", 174, 189], ["ORF3", "GENE_OR_GENE_PRODUCT", 88, 92], ["hepatic cell lines", "CELL", 112, 130], ["ORF3", "DNA", 88, 92], ["hepatic cell lines", "CELL_LINE", 112, 130], ["Various studies", "TEST", 0, 15], ["ORF3", "TREATMENT", 88, 92], ["hepatic cell lines", "TREATMENT", 112, 130], ["an efficient viral infection system", "PROBLEM", 161, 196], ["hepatic", "ANATOMY", 112, 119], ["cell lines", "OBSERVATION", 120, 130], ["viral", "OBSERVATION_MODIFIER", 174, 179], ["infection", "OBSERVATION", 180, 189]]], ["Nevertheless, these studies provide some insights into the possible multi-pronged functions of this HEV protein.Protein domains and effects on cellular functionsThe ORF3 protein was found to activate the extracellularly regulated kinase (Erk), a member of the MAPK family of signal transducing molecules (Korkaya et al., 2001) .", [["cellular", "ANATOMY", 143, 151], ["HEV", "ORGANISM", 100, 103], ["cellular", "CELL", 143, 151], ["ORF3", "GENE_OR_GENE_PRODUCT", 165, 169], ["extracellularly regulated kinase", "GENE_OR_GENE_PRODUCT", 204, 236], ["Erk", "GENE_OR_GENE_PRODUCT", 238, 241], ["MAPK", "GENE_OR_GENE_PRODUCT", 260, 264], ["HEV protein", "PROTEIN", 100, 111], ["Protein domains", "PROTEIN", 112, 127], ["ORF3 protein", "PROTEIN", 165, 177], ["extracellularly regulated kinase", "PROTEIN", 204, 236], ["Erk", "PROTEIN", 238, 241], ["MAPK family", "PROTEIN", 260, 271], ["signal transducing molecules", "PROTEIN", 275, 303], ["HEV", "SPECIES", 100, 103], ["these studies", "TEST", 14, 27], ["this HEV protein", "TREATMENT", 95, 111], ["Protein domains", "PROBLEM", 112, 127], ["cellular functions", "TEST", 143, 161], ["The ORF3 protein", "TEST", 161, 177], ["cellular functions", "OBSERVATION", 143, 161]]], ["This Erk activation was independent of the traditional Raf/MEK pathway, but depended upon the ability of the ORF3 protein to bind and inactivate Pyst1, a prototypic member of the Erk-specific MAPK phosphatase (Kar-Roy et al., 2004) .", [["Erk", "GENE_OR_GENE_PRODUCT", 5, 8], ["Raf", "GENE_OR_GENE_PRODUCT", 55, 58], ["MEK", "GENE_OR_GENE_PRODUCT", 59, 62], ["ORF3", "GENE_OR_GENE_PRODUCT", 109, 113], ["Pyst1", "GENE_OR_GENE_PRODUCT", 145, 150], ["MAPK", "GENE_OR_GENE_PRODUCT", 192, 196], ["Erk", "PROTEIN", 5, 8], ["Raf", "PROTEIN", 55, 58], ["MEK", "PROTEIN", 59, 62], ["ORF3 protein", "PROTEIN", 109, 121], ["Pyst1", "PROTEIN", 145, 150], ["Erk-specific MAPK phosphatase", "PROTEIN", 179, 208], ["Kar", "PROTEIN", 210, 213], ["the traditional Raf/MEK pathway", "TREATMENT", 39, 70], ["the Erk-specific MAPK phosphatase", "TEST", 175, 208]]], ["By binding to the central linker region of Pyst1 through its N-terminal D1 domain, the ORF3 protein was proposed to block conformational changes in the phosphatase, which are required for its Erk-mediated activation (Kar-Roy et al., 2004) .", [["N", "CHEMICAL", 61, 62], ["Pyst1", "GENE_OR_GENE_PRODUCT", 43, 48], ["ORF3", "GENE_OR_GENE_PRODUCT", 87, 91], ["central linker region", "PROTEIN", 18, 39], ["Pyst1", "PROTEIN", 43, 48], ["N-terminal D1 domain", "PROTEIN", 61, 81], ["ORF3 protein", "PROTEIN", 87, 99], ["phosphatase", "PROTEIN", 152, 163], ["the ORF3 protein", "TEST", 83, 99], ["block conformational changes in the phosphatase", "PROBLEM", 116, 163], ["central", "ANATOMY_MODIFIER", 18, 25], ["linker", "ANATOMY_MODIFIER", 26, 32]]], ["Prolonged Erk activation was proposed to generate a survival and proliferative signal.", [["Erk", "GENE_OR_GENE_PRODUCT", 10, 13], ["Erk", "PROTEIN", 10, 13], ["Prolonged Erk activation", "PROBLEM", 0, 24], ["a survival and proliferative signal", "PROBLEM", 50, 85]]], ["Cells expressing the ORF3 protein also displayed higher levels of hexokinase and oligomeric forms of the voltage-dependent anion channel (VDAC), which lead to Fig. 4 .", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ORF3", "GENE_OR_GENE_PRODUCT", 21, 25], ["hexokinase", "GENE_OR_GENE_PRODUCT", 66, 76], ["voltage-dependent anion channel", "GENE_OR_GENE_PRODUCT", 105, 136], ["VDAC", "GENE_OR_GENE_PRODUCT", 138, 142], ["ORF3 protein", "PROTEIN", 21, 33], ["hexokinase", "PROTEIN", 66, 76], ["voltage-dependent anion channel", "PROTEIN", 105, 136], ["VDAC", "PROTEIN", 138, 142], ["the ORF3 protein", "TEST", 17, 33], ["higher levels of hexokinase", "PROBLEM", 49, 76], ["dependent anion channel (VDAC)", "PROBLEM", 113, 143], ["oligomeric forms", "OBSERVATION", 81, 97], ["dependent", "OBSERVATION_MODIFIER", 113, 122], ["anion channel", "OBSERVATION", 123, 136]]], ["The ORF3 protein.", [["ORF3", "GENE_OR_GENE_PRODUCT", 4, 8], ["ORF3 protein", "PROTEIN", 4, 16], ["The ORF3 protein", "TEST", 0, 16], ["ORF3 protein", "OBSERVATION", 4, 16]]], ["The orf3 gene encodes a 114-amino acid multi-functional protein, which has two hydrophobic domains (D1 and D2) and two proline rich domains (P1 and P2).", [["amino acid", "CHEMICAL", 28, 38], ["proline", "CHEMICAL", 119, 126], ["amino acid", "CHEMICAL", 28, 38], ["proline", "CHEMICAL", 119, 126], ["orf3", "GENE_OR_GENE_PRODUCT", 4, 8], ["amino acid", "AMINO_ACID", 28, 38], ["orf3 gene", "DNA", 4, 13], ["114-amino acid multi-functional protein", "PROTEIN", 24, 63], ["hydrophobic domains", "PROTEIN", 79, 98], ["D1", "PROTEIN", 100, 102], ["D2", "PROTEIN", 107, 109], ["proline rich domains", "PROTEIN", 119, 139], ["P1", "PROTEIN", 141, 143], ["P2", "PROTEIN", 148, 150], ["amino acid multi-functional protein", "TEST", 28, 63], ["two proline rich domains (P1 and P2", "TREATMENT", 115, 150]]], ["In mammalian cells, the ORF3 protein is phosphorylated at Serine 71 (red dot) by cellular MAPK.", [["cells", "ANATOMY", 13, 18], ["cellular", "ANATOMY", 81, 89], ["Serine", "CHEMICAL", 58, 64], ["mammalian cells", "CELL", 3, 18], ["ORF3", "GENE_OR_GENE_PRODUCT", 24, 28], ["Serine 71", "AMINO_ACID", 58, 67], ["red dot)", "GENE_OR_GENE_PRODUCT", 69, 77], ["cellular MAPK", "GENE_OR_GENE_PRODUCT", 81, 94], ["mammalian cells", "CELL_TYPE", 3, 18], ["ORF3 protein", "PROTEIN", 24, 36], ["Serine 71", "PROTEIN", 58, 67], ["red dot", "PROTEIN", 69, 76], ["cellular MAPK", "PROTEIN", 81, 94], ["the ORF3 protein", "TEST", 20, 36], ["phosphorylated at Serine", "TEST", 40, 64], ["red dot", "TEST", 69, 76], ["cellular MAPK", "TEST", 81, 94], ["mammalian cells", "OBSERVATION", 3, 18]]], ["The proline-rich P2 domain contains a PXXP motif (RPSAP, in box) that is implicated in binding to SH3 domains in cellular proteins.", [["cellular", "ANATOMY", 113, 121], ["proline", "CHEMICAL", 4, 11], ["proline", "CHEMICAL", 4, 11], ["RPSAP", "GENE_OR_GENE_PRODUCT", 50, 55], ["SH3", "GENE_OR_GENE_PRODUCT", 98, 101], ["cellular", "CELL", 113, 121], ["proline-rich P2 domain", "PROTEIN", 4, 26], ["PXXP motif", "PROTEIN", 38, 48], ["RPSAP", "PROTEIN", 50, 55], ["SH3 domains", "PROTEIN", 98, 109], ["cellular proteins", "PROTEIN", 113, 130], ["The proline-rich P2 domain", "TREATMENT", 0, 26], ["a PXXP motif (RPSAP", "TREATMENT", 36, 55], ["cellular proteins", "OBSERVATION", 113, 130]]], ["An intact PSAP motif is also required for viral egress.", [["PSAP", "GENE_OR_GENE_PRODUCT", 10, 14], ["PSAP motif", "DNA", 10, 20], ["An intact PSAP motif", "TREATMENT", 0, 20], ["viral egress", "PROBLEM", 42, 54], ["intact", "OBSERVATION", 3, 9]]], ["Regions of the ORF3 protein experimentally shown to be involved in various interactions are indicated.", [["ORF3", "GENE_OR_GENE_PRODUCT", 15, 19], ["ORF3 protein", "PROTEIN", 15, 27], ["the ORF3 protein", "TEST", 11, 27], ["ORF3 protein experimentally", "OBSERVATION", 15, 42]]], ["(For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.) attenuation of mitochondrial death signaling (Moin et al., 2007) .", [["mitochondrial", "ANATOMY", 144, 157], ["mitochondrial death", "DISEASE", 144, 163], ["mitochondrial", "CELLULAR_COMPONENT", 144, 157], ["mitochondrial death signaling", "PROBLEM", 144, 173], ["mitochondrial death", "OBSERVATION", 144, 163]]], ["Subcellular localization of the ORF3 protein to early and recycling endosomes delayed post-internalization trafficking of the activated epidermal growth factor receptor (EGFR) (Chandra et al., 2008a) .", [["Subcellular", "ANATOMY", 0, 11], ["recycling endosomes", "ANATOMY", 58, 77], ["ORF3", "GENE_OR_GENE_PRODUCT", 32, 36], ["recycling endosomes", "CELLULAR_COMPONENT", 58, 77], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 136, 168], ["EGFR", "GENE_OR_GENE_PRODUCT", 170, 174], ["ORF3 protein", "PROTEIN", 32, 44], ["activated epidermal growth factor receptor", "PROTEIN", 126, 168], ["EGFR", "PROTEIN", 170, 174], ["the ORF3 protein", "TEST", 28, 44]]], ["This was recently found to be true for the hepatocyte growth factor receptor (c-Met) as well, and depended upon the ability of the ORF3 protein to interact with CIN85, a multidomain adaptor protein implicated in the downregulation of receptor tyrosine kinases (Chandra et al., 2010) .", [["tyrosine", "CHEMICAL", 243, 251], ["tyrosine", "CHEMICAL", 243, 251], ["hepatocyte growth factor receptor", "GENE_OR_GENE_PRODUCT", 43, 76], ["c-Met", "GENE_OR_GENE_PRODUCT", 78, 83], ["ORF3", "GENE_OR_GENE_PRODUCT", 131, 135], ["CIN85", "GENE_OR_GENE_PRODUCT", 161, 166], ["receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 234, 259], ["hepatocyte growth factor receptor", "PROTEIN", 43, 76], ["c", "PROTEIN", 78, 79], ["Met", "PROTEIN", 80, 83], ["ORF3 protein", "PROTEIN", 131, 143], ["CIN85", "PROTEIN", 161, 166], ["multidomain adaptor protein", "PROTEIN", 170, 197], ["receptor tyrosine kinases", "PROTEIN", 234, 259], ["CIN85", "TREATMENT", 161, 166], ["a multidomain adaptor protein", "TREATMENT", 168, 197], ["receptor tyrosine kinases", "TREATMENT", 234, 259], ["hepatocyte", "ANATOMY", 43, 53]]], ["In the suggested model, the ORF3 protein binds to CIN85, possibly through the proline-rich P2 domain in the former and SH3 domains in the latter.", [["proline", "CHEMICAL", 78, 85], ["proline", "CHEMICAL", 78, 85], ["ORF3", "GENE_OR_GENE_PRODUCT", 28, 32], ["CIN85", "GENE_OR_GENE_PRODUCT", 50, 55], ["SH3", "GENE_OR_GENE_PRODUCT", 119, 122], ["ORF3 protein", "PROTEIN", 28, 40], ["CIN85", "PROTEIN", 50, 55], ["proline-rich P2 domain", "PROTEIN", 78, 100], ["former and SH3 domains", "PROTEIN", 108, 130], ["the ORF3 protein binds", "TEST", 24, 46], ["SH3 domains", "OBSERVATION", 119, 130]]], ["This competes with formation of the growth factor receptor-Cbl-CIN85 complex, resulting in reduced trafficking of activated growth factors towards the late endosomal/lysosomal compartment where the receptor is degraded (Chandra et al., 2010) .", [["endosomal", "ANATOMY", 156, 165], ["lysosomal compartment", "ANATOMY", 166, 187], ["Cbl", "GENE_OR_GENE_PRODUCT", 59, 62], ["CIN85", "GENE_OR_GENE_PRODUCT", 63, 68], ["late endosomal", "CELLULAR_COMPONENT", 151, 165], ["lysosomal compartment", "CELLULAR_COMPONENT", 166, 187], ["growth factor receptor", "PROTEIN", 36, 58], ["Cbl", "PROTEIN", 59, 62], ["CIN85 complex", "PROTEIN", 63, 76], ["activated growth factors", "PROTEIN", 114, 138], ["activated growth factors", "PROBLEM", 114, 138], ["reduced", "OBSERVATION_MODIFIER", 91, 98], ["activated growth", "OBSERVATION", 114, 130], ["lysosomal compartment", "OBSERVATION", 166, 187]]], ["Such a scenario would prolong endomembrane growth factor signaling and again promote cell survival and proliferation.Protein domains and effects on cellular functionsGrowth factor receptor endocytosis and intracellular trafficking are also required for the nucleo-cytoplasmic transfer of phosphorylated forms of the signal transducer and activator of transcription 3 (STAT3) protein (Bild et al., 2002) .", [["endomembrane", "ANATOMY", 30, 42], ["cell", "ANATOMY", 85, 89], ["cellular", "ANATOMY", 148, 156], ["intracellular", "ANATOMY", 205, 218], ["cytoplasmic", "ANATOMY", 264, 275], ["endomembrane", "CELLULAR_COMPONENT", 30, 42], ["cell", "CELL", 85, 89], ["cellular", "CELL", 148, 156], ["Growth factor receptor", "GENE_OR_GENE_PRODUCT", 166, 188], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 205, 218], ["cytoplasmic", "ORGANISM_SUBSTANCE", 264, 275], ["signal transducer and activator of transcription 3", "GENE_OR_GENE_PRODUCT", 316, 366], ["STAT3", "GENE_OR_GENE_PRODUCT", 368, 373], ["endomembrane growth factor", "PROTEIN", 30, 56], ["Protein domains", "PROTEIN", 117, 132], ["Growth factor receptor", "PROTEIN", 166, 188], ["signal transducer and activator of transcription 3 (STAT3) protein", "PROTEIN", 316, 382], ["endomembrane growth factor signaling", "PROBLEM", 30, 66], ["proliferation", "PROBLEM", 103, 116], ["Protein domains", "PROBLEM", 117, 132], ["cellular functions", "TEST", 148, 166], ["Growth factor receptor endocytosis", "PROBLEM", 166, 200], ["intracellular trafficking", "PROBLEM", 205, 230], ["the nucleo", "TEST", 253, 263], ["cell survival", "OBSERVATION", 85, 98], ["proliferation", "OBSERVATION_MODIFIER", 103, 116], ["cellular functions", "OBSERVATION", 148, 166], ["receptor endocytosis", "OBSERVATION", 180, 200], ["intracellular trafficking", "OBSERVATION", 205, 230]]], ["As a consequence of its effects on EGFR trafficking, reduced levels of phospho-STAT3 (pSTAT3) are found in the nuclei of ORF3-expressing cells (Chandra et al., 2008a) .", [["nuclei", "ANATOMY", 111, 117], ["cells", "ANATOMY", 137, 142], ["phospho", "CHEMICAL", 71, 78], ["EGFR", "GENE_OR_GENE_PRODUCT", 35, 39], ["phospho-STAT3", "GENE_OR_GENE_PRODUCT", 71, 84], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 86, 92], ["nuclei", "CELLULAR_COMPONENT", 111, 117], ["ORF3", "GENE_OR_GENE_PRODUCT", 121, 125], ["cells", "CELL", 137, 142], ["EGFR", "PROTEIN", 35, 39], ["phospho", "PROTEIN", 71, 78], ["STAT3", "PROTEIN", 79, 84], ["pSTAT3", "PROTEIN", 86, 92], ["ORF3-expressing cells", "CELL_LINE", 121, 142], ["EGFR trafficking", "TEST", 35, 51], ["phospho", "TEST", 71, 78], ["nuclei", "ANATOMY", 111, 117]]], ["This leads to decreased transcription of genes involved in the acute phase response, a major determinant of inflammation in the host.", [["inflammation", "DISEASE", 108, 120], ["the acute phase response", "PROBLEM", 59, 83], ["inflammation in the host", "PROBLEM", 108, 132], ["decreased", "OBSERVATION_MODIFIER", 14, 23], ["acute phase", "OBSERVATION_MODIFIER", 63, 74], ["inflammation", "OBSERVATION", 108, 120]]], ["Again, this would create an environment conducive to viral replication.", [["viral replication", "TREATMENT", 53, 70], ["viral replication", "OBSERVATION", 53, 70]]], ["A proteomic study recently showed reduced levels of a number of acute phase proteins, such as serum amyloid P precursor, haptoglobin, hemopexin, alpha-1-acid glycoprotein, glycosylated fibrinogen, reinol binding protein, transthyretin and albumin, in the plasma of hepatitis E patients compared to healthy controls (Taneja et al., 2009; Taneja et al., 2011) .Protein domains and effects on cellular functionsIn a yeast two-hybrid screen for ORF3-interacting cellular proteins, the alpha-1-microglobulin and bikunin precursor protein (AMBP) and its constituents, alpha-1-microglobulin and bikunin (Tyagi et al., 2004 (Tyagi et al., , 2005 were identified.", [["serum", "ANATOMY", 94, 99], ["plasma", "ANATOMY", 255, 261], ["cellular", "ANATOMY", 390, 398], ["cellular", "ANATOMY", 458, 466], ["alpha-1-acid", "CHEMICAL", 145, 157], ["hepatitis E", "DISEASE", 265, 276], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["amyloid P precursor", "GENE_OR_GENE_PRODUCT", 100, 119], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 121, 132], ["hemopexin", "GENE_OR_GENE_PRODUCT", 134, 143], ["alpha-1-acid glycoprotein", "GENE_OR_GENE_PRODUCT", 145, 170], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 185, 195], ["reinol binding protein", "GENE_OR_GENE_PRODUCT", 197, 219], ["transthyretin", "GENE_OR_GENE_PRODUCT", 221, 234], ["albumin", "GENE_OR_GENE_PRODUCT", 239, 246], ["plasma", "ORGANISM_SUBSTANCE", 255, 261], ["hepatitis E", "ORGANISM", 265, 276], ["patients", "ORGANISM", 277, 285], ["cellular", "CELL", 390, 398], ["ORF3", "GENE_OR_GENE_PRODUCT", 441, 445], ["cellular", "CELL", 458, 466], ["alpha-1-microglobulin", "GENE_OR_GENE_PRODUCT", 481, 502], ["bikunin precursor protein", "GENE_OR_GENE_PRODUCT", 507, 532], ["AMBP", "GENE_OR_GENE_PRODUCT", 534, 538], ["alpha-1-microglobulin", "GENE_OR_GENE_PRODUCT", 562, 583], ["bikunin", "SIMPLE_CHEMICAL", 588, 595], ["acute phase proteins", "PROTEIN", 64, 84], ["serum amyloid P precursor", "PROTEIN", 94, 119], ["haptoglobin", "PROTEIN", 121, 132], ["hemopexin", "PROTEIN", 134, 143], ["alpha-1-acid glycoprotein", "PROTEIN", 145, 170], ["glycosylated fibrinogen", "PROTEIN", 172, 195], ["reinol binding protein", "PROTEIN", 197, 219], ["transthyretin", "PROTEIN", 221, 234], ["albumin", "PROTEIN", 239, 246], ["Protein domains", "PROTEIN", 359, 374], ["ORF3", "DNA", 441, 445], ["interacting cellular proteins", "PROTEIN", 446, 475], ["alpha-1-microglobulin", "PROTEIN", 481, 502], ["bikunin precursor protein", "PROTEIN", 507, 532], ["AMBP", "PROTEIN", 534, 538], ["alpha-1", "PROTEIN", 562, 569], ["patients", "SPECIES", 277, 285], ["yeast", "SPECIES", 413, 418], ["hepatitis E", "SPECIES", 265, 276], ["yeast", "SPECIES", 413, 418], ["A proteomic study", "TEST", 0, 17], ["reduced levels", "PROBLEM", 34, 48], ["acute phase proteins", "PROBLEM", 64, 84], ["serum amyloid P precursor", "TEST", 94, 119], ["haptoglobin", "TEST", 121, 132], ["hemopexin", "TEST", 134, 143], ["alpha", "TEST", 145, 150], ["acid glycoprotein", "TEST", 153, 170], ["glycosylated fibrinogen", "TEST", 172, 195], ["reinol binding protein", "TEST", 197, 219], ["transthyretin", "TEST", 221, 234], ["albumin", "TEST", 239, 246], ["hepatitis E patients", "TREATMENT", 265, 285], ["Protein domains", "PROBLEM", 359, 374], ["cellular functions", "TEST", 390, 408], ["ORF3", "TEST", 441, 445], ["the alpha-1-microglobulin", "TEST", 477, 502], ["bikunin precursor protein", "TEST", 507, 532], ["AMBP", "TEST", 534, 538], ["its constituents", "TEST", 544, 560], ["alpha-1", "TEST", 562, 569], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["hepatitis", "OBSERVATION", 265, 274], ["cellular functions", "OBSERVATION", 390, 408]]], ["Increased secretion of alpha-1-microglobulin was also observed from ORF3expressing cells (Surjit et al., 2006) .", [["ORF3expressing cells", "ANATOMY", 68, 88], ["alpha-1-microglobulin", "GENE_OR_GENE_PRODUCT", 23, 44], ["ORF3expressing cells", "CELL", 68, 88], ["alpha-1-microglobulin", "PROTEIN", 23, 44], ["ORF3expressing cells", "CELL_LINE", 68, 88], ["Increased secretion of alpha-1-microglobulin", "PROBLEM", 0, 44], ["secretion", "OBSERVATION_MODIFIER", 10, 19], ["alpha-1-microglobulin", "OBSERVATION_MODIFIER", 23, 44]]], ["This was mediated by the tumor susceptibility gene 101 (Tsg101) protein, a member of the endosomal-sorting complex, which bound the ORF3 protein through a conserved PSAP motif in its P2 domain.", [["tumor", "ANATOMY", 25, 30], ["endosomal", "ANATOMY", 89, 98], ["tumor", "DISEASE", 25, 30], ["tumor", "CANCER", 25, 30], ["Tsg101)", "GENE_OR_GENE_PRODUCT", 56, 63], ["endosomal", "CELLULAR_COMPONENT", 89, 98], ["ORF3", "GENE_OR_GENE_PRODUCT", 132, 136], ["tumor susceptibility gene 101", "DNA", 25, 54], ["Tsg101) protein", "PROTEIN", 56, 71], ["endosomal-sorting complex", "PROTEIN", 89, 114], ["ORF3 protein", "PROTEIN", 132, 144], ["PSAP motif", "DNA", 165, 175], ["P2 domain", "DNA", 183, 192], ["the tumor susceptibility gene", "TEST", 21, 50], ["Tsg", "TEST", 56, 59], ["the ORF3 protein", "TEST", 128, 144], ["tumor", "OBSERVATION", 25, 30]]], ["Since alpha-1-microglobulin is an immunosuppressive protein, this was also proposed to protect virus-infected cells in the liver (Surjit et al., 2006) .", [["cells", "ANATOMY", 110, 115], ["liver", "ANATOMY", 123, 128], ["alpha-1-microglobulin", "GENE_OR_GENE_PRODUCT", 6, 27], ["cells", "CELL", 110, 115], ["liver", "ORGAN", 123, 128], ["alpha-1-microglobulin", "PROTEIN", 6, 27], ["immunosuppressive protein", "PROTEIN", 34, 59], ["virus-infected cells", "CELL_TYPE", 95, 115], ["alpha-1-microglobulin", "TREATMENT", 6, 27], ["an immunosuppressive protein", "TREATMENT", 31, 59], ["virus", "PROBLEM", 95, 100], ["infected cells in the liver", "PROBLEM", 101, 128], ["infected cells", "OBSERVATION", 101, 115], ["liver", "ANATOMY", 123, 128]]], ["In support of these in vitro results, alpha-1-microglobulin levels were significantly higher in the urine of hepatitis E patients compared to acute hepatitis B patients and healthy controls (Taneja et al., 2009; Taneja et al., 2011) .Protein domains and effects on cellular functionsFibrinogen beta chain and hemopexin were also identified from the yeast two-hybrid screen.", [["urine", "ANATOMY", 100, 105], ["cellular", "ANATOMY", 265, 273], ["hepatitis E", "DISEASE", 109, 120], ["acute hepatitis B", "DISEASE", 142, 159], ["alpha-1-microglobulin", "GENE_OR_GENE_PRODUCT", 38, 59], ["urine", "ORGANISM_SUBSTANCE", 100, 105], ["hepatitis E", "ORGANISM", 109, 120], ["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 160, 168], ["cellular", "CELL", 265, 273], ["Fibrinogen beta chain", "GENE_OR_GENE_PRODUCT", 283, 304], ["hemopexin", "GENE_OR_GENE_PRODUCT", 309, 318], ["alpha-1", "PROTEIN", 38, 45], ["Protein domains", "PROTEIN", 234, 249], ["Fibrinogen beta chain", "PROTEIN", 283, 304], ["hemopexin", "PROTEIN", 309, 318], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 160, 168], ["yeast", "SPECIES", 349, 354], ["hepatitis E", "SPECIES", 109, 120], ["hepatitis B", "SPECIES", 148, 159], ["yeast", "SPECIES", 349, 354], ["alpha-1-microglobulin levels", "TEST", 38, 66], ["hepatitis E", "PROBLEM", 109, 120], ["acute hepatitis B patients", "PROBLEM", 142, 168], ["Protein domains", "PROBLEM", 234, 249], ["cellular functions", "TEST", 265, 283], ["Fibrinogen beta chain", "TEST", 283, 304], ["hemopexin", "PROBLEM", 309, 318], ["the yeast", "TEST", 345, 354], ["hepatitis", "OBSERVATION", 109, 118], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["hepatitis", "OBSERVATION", 148, 157], ["cellular functions", "OBSERVATION", 265, 283], ["hemopexin", "OBSERVATION", 309, 318]]], ["Its interaction with the ORF3 protein led to reduced fibrinogen beta secretion from cells; the transcription of alpha, beta and gamma fibrinogen genes, was also reduced in ORF3-expressing cells (Ratra et al., 2009) .", [["cells", "ANATOMY", 84, 89], ["cells", "ANATOMY", 188, 193], ["ORF3", "GENE_OR_GENE_PRODUCT", 25, 29], ["fibrinogen beta", "GENE_OR_GENE_PRODUCT", 53, 68], ["cells", "CELL", 84, 89], ["alpha, beta", "GENE_OR_GENE_PRODUCT", 112, 123], ["gamma fibrinogen", "GENE_OR_GENE_PRODUCT", 128, 144], ["ORF3", "GENE_OR_GENE_PRODUCT", 172, 176], ["cells", "CELL", 188, 193], ["ORF3 protein", "PROTEIN", 25, 37], ["fibrinogen beta", "PROTEIN", 53, 68], ["alpha, beta and gamma fibrinogen genes", "DNA", 112, 150], ["ORF3-expressing cells", "CELL_LINE", 172, 193], ["the ORF3 protein", "TEST", 21, 37], ["reduced fibrinogen beta secretion from cells", "PROBLEM", 45, 89], ["alpha, beta and gamma fibrinogen genes", "TEST", 112, 150], ["reduced", "OBSERVATION_MODIFIER", 45, 52], ["fibrinogen beta secretion", "OBSERVATION", 53, 78], ["alpha", "ANATOMY", 112, 117], ["reduced", "OBSERVATION_MODIFIER", 161, 168]]], ["This is likely to be due to the effects of the ORF3 protein on intracellular trafficking since fibrinogen is also an acute phase protein whose expression is induced by interleukin-6 (IL-6) through the STAT3 transcription factor.", [["intracellular", "ANATOMY", 63, 76], ["ORF3", "GENE_OR_GENE_PRODUCT", 47, 51], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 95, 105], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 168, 181], ["IL-6", "GENE_OR_GENE_PRODUCT", 183, 187], ["STAT3", "GENE_OR_GENE_PRODUCT", 201, 206], ["ORF3 protein", "PROTEIN", 47, 59], ["fibrinogen", "PROTEIN", 95, 105], ["acute phase protein", "PROTEIN", 117, 136], ["interleukin-6 (IL-6", "PROTEIN", 168, 187], ["STAT3 transcription factor", "PROTEIN", 201, 227], ["the ORF3 protein", "PROBLEM", 43, 59], ["intracellular trafficking", "TEST", 63, 88], ["fibrinogen", "TEST", 95, 105], ["an acute phase protein", "PROBLEM", 114, 136], ["interleukin", "TEST", 168, 179], ["likely to be due to", "UNCERTAINTY", 8, 27], ["acute", "OBSERVATION_MODIFIER", 117, 122]]], ["Hemopexin is a heme-binding 60 kDa acute phase plasma glycoprotein, which protects cells from hemoglobin-mediated oxidative damage during intravascular hemolysis.", [["cells", "ANATOMY", 83, 88], ["intravascular", "ANATOMY", 138, 151], ["Hemopexin", "CHEMICAL", 0, 9], ["intravascular hemolysis", "DISEASE", 138, 161], ["Hemopexin", "CHEMICAL", 0, 9], ["heme", "CHEMICAL", 15, 19], ["Hemopexin", "GENE_OR_GENE_PRODUCT", 0, 9], ["heme", "SIMPLE_CHEMICAL", 15, 19], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["cells", "CELL", 83, 88], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 94, 104], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 138, 151], ["Hemopexin", "PROTEIN", 0, 9], ["heme-binding 60 kDa acute phase plasma glycoprotein", "PROTEIN", 15, 66], ["hemoglobin", "PROTEIN", 94, 104], ["Hemopexin", "TEST", 0, 9], ["acute phase plasma glycoprotein", "PROBLEM", 35, 66], ["hemoglobin", "TEST", 94, 104], ["oxidative damage", "PROBLEM", 114, 130], ["intravascular hemolysis", "PROBLEM", 138, 161], ["oxidative damage", "OBSERVATION", 114, 130], ["intravascular hemolysis", "OBSERVATION", 138, 161]]], ["It also plays an important role in iron metabolism, and together with transferrin and haptoglobin is responsible for iron homeostasis.", [["iron", "CHEMICAL", 35, 39], ["iron", "CHEMICAL", 117, 121], ["iron", "CHEMICAL", 35, 39], ["iron", "CHEMICAL", 117, 121], ["iron", "SIMPLE_CHEMICAL", 35, 39], ["transferrin", "GENE_OR_GENE_PRODUCT", 70, 81], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 86, 97], ["iron", "SIMPLE_CHEMICAL", 117, 121], ["transferrin", "PROTEIN", 70, 81], ["haptoglobin", "PROTEIN", 86, 97], ["transferrin", "TEST", 70, 81], ["haptoglobin", "TEST", 86, 97], ["iron homeostasis", "PROBLEM", 117, 133]]], ["The ORF3 protein binds hemopexin through its D2 domain, and this is proposed to aid in viral infection by affecting cellular iron homeostasis (Ratra et al., 2008) .", [["cellular", "ANATOMY", 116, 124], ["viral infection", "DISEASE", 87, 102], ["iron", "CHEMICAL", 125, 129], ["iron", "CHEMICAL", 125, 129], ["ORF3", "GENE_OR_GENE_PRODUCT", 4, 8], ["hemopexin", "GENE_OR_GENE_PRODUCT", 23, 32], ["cellular", "CELL", 116, 124], ["iron", "SIMPLE_CHEMICAL", 125, 129], ["ORF3 protein", "PROTEIN", 4, 16], ["hemopexin", "PROTEIN", 23, 32], ["D2 domain", "PROTEIN", 45, 54], ["The ORF3 protein binds hemopexin", "TEST", 0, 32], ["viral infection", "PROBLEM", 87, 102], ["binds hemopexin", "OBSERVATION", 17, 32], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["infection", "OBSERVATION", 93, 102], ["iron homeostasis", "OBSERVATION", 125, 141]]], ["Reduced levels of hemopexin and haptoglobin have also been observed in the plasma of hepatitis E patients compared to healthy controls (Taneja et al., 2009; Taneja et al., 2011) .Protein domains and effects on cellular functionsA proteomic and transcriptional study of cells stably expressing the ORF3 protein revealed increased expression of many glycolytic enzymes (Moin et al., 2009 ).", [["plasma", "ANATOMY", 75, 81], ["cellular", "ANATOMY", 210, 218], ["cells", "ANATOMY", 269, 274], ["hepatitis E", "DISEASE", 85, 96], ["hemopexin", "GENE_OR_GENE_PRODUCT", 18, 27], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 32, 43], ["plasma", "ORGANISM_SUBSTANCE", 75, 81], ["hepatitis E patients", "ORGANISM", 85, 105], ["cellular", "CELL", 210, 218], ["cells", "CELL", 269, 274], ["ORF3", "GENE_OR_GENE_PRODUCT", 297, 301], ["glycolytic enzymes", "GENE_OR_GENE_PRODUCT", 348, 366], ["hemopexin", "PROTEIN", 18, 27], ["haptoglobin", "PROTEIN", 32, 43], ["Protein domains", "PROTEIN", 179, 194], ["ORF3 protein", "PROTEIN", 297, 309], ["glycolytic enzymes", "PROTEIN", 348, 366], ["patients", "SPECIES", 97, 105], ["hepatitis E", "SPECIES", 85, 96], ["Reduced levels of hemopexin", "PROBLEM", 0, 27], ["haptoglobin", "TEST", 32, 43], ["hepatitis E patients", "TREATMENT", 85, 105], ["Protein domains", "PROBLEM", 179, 194], ["cellular functions", "TEST", 210, 228], ["A proteomic", "TEST", 228, 239], ["transcriptional study of cells", "TEST", 244, 274], ["the ORF3 protein", "TEST", 293, 309], ["many glycolytic enzymes", "TEST", 343, 366], ["hemopexin", "OBSERVATION", 18, 27], ["hepatitis", "OBSERVATION", 85, 94], ["cellular functions", "OBSERVATION", 210, 228], ["increased", "OBSERVATION_MODIFIER", 319, 328]]], ["This was regulated by increased levels of the hypoxia inducible factor-1 (HIF-1) transcription factor, which in turn was brought about by increased stability of the alpha subunit of HIF-1 in ORF3-expressing cells (Moin et al., 2009 ).", [["cells", "ANATOMY", 207, 212], ["hypoxia inducible factor-1", "GENE_OR_GENE_PRODUCT", 46, 72], ["HIF-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["HIF-1", "GENE_OR_GENE_PRODUCT", 182, 187], ["ORF3", "GENE_OR_GENE_PRODUCT", 191, 195], ["cells", "CELL", 207, 212], ["hypoxia inducible factor-1 (HIF-1) transcription factor", "PROTEIN", 46, 101], ["alpha subunit", "PROTEIN", 165, 178], ["HIF-1", "PROTEIN", 182, 187], ["ORF3-expressing cells", "CELL_LINE", 191, 212], ["the hypoxia inducible factor", "PROBLEM", 42, 70], ["transcription factor", "PROBLEM", 81, 101], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["hypoxia", "OBSERVATION", 46, 53], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["stability", "OBSERVATION", 148, 157]]], ["The HIF-1 complex recruits phosphorylated p300/CBP to target gene promoters and the ORF3 protein increased p300/CBP phosphorylation through Erk activation.", [["HIF-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["p300", "GENE_OR_GENE_PRODUCT", 42, 46], ["CBP", "GENE_OR_GENE_PRODUCT", 47, 50], ["ORF3", "GENE_OR_GENE_PRODUCT", 84, 88], ["p300", "GENE_OR_GENE_PRODUCT", 107, 111], ["CBP", "GENE_OR_GENE_PRODUCT", 112, 115], ["Erk", "GENE_OR_GENE_PRODUCT", 140, 143], ["HIF-1 complex", "PROTEIN", 4, 17], ["p300", "PROTEIN", 42, 46], ["CBP", "PROTEIN", 47, 50], ["target gene promoters", "DNA", 54, 75], ["ORF3 protein", "PROTEIN", 84, 96], ["p300", "PROTEIN", 107, 111], ["CBP", "PROTEIN", 112, 115], ["Erk", "PROTEIN", 140, 143], ["CBP", "TREATMENT", 47, 50], ["target gene promoters", "TREATMENT", 54, 75], ["the ORF3 protein", "TEST", 80, 96], ["CBP phosphorylation", "TREATMENT", 112, 131]]], ["Thus, the ORF3 protein appears to use a dual strategy to modulate energy homoestasis.Protein domains and effects on cellular functionsTwo broad roles were predicted for the ORF3 protein in HEV pathogenesis (Chandra et al., 2008b) .", [["cellular", "ANATOMY", 116, 124], ["ORF3", "GENE_OR_GENE_PRODUCT", 10, 14], ["cellular", "CELL", 116, 124], ["ORF3", "GENE_OR_GENE_PRODUCT", 173, 177], ["HEV", "ORGANISM", 189, 192], ["ORF3 protein", "PROTEIN", 10, 22], ["Protein domains", "PROTEIN", 85, 100], ["ORF3 protein", "PROTEIN", 173, 185], ["HEV", "SPECIES", 189, 192], ["the ORF3 protein", "TEST", 6, 22], ["a dual strategy to modulate energy homoestasis", "TREATMENT", 38, 84], ["Protein domains", "PROBLEM", 85, 100], ["cellular functions", "TEST", 116, 134], ["the ORF3 protein", "TEST", 169, 185], ["energy homoestasis", "OBSERVATION", 66, 84], ["cellular functions", "OBSERVATION", 116, 134], ["HEV pathogenesis", "OBSERVATION", 189, 205]]], ["It promotes cell survival and proliferation through Erk activation, extended endomembrane signaling from activated growth factor receptors, and attenuation of mitochondrial death signals.", [["cell", "ANATOMY", 12, 16], ["endomembrane", "ANATOMY", 77, 89], ["mitochondrial", "ANATOMY", 159, 172], ["mitochondrial death", "DISEASE", 159, 178], ["cell", "CELL", 12, 16], ["Erk", "GENE_OR_GENE_PRODUCT", 52, 55], ["endomembrane", "CELLULAR_COMPONENT", 77, 89], ["mitochondrial", "CELLULAR_COMPONENT", 159, 172], ["Erk", "PROTEIN", 52, 55], ["activated growth factor receptors", "PROTEIN", 105, 138], ["Erk activation", "PROBLEM", 52, 66], ["activated growth factor receptors", "PROBLEM", 105, 138], ["mitochondrial death signals", "PROBLEM", 159, 186], ["cell survival", "OBSERVATION", 12, 25], ["proliferation", "OBSERVATION_MODIFIER", 30, 43], ["attenuation", "OBSERVATION_MODIFIER", 144, 155], ["mitochondrial death signals", "OBSERVATION", 159, 186]]], ["The ORF3 protein also dampens innate host responses through an attenuated acute phase response and increased secretion of immunosuppressive factors such as alpha-1-microglobulin.", [["ORF3", "GENE_OR_GENE_PRODUCT", 4, 8], ["alpha-1-microglobulin", "GENE_OR_GENE_PRODUCT", 156, 177], ["ORF3 protein", "PROTEIN", 4, 16], ["immunosuppressive factors", "PROTEIN", 122, 147], ["alpha-1-microglobulin", "PROTEIN", 156, 177], ["The ORF3 protein", "TEST", 0, 16], ["an attenuated acute phase response", "PROBLEM", 60, 94], ["increased secretion of immunosuppressive factors", "PROBLEM", 99, 147], ["alpha-1-microglobulin", "TREATMENT", 156, 177], ["attenuated", "OBSERVATION_MODIFIER", 63, 73], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["phase", "OBSERVATION_MODIFIER", 80, 85], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["secretion", "OBSERVATION_MODIFIER", 109, 118]]], ["A third possible role of regulating cellular energy homeostasis can be added to these.", [["cellular", "ANATOMY", 36, 44], ["cellular", "CELL", 36, 44], ["regulating cellular energy homeostasis", "TREATMENT", 25, 63], ["cellular", "OBSERVATION", 36, 44], ["energy homeostasis", "OBSERVATION", 45, 63]]], ["It must again be emphasized that almost all of these results are based on over-expression of the ORF3 protein in cell lines.", [["cell lines", "ANATOMY", 113, 123], ["ORF3", "GENE_OR_GENE_PRODUCT", 97, 101], ["cell lines", "CELL", 113, 123], ["ORF3 protein", "PROTEIN", 97, 109], ["cell lines", "CELL_LINE", 113, 123], ["the ORF3 protein in cell lines", "TREATMENT", 93, 123], ["cell lines", "OBSERVATION", 113, 123]]], ["They await confirmation in virus infection systems.Role in virion morphogenesis and releaseSome recent studies also suggest a role for the ORF3 protein in virus egress and its association with virions.", [["virion", "ANATOMY", 59, 65], ["virions", "ANATOMY", 193, 200], ["infection", "DISEASE", 33, 42], ["virion", "CELLULAR_COMPONENT", 59, 65], ["ORF3", "GENE_OR_GENE_PRODUCT", 139, 143], ["ORF3 protein", "PROTEIN", 139, 151], ["virus infection systems", "PROBLEM", 27, 50], ["releaseSome recent studies", "TEST", 84, 110], ["the ORF3 protein in virus egress", "PROBLEM", 135, 167], ["virion morphogenesis", "OBSERVATION", 59, 79]]], ["An ORF3-deficient mutant of the infectious cDNA clone pJE03-1760F/wt replicated efficiently in PLC/PRF/5 and A549 cells, but compared to the wild type clone produced less than 1% detectable virus in the culture supernatant .", [["PLC/PRF/5", "ANATOMY", 95, 104], ["A549 cells", "ANATOMY", 109, 119], ["supernatant", "ANATOMY", 211, 222], ["ORF3", "GENE_OR_GENE_PRODUCT", 3, 7], ["pJE03", "GENE_OR_GENE_PRODUCT", 54, 59], ["PLC", "CELL", 95, 98], ["PRF/5", "CELL", 99, 104], ["A549 cells", "CELL", 109, 119], ["clone", "CELL", 151, 156], ["ORF3", "DNA", 3, 7], ["infectious cDNA clone", "DNA", 32, 53], ["pJE03", "DNA", 54, 59], ["1760F", "DNA", 60, 65], ["PLC/PRF/5", "CELL_LINE", 95, 104], ["A549 cells", "CELL_LINE", 109, 119], ["wild type clone", "CELL_LINE", 141, 156], ["An ORF3", "TEST", 0, 7], ["the infectious cDNA clone pJE03", "TEST", 28, 59], ["PLC/PRF", "TEST", 95, 102], ["A549 cells", "PROBLEM", 109, 119], ["the wild type clone", "PROBLEM", 137, 156], ["the culture", "TEST", 199, 210], ["infectious", "OBSERVATION_MODIFIER", 32, 42]]], ["Using an immunocapture PCR assay, the ORF3 protein was found on the surface of cell culture generated HEV, which also showed a lower density than the ORF3deficient virus.", [["surface", "ANATOMY", 68, 75], ["cell culture", "ANATOMY", 79, 91], ["ORF3", "GENE_OR_GENE_PRODUCT", 38, 42], ["surface", "CELLULAR_COMPONENT", 68, 75], ["cell culture", "CELL", 79, 91], ["HEV", "ORGANISM", 102, 105], ["ORF3deficient virus", "ORGANISM", 150, 169], ["ORF3 protein", "PROTEIN", 38, 50], ["HEV", "SPECIES", 102, 105], ["ORF3deficient virus", "SPECIES", 150, 169], ["an immunocapture PCR assay", "TEST", 6, 32], ["the ORF3 protein", "TEST", 34, 50], ["cell culture", "TEST", 79, 91], ["HEV", "TEST", 102, 105], ["a lower density than the ORF3deficient virus", "PROBLEM", 125, 169], ["lower density", "OBSERVATION_MODIFIER", 127, 140], ["ORF3deficient virus", "OBSERVATION", 150, 169]]], ["These observations indicate that the ORF3 protein is The viral particles are concentrated on the surface of target cells through heparin sulfate proteoglycans acting as attachment factors (red wavy lines) (step 1) and subsequently bind a specific yet uncharacterized receptor (step 2), following which the particles are internalized (step 3).", [["surface", "ANATOMY", 97, 104], ["cells", "ANATOMY", 115, 120], ["heparin", "CHEMICAL", 129, 136], ["ORF3", "GENE_OR_GENE_PRODUCT", 37, 41], ["surface", "CELLULAR_COMPONENT", 97, 104], ["cells", "CELL", 115, 120], ["heparin sulfate proteoglycans", "SIMPLE_CHEMICAL", 129, 158], ["ORF3 protein", "PROTEIN", 37, 49], ["target cells", "CELL_TYPE", 108, 120], ["attachment factors", "PROTEIN", 169, 187], ["red wavy lines", "CELL_LINE", 189, 203], ["uncharacterized receptor", "PROTEIN", 251, 275], ["the ORF3 protein", "TEST", 33, 49], ["The viral particles", "PROBLEM", 53, 72], ["heparin sulfate proteoglycans", "TREATMENT", 129, 158], ["red wavy lines", "TREATMENT", 189, 203], ["viral particles", "OBSERVATION", 57, 72]]], ["The virus then uncoats (step 4) to release genomic RNA (red noodles) that is translated in the cytoplasm into nonstructural proteins (step 5).", [["cytoplasm", "ANATOMY", 95, 104], ["cytoplasm", "ORGANISM_SUBSTANCE", 95, 104], ["genomic RNA", "RNA", 43, 54], ["nonstructural proteins", "PROTEIN", 110, 132], ["The virus", "PROBLEM", 0, 9], ["red noodles", "TEST", 56, 67], ["virus", "OBSERVATION", 4, 9], ["genomic RNA", "OBSERVATION", 43, 54]]], ["These nonstructural proteins include the RNA dependent RNA polymerase that replicates the positive sense genomic RNA into negative sense transcripts (purple noodles) (step 6); the latter then act as templates for the synthesis of a 2.2 kb subgenomic RNA (step 7a) as well as full-length positive sense transcripts (step 7b).", [["nonstructural proteins", "PROTEIN", 6, 28], ["RNA dependent RNA polymerase", "PROTEIN", 41, 69], ["positive sense genomic RNA", "RNA", 90, 116], ["negative sense transcripts", "RNA", 122, 148], ["2.2 kb subgenomic RNA", "RNA", 232, 253], ["These nonstructural proteins", "PROBLEM", 0, 28], ["the RNA dependent RNA polymerase", "PROBLEM", 37, 69], ["a 2.2 kb subgenomic RNA", "PROBLEM", 230, 253], ["nonstructural proteins", "OBSERVATION", 6, 28], ["RNA dependent", "OBSERVATION_MODIFIER", 41, 54], ["RNA polymerase", "OBSERVATION", 55, 69], ["positive", "OBSERVATION_MODIFIER", 90, 98], ["sense genomic RNA", "OBSERVATION", 99, 116]]], ["The positive sense subgenomic RNA is translated into ORF2 (blue) and ORF3 (crimson) proteins (step 8).", [["ORF2 (blue)", "GENE_OR_GENE_PRODUCT", 53, 64], ["ORF3 (crimson) proteins", "GENE_OR_GENE_PRODUCT", 69, 92], ["positive sense subgenomic RNA", "RNA", 4, 33], ["ORF2 (blue) and ORF3 (crimson) proteins", "PROTEIN", 53, 92], ["The positive sense subgenomic RNA", "PROBLEM", 0, 33], ["ORF3 (crimson) proteins", "TEST", 69, 92], ["subgenomic RNA", "OBSERVATION", 19, 33]]], ["The ORF2 protein packages the genomic RNA to assemble new virions (step 9) while the ORF3 protein may optimize the host cell environment for viral replication.", [["virions", "ANATOMY", 58, 65], ["cell", "ANATOMY", 120, 124], ["ORF2", "GENE_OR_GENE_PRODUCT", 4, 8], ["ORF3", "GENE_OR_GENE_PRODUCT", 85, 89], ["host cell", "CELL", 115, 124], ["ORF2 protein", "PROTEIN", 4, 16], ["genomic RNA", "RNA", 30, 41], ["ORF3 protein", "PROTEIN", 85, 97], ["The ORF2 protein packages", "TREATMENT", 0, 25], ["the ORF3 protein", "TEST", 81, 97], ["viral replication", "TREATMENT", 141, 158], ["genomic RNA", "OBSERVATION", 30, 41], ["host cell", "OBSERVATION", 115, 124]]], ["The ORF3 protein is also associated with endomembranes (step 10a) or plasma membranes (step 10b) and may aid in viral egress.", [["endomembranes", "ANATOMY", 41, 54], ["plasma membranes", "ANATOMY", 69, 85], ["ORF3", "GENE_OR_GENE_PRODUCT", 4, 8], ["plasma membranes", "CELLULAR_COMPONENT", 69, 85], ["ORF3 protein", "PROTEIN", 4, 16], ["The ORF3 protein", "TEST", 0, 16], ["endomembranes", "PROBLEM", 41, 54], ["plasma membranes", "PROBLEM", 69, 85], ["viral egress", "PROBLEM", 112, 124], ["ORF3 protein", "OBSERVATION", 4, 16], ["viral egress", "OBSERVATION", 112, 124]]], ["Recent studies suggest that mature virions are associated with the ORF3 protein and lipids (step 11), which are subsequently removed through a process that is not understood at present, to resume a fresh infection cycle.", [["virions", "ANATOMY", 35, 42], ["infection", "DISEASE", 204, 213], ["ORF3", "GENE_OR_GENE_PRODUCT", 67, 71], ["ORF3 protein", "PROTEIN", 67, 79], ["Recent studies", "TEST", 0, 14], ["mature virions", "PROBLEM", 28, 42], ["the ORF3 protein", "TEST", 63, 79], ["a fresh infection cycle", "TREATMENT", 196, 219], ["mature", "OBSERVATION_MODIFIER", 28, 34], ["virions", "OBSERVATION", 35, 42], ["infection", "OBSERVATION", 204, 213]]], ["(For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.) important for HEV egress and that it is present on the virion surface, possibly in association with lipids ).", [["surface", "ANATOMY", 191, 198], ["HEV", "ORGANISM", 143, 146], ["lipids", "SIMPLE_CHEMICAL", 229, 235], ["HEV", "SPECIES", 143, 146], ["HEV egress", "PROBLEM", 143, 153]]], ["An earlier study had shown that anti-ORF3 antibodies could capture HEV particles from the serum, but not the feces of hepatitis E patients (Takahashi et al., 2008) .", [["serum", "ANATOMY", 90, 95], ["feces", "ANATOMY", 109, 114], ["hepatitis E", "DISEASE", 118, 129], ["anti-ORF3 antibodies", "GENE_OR_GENE_PRODUCT", 32, 52], ["HEV", "ORGANISM", 67, 70], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["feces", "ORGANISM_SUBDIVISION", 109, 114], ["hepatitis E patients", "ORGANISM", 118, 138], ["anti-ORF3 antibodies", "PROTEIN", 32, 52], ["patients", "SPECIES", 130, 138], ["HEV", "SPECIES", 67, 70], ["An earlier study", "TEST", 0, 16], ["anti-ORF3 antibodies", "TEST", 32, 52], ["HEV particles", "TEST", 67, 80], ["the serum", "TEST", 86, 95]]], ["In this study as well, the serum HEV banded at a lower density compared to fecal HEV, suggesting that the former is associated with lipids, and that this coat is possibly shed during its passage through the enteric system.Role in virion morphogenesis and releaseA genotype 1 HEV was similarly found to replicate in Caco-2 intestinal and Huh-7 hepatoma cells and its egress from these cells depended on the presence of a functional ORF3 protein (Emerson et al., 2010) .", [["serum", "ANATOMY", 27, 32], ["virion", "ANATOMY", 230, 236], ["Caco-2 intestinal", "ANATOMY", 315, 332], ["Huh-7 hepatoma cells", "ANATOMY", 337, 357], ["cells", "ANATOMY", 384, 389], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["HEV", "ORGANISM", 33, 36], ["fecal HEV", "ORGANISM", 75, 84], ["lipids", "SIMPLE_CHEMICAL", 132, 138], ["virion", "CELLULAR_COMPONENT", 230, 236], ["HEV", "ORGANISM", 275, 278], ["Caco-2 intestinal", "CELL", 315, 332], ["Huh-7 hepatoma cells", "CELL", 337, 357], ["cells", "CELL", 384, 389], ["ORF3", "GENE_OR_GENE_PRODUCT", 431, 435], ["Caco-2 intestinal and Huh-7 hepatoma cells", "CELL_LINE", 315, 357], ["ORF3 protein", "PROTEIN", 431, 443], ["HEV", "SPECIES", 33, 36], ["HEV", "SPECIES", 81, 84], ["HEV", "SPECIES", 275, 278], ["Huh-7", "SPECIES", 337, 342], ["this study", "TEST", 3, 13], ["the serum HEV banded", "PROBLEM", 23, 43], ["a lower density", "PROBLEM", 47, 62], ["fecal HEV", "TEST", 75, 84], ["lipids", "TREATMENT", 132, 138], ["virion morphogenesis", "TREATMENT", 230, 250], ["releaseA genotype 1 HEV", "PROBLEM", 255, 278], ["Caco", "TEST", 315, 319], ["Huh", "TEST", 337, 340], ["hepatoma cells", "PROBLEM", 343, 357], ["banded", "OBSERVATION_MODIFIER", 37, 43], ["lower density", "OBSERVATION_MODIFIER", 49, 62], ["fecal", "ANATOMY", 75, 80], ["HEV", "OBSERVATION", 81, 84], ["enteric system", "ANATOMY", 207, 221], ["virion morphogenesis", "OBSERVATION", 230, 250], ["intestinal", "ANATOMY", 322, 332], ["hepatoma cells", "OBSERVATION", 343, 357]]], ["In the polarized Caco-2 cells, the ORF3 protein accumulated at the apical membrane and virus egress also took place from this surface.", [["Caco-2 cells", "ANATOMY", 17, 29], ["apical membrane", "ANATOMY", 67, 82], ["surface", "ANATOMY", 126, 133], ["Caco-2 cells", "CELL", 17, 29], ["ORF3", "GENE_OR_GENE_PRODUCT", 35, 39], ["apical membrane", "CELLULAR_COMPONENT", 67, 82], ["surface", "CELLULAR_COMPONENT", 126, 133], ["polarized Caco-2 cells", "CELL_LINE", 7, 29], ["ORF3 protein", "PROTEIN", 35, 47], ["the ORF3 protein", "TEST", 31, 47], ["virus egress", "PROBLEM", 87, 99], ["2 cells", "ANATOMY_MODIFIER", 22, 29], ["ORF3", "OBSERVATION", 35, 39], ["protein accumulated", "OBSERVATION", 40, 59], ["apical", "ANATOMY_MODIFIER", 67, 73], ["membrane", "ANATOMY_MODIFIER", 74, 82], ["virus egress", "OBSERVATION", 87, 99]]], ["The PXXP motif in the P2 domain of the ORF3 protein was found to be important for virus egress, but not for its accumulation at the apical end.", [["apical end", "ANATOMY", 132, 142], ["PXXP", "GENE_OR_GENE_PRODUCT", 4, 8], ["ORF3", "GENE_OR_GENE_PRODUCT", 39, 43], ["PXXP motif", "DNA", 4, 14], ["P2 domain", "DNA", 22, 31], ["ORF3 protein", "PROTEIN", 39, 51], ["The PXXP motif", "TEST", 0, 14], ["the ORF3 protein", "TEST", 35, 51], ["virus egress", "PROBLEM", 82, 94], ["apical", "ANATOMY_MODIFIER", 132, 138]]], ["One of the mutant viruses showed no infection following intrahepatic inoculation in macaques, but another was infectious and the recovered virus was found to have completely reverted to a wild type ORF3 sequence.", [["intrahepatic", "ANATOMY", 56, 68], ["infection", "DISEASE", 36, 45], ["macaques", "ORGANISM", 84, 92], ["ORF3", "GENE_OR_GENE_PRODUCT", 198, 202], ["wild type ORF3 sequence", "DNA", 188, 211], ["the mutant viruses", "PROBLEM", 7, 25], ["infection", "PROBLEM", 36, 45], ["intrahepatic inoculation in macaques", "PROBLEM", 56, 92], ["infectious", "PROBLEM", 110, 120], ["the recovered virus", "PROBLEM", 125, 144], ["a wild type ORF3 sequence", "PROBLEM", 186, 211], ["viruses", "OBSERVATION", 18, 25], ["no", "UNCERTAINTY", 33, 35], ["infection", "OBSERVATION", 36, 45], ["intrahepatic", "ANATOMY", 56, 68], ["inoculation", "OBSERVATION", 69, 80], ["infectious", "OBSERVATION", 110, 120]]], ["These results support previous observations of the ORF3 requirement for infection (Graff et al., 2005) .", [["infection", "DISEASE", 72, 81], ["ORF3", "GENE_OR_GENE_PRODUCT", 51, 55], ["ORF3", "DNA", 51, 55], ["the ORF3 requirement", "PROBLEM", 47, 67], ["infection", "PROBLEM", 72, 81]]], ["In this study also, the ORF3 protein, in association with lipids, was found to coat the virion surface.Role in virion morphogenesis and releaseA recent study shows the requirement of an intact PSAP motif within the P2 domain for the formation of membrane associated HEV particles with the ORF3 protein on their surface .", [["surface", "ANATOMY", 95, 102], ["virion", "ANATOMY", 111, 117], ["membrane", "ANATOMY", 246, 254], ["surface", "ANATOMY", 311, 318], ["ORF3", "GENE_OR_GENE_PRODUCT", 24, 28], ["lipids", "SIMPLE_CHEMICAL", 58, 64], ["virion surface", "CELLULAR_COMPONENT", 88, 102], ["virion", "CELLULAR_COMPONENT", 111, 117], ["PSAP", "GENE_OR_GENE_PRODUCT", 193, 197], ["membrane", "CELLULAR_COMPONENT", 246, 254], ["ORF3", "GENE_OR_GENE_PRODUCT", 289, 293], ["surface", "CELLULAR_COMPONENT", 311, 318], ["ORF3 protein", "PROTEIN", 24, 36], ["PSAP motif", "DNA", 193, 203], ["P2 domain", "DNA", 215, 224], ["ORF3 protein", "PROTEIN", 289, 301], ["this study", "TEST", 3, 13], ["the ORF3 protein", "TEST", 20, 36], ["lipids", "TREATMENT", 58, 64], ["A recent study", "TEST", 143, 157], ["an intact PSAP motif within the P2 domain", "TREATMENT", 183, 224], ["membrane associated HEV particles", "PROBLEM", 246, 279], ["the ORF3 protein", "TEST", 285, 301], ["virion", "OBSERVATION_MODIFIER", 88, 94], ["surface", "OBSERVATION_MODIFIER", 95, 102], ["virion morphogenesis", "OBSERVATION", 111, 131], ["HEV particles", "OBSERVATION", 266, 279]]], ["Though neither this nor the Emerson et al. (2010) study implicated the role of any host protein in ORF3-mediated HEV release, the requirement of the PSAP motif suggests a possible role for Tsg101, which was earlier shown to bind the ORF3 protein (Surjit et al., 2006) .", [["ORF3", "GENE_OR_GENE_PRODUCT", 99, 103], ["HEV", "ORGANISM", 113, 116], ["PSAP", "GENE_OR_GENE_PRODUCT", 149, 153], ["Tsg101", "GENE_OR_GENE_PRODUCT", 189, 195], ["ORF3", "GENE_OR_GENE_PRODUCT", 233, 237], ["ORF3", "DNA", 99, 103], ["PSAP motif", "DNA", 149, 159], ["Tsg101", "PROTEIN", 189, 195], ["ORF3 protein", "PROTEIN", 233, 245], ["the PSAP motif", "TEST", 145, 159], ["Tsg", "TEST", 189, 192]]], ["Several RNA viruses bear proline-rich sequences in their 'late domains', which are required for viral budding.", [["proline", "CHEMICAL", 25, 32], ["proline", "CHEMICAL", 25, 32], ["late domains'", "CELLULAR_COMPONENT", 58, 71], ["proline-rich sequences", "PROTEIN", 25, 47], ["Several RNA viruses bear proline", "PROBLEM", 0, 32], ["viral budding", "PROBLEM", 96, 109], ["viruses", "OBSERVATION", 12, 19]]], ["These include P(S/T)AP and PPXY (X, any amino acid) motifs, which hijack host proteins in the vacuolar protein sorting (VPS) pathway.", [["vacuolar", "ANATOMY", 94, 102], ["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 40, 50], ["T)AP", "GENE_OR_GENE_PRODUCT", 18, 22], ["amino acid", "AMINO_ACID", 40, 50], ["vacuolar protein sorting", "GENE_OR_GENE_PRODUCT", 94, 118], ["VPS", "GENE_OR_GENE_PRODUCT", 120, 123], ["PPXY (X, any amino acid) motifs", "DNA", 27, 58], ["host proteins", "PROTEIN", 73, 86], ["vacuolar protein", "PROTEIN", 94, 110], ["VPS", "PROTEIN", 120, 123], ["AP and PPXY", "TEST", 20, 31], ["any amino acid) motifs", "TREATMENT", 36, 58]]], ["This pathway gives rise to multivesicular bodies (MVBs), which is topologically identical to virus budding (Chen and Lamb, 2008) .", [["multivesicular bodies", "ANATOMY", 27, 48], ["MVBs", "ANATOMY", 50, 54], ["multivesicular bodies", "CELLULAR_COMPONENT", 27, 48], ["MVBs", "CELLULAR_COMPONENT", 50, 54], ["multivesicular bodies", "OBSERVATION", 27, 48]]], ["Viral 'late domains' interact with members of the VPS pathway, and redirect the complexes to the site of virus budding on the plasma membrane (Chen and Lamb, 2008) .", [["plasma membrane", "ANATOMY", 126, 141], ["VPS", "GENE_OR_GENE_PRODUCT", 50, 53], ["plasma membrane", "CELLULAR_COMPONENT", 126, 141], ["VPS", "PROTEIN", 50, 53], ["Viral 'late domains'", "PROBLEM", 0, 20], ["the VPS pathway", "TREATMENT", 46, 61], ["virus budding", "PROBLEM", 105, 118]]], ["Though HEV is a non-enveloped virus, its association with lipids, subcellular localization of the ORF3 protein to endosomes (Chandra et al., 2008a ) and a requirement for its PSAP motif in viral egress suggests that HEV follows the VPS pathway for its release from infected cells (Fig. 5) .HEV life cycle and genome replicationThe life cycle of HEV is poorly understood, largely because of the non-availability of efficient in vitro culture methods or small animal models of infection.", [["subcellular", "ANATOMY", 66, 77], ["endosomes", "ANATOMY", 114, 123], ["cells", "ANATOMY", 274, 279], ["infection", "DISEASE", 475, 484], ["HEV", "ORGANISM", 7, 10], ["lipids", "SIMPLE_CHEMICAL", 58, 64], ["ORF3", "GENE_OR_GENE_PRODUCT", 98, 102], ["endosomes", "CELLULAR_COMPONENT", 114, 123], ["PSAP", "GENE_OR_GENE_PRODUCT", 175, 179], ["HEV", "ORGANISM", 216, 219], ["VPS", "GENE_OR_GENE_PRODUCT", 232, 235], ["cells", "CELL", 274, 279], ["HEV", "ORGANISM", 345, 348], ["ORF3 protein", "PROTEIN", 98, 110], ["PSAP motif", "DNA", 175, 185], ["VPS", "PROTEIN", 232, 235], ["infected cells", "CELL_TYPE", 265, 279], ["HEV", "SPECIES", 7, 10], ["HEV", "SPECIES", 216, 219], ["HEV", "SPECIES", 290, 293], ["HEV", "SPECIES", 345, 348], ["a non-enveloped virus", "PROBLEM", 14, 35], ["lipids", "TREATMENT", 58, 64], ["its PSAP motif", "TREATMENT", 171, 185], ["infected cells", "PROBLEM", 265, 279], ["HEV life cycle", "TREATMENT", 290, 304], ["genome replication", "TREATMENT", 309, 327], ["efficient in vitro culture methods", "PROBLEM", 414, 448], ["small animal models of infection", "PROBLEM", 452, 484], ["non-enveloped", "OBSERVATION_MODIFIER", 16, 29], ["virus", "OBSERVATION", 30, 35], ["infected cells", "OBSERVATION", 265, 279], ["small", "OBSERVATION_MODIFIER", 452, 457], ["infection", "OBSERVATION", 475, 484]]], ["The original view of the HEV life cycle , which was based primarily on its genome analysis and analogy to other positive-strand RNA viruses, is still broadly relevant.", [["HEV", "ORGANISM", 25, 28], ["its genome analysis", "TEST", 71, 90], ["other positive-strand RNA viruses", "PROBLEM", 106, 139], ["strand RNA viruses", "OBSERVATION", 121, 139]]], ["However, based on in vitro expression and replicon studies, some details have now begun to emerge.", [["replicon studies", "TEST", 42, 58]]], ["The basic model and additions to it are shown in Fig. 5 .HEV life cycle and genome replicationVarious transformed cell lines are permissive for HEV infection and virion production.", [["cell lines", "ANATOMY", 114, 124], ["HEV infection", "DISEASE", 144, 157], ["cell lines", "CELL", 114, 124], ["HEV", "ORGANISM", 144, 147], ["transformed cell lines", "CELL_LINE", 102, 124], ["HEV", "SPECIES", 57, 60], ["HEV", "SPECIES", 144, 147], ["HEV life cycle", "TREATMENT", 57, 71], ["genome replication", "TREATMENT", 76, 94], ["Various transformed cell lines", "TREATMENT", 94, 124], ["HEV infection", "PROBLEM", 144, 157], ["virion production", "PROBLEM", 162, 179], ["cell lines", "OBSERVATION", 114, 124], ["infection", "OBSERVATION", 148, 157], ["virion production", "OBSERVATION", 162, 179]]], ["These include hepatic cell lines such as Huh7, PLC/PRF/5 and HepG2, the lung carcinoma A549 cell line and the colon carcinoma Caco-2 cell line.", [["hepatic cell lines", "ANATOMY", 14, 32], ["Huh7", "ANATOMY", 41, 45], ["PLC/PRF/5", "ANATOMY", 47, 56], ["HepG2", "ANATOMY", 61, 66], ["lung carcinoma A549 cell line", "ANATOMY", 72, 101], ["colon carcinoma Caco-2 cell line", "ANATOMY", 110, 142], ["lung carcinoma", "DISEASE", 72, 86], ["colon carcinoma", "DISEASE", 110, 125], ["hepatic cell lines", "CELL", 14, 32], ["Huh7", "CELL", 41, 45], ["PLC", "CELL", 47, 50], ["PRF/5", "CELL", 51, 56], ["HepG2", "CELL", 61, 66], ["lung carcinoma A549 cell line", "CELL", 72, 101], ["colon carcinoma Caco-2 cell line", "CELL", 110, 142], ["hepatic cell lines", "CELL_LINE", 14, 32], ["Huh7", "CELL_LINE", 41, 45], ["PLC/PRF/5", "CELL_LINE", 47, 56], ["HepG2", "CELL_LINE", 61, 66], ["lung carcinoma A549 cell line", "CELL_LINE", 72, 101], ["colon carcinoma Caco-2 cell line", "CELL_LINE", 110, 142], ["hepatic cell lines", "TREATMENT", 14, 32], ["Huh7, PLC/PRF", "TREATMENT", 41, 54], ["HepG2", "TREATMENT", 61, 66], ["the lung carcinoma", "PROBLEM", 68, 86], ["A549 cell line", "TREATMENT", 87, 101], ["the colon carcinoma", "PROBLEM", 106, 125], ["Caco-2 cell line", "TREATMENT", 126, 142], ["hepatic", "ANATOMY", 14, 21], ["cell lines", "OBSERVATION", 22, 32], ["HepG2", "ANATOMY", 61, 66], ["lung", "ANATOMY", 72, 76], ["carcinoma", "OBSERVATION", 77, 86], ["A549 cell line", "OBSERVATION", 87, 101], ["colon", "ANATOMY", 110, 115], ["carcinoma", "OBSERVATION", 116, 125], ["2 cell line", "OBSERVATION", 131, 142]]], ["The binding and entry of HEV is poorly understood.", [["HEV", "ORGANISM", 25, 28], ["HEV", "SPECIES", 25, 28]]], ["No cellular receptor for HEV has been identified, but HSPGs appear to be required as attachment factors ).", [["cellular", "ANATOMY", 3, 11], ["cellular", "CELL", 3, 11], ["HEV", "ORGANISM", 25, 28], ["HSPGs", "GENE_OR_GENE_PRODUCT", 54, 59], ["cellular receptor", "PROTEIN", 3, 20], ["HSPGs", "PROTEIN", 54, 59], ["attachment factors", "PROTEIN", 85, 103], ["HEV", "SPECIES", 25, 28], ["HEV", "PROBLEM", 25, 28]]], ["The intracellular trafficking following entry is also poorly understood; HSP90 and tubulin appear to be involved in this process (Zheng et al., 2010) .", [["intracellular", "ANATOMY", 4, 17], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["HSP90", "GENE_OR_GENE_PRODUCT", 73, 78], ["tubulin", "GENE_OR_GENE_PRODUCT", 83, 90], ["HSP90", "PROTEIN", 73, 78], ["tubulin", "PROTEIN", 83, 90], ["HSP90", "TEST", 73, 78], ["intracellular trafficking", "OBSERVATION", 4, 29]]], ["The location and mechanism of uncoating to release viral RNA is also not known.HEV life cycle and genome replicationOnce viral RNA is released in the cytosol it is translated directly into the ORF1 polyprotein, as is the case with all positive-sense RNA viruses.", [["cytosol", "ANATOMY", 150, 157], ["cytosol", "CELLULAR_COMPONENT", 150, 157], ["ORF1", "GENE_OR_GENE_PRODUCT", 193, 197], ["viral RNA", "RNA", 51, 60], ["viral RNA", "RNA", 121, 130], ["ORF1 polyprotein", "DNA", 193, 209], ["HEV", "SPECIES", 79, 82], ["uncoating to release viral RNA", "PROBLEM", 30, 60], ["HEV life cycle", "TREATMENT", 79, 93], ["genome replication", "TREATMENT", 98, 116], ["all positive-sense RNA viruses", "PROBLEM", 231, 261], ["viral RNA", "OBSERVATION", 51, 60], ["viral RNA", "OBSERVATION", 121, 130], ["RNA viruses", "OBSERVATION", 250, 261]]], ["It is not clear whether the polyprotein is processed into individual functional units (see Section 3.1).", [["the polyprotein", "PROBLEM", 24, 39], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["polyprotein", "OBSERVATION", 28, 39]]], ["However, the regions predicted to encode viral methyltransferase, helicase and replicase produce functionally active proteins when expressed in heterologous systems (see Sections 3.", [["viral methyltransferase", "GENE_OR_GENE_PRODUCT", 41, 64], ["viral methyltransferase", "PROTEIN", 41, 64], ["helicase and replicase", "PROTEIN", 66, 88], ["viral methyltransferase", "TREATMENT", 41, 64], ["functionally active proteins", "PROBLEM", 97, 125], ["viral methyltransferase", "OBSERVATION", 41, 64], ["active", "OBSERVATION_MODIFIER", 110, 116]]], ["The genomic RNA would replicate into negative-sense RNA intermediates, which have been detected in replicon-transfected cells as well as in the livers of experimentally infected macaques (Nanda et al., 1994) and pigs (Meng et al., 1998) .", [["cells", "ANATOMY", 120, 125], ["livers", "ANATOMY", 144, 150], ["cells", "CELL", 120, 125], ["livers", "ORGAN", 144, 150], ["macaques", "ORGANISM", 178, 186], ["pigs", "ORGANISM", 212, 216], ["genomic RNA", "RNA", 4, 15], ["replicon-transfected cells", "CELL_LINE", 99, 125], ["macaques", "SPECIES", 178, 186], ["pigs", "SPECIES", 212, 216], ["The genomic RNA", "TEST", 0, 15], ["genomic RNA", "OBSERVATION", 4, 15], ["transfected cells", "OBSERVATION", 108, 125], ["livers", "ANATOMY", 144, 150]]], ["These would serve as templates for the synthesis of genomic as well as subgenomic positive-sense RNAs, of which the latter are translated into the ORF2 (capsid) and ORF3 proteins (Graff et al., 2006; Huang et al., 2007; Ichiyama et al., 2009) .", [["ORF2", "GENE_OR_GENE_PRODUCT", 147, 151], ["ORF3", "GENE_OR_GENE_PRODUCT", 165, 169], ["subgenomic positive-sense RNAs", "RNA", 71, 101], ["ORF2", "DNA", 147, 151], ["capsid", "PROTEIN", 153, 159], ["ORF3 proteins", "PROTEIN", 165, 178], ["the synthesis of genomic", "PROBLEM", 35, 59], ["subgenomic positive-sense RNAs", "PROBLEM", 71, 101]]], ["The ORF2 protein packages the genomic positive-sense RNA into progeny virions (see Section 3.2.2), and recent evidence suggests that the ORF3 protein together with lipids coats this particle, possibly during the budding process (see Section 3.3.3).HEV life cycle and genome replicationIt is believed that the primary site of HEV replication is the liver, with hepatocytes being the most likely cell type.", [["virions", "ANATOMY", 70, 77], ["liver", "ANATOMY", 348, 353], ["hepatocytes", "ANATOMY", 360, 371], ["cell", "ANATOMY", 394, 398], ["ORF2", "GENE_OR_GENE_PRODUCT", 4, 8], ["ORF3", "GENE_OR_GENE_PRODUCT", 137, 141], ["HEV", "ORGANISM", 325, 328], ["liver", "ORGAN", 348, 353], ["hepatocytes", "CELL", 360, 371], ["cell type", "CELL", 394, 403], ["ORF2 protein", "PROTEIN", 4, 16], ["genomic positive-sense RNA", "RNA", 30, 56], ["ORF3 protein", "PROTEIN", 137, 149], ["hepatocytes", "CELL_TYPE", 360, 371], ["HEV", "SPECIES", 248, 251], ["HEV", "SPECIES", 325, 328], ["The ORF2 protein", "TEST", 0, 16], ["the ORF3 protein", "TEST", 133, 149], ["lipids coats this particle", "PROBLEM", 164, 190], ["HEV life cycle", "TREATMENT", 248, 262], ["genome replication", "TREATMENT", 267, 285], ["HEV replication", "TREATMENT", 325, 340], ["hepatocytes", "PROBLEM", 360, 371], ["positive", "OBSERVATION_MODIFIER", 38, 46], ["HEV replication", "OBSERVATION", 325, 340], ["liver", "ANATOMY", 348, 353], ["hepatocytes", "ANATOMY", 360, 371], ["most likely", "UNCERTAINTY", 382, 393], ["cell type", "OBSERVATION", 394, 403]]], ["However, in vitro results also support infection and replication in non-hepatic cell types such as A549 lung carcinoma cells and in Caco-2 colon carcinoma cells.", [["non-hepatic cell", "ANATOMY", 68, 84], ["A549 lung carcinoma cells", "ANATOMY", 99, 124], ["Caco-2 colon carcinoma cells", "ANATOMY", 132, 160], ["infection", "DISEASE", 39, 48], ["lung carcinoma", "DISEASE", 104, 118], ["colon carcinoma", "DISEASE", 139, 154], ["non-hepatic cell", "CELL", 68, 84], ["A549 lung carcinoma cells", "CELL", 99, 124], ["Caco-2 colon carcinoma cells", "CELL", 132, 160], ["A549 lung carcinoma cells", "CELL_LINE", 99, 124], ["Caco-2 colon carcinoma cells", "CELL_LINE", 132, 160], ["infection", "PROBLEM", 39, 48], ["non-hepatic cell types", "PROBLEM", 68, 90], ["A549 lung carcinoma cells", "PROBLEM", 99, 124], ["Caco-2 colon carcinoma cells", "PROBLEM", 132, 160], ["infection", "OBSERVATION", 39, 48], ["non-hepatic", "ANATOMY", 68, 79], ["cell types", "OBSERVATION", 80, 90], ["A549", "OBSERVATION", 99, 103], ["lung", "ANATOMY", 104, 108], ["carcinoma cells", "OBSERVATION", 109, 124], ["Caco", "OBSERVATION_MODIFIER", 132, 136], ["2", "ANATOMY_MODIFIER", 137, 138], ["colon", "ANATOMY", 139, 144], ["carcinoma cells", "OBSERVATION", 145, 160]]], ["In pigs experimentally infected with swine HEV, while positive-sense viral RNA was detected in almost all tissues at some point during the infection, negative-sense replicative RNA intermediates were detected primarily in the small intestine, lymph node, colon and liver (Williams et al., 2001) .", [["tissues", "ANATOMY", 106, 113], ["small intestine", "ANATOMY", 226, 241], ["lymph node", "ANATOMY", 243, 253], ["colon", "ANATOMY", 255, 260], ["liver", "ANATOMY", 265, 270], ["infection", "DISEASE", 139, 148], ["pigs", "ORGANISM", 3, 7], ["swine HEV", "ORGANISM", 37, 46], ["tissues", "TISSUE", 106, 113], ["intestine", "ORGAN", 232, 241], ["lymph node", "MULTI-TISSUE_STRUCTURE", 243, 253], ["colon", "ORGAN", 255, 260], ["liver", "ORGAN", 265, 270], ["viral RNA", "RNA", 69, 78], ["pigs", "SPECIES", 3, 7], ["swine", "SPECIES", 37, 42], ["pigs", "SPECIES", 3, 7], ["swine", "SPECIES", 37, 42], ["HEV", "SPECIES", 43, 46], ["swine HEV", "PROBLEM", 37, 46], ["sense viral RNA", "PROBLEM", 63, 78], ["the infection", "PROBLEM", 135, 148], ["sense replicative RNA intermediates", "PROBLEM", 159, 194], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["viral RNA", "OBSERVATION", 69, 78], ["infection", "OBSERVATION", 139, 148], ["small intestine", "ANATOMY", 226, 241], ["lymph node", "OBSERVATION", 243, 253], ["colon", "ANATOMY", 255, 260], ["liver", "ANATOMY", 265, 270]]], ["In a recent report from hepatitis E patients, HEV RNA was detected in peripheral blood mononuclear cells, but there was no evidence for viral replication in this compartment (Ippagunta et al., 2010) .Potential targets and antiviral agentsVarious steps in the HEV life cycle can be potential targets for the development of antiviral drugs.", [["peripheral blood mononuclear cells", "ANATOMY", 70, 104], ["hepatitis E", "DISEASE", 24, 35], ["hepatitis E", "ORGANISM", 24, 35], ["patients", "ORGANISM", 36, 44], ["HEV", "ORGANISM", 46, 49], ["peripheral blood mononuclear cells", "CELL", 70, 104], ["HEV", "ORGANISM", 259, 262], ["HEV RNA", "RNA", 46, 53], ["peripheral blood mononuclear cells", "CELL_TYPE", 70, 104], ["patients", "SPECIES", 36, 44], ["hepatitis E", "SPECIES", 24, 35], ["HEV", "SPECIES", 46, 49], ["HEV", "SPECIES", 259, 262], ["HEV RNA", "TEST", 46, 53], ["peripheral blood mononuclear cells", "TEST", 70, 104], ["viral replication", "PROBLEM", 136, 153], ["antiviral agents", "TREATMENT", 222, 238], ["antiviral drugs", "TREATMENT", 322, 337], ["peripheral", "ANATOMY_MODIFIER", 70, 80], ["blood", "ANATOMY", 81, 86], ["mononuclear cells", "OBSERVATION", 87, 104], ["no evidence for", "UNCERTAINTY", 120, 135], ["viral replication", "OBSERVATION", 136, 153], ["antiviral agents", "OBSERVATION", 222, 238], ["antiviral drugs", "OBSERVATION", 322, 337]]], ["The methyltransferase and guanyltransferase activities in the ORF1 protein (see Section 3.1.1) are strictly virus-specific and thus good targets for antiviral development (Magden et al., 2001) .", [["guanyltransferase", "GENE_OR_GENE_PRODUCT", 26, 43], ["ORF1", "GENE_OR_GENE_PRODUCT", 62, 66], ["see Section 3.1.1", "GENE_OR_GENE_PRODUCT", 76, 93], ["methyltransferase", "PROTEIN", 4, 21], ["guanyltransferase", "PROTEIN", 26, 43], ["ORF1 protein", "PROTEIN", 62, 74], ["The methyltransferase and guanyltransferase activities", "TREATMENT", 0, 54], ["the ORF1 protein", "TEST", 58, 74], ["strictly virus", "PROBLEM", 99, 113]]], ["The RNA helicase of HEV has been biochemically characterized and is essential for replication of the viral RNA genome (Karpe and Lole, 2010a) , but it is not clear how distinct it is from human helicases to be a potential drug target.", [["HEV", "ORGANISM", 20, 23], ["human", "ORGANISM", 188, 193], ["RNA helicase", "PROTEIN", 4, 16], ["viral RNA genome", "DNA", 101, 117], ["human helicases", "PROTEIN", 188, 203], ["human", "SPECIES", 188, 193], ["HEV", "SPECIES", 20, 23], ["human", "SPECIES", 188, 193], ["The RNA helicase of HEV", "PROBLEM", 0, 23], ["essential for", "UNCERTAINTY", 68, 81], ["viral RNA genome", "OBSERVATION", 101, 117]]], ["The HEV RdRp expressed in E. coli was shown to bind the 3 end of the viral RNA genome (Agrawal et al., 2001) , but its biochemical activity has so far not been characterized.", [["HEV RdRp", "ORGANISM", 4, 12], ["E. coli", "ORGANISM", 26, 33], ["HEV RdRp", "PROTEIN", 4, 12], ["viral RNA genome", "DNA", 69, 85], ["E. coli", "SPECIES", 26, 33], ["HEV", "SPECIES", 4, 7], ["E. coli", "SPECIES", 26, 33], ["The HEV RdRp", "TREATMENT", 0, 12], ["E. coli", "PROBLEM", 26, 33], ["the viral RNA genome", "PROBLEM", 65, 85], ["HEV RdRp", "OBSERVATION", 4, 12], ["E. coli", "OBSERVATION", 26, 33], ["viral RNA genome", "OBSERVATION", 69, 85]]], ["Since the RdRp is unique to RNA viruses, it would again be a good drug target, and perhaps pan-viral inhibitors can be explored against this target.Potential targets and antiviral agentsInterference with HEV RNA replication has been attempted using ribozymes and small interfering RNAs.", [["RdRp", "GENE_OR_GENE_PRODUCT", 10, 14], ["HEV", "ORGANISM", 204, 207], ["RdRp", "PROTEIN", 10, 14], ["small interfering RNAs", "RNA", 263, 285], ["HEV", "SPECIES", 204, 207], ["the RdRp", "PROBLEM", 6, 14], ["RNA viruses", "PROBLEM", 28, 39], ["pan-viral inhibitors", "TREATMENT", 91, 111], ["antiviral agents", "TREATMENT", 170, 186], ["HEV RNA replication", "TREATMENT", 204, 223], ["ribozymes", "TREATMENT", 249, 258], ["small interfering RNAs", "PROBLEM", 263, 285], ["RNA viruses", "OBSERVATION", 28, 39], ["antiviral agents", "OBSERVATION", 170, 186], ["RNA replication", "OBSERVATION", 208, 223], ["small", "OBSERVATION_MODIFIER", 263, 268], ["interfering RNAs", "OBSERVATION", 269, 285]]], ["Mono-and dihammerhead ribozymes designed against the 3 end of the HEV genomic RNA were shown to inhibit expression from a reporter construct in HepG2 cells (Sriram et al., 2003) .", [["HepG2 cells", "ANATOMY", 144, 155], ["HEV", "ORGANISM", 66, 69], ["HepG2 cells", "CELL", 144, 155], ["HEV genomic RNA", "RNA", 66, 81], ["HepG2 cells", "CELL_LINE", 144, 155], ["HEV", "SPECIES", 66, 69], ["Mono", "TEST", 0, 4], ["dihammerhead ribozymes", "TREATMENT", 9, 31], ["the HEV genomic RNA", "PROBLEM", 62, 81]]], ["In A549 cells infected with HEV, small interfering RNAs (siRNAs) against the orf2 region were shown to offer protection .", [["A549 cells", "ANATOMY", 3, 13], ["A549 cells", "CELL", 3, 13], ["HEV", "ORGANISM", 28, 31], ["small interfering RNAs", "GENE_OR_GENE_PRODUCT", 33, 55], ["orf2", "GENE_OR_GENE_PRODUCT", 77, 81], ["A549 cells", "CELL_LINE", 3, 13], ["small interfering RNAs", "RNA", 33, 55], ["orf2 region", "DNA", 77, 88], ["HEV", "SPECIES", 28, 31], ["HEV", "PROBLEM", 28, 31], ["small interfering RNAs (siRNAs", "PROBLEM", 33, 63], ["A549 cells", "OBSERVATION", 3, 13], ["small", "OBSERVATION_MODIFIER", 33, 38], ["interfering RNAs", "OBSERVATION", 39, 55]]], ["While such approaches are feasible in vitro, the delivery and targeting of such inhibitors in vivo would be the real challenge.", [["the delivery", "TREATMENT", 45, 57], ["such inhibitors", "TREATMENT", 75, 90]]], ["At least one study in immunocompromised transplant patients with chronic HEV infection has also shown the efficacy of Ribavarin monotherapy (Kamar et al., 2010) .", [["HEV infection", "DISEASE", 73, 86], ["Ribavarin", "CHEMICAL", 118, 127], ["Ribavarin", "CHEMICAL", 118, 127], ["patients", "ORGANISM", 51, 59], ["Ribavarin", "SIMPLE_CHEMICAL", 118, 127], ["patients", "SPECIES", 51, 59], ["HEV", "SPECIES", 73, 76], ["one study", "TEST", 9, 18], ["immunocompromised transplant patients", "TREATMENT", 22, 59], ["chronic HEV infection", "PROBLEM", 65, 86], ["Ribavarin monotherapy", "TREATMENT", 118, 139], ["immunocompromised transplant", "OBSERVATION", 22, 50], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["HEV", "OBSERVATION_MODIFIER", 73, 76], ["infection", "OBSERVATION", 77, 86]]], ["Again, the utility of this approach among the vast majority of HEV infections that are acute remains questionable.SummarySince the discovery of HEV in the early 1970s and the molecular cloning of its genome two decades later, research on the molecular virology of HEV has been slow due to the lack of in vitro culture systems or small animal models of viral infection.", [["HEV infections", "DISEASE", 63, 77], ["HEV", "DISEASE", 264, 267], ["viral infection", "DISEASE", 352, 367], ["HEV", "ORGANISM", 63, 66], ["HEV", "ORGANISM", 144, 147], ["HEV", "ORGANISM", 264, 267], ["HEV", "SPECIES", 63, 66], ["HEV", "SPECIES", 144, 147], ["HEV", "SPECIES", 264, 267], ["this approach", "TREATMENT", 22, 35], ["HEV infections", "PROBLEM", 63, 77], ["HEV", "PROBLEM", 144, 147], ["vitro culture systems", "PROBLEM", 304, 325], ["viral infection", "PROBLEM", 352, 367], ["HEV", "OBSERVATION_MODIFIER", 63, 66], ["infections", "OBSERVATION", 67, 77], ["acute", "OBSERVATION_MODIFIER", 87, 92], ["small", "OBSERVATION_MODIFIER", 329, 334], ["viral infection", "OBSERVATION", 352, 367]]], ["Much of the early information and models of the HEV life cycle and genome replication were based on comparative information from other better-characterized positive-strand RNA viruses.", [["HEV", "SPECIES", 48, 51], ["the HEV life cycle", "TREATMENT", 44, 62], ["genome replication", "TREATMENT", 67, 85], ["strand RNA viruses", "PROBLEM", 165, 183], ["RNA viruses", "OBSERVATION", 172, 183]]], ["Viral ORFs have been expressed in various heterologous systems and the proteins characterized biochemically.", [["Viral", "ORGANISM", 0, 5], ["Viral ORFs", "DNA", 0, 10], ["Viral ORFs", "PROBLEM", 0, 10], ["the proteins", "TEST", 67, 79]]], ["With the recent availability of replicon-and infection-based in vitro cell culture models, the molecular virology of HEV is becoming increasingly clear.", [["cell culture", "ANATOMY", 70, 82], ["infection", "DISEASE", 45, 54], ["HEV", "DISEASE", 117, 120], ["cell culture", "CELL", 70, 82], ["HEV", "ORGANISM", 117, 120], ["HEV", "SPECIES", 117, 120], ["replicon", "TREATMENT", 32, 40], ["infection", "PROBLEM", 45, 54], ["vitro cell culture models", "TEST", 64, 89], ["infection", "OBSERVATION", 45, 54], ["increasingly", "OBSERVATION_MODIFIER", 133, 145], ["clear", "OBSERVATION", 146, 151]]], ["While there are a few surprises, such as the association of lipids with a non-enveloped virus, many earlier observations have also been confirmed in recent experiments.SummaryThis review summarizes the current knowledge in the area and presents a modified view of the HEV life cycle.", [["HEV", "ORGANISM", 268, 271], ["a non-enveloped virus", "PROBLEM", 72, 93], ["few", "OBSERVATION_MODIFIER", 18, 21], ["surprises", "OBSERVATION", 22, 31], ["non-enveloped", "OBSERVATION_MODIFIER", 74, 87], ["virus", "OBSERVATION", 88, 93]]]], "f383499514eace4a8aa09fe364d17db3861fedd2": [["RNA is a dynamic and diverse biomolecule with an essential role in numerous biological processes.", [["RNA", "RNA", 0, 3], ["a dynamic and diverse biomolecule", "PROBLEM", 7, 40], ["dynamic", "OBSERVATION_MODIFIER", 9, 16], ["diverse", "OBSERVATION_MODIFIER", 21, 28], ["biomolecule", "OBSERVATION", 29, 40], ["numerous", "OBSERVATION_MODIFIER", 67, 75], ["biological processes", "OBSERVATION", 76, 96]]], ["From a molecular diagnostic standpoint, RNA-based measurements have the potential for broad application across diverse areas of human health, including disease diagnosis, prognosis and therapeutic selection.", [["human", "ORGANISM", 128, 133], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["RNA", "TEST", 40, 43], ["broad application", "TREATMENT", 86, 103], ["therapeutic selection", "TREATMENT", 185, 206]]], ["Technological advancements have continually shaped the way that RNA-based measurements are used in the clinic (BOX 1) .", [["Technological advancements", "TREATMENT", 0, 26], ["RNA-based measurements", "TEST", 64, 86]]], ["With the evolution of next-generation sequencing (NGS) technologies, the use of RNA sequencing (RNA-seq) to investigate the vast diversity of RNA species is an obvious and exciting application, which opens up entirely new opportunities for improving diagnosis and treatment of human disease.", [["human", "ORGANISM", 277, 282], ["human", "SPECIES", 277, 282], ["human", "SPECIES", 277, 282], ["RNA sequencing", "TEST", 80, 94], ["RNA species", "PROBLEM", 142, 153], ["human disease", "PROBLEM", 277, 290], ["RNA species", "OBSERVATION", 142, 153]]], ["RNA-seq provides an in-depth view of the transcriptome, detecting novel RNA transcript variation 1 .", [["RNA transcript", "RNA", 72, 86], ["RNA", "TEST", 0, 3], ["RNA", "OBSERVATION", 72, 75], ["transcript variation", "OBSERVATION", 76, 96]]], ["Beyond operating as an open platform technology, RNA-seq has a number of potential advantages over gene expression microarrays, including an increased dynamic range of expression, measurement of focal changes (such as single nucleotide variants (SNVs), insertions and deletions), detection of different transcript isoforms, splice variants and chimeric gene fusions (including previously unidentified genes and/or transcripts), and, fundamentally, it can be performed on any species.", [["RNA-seq", "DNA", 49, 56], ["transcript isoforms", "RNA", 303, 322], ["chimeric gene fusions", "DNA", 344, 365], ["an open platform technology", "TEST", 20, 47], ["RNA", "TEST", 49, 52], ["gene expression microarrays", "TEST", 99, 126], ["focal changes", "PROBLEM", 195, 208], ["single nucleotide variants (SNVs)", "PROBLEM", 218, 251], ["insertions and deletions", "TREATMENT", 253, 277], ["different transcript isoforms", "PROBLEM", 293, 322], ["splice variants", "PROBLEM", 324, 339], ["chimeric gene fusions", "TREATMENT", 344, 365], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["focal", "OBSERVATION_MODIFIER", 195, 200], ["splice variants", "OBSERVATION", 324, 339]]], ["Although RNA-seq assays are now commercially available 2,3 , these early tests belie the considerable promise for broader applicability of RNA-seq-based clinical tests.", [["RNA-seq assays", "TEST", 9, 23], ["these early tests", "TEST", 61, 78], ["RNA", "TEST", 139, 142], ["clinical tests", "TEST", 153, 167]]]], "PMC7121143": [["For the third time in as many decades, a zoonotic coronavirus has crossed species to infect human populations.", [["zoonotic coronavirus", "DISEASE", 41, 61], ["coronavirus", "ORGANISM", 50, 61], ["human", "ORGANISM", 92, 97], ["human", "SPECIES", 92, 97], ["zoonotic coronavirus", "SPECIES", 41, 61], ["human", "SPECIES", 92, 97], ["a zoonotic coronavirus", "PROBLEM", 39, 61], ["zoonotic coronavirus", "OBSERVATION", 41, 61]]], ["This virus, provisionally called 2019-nCoV, was first identified in Wuhan, China, in persons exposed to a seafood or wet market.", [["persons", "ORGANISM", 85, 92], ["persons", "SPECIES", 85, 92]]], ["The rapid response of the Chinese public health, clinical, and scientific communities facilitated recognition of the clinical disease and initial understanding of the epidemiology of the infection.", [["infection", "DISEASE", 187, 196], ["the clinical disease", "PROBLEM", 113, 133], ["the infection", "PROBLEM", 183, 196], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["response", "OBSERVATION_MODIFIER", 10, 18], ["infection", "OBSERVATION", 187, 196]]], ["First reports indicated that human-to-human transmission was limited or nonexistent, but we now know that such transmission occurs, although to what extent remains unknown.", [["human", "ORGANISM", 29, 34], ["human", "ORGANISM", 38, 43], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 38, 43]]], ["Like outbreaks caused by two other pathogenic human respiratory coronaviruses (severe acute respiratory syndrome coronavirus [SARS-CoV] and Middle East respiratory syndrome coronavirus [MERS-CoV]), 2019-nCoV causes respiratory disease that is often severe.1 As of January 24, 2020, there were more than 800 reported cases, with a mortality rate of 3% (https://promedmail.org/).", [["respiratory", "ANATOMY", 215, 226], ["respiratory coronaviruses", "DISEASE", 52, 77], ["acute respiratory syndrome coronavirus", "DISEASE", 86, 124], ["SARS-CoV", "DISEASE", 126, 134], ["Middle East respiratory syndrome coronavirus", "DISEASE", 140, 184], ["respiratory disease", "DISEASE", 215, 234], ["human", "ORGANISM", 46, 51], ["respiratory coronaviruses", "ORGANISM", 52, 77], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 79, 124], ["SARS-CoV", "ORGANISM", 126, 134], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 140, 184], ["MERS-CoV", "ORGANISM", 186, 194], ["human", "SPECIES", 46, 51], ["human respiratory coronaviruses (severe acute respiratory syndrome coronavirus", "SPECIES", 46, 124], ["SARS-CoV", "SPECIES", 126, 134], ["Middle East respiratory syndrome coronavirus", "SPECIES", 140, 184], ["MERS-CoV", "SPECIES", 186, 194], ["two other pathogenic human respiratory coronaviruses", "PROBLEM", 25, 77], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 79, 124], ["SARS", "PROBLEM", 126, 130], ["CoV]", "PROBLEM", 131, 135], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 140, 184], ["respiratory disease", "PROBLEM", 215, 234], ["a mortality rate", "TEST", 328, 344], ["respiratory coronaviruses", "OBSERVATION", 52, 77], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["respiratory syndrome", "OBSERVATION", 92, 112], ["Middle", "ANATOMY_MODIFIER", 140, 146], ["respiratory syndrome", "OBSERVATION", 152, 172], ["respiratory disease", "OBSERVATION", 215, 234], ["severe", "OBSERVATION_MODIFIER", 249, 255]]]]}